


**CUMULATIVE
SUPPLEMENT 6
June 2024**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2024

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**Cumulative Supplement 6
June 2024**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	ix
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xii
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**CUMULATIVE SUPPLEMENT 6
June 2024**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug

Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
CADILA HEALTHCARE LTD (CADILA)	ZYDUS LIFESCIENCES LTD (ZYDUS LIFESCIENCES)
GLAXOSMITHKLINE (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLENMARK GENERICS INC USA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)

GLENMARK GENERICS LIMITED (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD INDIA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK PHARMACEUTICALS SA (GLENMARK PHARMS)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
GLENMARK PHARMACEUTICALS SA SWITZERLAND (GLENMARK PHARMS SA)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
LUPIN LTD (LUPIN LTD)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	XIROMED LLC (XIROMED)
PAR PHARMACEUTICAL (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM INC)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR STERILE PRODUCTS LLC (PAR STERILE PRODUCTS)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
TARO PHARMACEUTICALS USA INC (TARO)	TARO PHARMACEUTICALS INC (TARO)
VERTICE PHARMA MANAGEMENT CORP (VERTICE)	ENCUBE ETHICALS PRIVATE LTD (ENCUBE)
ZYDUS WORLDWIDE DMCC (ZYDUS)	ZYDUS LIFESCIENCES GLOBAL FZE (ZYDUS LIFESCIENCES)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levotheroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2023</u>	<u>MAR</u> <u>2024</u>	<u>JUN</u> <u>2024</u>	<u>SEP</u> <u>2024</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23099 (12.1%)	23058 (12.2%)	23182 (11.9%)		
MULTISOURCE	20315 (87.9%)	20256 (87.8%)	20419 (88.1%)		
THERAPEUTICALLY EQUIVALENT	20252 (87.7%)	20198 (87.6%)	20332 (87.7%)		
NOT THERAPEUTICALLY EQUIVALENT	63 (0.3%)	58 (0.3%)	87 (0.4%)		
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)	47 (0.2%)		
NEW MOLECULAR ENTITIES APPROVED	32	18	14		
NUMBER OF APPLICANTS	1214	1219	1214		

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL		ABACAVIR SULFATE AND LAMIVUDINE					
AB	! CIPLA	EQ 600MG BASE;300MG		A 091144	001	Mar 28, 2017	Jan CHRS
	EPZICOM						
	+ @ VIIV HLTHCARE	EQ 600MG BASE;300MG		N 021652	001	Aug 02, 2004	Jan DISC
TABLET, FOR SUSPENSION;ORAL		ABACAVIR SULFATE AND LAMIVUDINE					
	+ @ MYLAN LABS LTD	EQ 60MG BASE;30MG		N 204311	001	Dec 22, 2023	Jan DISC

ABIRATERONE ACETATE

TABLET;ORAL		ABIRATERONE ACETATE					
AB	MSN	500MG		A 210686	002	Apr 24, 2024	Apr NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL		BUTALBITAL AND ACETAMINOPHEN					
AA	QUAGEN	300MG;50MG		A 214305	001	Feb 01, 2024	Jan NEWA
AA		325MG;50MG		A 214291	001	Jan 18, 2024	Jan NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
	@ KEY THERAP	300MG;50MG;40MG		A 206615	001	Aug 04, 2017	May DISC
AA		300MG;50MG;40MG		A 206615	001	Aug 04, 2017	Apr CAHN
AA	QUAGEN	300MG;50MG;40MG		A 214288	001	Feb 08, 2024	Jan NEWA
AA		325MG;50MG;40MG		A 216376	001	Mar 12, 2024	Mar NEWA
AA	SENORES PHARMS	300MG;50MG;40MG		A 214087	001	Aug 13, 2021	Feb CAHN
AA		325MG;50MG;40MG		A 214087	002	Aug 13, 2021	Feb CAHN
TABLET;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AA	QUAGEN	325MG;50MG;40MG		A 214287	001	Jan 18, 2024	Jan NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE					
	@ NOSTRUM LABS INC	325MG;50MG;40MG;30MG		A 075929	001	Apr 22, 2002	May DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL		TREZIX					
	@ KEY THERAP	320.5MG;30MG;16MG		A 204785	001	Nov 26, 2014	May DISC
		320.5MG;30MG;16MG		A 204785	001	Nov 26, 2014	Apr CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE					
	@ AKORN	120MG/5ML;12MG/5ML		A 040119	001	Apr 26, 1996	Feb DISC
	@ PAI HOLDINGS	120MG/5ML;12MG/5ML		A 040119	001	Apr 26, 1996	May CAHN
TABLET;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE					
AA	! SPECGX LLC	300MG;60MG		A 040419	003	May 31, 2001	Apr CHRS
AA	STRIDES PHARMA	300MG;15MG		A 089990	001	Sep 30, 1988	Apr CMFD
AA		300MG;30MG		A 089805	001	Sep 30, 1988	Apr CMFD
AA		300MG;60MG		A 089828	001	Sep 30, 1988	Apr CMFD
	@ SUN PHARM INDS LTD	300MG;30MG		A 085868	001		Jan DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL		HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
>A>	@ ELITE LABS INC	325MG;2.5MG		A 209924	001	Nov 16, 2018	Jun CAHN
>A>	@	325MG;5MG		A 209924	002	Nov 16, 2018	Jun CAHN
>A>	@	325MG;7.5MG		A 209924	003	Nov 16, 2018	Jun CAHN
>A>	@	325MG;10MG		A 209924	004	Nov 16, 2018	Jun CAHN
	@ ENDO OPERATIONS	300MG;5MG		A 090415	001	Jan 24, 2011	May CAHN
	@	300MG;7.5MG		A 090415	002	Jan 24, 2011	May CAHN
	@	300MG;10MG		A 090415	003	Jan 24, 2011	May CAHN
>D>	@ NOSTRUM LABS INC	325MG;2.5MG		A 209924	001	Nov 16, 2018	Jun CAHN

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>	@	325MG;5MG	A209924	002	Nov 16, 2018	Jun	CAHN
>D>	@	325MG;7.5MG	A209924	003	Nov 16, 2018	Jun	CAHN
>D>	@	325MG;10MG	A209924	004	Nov 16, 2018	Jun	CAHN
	@ PRINSTON INC	325MG;5MG	A214928	001	Dec 30, 2021	Mar	DISC
	@	325MG;7.5MG	A214928	002	Dec 30, 2021	Mar	DISC
	@	325MG;10MG	A214928	003	Dec 30, 2021	Mar	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

	@ ENDO OPERATIONS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014	May	CAHN
--	-------------------	-------------------	---------	-----	--------------	-----	------

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

>A>	@ ELITE LABS INC	325MG;5MG	A209385	001	Jul 02, 2018	Jun	CAHN
>A>	@	325MG;7.5MG	A209385	002	Jul 02, 2018	Jun	CAHN
>A>	@	325MG;10MG	A209385	003	Jul 02, 2018	Jun	CAHN
	@ ENDO OPERATIONS	325MG;2.5MG	A090733	001	Jul 11, 2013	May	CAHN
	@	325MG;5MG	A040105	001	Jul 30, 1996	May	CAHN
	@	325MG;7.5MG	A090734	001	Jul 11, 2013	May	CAHN
	@	325MG;10MG	A090734	002	Jul 11, 2013	May	CAHN
>D>	@ NOSTRUM LABS INC	325MG;5MG	A209385	001	Jul 02, 2018	Jun	CAHN
>D>	@	325MG;7.5MG	A209385	002	Jul 02, 2018	Jun	CAHN
>D>	@	325MG;10MG	A209385	003	Jul 02, 2018	Jun	CAHN

PERCOCET

AA	!	ENDO OPERATIONS	325MG;2.5MG	A040330	001	Jun 25, 1999	Apr	CAHN
AA	!		325MG;5MG	A040330	002	Jun 25, 1999	Apr	CAHN
	+	@	325MG;5MG	A085106	002		May	CAHN
AA	!		325MG;7.5MG	A040330	003	Nov 23, 2001	Apr	CAHN
AA	!		325MG;10MG	A040330	004	Nov 23, 2001	Apr	CAHN

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

	@ AJANTA PHARMA LTD	125MG	A211151	001	Sep 11, 2023	Feb	DISC	
	@	250MG	A211151	002	Sep 11, 2023	Feb	DISC	
AB	EPIC PHARMA LLC	125MG	A218023	001	May 14, 2024	May	NEWA	
AB		250MG	A218023	002	May 14, 2024	May	NEWA	
>D>	AB	EYWA PHARMA	125MG	A211556	001	Oct 18, 2019	Jun	CTEC
>A>	BX		125MG	A211556	001	Oct 18, 2019	Jun	CTEC
>D>	AB		250MG	A211556	002	Oct 18, 2019	Jun	CTEC
>A>	BX		250MG	A211556	002	Oct 18, 2019	Jun	CTEC
	@ TORRENT	125MG	A213706	001	Jan 26, 2024	Jan	DISC	
AB		125MG	A213706	001	Jan 26, 2024	Jan	NEWA	
	@	250MG	A213706	002	Jan 26, 2024	Jan	DISC	
AB		250MG	A213706	002	Jan 26, 2024	Jan	NEWA	

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

	@ ENDO OPERATIONS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	May	CAHN
--	-------------------	--------------------	---------	-----	--------------	-----	------

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

AT	!	SAPTALIS PHARMS	2%	A040607	001	Feb 24, 2005	Apr	CHRS
		VOSOL						
	+	@ HIKMA	2%	N012179	001		Apr	CRLD
	@		2%	N012179	001		Apr	DISC

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP		SOMERSET THERAPS LLC	6GM/30ML (200MG/ML)	A218397	001	Jun 07, 2024	May	NEWA
		SOLUTION;INHALATION, ORAL						
		ACETYLCYSTEINE						
	@	EXELA PHARMA	20%	A205643	001	Nov 01, 2023	Feb	DISC

>D>	<u>ACETYLCYSTEINE LYSINE</u>								
>D>	FOR SOLUTION;ORAL								
>D>	LEGUBETI								
>D>	+!	GALEPHAR	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jun	DISC	
>A>	+ @		EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jun	DISC	
	+!		EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Feb	NEWA	
>D>	+!		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jun	DISC	
>A>	+ @		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jun	DISC	
	+!		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Feb	NEWA	
	<u>ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	SEMPREX-D								
	+ @	ENDO OPERATIONS	8MG;60MG	N019806	001	Mar 25, 1994	May	CAHN	
	<u>ACYCLOVIR</u>								
	CREAM;TOPICAL								
	ACYCLOVIR								
AB	TARO		5%	A205470	001	Jun 12, 2024	May	NEWA	
	OINTMENT;TOPICAL								
	ACYCLOVIR								
	@	COSETTE	5%	A205591	001	Nov 13, 2017	Mar	DISC	
	SUSPENSION;ORAL								
	ACYCLOVIR								
	@	HIKMA	200MG/5ML	A077026	001	Jun 07, 2005	Mar	DISC	
	@	VISTAPHARM LLC	200MG/5ML	A213951	001	Jan 11, 2021	Mar	CAHN	
	<u>ACYCLOVIR SODIUM</u>								
	INJECTABLE;INJECTION								
	ACYCLOVIR SODIUM								
>A>	AP	DDREG PHARMA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Jun	NEWA	
>D>	@	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017	Jun	CAHN	
>D>	@		EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Jun	CAHN	
>A>	@	NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017	Jun	CAHN	
>A>	@		EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Jun	CAHN	
	<u>ADAPALENE</u>								
	LOTION;TOPICAL								
	DIFFERIN								
	+ @	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010	May	DISC	
	<u>ADEFOVIR DIPIVOXIL</u>								
	TABLET;ORAL								
	ADEFOVIR DIPIVOXIL								
>D>	AB	SIGMAPHARM LABS LLC	10MG	A202051	001	Aug 29, 2013	Jun	CHRS	
>A>	AB	!	10MG	A202051	001	Aug 29, 2013	Jun	CHRS	
>D>	HEPSERA								
>D>	AB	+!	GILEAD	10MG	N021449	001	Sep 20, 2002	Jun	DISC
>A>		+ @		10MG	N021449	001	Sep 20, 2002	Jun	DISC
	<u>ADENOSINE</u>								
	SOLUTION;INTRAVENOUS								
	ADENOSINE								
	@	HOSPIRA	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Feb	DISC	
	@		90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Feb	DISC	
	<u>ALBUTEROL SULFATE</u>								
	AEROSOL, METERED;INHALATION								
	ALBUTEROL SULFATE								
AB2	ARMSTRONG PHARMS		EQ 0.09MG BASE/INH	A212447	001	May 21, 2024	May	NEWA	
	POWDER, METERED;INHALATION								
>D>	PROAIR DIGIHALER								
>D>	+ @	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Jun	DISC	
>A>	+ @		EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Jun	DISC	
	SOLUTION;INHALATION								
	ALBUTEROL SULFATE								
AN	LEXENPHARM		EQ 0.021% BASE	A215571	001	May 03, 2024	Apr	NEWA	
AN			EQ 0.042% BASE	A215571	002	May 03, 2024	Apr	NEWA	
>D>	@	LUOXIN AUROVITAS	EQ 0.021% BASE	A211888	001	Apr 20, 2020	Jun	CMFD	
>A>	AN		EQ 0.021% BASE	A211888	001	Apr 20, 2020	Jun	CMFD	
>D>	@		EQ 0.042% BASE	A211888	002	Apr 20, 2020	Jun	CMFD	

SOLUTION; INHALATION

ALBUTEROL SULFATE

>A>	AN		EQ 0.042% BASE	A211888	002	Apr 20, 2020	Jun CMFD
>D>		@ MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Jun CAHN
>A>		@ NORVIUM BIOSCIENCE	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Jun CAHN
>D>	AN	WATSON LABS	EQ 0.021% BASE	A077772	001	Sep 25, 2007	Jun DISC
>A>		@	EQ 0.021% BASE	A077772	001	Sep 25, 2007	Jun DISC
>D>	AN		EQ 0.042% BASE	A077772	002	Sep 25, 2007	Jun DISC
>A>		@	EQ 0.042% BASE	A077772	002	Sep 25, 2007	Jun DISC

SYRUP; ORAL

ALBUTEROL SULFATE

@ HIKMA

EQ 2MG BASE/5ML

A074749 001 Jan 30, 1998 Mar DISC

TABLET; ORAL

ALBUTEROL SULFATE

>D>	AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Jun CTEC
>A>	BX		EQ 2MG BASE	A210948	001	Mar 15, 2019	Jun CTEC
>D>	AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Jun CTEC
>A>	BX		EQ 4MG BASE	A210948	002	Mar 15, 2019	Jun CTEC

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED; INHALATION

AIRSUPRA

+!	ASTRAZENECA	EQ 0.09MG BASE/INH; 0.08MG/INH	N214070	001	Jan 10, 2023	Jan CPOT
----	-------------	--------------------------------	---------	-----	--------------	----------

ALCOHOL

SOLUTION; INTRA-ARTERIAL

ABLYSINOL

>D>	+	BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jun DISC
>A>	+	@	99% (1ML)	N207987	001	Jun 21, 2018	Jun DISC

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB		IPCA LABS LTD	EQ 10MG BASE	A206387	001	Jun 04, 2024	May NEWA
AB			EQ 35MG BASE	A206387	002	Jun 04, 2024	May NEWA
AB			EQ 40MG BASE	A206387	003	Jun 04, 2024	May NEWA
AB			EQ 70MG BASE	A206387	004	Jun 04, 2024	May NEWA

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

>D>		@ MYLAN	10MG	A079014	001	Jul 18, 2011	Jun CAHN
>A>		@ NORVIUM BIOSCIENCE	10MG	A079014	001	Jul 18, 2011	Jun CAHN

ALISKIREN HEMIFUMARATE

TABLET; ORAL

ALISKIREN HEMIFUMARATE

AB		ENDO OPERATIONS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Apr CAHN
AB			EQ 300MG BASE	A206665	002	Mar 22, 2019	Apr CAHN

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB		ENDO OPERATIONS	100MG	A075798	001	Jun 27, 2003	Apr CAHN
AB			300MG	A075798	002	Jun 27, 2003	Apr CAHN
>A>	AB	HARMAN FINOCHEM	200MG	A214443	003	Jun 17, 2024	Jun NFTG
		@ LUPIN LTD	100MG	A211807	001	Dec 14, 2023	Apr DISC
		@	300MG	A211807	002	Dec 14, 2023	Apr DISC
		ZYLOPRIM					
>D>	+	CASPER PHARMA LLC	200MG	N016084	003	Aug 04, 2022	Jun CFTG
>A>	AB	+	200MG	N016084	003	Aug 04, 2022	Jun CFTG

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

@ ENDO OPERATIONS

EQ 0.5MG BASE

A206113 001 Feb 23, 2018 May CAHN

@

EQ 1MG BASE

A206113 002 Feb 23, 2018 May CAHN

ALPELISIBGRANULES;ORAL
VIJOICE

+! NOVARTIS 50MG/PACKET N218466 001 Apr 24, 2024 Apr NEWA

ALPRAZOLAMTABLET;ORAL
ALPRAZOLAM

AB	CHARTWELL RX	0.25MG	A207507	001	Jul 09, 2018	Mar	CAHN
AB		0.5MG	A207507	002	Jul 09, 2018	Mar	CAHN
AB		1MG	A207507	003	Jul 09, 2018	Mar	CAHN
AB		2MG	A207507	004	Jul 09, 2018	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

@	ANCHEN PHARMS	0.5MG	A078469	001	Sep 29, 2011	Mar	DISC
@		1MG	A078469	002	Sep 29, 2011	Mar	DISC
@		2MG	A078469	003	Sep 29, 2011	Mar	DISC
@		3MG	A078469	004	Sep 29, 2011	Mar	DISC
@	ENDO OPERATIONS	0.5MG	A078442	001	Oct 15, 2007	May	CAHN
@		0.5MG	A078469	001	Sep 29, 2011	May	CAHN
@		1MG	A078442	002	Oct 15, 2007	May	CAHN
@		1MG	A078469	002	Sep 29, 2011	May	CAHN
@		2MG	A078442	003	Oct 15, 2007	May	CAHN
@		2MG	A078469	003	Sep 29, 2011	May	CAHN
@		3MG	A078442	004	Oct 15, 2007	May	CAHN
@		3MG	A078469	004	Sep 29, 2011	May	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

AB	ENDO OPERATIONS	0.25MG	A078088	001	Jan 09, 2009	Apr	CAHN
AB		0.5MG	A078088	002	Jan 09, 2009	Apr	CAHN
AB	!	1MG	A078088	003	Jan 09, 2009	Apr	CAHN
AB		2MG	A078088	004	Jan 09, 2009	Apr	CAHN

ALPROSTADILINJECTABLE;INJECTION
EDEX

@	ENDO OPERATIONS	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr	CAHN
AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr	CAHN
	+!	0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr	CAHN
AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr	CAHN
	+!	0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr	CAHN
AP	+!	0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr	CAHN
	+!	0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr	CAHN

>D> SUPPOSITORY;URETHRAL

>D> MUSE

>D>	+!	MYLAN SPECIALITY LP	0.25MG	N020700	002	Nov 19, 1996	Jun	DISC
>A>	+ @		0.25MG	N020700	002	Nov 19, 1996	Jun	DISC
>D>	+!		0.5MG	N020700	003	Nov 19, 1996	Jun	DISC
>A>	+ @		0.5MG	N020700	003	Nov 19, 1996	Jun	DISC
>D>	+!		1MG	N020700	004	Nov 19, 1996	Jun	DISC
>A>	+ @		1MG	N020700	004	Nov 19, 1996	Jun	DISC

AMANTADINE HYDROCHLORIDE

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

@	ENDO OPERATIONS	50MG/5ML	A077992	001	Dec 12, 2006	May	CAHN
@	GENUS	50MG/5ML	A076352	001	Sep 10, 2004	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

+ @	ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Apr	DISC
+ @		EQ 193MG BASE	N209410	002	Feb 16, 2018	Apr	DISC

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

@	ENDO OPERATIONS	5MG	A209509	001	Apr 10, 2019	May	CAHN
@		10MG	A209509	002	Apr 10, 2019	May	CAHN
@	PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Apr	DISC
@		10MG	A209509	002	Apr 10, 2019	Apr	DISC

AMCINONIDE

	LOTION; TOPICAL								
	AMCINONIDE								
	! GENUS	0.1%		A076329	001	Nov 06, 2002	Jan	CAHN	
	OINTMENT; TOPICAL								
	AMCINONIDE								
AB	! GENUS	0.1%		A076096	001	Nov 19, 2002	Jan	CAHN	

AMIKACIN SULFATE

	INJECTABLE; INJECTION								
	AMIKACIN SULFATE								
AP	QILU	EQ 250MG BASE/ML		A218146	001	Mar 19, 2024	Mar	NEWA	

AMILORIDE HYDROCHLORIDE

	TABLET; ORAL								
	AMILORIDE HYDROCHLORIDE								
AB	! ENDO OPERATIONS	5MG		A070346	001	Jan 22, 1986	Apr	CAHN	

AMINO ACIDS; DEXTROSE

	INJECTABLE; INJECTION								
	CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER								
	BAXTER HLTHCARE	8%; 14GM/100ML		N020734	019	Apr 13, 2021	Apr	NEWA	

AMINOCAPROIC ACID

	SOLUTION; ORAL								
	AMICAR								
	+ @ HIKMA	0.25GM/ML		N015230	002		Mar	DISC	
	AMINOCAPROIC ACID								
AA	! TULEX PHARMS INC	0.25GM/ML		A212494	001	Aug 11, 2020	Mar	CHRS	
	@ VISTAPHARM LLC	0.25GM/ML		A212814	001	Feb 26, 2020	Mar	CAHN	
	TABLET; ORAL								
	AMICAR								
	+ @ HIKMA	500MG		N015197	001		Mar	DISC	
	+ @	1GM		N015197	002	Jun 24, 2004	Mar	DISC	

AMIODARONE HYDROCHLORIDE

	INJECTABLE; INJECTION								
	AMIODARONE HYDROCHLORIDE								
	@ HOSPIRA	50MG/ML		A203884	001	Nov 25, 2013	May	DISC	

AMITRIPTYLINE HYDROCHLORIDE

	TABLET; ORAL								
	AMITRIPTYLINE HYDROCHLORIDE								
AB	AIPING PHARM INC	10MG		A212654	002	Sep 29, 2021	May	CMFD	
AB		25MG		A212654	001	Apr 07, 2020	May	CMFD	
AB		50MG		A212654	003	Sep 29, 2021	May	CMFD	
AB		75MG		A212654	004	Sep 29, 2021	May	CMFD	
AB		100MG		A212654	005	Sep 29, 2021	May	CMFD	
AB		150MG		A212654	006	Sep 29, 2021	May	CMFD	
	@ ENDO OPERATIONS	10MG		A040218	001	Sep 11, 1997	May	CAHN	
	@	25MG		A040218	002	Sep 11, 1997	May	CAHN	
	@	50MG		A040218	003	Sep 11, 1997	May	CAHN	
	@	75MG		A040218	004	Sep 11, 1997	May	CAHN	
	@	100MG		A040218	005	Sep 11, 1997	May	CAHN	
	@	150MG		A040218	006	Sep 11, 1997	May	CAHN	

AMLODIPINE BESYLATE

	TABLET; ORAL								
	AMLODIPINE BESYLATE								
	@ AIPING PHARM INC	EQ 2.5MG BASE		A077759	001	Jul 09, 2007	Feb	CAHN	
	@	EQ 5MG BASE		A077759	002	Jul 09, 2007	Feb	CAHN	
	@	EQ 10MG BASE		A077759	003	Jul 09, 2007	Feb	CAHN	
>D>	AB LUPIN	EQ 2.5MG BASE		A078043	001	Jul 12, 2007	Jun	CTEC	
>A>	BX	EQ 2.5MG BASE		A078043	001	Jul 12, 2007	Jun	CTEC	
>D>	AB	EQ 5MG BASE		A078043	002	Jul 12, 2007	Jun	CTEC	
>A>	BX	EQ 5MG BASE		A078043	002	Jul 12, 2007	Jun	CTEC	
>D>	AB	EQ 10MG BASE		A078043	003	Jul 12, 2007	Jun	CTEC	
>A>	BX	EQ 10MG BASE		A078043	003	Jul 12, 2007	Jun	CTEC	
	@ SUN PHARM INDS LTD	EQ 2.5MG BASE		A077974	001	Jul 09, 2007	Jan	DISC	
	@	EQ 5MG BASE		A077974	002	Jul 09, 2007	Jan	DISC	
	@	EQ 10MG BASE		A077974	003	Jul 09, 2007	Jan	DISC	

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	AMNEAL	EQ 2.5MG BASE;10MG	A 077215	001	Dec 07, 2018	Apr CAHN
@		EQ 5MG BASE;10MG	A 077215	002	Dec 07, 2018	Apr CAHN
@		EQ 5MG BASE;20MG	A 077215	003	Dec 07, 2018	Apr CAHN
@		EQ 10MG BASE;20MG	A 077215	004	Dec 07, 2018	Apr CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	SCIENGEN PHARMS INC	EQ 5MG BASE;20MG	A 209010	001	Dec 03, 2018	Feb CMFD
AB		EQ 5MG BASE;40MG	A 209010	002	Dec 03, 2018	Feb CMFD
AB		EQ 10MG BASE;20MG	A 209010	003	Dec 03, 2018	Feb CMFD
AB		EQ 10MG BASE;40MG	A 209010	004	Dec 03, 2018	Feb CMFD

AMOXAPINE

TABLET;ORAL

AMOXAPINE

>A>	@	CHARTWELL RX	25MG	A 072879	002	Jun 28, 1991	Jun CMS1
>A>	@		50MG	A 072879	003	Jun 28, 1991	Jun CMS1
>A>	@		100MG	A 072879	004	Jun 28, 1991	Jun CMS1

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

AB	CHARTWELL RX	400MG/5ML	A 065319	002	Jun 18, 2007	May CAHN	
	@	DAVA PHARMS INC	125MG/5ML	A 062927	001	Nov 25, 1988	Mar DISC
	@		250MG/5ML	A 062927	002	Nov 25, 1988	Mar DISC
	@	ENDO OPERATIONS	125MG/5ML	A 062927	001	Nov 25, 1988	May CAHN
	@		250MG/5ML	A 062927	002	Nov 25, 1988	May CAHN
AB	+	US ANTIBIOTICS	400MG/5ML	N 050760	002	Apr 15, 1999	Apr CMFD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

ADDERALL XR 10

AB1	+	TAKEDA PHARMS USA	2.5MG;2.5MG;2.5MG;2.5MG	N 021303	001	Oct 11, 2001	Jan CTEC
		ADDERALL XR 15					
AB1	+	TAKEDA PHARMS USA	3.75MG;3.75MG;3.75MG;3.75MG	N 021303	006	May 22, 2002	Jan CTEC
		ADDERALL XR 20					
AB1	+	TAKEDA PHARMS USA	5MG;5MG;5MG;5MG	N 021303	002	Oct 11, 2001	Jan CTEC
		ADDERALL XR 25					
AB1	+	TAKEDA PHARMS USA	6.25MG;6.25MG;6.25MG;6.25MG	N 021303	004	May 22, 2002	Jan CTEC
		ADDERALL XR 30					
AB1	+	TAKEDA PHARMS USA	7.5MG;7.5MG;7.5MG;7.5MG	N 021303	003	Oct 11, 2001	Jan CTEC
		ADDERALL XR 5					
AB1	+	TAKEDA PHARMS USA	1.25MG;1.25MG;1.25MG;1.25MG	N 021303	005	May 22, 2002	Jan CTEC
		DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
AB1		ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A 077302	001	Jun 22, 2012	Jan CTEC
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A 077302	002	Jun 22, 2012	Jan CTEC
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A 077302	003	Jun 22, 2012	Jan CTEC
AB1			5MG;5MG;5MG;5MG	A 077302	004	Jun 22, 2012	Jan CTEC
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A 077302	005	Jun 22, 2012	Jan CTEC
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A 077302	006	Jun 22, 2012	Jan CTEC
AB1		ANI PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A 205401	001	Jan 22, 2019	Jan CTEC
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A 205401	002	Jan 22, 2019	Jan CTEC
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A 205401	003	Jan 22, 2019	Jan CTEC
AB1			5MG;5MG;5MG;5MG	A 205401	004	Jan 22, 2019	Jan CTEC
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A 205401	005	Jan 22, 2019	Jan CTEC
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A 205401	006	Jan 22, 2019	Jan CTEC
AB1		ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A 214959	001	Sep 29, 2021	Jan CTEC
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A 214959	002	Sep 29, 2021	Jan CTEC
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A 214959	003	Sep 29, 2021	Jan CTEC
AB1			5MG;5MG;5MG;5MG	A 214959	004	Sep 29, 2021	Jan CTEC
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A 214959	005	Sep 29, 2021	Jan CTEC
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A 214959	006	Sep 29, 2021	Jan CTEC
AB1		ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A 212037	001	Dec 11, 2019	Jan CTEC
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A 212037	002	Dec 11, 2019	Jan CTEC
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A 212037	003	Dec 11, 2019	Jan CTEC
AB1			5MG;5MG;5MG;5MG	A 212037	004	Dec 11, 2019	Jan CTEC

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE									
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A212037	005	Dec 11, 2019	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A212037	006	Dec 11, 2019	Jan	CTEC		
	@ ENDO OPERATIONS	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019	May	CAHN		
	@	2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019	May	CAHN		
	@	3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019	May	CAHN		
	@	5MG;5MG;5MG;5MG	A206159	004	May 31, 2019	May	CAHN		
	@	6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019	May	CAHN		
	@	7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019	May	CAHN		
AB1	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Jan	CTEC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Jan	CTEC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Jan	CTEC		
AB1		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Jan	CTEC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A217027	006	Jan 23, 2023	Jan	CTEC		
AB1	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Jan	CTEC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Jan	CTEC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Jan	CTEC		
AB1		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Jan	CTEC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Jan	CTEC		
AB1	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Jan	CTEC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Jan	CTEC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Jan	CTEC		
AB1		5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Jan	CTEC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Jan	CTEC		
AB1	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019	Jan	CTEC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019	Jan	CTEC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019	Jan	CTEC		
AB1		5MG;5MG;5MG;5MG	A210651	004	May 17, 2019	Jan	CTEC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019	Jan	CTEC		
AB1	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019	Jan	CTEC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019	Jan	CTEC		
AB2		3.125MG;3.125MG;3.125MG;3.125MG	A211546	001	Aug 31, 2023	Jan	CTEC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019	Jan	CTEC		
AB1		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019	Jan	CTEC		
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A211546	002	Aug 31, 2023	Jan	CTEC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019	Jan	CTEC		
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A211546	003	Aug 31, 2023	Jan	CTEC		
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A211546	004	Aug 31, 2023	Jan	CTEC		
AB2	SUN PHARM INDS INC	3.125MG;3.125MG;3.125MG;3.125MG	A215997	001	Sep 27, 2023	Jan	CTEC		
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A215997	002	Sep 27, 2023	Jan	CTEC		
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A215997	003	Sep 27, 2023	Jan	CTEC		
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A215997	004	Sep 27, 2023	Jan	CTEC		
AB2	TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Jan	CTEC		
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Jan	CTEC		
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Jan	CTEC		
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Jan	CTEC		
	MYDAYIS								
AB2	+ TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Jan	CTEC		
AB2	+	6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Jan	CTEC		
AB2	+	9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Jan	CTEC		
AB2	+!	12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Jan	CTEC		

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE									
AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Feb	CAHN		
AA		10MG	A212901	002	May 22, 2020	Feb	CAHN		
	@ SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Mar	DISC		
	@	10MG	A214574	002	Jan 27, 2021	Mar	DISC		
	EVEKEO								
AA	AZURITY	5MG	A200166	001	Aug 09, 2012	Mar	CAHN		
AA	!	10MG	A200166	002	Aug 09, 2012	Mar	CAHN		
TABLET, ORALLY DISINTEGRATING;ORAL									
EVEKEO ODT									
	+ @ AZURITY	5MG	N209905	001	Jan 30, 2019	Apr	DISC		
	+ @	10MG	N209905	002	Jan 30, 2019	Apr	DISC		
	+ @	15MG	N209905	003	Jan 30, 2019	Apr	DISC		

TABLET, ORALLY DISINTEGRATING;ORAL
EVEKEO ODT

+ @ 20MG N209905 004 Jan 30, 2019 Apr DISC

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL
AMPICILLIN TRIHYDRATE

@ ENDO OPERATIONS EQ 125MG BASE/5ML A062982 001 Feb 10, 1989 May CAHN
@ EQ 250MG BASE/5ML A062982 002 Feb 10, 1989 May CAHN

APIXABAN

TABLET;ORAL
APIXABAN

@ APOTEX 2.5MG A210091 001 Feb 16, 2024 May DISC
AB 2.5MG A210091 001 Feb 16, 2024 Feb NEWA
@ 5MG A210091 002 Feb 16, 2024 May DISC
AB 5MG A210091 002 Feb 16, 2024 Feb NEWA

APREMILAST

TABLET;ORAL
APREMILAST

AB MANKIND PHARMA 10MG A211734 001 Feb 07, 2024 Jan NEWA
AB 20MG A211734 002 Feb 07, 2024 Jan NEWA
AB 30MG A211734 003 Feb 07, 2024 Jan NEWA

APROCITENTAN

TABLET;ORAL
TRYVIO

+! IDORSIA 12.5MG N217686 001 Mar 19, 2024 Mar NEWA

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION
ARFORMOTEROL TARTRATE

AN CF PHARMTECH EQ 0.015MG BASE/2ML A216303 001 May 17, 2024 May NEWA
AN DR REDDYS EQ 0.015MG BASE/2ML A215032 001 Jun 03, 2024 May NEWA
AN PHARMAMAX EQ 0.015MG BASE/2ML A214901 001 Apr 02, 2024 Mar NEWA

ARIPIPRAZOLE

TABLET;ORAL
ARIPIPRAZOLE

AB LUPIN 2MG A205589 001 Mar 18, 2024 Mar NEWA
AB 5MG A205589 002 Mar 18, 2024 Mar NEWA
AB 10MG A205589 003 Mar 18, 2024 Mar NEWA
AB 15MG A205589 004 Mar 18, 2024 Mar NEWA
AB 20MG A205589 005 Mar 18, 2024 Mar NEWA
AB 30MG A205589 006 Mar 18, 2024 Mar NEWA

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA INITIO KIT

+ ALKERMES INC 675MG/2.4ML (281.25MG/ML) N209830 001 Jun 29, 2018 Jan CPOT

ASCIMINIB HYDROCHLORIDE

TABLET;ORAL
SCEMBLIX

+ NOVARTIS EQ 100MG BASE N215358 003 Apr 18, 2024 Apr NEWA

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

>A> AA PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID
TARO 4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM A207498 001 Jun 28, 2024 Jun NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
LANORINAL

AA ! SANDOZ 325MG;50MG;40MG A086996 002 Oct 11, 1985 Jan CAHN

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL
ASPIRIN AND DIPYRIDAMOLE

AB ENDO OPERATIONS 25MG;200MG A207944 001 Jan 18, 2017 Apr CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL
PERCODAN

AA +! ENDO OPERATIONS 325MG;4.8355MG N007337 007 Aug 05, 2005 May CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL
PERCODAN

@ ENDO OPERATIONS 325MG;4.5MG;0.38MG N007337 006 May CAHN

PERCODAN-DEMI
@ ENDO OPERATIONS 325MG;2.25MG;0.19MG N007337 005 May CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	APOTEX	EQ 10MG BASE	A078983	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A078983	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A078983	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A078983	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A078983	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A078983	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A078983	007	May 30, 2017	Mar	CPOT
AB	AUROBINDO PHARMA	EQ 10MG BASE	A079016	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079016	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079016	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079016	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079016	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079016	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079016	007	May 30, 2017	Mar	CPOT
AB	DR REDDYS	EQ 10MG BASE	A090609	001	Feb 23, 2018	Mar	CPOT
AB		EQ 18MG BASE	A090609	002	Feb 23, 2018	Mar	CPOT
AB		EQ 25MG BASE	A090609	003	Feb 23, 2018	Mar	CPOT
AB		EQ 40MG BASE	A090609	004	Feb 23, 2018	Mar	CPOT
AB		EQ 60MG BASE	A090609	005	Feb 23, 2018	Mar	CPOT
AB		EQ 80MG BASE	A090609	006	Feb 23, 2018	Mar	CPOT
AB		EQ 100MG BASE	A090609	007	Feb 23, 2018	Mar	CPOT
AB	GLENMARK PHARMS LTD	EQ 10MG BASE	A079019	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079019	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079019	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079019	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079019	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079019	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079019	007	May 30, 2017	Mar	CPOT
AB	HETERO LABS LTD V	EQ 10MG BASE	A202682	001	Mar 11, 2021	Mar	CPOT
AB		EQ 18MG BASE	A202682	002	Mar 11, 2021	Mar	CPOT
AB		EQ 25MG BASE	A202682	003	Mar 11, 2021	Mar	CPOT
AB		EQ 40MG BASE	A202682	004	Mar 11, 2021	Mar	CPOT
AB		EQ 60MG BASE	A202682	005	Mar 11, 2021	Mar	CPOT
AB		EQ 80MG BASE	A202682	006	Mar 11, 2021	Mar	CPOT
AB		EQ 100MG BASE	A202682	007	Mar 11, 2021	Mar	CPOT
	@ STRIDES PHARMA	EQ 10MG BASE	A079021	001	Feb 18, 2021	Mar	CPOT
	@	EQ 18MG BASE	A079021	002	Feb 18, 2021	Mar	CPOT
	@	EQ 25MG BASE	A079021	003	Feb 18, 2021	Mar	CPOT
	@	EQ 40MG BASE	A079021	004	Feb 18, 2021	Mar	CPOT
	@	EQ 60MG BASE	A079021	005	Feb 18, 2021	Mar	CPOT
	@	EQ 80MG BASE	A079021	006	Feb 18, 2021	Mar	CPOT
	@	EQ 100MG BASE	A079021	007	Feb 18, 2021	Mar	CPOT
AB	TEVA PHARMS USA	EQ 10MG BASE	A079022	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079022	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079022	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079022	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079022	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079022	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079022	007	May 30, 2017	Mar	CPOT
AB	ZYDUS PHARMS USA INC	EQ 10MG BASE	A079017	007	Apr 05, 2023	Mar	CPOT
AB		EQ 18MG BASE	A079017	001	Sep 16, 2010	Mar	CPOT
AB		18MG	A079017	001	Sep 16, 2010	Jan	CMS1

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		EQ 25MG BASE	A079017	002	Sep 16, 2010	Mar	CPOT
AB		25MG	A079017	002	Sep 16, 2010	Jan	CMS1
AB		EQ 40MG BASE	A079017	003	Sep 16, 2010	Mar	CPOT
AB		40MG	A079017	003	Sep 16, 2010	Jan	CMS1
AB		EQ 60MG BASE	A079017	004	Sep 16, 2010	Mar	CPOT
AB		60MG	A079017	004	Sep 16, 2010	Jan	CMS1
AB		EQ 80MG BASE	A079017	005	Sep 16, 2010	Mar	CPOT
AB		80MG	A079017	005	Sep 16, 2010	Jan	CMS1
AB		EQ 100MG BASE	A079017	006	Sep 16, 2010	Mar	CPOT
AB		100MG	A079017	006	Sep 16, 2010	Jan	CMS1

STRATTERA

@ LILLY

		EQ 5MG BASE	N021411	001	Nov 26, 2002	Mar	CPOT
AB	+	EQ 10MG BASE	N021411	002	Nov 26, 2002	Mar	CPOT
AB	+	EQ 18MG BASE	N021411	003	Nov 26, 2002	Mar	CPOT
AB	+	EQ 25MG BASE	N021411	004	Nov 26, 2002	Mar	CPOT
AB	+	EQ 40MG BASE	N021411	005	Nov 26, 2002	Mar	CPOT
AB	+	EQ 60MG BASE	N021411	006	Nov 26, 2002	Mar	CPOT
AB	+	EQ 80MG BASE	N021411	007	Feb 14, 2005	Mar	CPOT
AB	+	EQ 100MG BASE	N021411	008	Feb 14, 2005	Mar	CPOT

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		ANBISON LAB	EQ 10MG BASE	A211886	001	Jan 25, 2024	Jan	NEWA
AB			EQ 20MG BASE	A211886	002	Jan 25, 2024	Jan	NEWA
AB			EQ 40MG BASE	A211886	003	Jan 25, 2024	Jan	NEWA
AB			EQ 80MG BASE	A211886	004	Jan 25, 2024	Jan	NEWA
AB		AUROBINDO PHARMA LTD	EQ 10MG BASE	A217118	001	Feb 13, 2024	Feb	NEWA
AB			EQ 20MG BASE	A217118	002	Feb 13, 2024	Feb	NEWA
AB			EQ 40MG BASE	A217118	003	Feb 13, 2024	Feb	NEWA
AB			EQ 80MG BASE	A217118	004	Feb 13, 2024	Feb	NEWA
		@ CADILA PHARMS LTD	EQ 10MG BASE	A212103	001	Oct 16, 2023	Apr	DISC
		@	EQ 20MG BASE	A212103	002	Oct 16, 2023	Apr	DISC
		@	EQ 40MG BASE	A212103	003	Oct 16, 2023	Apr	DISC
		@	EQ 80MG BASE	A212103	004	Oct 16, 2023	Apr	DISC
		@ INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017	Mar	DISC
		@	EQ 20MG BASE	A204846	002	Jan 09, 2017	Mar	DISC
		@	EQ 40MG BASE	A204846	003	Jan 09, 2017	Mar	DISC
		@	EQ 80MG BASE	A204846	004	Jan 09, 2017	Mar	DISC
AB		LAURUS	EQ 10MG BASE	A214513	001	Jan 22, 2024	Jan	NEWA
AB			EQ 20MG BASE	A214513	002	Jan 22, 2024	Jan	NEWA
AB			EQ 40MG BASE	A214513	003	Jan 22, 2024	Jan	NEWA
AB			EQ 80MG BASE	A214513	004	Jan 22, 2024	Jan	NEWA
>D>	AB	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Jun	CTEC
>A>	BX		EQ 10MG BASE	A204991	001	Mar 06, 2019	Jun	CTEC
>D>	AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Jun	CTEC
>A>	BX		EQ 20MG BASE	A204991	002	Mar 06, 2019	Jun	CTEC
>D>	AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Jun	CTEC
>A>	BX		EQ 40MG BASE	A204991	003	Mar 06, 2019	Jun	CTEC
>D>	AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Jun	CTEC
>A>	BX		EQ 80MG BASE	A204991	004	Mar 06, 2019	Jun	CTEC
AB		MACLEODS PHARMS LTD	EQ 10MG BASE	A208480	001	Jun 03, 2024	May	NEWA
AB			EQ 20MG BASE	A208480	002	Jun 03, 2024	May	NEWA
AB			EQ 40MG BASE	A208480	003	Jun 03, 2024	May	NEWA
AB			EQ 80MG BASE	A208480	004	Jun 03, 2024	May	NEWA
AB		SHANDONG XINHUA	EQ 10MG BASE	A211886	001	Jan 25, 2024	Mar	CAHN
AB			EQ 20MG BASE	A211886	002	Jan 25, 2024	Mar	CAHN
AB			EQ 40MG BASE	A211886	003	Jan 25, 2024	Mar	CAHN
AB			EQ 80MG BASE	A211886	004	Jan 25, 2024	Mar	CAHN
>D>	AB	UMEDICA	EQ 10MG BASE	A213853	001	Aug 19, 2020	Jun	CTEC
>A>	BX		EQ 10MG BASE	A213853	001	Aug 19, 2020	Jun	CTEC
>D>	AB		EQ 20MG BASE	A213853	002	Aug 19, 2020	Jun	CTEC
>A>	BX		EQ 20MG BASE	A213853	002	Aug 19, 2020	Jun	CTEC
>D>	AB		EQ 40MG BASE	A213853	003	Aug 19, 2020	Jun	CTEC
>A>	BX		EQ 40MG BASE	A213853	003	Aug 19, 2020	Jun	CTEC
>D>	AB		EQ 80MG BASE	A213853	004	Aug 19, 2020	Jun	CTEC
>A>	BX		EQ 80MG BASE	A213853	004	Aug 19, 2020	Jun	CTEC

ATRACURIUM BESYLATEINJECTABLE; INJECTION
ATRACURIUM BESYLATE

>D>	@ MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017	Jun CAHN
>A>	@ NORVIUM BIOSCIENCE	10MG/ML	A206096	001	Jun 22, 2017	Jun CAHN
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
>D>	@ MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017	Jun CAHN
>A>	@ NORVIUM BIOSCIENCE	10MG/ML	A206001	001	Apr 07, 2017	Jun CAHN

ATROPINE SULFATESOLUTION; INTRAVENOUS
ATROPINE SULFATE

>A>	AP	SOMERSET THERAPS LLC	0.4MG/ML (0.4MG/ML)	A215969	001	Jul 03, 2024	Jun NEWA
>A>	AP		1MG/ML (1MG/ML)	A215969	002	Jul 03, 2024	Jun NEWA

SOLUTION/DROPS; OPHTHALMIC
ATROPINE SULFATE

AT1	!	AMNEAL	1%	A214752	001	Jul 14, 2022	Apr CTEC
AT1		APOTEX	1%	A215624	001	Nov 26, 2021	Apr CTEC
AT1		MANKIND PHARMA	1%	A218148	001	Jan 08, 2024	Apr CTEC
AT1	+	RISING	1%	N206289	001	Jul 18, 2014	Apr CTEC
AT2		SOMERSET	1%	A217791	001	Apr 29, 2024	Apr NFTG
>A>	AT1	SOMERSET THERAPS LLC	1%	A215618	001	Jul 01, 2024	Jun NEWA
		ISOPTO ATROPINE					
AT2	+	ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Apr CFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	@ ANI PHARMS	0.025MG; 2.5MG	A086727	001			Mar DISC
	@ MYLAN	0.025MG; 2.5MG	A085762	001			Apr DISC

AVACINCAPTAD PEGOL SODIUMSOLUTION; INTRAVITREAL
IZERVAY

+	!	ASTELLAS	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023	Jan CAHN
---	---	----------	---------------------------------------	---------	-----	--------------	----------

AVANAFIL

TABLET; ORAL

AVANAFIL

>A>	AB	HETERO LABS LTD V	50MG	A209266	001	Jun 14, 2024	Jun NFTG
>A>	AB		100MG	A209266	002	Jun 14, 2024	Jun NFTG
>A>	AB		200MG	A209266	003	Jun 14, 2024	Jun NFTG
		STENDRA					
>D>	+	METUCHEN PHARMS	50MG	N202276	001	Apr 27, 2012	Jun CFTG
>A>	AB		50MG	N202276	001	Apr 27, 2012	Jun CFTG
>D>	+		100MG	N202276	002	Apr 27, 2012	Jun CFTG
>A>	AB		100MG	N202276	002	Apr 27, 2012	Jun CFTG
>D>	+		200MG	N202276	003	Apr 27, 2012	Jun CFTG
>A>	AB		200MG	N202276	003	Apr 27, 2012	Jun CFTG

AZACITIDINEPOWDER; INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP		MSN LABS PVT LTD	100MG/VIAL	A212580	001	May 16, 2024	May NEWA
----	--	------------------	------------	---------	-----	--------------	----------

AZELAIC ACIDGEL; TOPICAL
AZELAIC ACID

AB		TARO	15%	A210549	001	Aug 23, 2019	Apr CAHN
----	--	------	-----	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDESPRAY, METERED; NASAL
AZELASTINE HYDROCHLORIDE

>D>		@ AKORN	0.2055MG/SPRAY	A210032	001	Aug 23, 2019	Jun CAHN
		@ HIKMA	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Mar DISC
>A>		@ SAPTALIS PHARMS	0.2055MG/SPRAY	A210032	001	Aug 23, 2019	Jun CAHN

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

>D>	@ MYLAN ASI	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Jun	CAHN
	@ SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	May	DISC

TABLET; ORAL

AZITHROMYCIN

	@ YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb	DISC
--	-------------------	---------------	---------	-----	--------------	-----	------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

	@ SAPTALIS PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012	May	CAHN
--	-------------------	-----------------------------------------------------	---------	-----	--------------	-----	------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

	@ SAPTALIS PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088	001	Feb 06, 2004	Apr	CAHN
--	-------------------	--------------------------------------------------	---------	-----	--------------	-----	------

>D> BACITRACIN ZINC; POLYMYXIN B SULFATE

>D> OINTMENT; OPHTHALMIC

>D> BACITRACIN ZINC AND POLYMYXIN B SULFATE

>D> AT	SAPTALIS PHARMS	500 UNITS/GM;10,000 UNITS/GM	A064028	001	Jan 30, 1995	Jun	DISC
>A>	@	500 UNITS/GM;10,000 UNITS/GM	A064028	001	Jan 30, 1995	Jun	DISC
AT		500 UNITS/GM;10,000 UNITS/GM	A064028	001	Jan 30, 1995	Mar	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

	@ ACIC PHARMS	0.5MG/ML	A216309	001	Aug 10, 2023	Jan	DISC
	@	2MG/ML	A216309	002	Aug 10, 2023	Jan	DISC

TABLET; ORAL

BACLOFEN

AB	ENDO OPERATIONS	10MG	A077068	002	Aug 30, 2005	Apr	CAHN
AB		20MG	A077068	001	Aug 30, 2005	Apr	CAHN
>D> AB	EYWA PHARMA	5MG	A211555	003	Nov 30, 2021	Jun	CTEC
>A> BX		5MG	A211555	003	Nov 30, 2021	Jun	CTEC
>D> AB		10MG	A211555	001	Feb 01, 2019	Jun	CTEC
>A> BX		10MG	A211555	001	Feb 01, 2019	Jun	CTEC
>D> AB		20MG	A211555	002	Feb 01, 2019	Jun	CTEC
>A> BX		20MG	A211555	002	Feb 01, 2019	Jun	CTEC
	@ IMPAX	5MG	A077971	003	Jul 07, 2021	Mar	DISC
	@	10MG	A077971	001	Oct 26, 2007	Mar	DISC
	@	20MG	A077971	002	Oct 26, 2007	Mar	DISC
AB	RUBICON	15MG	A209102	004	Feb 05, 2024	Feb	CTEC
		15MG	A209102	004	Feb 05, 2024	Jan	NEWA

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

AB	ZYDUS LIFESCIENCES	750MG	A217592	001	Jun 08, 2023	Mar	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

>D> AP	KINDOS	25MG/VIAL	A211001	001	Jun 05, 2023	Jun	CAHN
>D> AP		100MG/VIAL	A211001	002	Jun 05, 2023	Jun	CAHN
>A> AP	MEITHEAL	25MG/VIAL	A211001	001	Jun 05, 2023	Jun	CAHN
>A> AP		100MG/VIAL	A211001	002	Jun 05, 2023	Jun	CAHN
>D>	@ MYLAN LABS LTD	25MG/VIAL	A204104	001	Apr 28, 2023	Jun	CAHN
>D>	@	100MG/VIAL	A204104	002	Apr 28, 2023	Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	25MG/VIAL	A204104	001	Apr 28, 2023	Jun	CAHN
>A>	@	100MG/VIAL	A204104	002	Apr 28, 2023	Jun	CAHN

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	ENDO OPERATIONS	0.5MG	A040715	001	Aug 27, 2007	Apr	CAHN
AA		1MG	A040715	002	Aug 27, 2007	Apr	CAHN
AA		2MG	A040715	003	Aug 27, 2007	Apr	CAHN
	@ INVAGEN PHARMS	0.5MG	A090294	001	Mar 29, 2010	Mar	DISC
	@	1MG	A090294	002	Mar 29, 2010	Mar	DISC
	@	2MG	A090294	003	Mar 29, 2010	Mar	DISC

BERDAZIMER SODIUM

GEL; TOPICAL

ZELSUVMI

+!	LNHC	EQ 10.3% BASE	N217424	001	Jan 05, 2024	Jan	NEWA
----	------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

@ HIKMA EQ 0.05% BASE

A208849 001 Oct 11, 2019 Mar DISC

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	AUROBINDO PHARMA LTD	EQ 0.05% BASE	A218289	001	Apr 10, 2024	Mar	NEWA
	@ PADAGIS US	EQ 0.05% BASE	A206118	001	Nov 09, 2017	Jan	CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	!	TARO	EQ 0.05% BASE; 1%	A075673	001	May 29, 2001	Apr	CAHN
----	---	------	-------------------	---------	-----	--------------	-----	------

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	CHARTWELL RX	50MG	A091011	001	Jun 10, 2015	Jan	CAHN
	@ RISING	50MG	A079185	001	Jul 06, 2009	Feb	CAHN

BIMATOPROST

SOLUTION/DROPS; TOPICAL

BIMATOPROST

@ HIKMA 0.03% A203051 001 Oct 09, 2018 Mar DISC

BIRCH TRITERPENES

GEL; TOPICAL

FILSUVEZ

+!	CHIESI	10%	N215064	001	Dec 18, 2023	Jan	CAHN
----	--------	-----	---------	-----	--------------	-----	------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	HARMAN FINOCHEM	5MG	A217617	001	Jan 18, 2024	Jan	NEWA
AB		10MG	A217617	002	Jan 18, 2024	Jan	NEWA

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

@ HOSPIRA 250MG/VIAL A090816 001 Jul 14, 2015 May DISC

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

@ TEVA PHARMS USA EQ 15 UNITS BASE/VIAL A065033 001 Jun 27, 2000 Jan DISC

@ EQ 30 UNITS BASE/VIAL A065033 002 Jun 27, 2000 Jan DISC

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP	HETERO LABS LTD VI	3.5MG/VIAL	A212204	001	May 03, 2024	Apr	NEWA
>D>	@ MYLAN LABS LTD	3.5MG/VIAL	A205160	001	Oct 31, 2022	Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	3.5MG/VIAL	A205160	001	Oct 31, 2022	Jun	CAHN
AP	RELIANCE LIFE SCI	3.5MG/VIAL	A211898	001	Oct 11, 2022	May	CAHN

BOSENTAN

TABLET; ORAL

BOSENTAN

@	ENDO OPERATIONS	62.5MG	A205699	001	Apr 26, 2019	Apr	CAHN
@		125MG	A205699	002	Apr 26, 2019	Apr	CAHN

BREMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

+	COSETTE	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Apr	CAHN
---	---------	----------------------------------------------	---------	-----	--------------	-----	------

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AB	SANDOZ	0.1%	A203172	001	Mar 04, 2024	Feb	NEWA
AT	UPSHER SMITH LABS	0.15%	A216772	001	Jun 12, 2024	May	NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB	GLENMARK PHARMS LTD	0.2%; EQ 0.5% BASE	A214987	001	May 16, 2024	May	NEWA
----	---------------------	--------------------	---------	-----	--------------	-----	------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

>A>	AB	ALEMBIC	EQ 0.07% ACID	A214340	001	Jul 08, 2024	Jun	NEWA
>A>	AB	APOTEX	EQ 0.07% ACID	A207334	001	Jul 08, 2024	Jun	NEWA
	AB	LUPIN LTD	EQ 0.075% ACID	A211239	001	Feb 02, 2024	Jan	NFTG
		BROMSITE						
AB	+	SUN PHARM	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jan	CFTG

BUDESONIDE

AEROSOL, FOAM; RECTAL

BUDESONIDE

>D>	AB	PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Jun	CHRS	
>A>	AB	!	2MG/ACTUATION	A215328	001	Apr 12, 2023	Jun	CHRS	
		UCERIS							
>D>	AB	+	SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Jun	CHRS
>A>	AB	+		2MG/ACTUATION	N205613	001	Oct 07, 2014	Jun	CHRS

POWDER, METERED; INHALATION

PULMICORT FLEXHALER

>D>	+	ASTRAZENECA	0.08MG/INH	N021949	001	Jul 12, 2006	Jun	CAHN
>D>	+	!	0.16MG/INH	N021949	002	Jul 12, 2006	Jun	CAHN
>A>	+	CHEPLAPHARM	0.08MG/INH	N021949	001	Jul 12, 2006	Jun	CAHN
>A>	+	!	0.16MG/INH	N021949	002	Jul 12, 2006	Jun	CAHN

SUSPENSION; INHALATION

BUDESONIDE

@	EUGIA PHARMA	0.5MG/2ML	A216667	001	Nov 29, 2023	May	DISC
---	--------------	-----------	---------	-----	--------------	-----	------

SUSPENSION; ORAL

EOHILIA

+	TAKEDA PHARMS USA	2MG/10ML	N213976	001	Feb 09, 2024	Feb	NEWA
---	-------------------	----------	---------	-----	--------------	-----	------

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

@	HOSPIRA	0.25MG/ML	A074332	001	Oct 31, 1994	May	DISC
---	---------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

BUMETANIDE

>D>	BX	RISING	0.5MG	A212019	001	Dec 12, 2019	Jun	CTEC
>A>	AB		0.5MG	A212019	001	Dec 12, 2019	Jun	CTEC
>D>	BX		1MG	A212019	002	Dec 12, 2019	Jun	CTEC
>A>	AB		1MG	A212019	002	Dec 12, 2019	Jun	CTEC
>D>	BX		2MG	A212019	003	Dec 12, 2019	Jun	CTEC
>A>	AB		2MG	A212019	003	Dec 12, 2019	Jun	CTEC

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

>A>		BUPIVACAINE LIPOSOME							
>A>	AP	HENGRUI PHARMA	133MG/10ML (13.3MG/ML)	A214348	001	Jul 01, 2024	Jun	NFTG	
>A>	AP		266MG/20ML (13.3MG/ML)	A214348	002	Jul 01, 2024	Jun	NFTG	
		EXPAREL							
>D>	+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Jun	CFTG	
>A>	AP	+	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Jun	CFTG	
>D>	+		266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Jun	CFTG	
>A>	AP	+	266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Jun	CFTG	

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

	AP	ASPIRO	0.25%	A217821	001	Mar 27, 2024	Mar	NEWA	
	AP		0.5%	A217821	002	Mar 27, 2024	Mar	NEWA	
	AP		0.75%	A217821	003	Mar 27, 2024	Mar	NEWA	
>D>	AP	KINDOS	0.25%	A216039	001	Jun 23, 2023	Jun	CAHN	
>D>	AP		0.25%	A216040	001	Dec 27, 2023	Jun	CAHN	
>D>	AP		0.5%	A216039	002	Jun 23, 2023	Jun	CAHN	
>D>	AP		0.5%	A216040	002	Dec 27, 2023	Jun	CAHN	
>D>	AP		0.75%	A216040	003	Dec 27, 2023	Jun	CAHN	
>A>	AP	MEITHEAL	0.25%	A216039	001	Jun 23, 2023	Jun	CAHN	
>A>	AP		0.25%	A216040	001	Dec 27, 2023	Jun	CAHN	
>A>	AP		0.5%	A216039	002	Jun 23, 2023	Jun	CAHN	
>A>	AP		0.5%	A216040	002	Dec 27, 2023	Jun	CAHN	
>A>	AP		0.75%	A216040	003	Dec 27, 2023	Jun	CAHN	

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

VIVACAINE

!	SEPTODONT	0.5%; 0.0091MG/ML		A077250	001	Sep 27, 2006	Jan	CTNA	
---	-----------	-------------------	--	---------	-----	--------------	-----	------	--

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION

PROBUPHINE

+	@	REACX PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Apr	CAHN	
---	---	--------------	----------------------	---------	-----	--------------	-----	------	--

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

@	AM	REGENT	EQ 0.3MG BASE/ML	A078331	001	Mar 27, 2007	Jan	DISC	
---	----	--------	------------------	---------	-----	--------------	-----	------	--

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

>D>	@	MYLAN	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun	CAHN	
>D>	@		EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun	CAHN	
>A>	@	NORVIUM BIOSCIENCE	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun	CAHN	
>A>	@		EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun	CAHN	

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB		AUROBINDO PHARMA USA	75MG	A075491	001	Apr 17, 2000	Apr	CMFD	
AB			100MG	A075491	002	Apr 17, 2000	Apr	CMFD	
	@	INVAGEN PHARMS	75MG	A207389	001	Sep 18, 2017	Mar	DISC	
	@		100MG	A207389	002	Sep 18, 2017	Mar	DISC	

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@	ANCHEN	PHARMS	100MG	A091459	001	Jun 09, 2011	Feb	DISC	
@			150MG	A091459	002	Jun 09, 2011	Feb	DISC	
@			150MG	A091520	001	Jun 09, 2011	Feb	DISC	
@			200MG	A091459	003	Jun 09, 2011	Feb	DISC	
@	ENDO	OPERATIONS	100MG	A091459	001	Jun 09, 2011	May	CAHN	
@			150MG	A077284	001	Dec 14, 2006	May	CAHN	
@			150MG	A091459	002	Jun 09, 2011	May	CAHN	
@			150MG	A091520	001	Jun 09, 2011	May	CAHN	
@			200MG	A091459	003	Jun 09, 2011	May	CAHN	
@			300MG	A077284	002	Dec 14, 2006	May	CAHN	
@	INVAGEN	PHARMS	100MG	A206674	001	Feb 09, 2016	Mar	DISC	
@			150MG	A206556	001	Aug 26, 2016	Mar	DISC	
@			150MG	A206674	002	Feb 09, 2016	Mar	DISC	
@			200MG	A206674	003	Feb 09, 2016	Mar	DISC	
@			300MG	A206556	002	Aug 26, 2016	Mar	DISC	

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE							
	@ RISING	150MG	A090941	001	May 03, 2010	Feb	CAHN
	@ SUN PHARM	200MG	A078866	003	Apr 06, 2010	May	DISC
AB3	TWI PHARMS	150MG	A210081	001	Nov 03, 2017	Mar	CAHN
AB3		300MG	A210081	002	Nov 03, 2017	Mar	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL							
BUSPIRONE HYDROCHLORIDE							
AB	AIPING PHARM INC	5MG	A202087	001	Dec 16, 2015	Jan	CAHN
AB		10MG	A202087	002	Dec 16, 2015	Jan	CAHN
AB		15MG	A202087	003	Dec 16, 2015	Jan	CAHN
AB		30MG	A202087	004	Dec 16, 2015	Jan	CAHN
	@ AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	Mar	DISC
	@	7.5MG	A208829	002	May 24, 2017	Mar	DISC
	@	10MG	A208829	003	May 24, 2017	Mar	DISC
	@	15MG	A208829	004	May 24, 2017	Mar	DISC
	@	30MG	A208829	005	May 24, 2017	Mar	DISC

BUSULFAN

INJECTABLE;INJECTION							
BUSULFAN							
>A>	AP EUGIA PHARMA	6MG/ML	A215102	001	Jun 25, 2024	Jun	NEWA
>D>	@ MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018	Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	6MG/ML	A205184	001	Jul 13, 2018	Jun	CAHN

BUTABARBITAL SODIUM

TABLET;ORAL							
BUTISOL SODIUM							
>D>	@ MYLAN SPECIALITY LP	15MG	N000793	002		Jun	CAHN
>D>	+ @	30MG	N000793	004		Jun	CAHN
>D>	@	50MG	N000793	003		Jun	CAHN
>D>	@	100MG	N000793	005		Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	15MG	N000793	002		Jun	CAHN
>A>	+ @	30MG	N000793	004		Jun	CAHN
>A>	@	50MG	N000793	003		Jun	CAHN
>A>	@	100MG	N000793	005		Jun	CAHN

CABAZITAXEL

SOLUTION;INTRAVENOUS							
CABAZITAXEL							
>D>	+! ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Jun	DISC
>A>	+ @	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Jun	DISC
	+! ACTAVIS	60MG/6ML (10MG/ML)	N207970	001	Mar 14, 2024	Mar	NEWA

CABERGOLINE

TABLET;ORAL							
CABERGOLINE							
>D>	@ MYLAN	0.5MG	A202947	001	Dec 02, 2013	Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	0.5MG	A202947	001	Dec 02, 2013	Jun	CAHN
>A>	AB SKG PHARMA	0.5MG	A218618	001	Jun 26, 2024	Jun	NEWA

CALCIPOTRIENE

SOLUTION;TOPICAL							
CALCIPOTRIENE							
	@ HIKMA	0.005%	A077579	001	Nov 19, 2009	Mar	DISC

CALCITONIN SALMON

INJECTABLE;INJECTION							
CALCITONIN-SALMON							
AP	DR REDDYS	200 IU/ML	A215715	001	Apr 11, 2024	Apr	NEWA
	SPRAY, METERED;NASAL						
	CALCITONIN-SALMON						
	@ ENDO OPERATIONS	200 IU/SPRAY	A076979	001	Jun 08, 2009	May	CAHN

CALCIUM ACETATE

CAPSULE;ORAL							
CALCIUM ACETATE							
AB	! INVAGEN PHARMS	667MG	A203135	001	Feb 07, 2013	Apr	CHRS
	PHOSLO GELCAPS						
	+ @ FRESENIUS MEDCL	667MG	N021160	003	Apr 02, 2001	Apr	DISC

CALCIUM CHLORIDEINJECTABLE; INJECTION
CALCIUM CHLORIDE

>A>	AP	AMNEAL	100MG/ML	A217524	001	Jul 08, 2024	Jun NEWA
-----	----	--------	----------	---------	-----	--------------	----------

CALCIUM GLUCONATESOLUTION; INTRAVENOUS
CALCIUM GLUCONATE

AP	AMNEAL	1GM/10ML (100MG/ML)	A216611	001	May 10, 2024	May NEWA
AP		5GM/50ML (100MG/ML)	A216611	002	May 10, 2024	May NEWA
AP		10GM/100ML (100MG/ML)	A216611	003	May 10, 2024	May NEWA
AP	NIVAGEN PHARMS INC	10GM/100ML (100MG/ML)	A213071	003	Apr 30, 2024	Apr NEWA

CAPECITABINETABLET; ORAL
CAPECITABINE

AB	HETERO LABS LTD V	150MG	A210203	001	Mar 05, 2024	Feb NEWA
AB		500MG	A210203	002	Mar 05, 2024	Feb NEWA

CAPREOMYCIN SULFATEINJECTABLE; INJECTION
CAPREOMYCIN SULFATE

>D>	@ MYLAN LABS LTD	EQ 1GM BASE/VIAL	A202634	001	Nov 27, 2017	Jun CAHN
>A>	@ NORVIUM BIOSCIENCE	EQ 1GM BASE/VIAL	A202634	001	Nov 27, 2017	Jun CAHN

CAPTOPRILTABLET; ORAL
CAPTOPRIL

AB	INNOGENIX	12.5MG	A074677	004	May 30, 1997	Mar CAHN
AB		25MG	A074677	002	May 30, 1997	Mar CAHN
AB		50MG	A074677	001	May 30, 1997	Mar CAHN
AB		100MG	A074677	003	May 30, 1997	Mar CAHN
AB	STASON PHARMS	12.5MG	A074677	004	May 30, 1997	Feb CAHN
AB		25MG	A074677	002	May 30, 1997	Feb CAHN
AB		50MG	A074677	001	May 30, 1997	Feb CAHN
AB		100MG	A074677	003	May 30, 1997	Feb CAHN

CARBAMAZEPINETABLET; ORAL
CARBAMAZEPINE

AB	BIONPHARMA	200MG	A218221	001	Feb 16, 2024	Feb NEWA
>D>	AB	UMEDICA	A207798	001	Apr 15, 2020	Jun CTEC
>A>	BX	100MG	A207798	001	Apr 15, 2020	Jun CTEC
>D>	AB	200MG	A207798	002	Apr 15, 2020	Jun CTEC
>A>	BX	200MG	A207798	002	Apr 15, 2020	Jun CTEC

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

	@ AMNEAL PHARMS	100MG	A212704	001	Sep 22, 2023	Feb DISC
	@	200MG	A212704	002	Sep 22, 2023	Feb DISC
	@	400MG	A212704	003	Sep 22, 2023	Feb DISC
	@ APOTEX	100MG	A213159	001	Mar 08, 2024	May DISC
AB		100MG	A213159	001	Mar 08, 2024	Mar NEWA
	@	200MG	A213159	002	Mar 08, 2024	May DISC
AB		200MG	A213159	002	Mar 08, 2024	Mar NEWA
	@	400MG	A213159	003	Mar 08, 2024	May DISC
AB		400MG	A213159	003	Mar 08, 2024	Mar NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

>D>	@ MYLAN	12.5MG; 200MG; 50MG	A203424	001	Aug 13, 2020	Jun CAHN
>D>	@	18.75MG; 200MG; 75MG	A203424	002	Aug 13, 2020	Jun CAHN
>D>	@	25MG; 200MG; 100MG	A203424	003	Aug 13, 2020	Jun CAHN
>D>	@	31.25MG; 200MG; 125MG	A203424	004	Aug 13, 2020	Jun CAHN
>D>	@	37.5MG; 200MG; 150MG	A203424	005	Aug 13, 2020	Jun CAHN
>D>	@	50MG; 200MG; 200MG	A203424	006	Aug 13, 2020	Jun CAHN
>A>	@ NORVIUM BIOSCIENCE	12.5MG; 200MG; 50MG	A203424	001	Aug 13, 2020	Jun CAHN
>A>	@	18.75MG; 200MG; 75MG	A203424	002	Aug 13, 2020	Jun CAHN
>A>	@	25MG; 200MG; 100MG	A203424	003	Aug 13, 2020	Jun CAHN
>A>	@	31.25MG; 200MG; 125MG	A203424	004	Aug 13, 2020	Jun CAHN
>A>	@	37.5MG; 200MG; 150MG	A203424	005	Aug 13, 2020	Jun CAHN

	TABLET;ORAL								
	CARBIDOPA, LEVODOPA AND ENTACAPONE								
>A>	@	50MG;200MG;200MG	A203424	006	Aug 13, 2020	Jun	CAHN		
	<u>CARBIDOPA; LEVODOPA</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	RYTARY								
	+ IMPAX	23.75MG;95MG	N203312	001	Jan 07, 2015	May	CAHN		
	+	36.25MG;145MG	N203312	002	Jan 07, 2015	May	CAHN		
	+	48.75MG;195MG	N203312	003	Jan 07, 2015	May	CAHN		
	+!	61.25MG;245MG	N203312	004	Jan 07, 2015	May	CAHN		
	TABLET, EXTENDED RELEASE;ORAL								
	CARBIDOPA AND LEVODOPA								
AB	RUBICON	25MG;100MG	A217482	001	Jun 04, 2024	May	NEWA		
AB		50MG;200MG	A217482	002	Jun 04, 2024	May	NEWA		
	<u>CARBINOXAMINE MALEATE</u>								
	SOLUTION;ORAL								
	CARBINOXAMINE MALEATE								
	@ ENDO OPERATIONS	4MG/5ML	A040814	001	Feb 26, 2008	May	CAHN		
	TABLET;ORAL								
	CARBINOXAMINE MALEATE								
	@ INVAGEN PHARMS	4MG	A090435	001	Apr 15, 2010	Mar	DISC		
	<u>CARBOPROST TROMETHAMINE</u>								
	INJECTABLE;INJECTION								
	CARBOPROST TROMETHAMINE								
AP	MICRO LABS	EQ 0.25MG BASE/ML	A218013	001	Apr 03, 2024	Mar	NEWA		
	<u>CARMUSTINE</u>								
	INJECTABLE;INJECTION								
	CARMUSTINE								
>D>	@ MYLAN LABS LTD	100MG/VIAL	A215368	001	Mar 03, 2023	Jun	CAHN		
>A>	@ NORVIUM BIOSCIENCE	100MG/VIAL	A215368	001	Mar 03, 2023	Jun	CAHN		
	POWDER;INTRAVENOUS								
	CARMUSTINE								
	+ @ ACCORD HLTHCARE	50MG/VIAL	N215000	001	May 16, 2022	May	DISC		
	+ @	300MG/VIAL	N215000	002	May 16, 2022	May	DISC		
	<u>CARVEDILOL</u>								
	TABLET;ORAL								
	CARVEDILOL								
	@ MYLAN	3.125MG	A077316	001	Sep 05, 2007	Apr	DISC		
	@ SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Jan	DISC		
	@	6.25MG	A076989	002	Sep 05, 2007	Jan	DISC		
	@	12.5MG	A076989	003	Sep 05, 2007	Jan	DISC		
	@	25MG	A076989	004	Sep 05, 2007	Jan	DISC		
	COREG								
AB	+ WAYLIS THERAP	3.125MG	N020297	004	May 29, 1997	Apr	CAHN		
AB	+	6.25MG	N020297	003	Sep 14, 1995	Apr	CAHN		
AB	+!	12.5MG	N020297	002	Sep 14, 1995	Apr	CAHN		
AB	+	25MG	N020297	001	Sep 14, 1995	Apr	CAHN		
	<u>CARVEDILOL PHOSPHATE</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	COREG CR								
AB	+ WAYLIS THERAP	10MG	N022012	001	Oct 20, 2006	Apr	CAHN		
AB	+	20MG	N022012	002	Oct 20, 2006	Apr	CAHN		
AB	+!	40MG	N022012	003	Oct 20, 2006	Apr	CAHN		
AB	+	80MG	N022012	004	Oct 20, 2006	Apr	CAHN		
	<u>CASPOFUNGIN ACETATE</u>								
	POWDER;INTRAVENOUS								
	CASPOFUNGIN ACETATE								
AP	AREVA PHARMS	50MG/VIAL	A211263	001	Oct 01, 2021	Mar	CAHN		
AP		70MG/VIAL	A211263	002	Oct 01, 2021	Mar	CAHN		

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

	QILU	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan	NEWA
	SOLUTION; INTRAVENOUS						
	CEFAZOLIN IN DEXTROSE						
+	!	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	May CTNA
+	!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	May CTNA
+	!		EQ 3GM BASE/150ML (EQ 20MG BASE/ML)	N207131	003	May 31, 2024	May NEWA

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

>A>	@	CHARTWELL RX	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jun CAHN
>A>	@		EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jun CAHN
>A>	@		EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jun CAHN
>D>	@	FOSUN PHARMA	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jun CAHN
>D>	@		EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jun CAHN
>D>	@		EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jun CAHN
AP		HIKMA	EQ 1GM BASE/VIAL	A214402	001	May 22, 2024	May NEWA
AP			EQ 2GM BASE/VIAL	A214402	002	May 22, 2024	May NEWA

POWDER; INTRAVENOUS

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

!	SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018	Apr	CHRS
---	--------------	---------------	---------	-----	--------------	-----	------

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM

POWDER; INTRAVENOUS

EXBLIFEP

+	@	ALLECRA THERAPS	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	May DISC
+	!		EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

+	@	STERIMAX	EQ 500MG BASE/VIAL	N050547	001		Jan CAHN
+	@		EQ 1GM BASE/VIAL	N050547	002		Jan CAHN
+	@		EQ 2GM BASE/VIAL	N050547	003		Jan CAHN
+	@		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan CAHN

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	STERIMAX	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jan	CAHN
---	----------	-----------------	---------	-----	--------------	-----	------

@

		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN
--	--	-----------------	---------	-----	--------------	-----	------

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	STERIMAX	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
---	----------	-----------------	---------	-----	--------------	-----	------

@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN
---	--	-----------------	---------	-----	--------------	-----	------

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

AP	+	PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb CMFD
AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb CMFD

CEFOTETAN

AP	!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	Feb CTEC
----	---	--------------------	------------------	---------	-----	--------------	----------

AP	!		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	Feb CTEC
----	---	--	------------------	---------	-----	--------------	----------

CEFPROZIL

TABLET; ORAL

CEFPROZIL

AB		ALKEM LABS LTD	250MG	A090857	001	Apr 09, 2024	Mar NEWA
AB			500MG	A090857	002	Apr 09, 2024	Mar NEWA

CEFTOBIPROLE MEDOCARIL SODIUM

POWDER; INTRAVENOUS

ZEVTERA

+	!	BASILEA PHARM ALLSCH	667MG/VIAL	N218275	001	Apr 03, 2024	Apr NEWA
---	---	----------------------	------------	---------	-----	--------------	----------

CEFTRIAZONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
 CEFTRIAZONE

	@ ASTRAL	EQ 250MG BASE/VIAL	A091049	001	Jun 11, 2018	Apr	DISC
	@	EQ 500MG BASE/VIAL	A091049	002	Jun 11, 2018	Apr	DISC
	@	EQ 1GM BASE/VIAL	A091049	003	Jun 11, 2018	Apr	DISC
	@	EQ 2GM BASE/VIAL	A091049	004	Jun 11, 2018	Apr	DISC
AP	DEVA HOLDING AS	EQ 250MG BASE/VIAL	A210197	001	Jan 12, 2024	Jan	NEWA
AP		EQ 500MG BASE/VIAL	A210197	002	Jan 12, 2024	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A210197	003	Jan 12, 2024	Jan	NEWA
AP		EQ 2GM BASE/VIAL	A210197	004	Jan 12, 2024	Jan	NEWA

CELECOXIB

SOLUTION; ORAL
 ELYXYB

>D>	+!	SCILEX HLDG	25MG/ML	N212157	001	May 05, 2020	Jun	CAHN
>A>	+!	SCILEX PHARMS	25MG/ML	N212157	001	May 05, 2020	Jun	CAHN

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL
 CETIRIZINE HYDROCHLORIDE

	@	ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010	Feb	CDFR
AA		AMNEAL PHARMS	5MG/5ML	A090766	001	Oct 07, 2009	Feb	CDFR
	@	APOZEAL PHARMS	5MG/5ML	A078870	001	Apr 27, 2009	Feb	CDFR
	@	AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009	Feb	CDFR
AA		BAJAJ	5MG/5ML	A090191	001	Nov 12, 2009	Feb	CDFR
AA		BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	Feb	CDFR
AA		CHARTWELL MOLECULAR	5MG/5ML	A078876	001	May 11, 2012	Feb	CDFR
	@	LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	Feb	CDFR
AA	!	PADAGIS US	5MG/5ML	A078398	001	Jun 17, 2008	Feb	CDFR
AA		PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Feb	CDFR
	@	RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008	Feb	CDFR
AA		TARO	5MG/5ML	A076601	001	Jun 20, 2008	Feb	CDFR
	@	TEVA PHARMS	5MG/5ML	A077279	001	May 27, 2008	Mar	DISC
AA			5MG/5ML	A077279	001	May 27, 2008	Feb	CDFR
	@	WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Feb	CDFR
		ZYRTEC						
	@	J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb	CDFR

SYRUP; ORAL

AA		PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Jan	CMFD
----	--	-------------	---------	---------	-----	--------------	-----	------

CETRORELIX ACETATE

POWDER; SUBCUTANEOUS
 CETRORELIX ACETATE

AP		GLAND	EQ 0.25MG BASE/VIAL	A218150	001	Apr 25, 2024	Apr	NEWA
AP		LIVZON GRP	EQ 0.25MG BASE/VIAL	A214540	001	Apr 24, 2024	Apr	NEWA
AP		QILU	EQ 0.25MG BASE/VIAL	A217776	001	Apr 16, 2024	Apr	NEWA

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
 CHLORAMPHENICOL SODIUM SUCCINATE

	@	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982	Feb	DISC
--	---	--------------------	------------------	---------	-----	--------------	-----	------

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL
 CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

>A>	AB	WINDER LABS LLC	5MG; 2.5MG	A212344	001	Jul 08, 2024	Jun	NEWA
-----	----	-----------------	------------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
 CHLORHEXIDINE GLUCONATE

>D>		@ AKORN	0.12%	A074356	001	May 07, 1996	Jun	CAHN
>A>		@ SAPTALIS PHARMS	0.12%	A074356	001	May 07, 1996	Jun	CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
 CHLOROTHIAZIDE SODIUM

	@	RK PHARMA	EQ 500MG BASE/VIAL	A202493	001	Jun 18, 2014	Mar	DISC
--	---	-----------	--------------------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP	DR REDDYS	25MG/ML	A 080365	001		Apr	CMFD
>A>	AP	+! HIKMA	25MG/ML	A 083329	001	Jun	CAHN
>D>	AP	+! WEST-WARD PHARMS INT	25MG/ML	A 083329	001	Jun	CAHN
AP	ZYDUS PHARMS	25MG/ML	A 217275	001	Mar 13, 2024	Mar	NEWA

SYRUP; ORAL

SONAZINE

@ CHARTWELL RX 10MG/5ML

A 083040 001 May CAHN

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	ZAMEER PHARMS	10MG	A 212630	001	Nov 29, 2021	Feb	CAHN
AB		25MG	A 212630	002	Nov 29, 2021	Feb	CAHN
AB		50MG	A 212630	003	Nov 29, 2021	Feb	CAHN
AB		100MG	A 212630	004	Nov 29, 2021	Feb	CAHN
AB		200MG	A 212630	005	Nov 29, 2021	Feb	CAHN

CHLORZOAZONE

TABLET; ORAL

CHLORZOAZONE

	@ APTAPHARMA INC	375MG	A 212053	001	Sep 14, 2020	Apr	DISC
	@	750MG	A 212053	002	Sep 14, 2020	Apr	DISC
AB	ENDO OPERATIONS	375MG	A 212743	002	Apr 29, 2021	Apr	CAHN
AB		750MG	A 212743	001	Nov 02, 2020	Apr	CAHN
AA	HAVIX	500MG	A 210961	001	Jan 22, 2024	Jan	NEWA
AA	SENORES PHARMS	250MG	A 215158	001	Jul 29, 2021	Feb	CAHN
AA		500MG	A 210961	001	Jan 22, 2024	Feb	CAHN

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE LIGHT

AB	ENDO OPERATIONS	EQ 4GM RESIN/PACKET	A 077203	001	Aug 26, 2005	May	CAHN
AB		EQ 4GM RESIN/SCOOPFUL	A 077203	002	Aug 26, 2005	May	CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

	@ ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A 201573	002	Jul 18, 2013	Mar	DISC
	@	EQ 135MG FENOFIBRIC ACID	A 201573	001	Jul 18, 2013	Mar	DISC
	@ ENDO OPERATIONS	EQ 45MG FENOFIBRIC ACID	A 201573	002	Jul 18, 2013	May	CAHN
	@	EQ 135MG FENOFIBRIC ACID	A 201573	001	Jul 18, 2013	May	CAHN
AB	MACLEODS PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A 207796	001	Feb 08, 2024	Feb	NEWA
AB		EQ 135MG FENOFIBRIC ACID	A 207796	002	Feb 08, 2024	Feb	NEWA
AB	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A 210469	001	Jul 05, 2019	Mar	CAHN
AB		EQ 135MG FENOFIBRIC ACID	A 210469	002	Jul 05, 2019	Mar	CAHN

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	TARO	0.77%	A 076790	001	Apr 12, 2005	Jan	CAHN
----	------	-------	----------	-----	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

@ HIKMA 8% A 078270 001 Sep 18, 2007 Mar DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

>D>	@ CASI PHARMS INC	50MG	A 077310	001	Nov 08, 2005	Jun	CAHN
>D>	@	100MG	A 077021	001	Nov 23, 2004	Jun	CAHN
>A>	@ CHARTWELL RX	50MG	A 077310	001	Nov 08, 2005	Jun	CAHN
>A>	@	100MG	A 077021	001	Nov 23, 2004	Jun	CAHN
	@ RISING	50MG	A 077323	002	Apr 20, 2006	Feb	CAHN
	@	100MG	A 077323	001	Apr 20, 2006	Feb	CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

>A>	@ COSETTE	EQ 300MG BASE/2ML	A 074296	001	Mar 28, 1997	Jun	CAHN
	@ ENDO OPERATIONS	EQ 300MG BASE/2ML	A 074005	001	Aug 31, 1994	May	CAHN
	@	EQ 300MG BASE/2ML	A 074428	001	Apr 25, 1996	May	CAHN

	INJECTABLE; INJECTION								
	CIMETIDINE HYDROCHLORIDE								
>D>	@ HOSPIRA	EQ 300MG BASE/2ML	A 074296	001	Mar 28, 1997	Jun	CAHN		
	SOLUTION; ORAL								
	CIMETIDINE HYDROCHLORIDE								
	@ PAI HOLDINGS PHARM	EQ 300MG BASE/5ML	A 074664	001	Oct 28, 1997	Feb	DISC		
	@ PHARM ASSOC	EQ 300MG BASE/5ML	A 074553	001	Jan 27, 1997	Feb	DISC		
	<u>CIPROFLOXACIN HYDROCHLORIDE</u>								
	SOLUTION/DROPS; OPHTHALMIC								
	CIPROFLOXACIN HYDROCHLORIDE								
>D>	@ PAI HOLDINGS PHARM	EQ 0.3% BASE	A 076754	001	Jun 09, 2004	Jun	CAHN		
	@ SAPTALIS PHARMS	EQ 0.3% BASE	A 076555	001	Dec 11, 2008	Mar	CAHN		
>A>	@ THE J MOLNER	EQ 0.3% BASE	A 076754	001	Jun 09, 2004	Jun	CAHN		
	SOLUTION/DROPS; OTIC								
	CETRALAX								
	+! KEY THERAP	EQ 0.2% BASE	N 021918	001	May 01, 2009	Apr	CAHN		
	TABLET; ORAL								
	CIPROFLOXACIN HYDROCHLORIDE								
AB	AIPING PHARM INC	EQ 250MG BASE	A 076593	002	Jun 09, 2004	Apr	CMFD		
AB		EQ 500MG BASE	A 076593	003	Jun 09, 2004	Apr	CMFD		
AB		EQ 750MG BASE	A 076593	004	Jun 09, 2004	Apr	CMFD		
	<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE</u>								
	TABLET, EXTENDED RELEASE; ORAL								
	CIPROFLOXACIN EXTENDED RELEASE								
	@ ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A 078166	002	Nov 27, 2007	Mar	DISC		
	@	425.2MG;EQ 574.9MG BASE	A 078166	001	Nov 27, 2007	Mar	DISC		
	! DR REDDYS LABS LTD	425.2MG;EQ 574.9MG BASE	A 077701	001	Mar 26, 2007	Mar	CTEC		
AB	!	425.2MG;EQ 574.9MG BASE	A 077701	001	Mar 26, 2007	Mar	CHRS		
	@ ENDO OPERATIONS	212.6MG;EQ 287.5MG BASE	A 078166	002	Nov 27, 2007	May	CAHN		
	@	425.2MG;EQ 574.9MG BASE	A 078166	001	Nov 27, 2007	May	CAHN		
	<u>CIPROFLOXACIN; DEXAMETHASONE</u>								
	SUSPENSION/DROPS; OTIC								
	CIPROFLOXACIN; DEXAMETHASONE								
AB	AMNEAL	0.3%;0.1%	A 216501	001	Mar 22, 2024	Mar	NEWA		
	<u>CISATRACURIUM BESYLATE</u>								
	INJECTABLE; INJECTION								
	CISATRACURIUM BESYLATE								
	@ CAPLIN	EQ 2MG BASE/ML	A 217725	001	Jun 09, 2023	Apr	DISC		
	@	EQ 10MG BASE/ML	A 217725	002	Jun 09, 2023	Apr	DISC		
AP	HAINAN POLY	EQ 2MG BASE/ML	A 216538	001	Mar 08, 2024	Mar	NEWA		
AP	! MEITHEAL	EQ 2MG BASE/ML	A 211668	001	Apr 25, 2019	Apr	CHRS		
AP	!	EQ 2MG BASE/ML	A 211669	001	Apr 25, 2019	Apr	CHRS		
AP	!	EQ 10MG BASE/ML	A 211668	002	Apr 25, 2019	Apr	CHRS		
AP	PIRAMAL CRITICAL	EQ 2MG BASE/ML	A 215516	003	Dec 14, 2022	Mar	CMS1		
	NIMBEX								
	+ @ ABBVIE	EQ 2MG BASE/ML	N 020551	001	Dec 15, 1995	Apr	DISC		
	NIMBEX PRESERVATIVE FREE								
	+ @ ABBVIE	EQ 2MG BASE/ML	N 020551	003	Dec 15, 1995	Apr	DISC		
	+ @	EQ 10MG BASE/ML	N 020551	002	Dec 15, 1995	Apr	DISC		
	<u>CISPLATIN</u>								
	INJECTABLE; INJECTION								
	CISPLATIN								
AP	QILU	1MG/ML	A 218868	001	May 10, 2024	May	NEWA		
	<u>CITALOPRAM HYDROBROMIDE</u>								
	TABLET; ORAL								
	CITALOPRAM HYDROBROMIDE								
AB	APOTEX	EQ 10MG BASE	A 077046	001	Nov 24, 2004	Jan	CAHN		
AB		EQ 20MG BASE	A 077046	002	Nov 24, 2004	Jan	CAHN		
AB		EQ 40MG BASE	A 077046	003	Nov 24, 2004	Jan	CAHN		
	@ COSETTE	EQ 10MG BASE	A 077048	001	Nov 16, 2004	Apr	DISC		
	@	EQ 20MG BASE	A 077048	002	Nov 16, 2004	Apr	DISC		
	@	EQ 40MG BASE	A 077048	003	Nov 16, 2004	Apr	DISC		
	@ TARO	EQ 10MG BASE	A 077278	001	Mar 22, 2006	Jan	CAHN		
	@	EQ 20MG BASE	A 077278	002	Mar 22, 2006	Jan	CAHN		
	@	EQ 40MG BASE	A 077278	003	Mar 22, 2006	Jan	CAHN		

CLADRIBINE

	INJECTABLE; INJECTION						
	CLADRIBINE						
>D>	@ MYLAN LABS LTD	1MG/ML	A200510	001	Oct 06, 2011	Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	1MG/ML	A200510	001	Oct 06, 2011	Jun	CAHN

CLEMASTINE FUMARATE

	SYRUP; ORAL						
	CLEMASTINE FUMARATE						
	@ NEW HEIGHTS	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Jan	CAHN
	TABLET; ORAL						
	CLEMASTINE FUMARATE						
>A>	@ OMNIVIUM PHARMS	2.68MG	A073459	001	Oct 31, 1993	Jun	CAHN
>D>	@ SANDOZ	2.68MG	A073459	001	Oct 31, 1993	Jun	CAHN

CLINDAMYCIN HYDROCHLORIDE

	CAPSULE; ORAL						
	CLINDAMYCIN HYDROCHLORIDE						
	@ COSETTE	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	DISC
	@	EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

	FOR SOLUTION; ORAL						
	CLINDAMYCIN PALMITATE HYDROCHLORIDE						
>A>	@ EXTROVIS	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Jun	CAHN
>D>	@ MYLAN	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Jun	CAHN

CLINDAMYCIN PHOSPHATE

	GEL; TOPICAL						
	CLINDAMYCIN PHOSPHATE						
AB1	ALEMBIC	EQ 1% BASE	A212466	001	Apr 02, 2024	Mar	NEWA
	@ AMNEAL	EQ 1% BASE	A215219	001	Nov 03, 2022	Feb	DISC
	GEL; VAGINAL						
	XACIATO						
	+! ORGANON LLC	EQ 2% BASE	N215650	001	Dec 07, 2021	Jan	CAHN
	SOLUTION; TOPICAL						
	CLINDAMYCIN PHOSPHATE						
	@ ENDO OPERATIONS	EQ 1% BASE	A203343	001	May 29, 2015	Apr	CAHN

CLOBAZAM

	TABLET; ORAL						
	CLOBAZAM						
	@ BRECKENRIDGE	20MG	A209308	002	Oct 22, 2018	Jan	DISC

CLOBETASOL PROPIONATE

	AEROSOL, FOAM; TOPICAL						
	CLOBETASOL PROPIONATE						
AB2	TARO	0.05%	A208563	001	Mar 14, 2024	Mar	NEWA
	CREAM; TOPICAL						
	CLOBETASOL PROPIONATE						
	@ COSETTE	0.05%	A074139	001	Aug 03, 1994	Apr	DISC
	CORMAX						
	@ HIKMA	0.05%	A074220	001	May 16, 1997	Mar	DISC
	GEL; TOPICAL						
	EMBELINE						
	@ HIKMA	0.05%	A076141	001	Apr 12, 2002	Mar	DISC
	OINTMENT; TOPICAL						
	EMBELINE						
	@ HIKMA	0.05%	A074221	001	Mar 31, 1995	Mar	DISC
	SHAMPOO; TOPICAL						
	CLOBETASOL PROPIONATE						
	@ HIKMA	0.05%	A209871	001	Oct 27, 2017	Mar	DISC
	SOLUTION; TOPICAL						
	CLOBETASOL PROPIONATE						
	@ COSETTE	0.05%	A074331	001	Dec 15, 1995	Apr	DISC
AT	ENCUBE	0.05%	A076977	001	Aug 05, 2005	May	CMFD
	EMBELINE						
	@ HIKMA	0.05%	A074222	001	Dec 06, 1995	Mar	DISC

	SPRAY; TOPICAL							
	CLOBETASOL PROPIONATE							
>D>	@ AKORN	0.05%	A207218	001	Apr 28, 2017	Jun	CAHN	
>A>	@ SAPTALIS PHARMS	0.05%	A207218	001	Apr 28, 2017	Jun	CAHN	
	SUSPENSION/DROPS; OPHTHALMIC							
	CLOBETASOL PROPIONATE							
	+! EYENOVIA	0.05%	N218158	001	Mar 04, 2024	May	CAHN	
	+! FORMOSA	0.05%	N218158	001	Mar 04, 2024	Mar	NEWA	
	<u>CLOCORTOLONE PIVALATE</u>							
	CREAM; TOPICAL							
	CLODERM							
AB	+! LEGACY PHARMA	0.1%	N017765	001		Apr	CAHN	
	<u>CLOMIPRAMINE HYDROCHLORIDE</u>							
	CAPSULE; ORAL							
	CLOMIPRAMINE HYDROCHLORIDE							
AB	CHARTWELL RX	25MG	A074364	001	Mar 29, 1996	Mar	CAHN	
AB		50MG	A074364	002	Mar 29, 1996	Mar	CAHN	
AB		75MG	A074364	003	Mar 29, 1996	Mar	CAHN	
	@ MYLAN	25MG	A074947	001	Apr 30, 1998	May	DISC	
	@	50MG	A074947	002	Apr 30, 1998	May	DISC	
	@	75MG	A074947	003	Apr 30, 1998	May	DISC	
	@ RK PHARMA	25MG	A213221	001	Jun 22, 2020	Mar	DISC	
	@	50MG	A213221	002	Jun 22, 2020	Mar	DISC	
	@	75MG	A213221	003	Jun 22, 2020	Mar	DISC	
	<u>CLONAZEPAM</u>							
	TABLET, ORALLY DISINTEGRATING; ORAL							
	CLONAZEPAM							
AB	ENDO OPERATIONS	0.125MG	A077171	001	Aug 03, 2005	Apr	CAHN	
AB		0.25MG	A077171	002	Aug 03, 2005	Apr	CAHN	
AB		0.5MG	A077171	003	Aug 03, 2005	Apr	CAHN	
AB	!	1MG	A077171	004	Aug 03, 2005	Apr	CAHN	
AB		2MG	A077171	005	Aug 03, 2005	Apr	CAHN	
	<u>CLONIDINE HYDROCHLORIDE</u>							
	SUSPENSION, EXTENDED RELEASE; ORAL							
	ONYDA XR							
	+! TRIS PHARMA INC	0.1MG/ML	N217645	001	May 24, 2024	May	NEWA	
	TABLET, EXTENDED RELEASE; ORAL							
	CLONIDINE HYDROCHLORIDE							
	@ ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	Mar	DISC	
	@ BLUEPHARMA INDUSTRIA	0.1MG	A211433	001	Oct 12, 2018	Jan	CAHN	
	@ ENDO OPERATIONS	0.1MG	A202983	001	Apr 02, 2014	May	CAHN	
	@	0.1MG	A202984	001	Sep 30, 2013	May	CAHN	
	@	0.2MG	A202983	002	Apr 02, 2014	May	CAHN	
	@	0.2MG	A202984	002	Sep 30, 2013	May	CAHN	
	@ SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	May	CAHN	
	<u>CLOPIDOGREL BISULFATE</u>							
	TABLET; ORAL							
	CLOPIDOGREL BISULFATE							
	@ ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013	May	DISC	
	@	EQ 300MG BASE	A202925	002	Mar 27, 2013	May	DISC	
	<u>CLOTRIMAZOLE</u>							
	TROCHE/LOZENGE; ORAL							
	CLOTRIMAZOLE							
AB	THINQ PHARM-CRO PVT	10MG	A215641	001	Feb 29, 2024	Feb	NEWA	
	<u>CLOZAPINE</u>							
	TABLET, ORALLY DISINTEGRATING; ORAL							
	CLOZAPINE							
>A>	AB	BARR LABS INC	150MG	A090308	004	Nov 25, 2015	Jun	CMS1
>A>	AB		200MG	A090308	005	Nov 25, 2015	Jun	CMS1

COBICISTAT

TABLET; ORAL		COBICISTAT							
AB	MYLAN LABS LTD	150MG	A209986	001	Feb 07, 2024	Jan	NFTG		
TYBOST									
AB	+! GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Jan	CFTG		

COCAINE HYDROCHLORIDE

SOLUTION; NASAL		GOPRELTO							
+!	NODEN PHARMA	4%	N209963	001	Dec 14, 2017	Jan	CAHN		

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL		PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE							
AA	! GENUS	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040660	001	Dec 07, 2006	Apr	CAHN		
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE									
@	HIKMA	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040674	001	Dec 23, 2014	Mar	DISC		

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL		PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE							
@	HIKMA	10MG/5ML; 6.25MG/5ML	A040151	001	Aug 26, 1997	Mar	DISC		

COLCHICINE

CAPSULE; ORAL		COLCHICINE							
AB	ANNORA PHARMA	0.6MG	A217620	001	Apr 29, 2024	Apr	NEWA		
AB	AUROBINDO PHARMA LTD	0.6MG	A215463	001	Apr 29, 2024	Apr	NEWA		
AB	GRANULES	0.6MG	A210757	001	Apr 29, 2024	Apr	NEWA		
TABLET; ORAL		COLCHICINE							
AB	! ENDO OPERATIONS	0.6MG	A203976	001	Aug 12, 2021	May	CHRS		
@	MYLAN	0.6MG	A209470	001	Sep 16, 2019	Apr	DISC		
COLCRYS									
+	@ TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	May	DISC		

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL		COLESEVELAM HYDROCHLORIDE							
@	IMPAX	3.75GM/PACKET	A212886	001	Jan 18, 2023	May	DISC		

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL		FLAVORED COLESTID							
>D>	+ PFIZER	5GM/PACKET	N017563	001		Jun	DISC		
>A>	+ @	5GM/PACKET	N017563	001		Jun	DISC		
>D>	+ @	5GM/SCOOPFUL	N017563	002		Jun	DISC		
>A>	+ @	5GM/SCOOPFUL	N017563	002		Jun	DISC		

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC		COLY-MYCIN S							
+!	ENDO OPERATIONS	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001		Apr	CAHN		

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE		PARAGARD T 380A							
>D>	+!	COOPERSURGICAL	309MG/COPPER	N018680	001	Nov 15, 1984	Jun	CDFR	
>A>	SYSTEM; INTRAUTERINE								
>A>	PARAGARD T 380A								
>A>	+!	COOPERSURGICAL	309MG/COPPER	N018680	001	Nov 15, 1984	Jun	CDFR	

CORTICOTROPIN

INJECTABLE; INJECTION		ACTHAR GEL (AUTOINJECTOR)							
+!	MALLINCKRODT ARD	40 UNITS/0.5ML	N008372	003	Feb 29, 2024	Mar	NEWA		
+!		80 UNITS/ML	N008372	004	Feb 29, 2024	Mar	NEWA		

COSYNTROPININJECTABLE; INJECTION
COSYNTROPIN

@ MYLAN INSTITUTIONAL 0.25MG/VIAL A090574 001 Dec 17, 2009 May DISC

CROMOLYN SODIUMSOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM>D> @ AKORN 4% A074706 001 Apr 29, 1998 Jun CAHN
>A> @ SAPTALIS PHARMS 4% A074706 001 Apr 29, 1998 Jun CAHNCUPRIC CHLORIDEINJECTABLE; INJECTION
CUPRIC CHLORIDEAP RK PHARMA EQ 0.4MG COPPER/ML A217626 001 Apr 30, 2024 May CAHN
AP SOMERSET EQ 0.4MG COPPER/ML A216113 001 Apr 30, 2024 Apr NEWA
AP STIRA EQ 0.4MG COPPER/ML A217626 001 Apr 30, 2024 Apr NEWACYANOCOBALAMINGEL, METERED; NASAL
NASCOBAL

@ ENDO OPERATIONS 0.5MG/INH N019722 001 Nov 05, 1996 May CAHN

INJECTABLE; INJECTION
CYANOCOBALAMIN>D> AP EUGIA PHARMA 1MG/ML A213874 001 Dec 08, 2020 Jun DISC
>A> @ 1MG/ML A213874 001 Dec 08, 2020 Jun DISC
>A> AP MANKIND PHARMA 1MG/ML A217839 001 Jul 10, 2024 Jun NEWASPRAY, METERED; NASAL
CALOMIST

@ ENDO OPERATIONS 25MCG/SPRAY N022102 001 Jul 27, 2007 May CAHN

NASCOBAL

AB +! ENDO OPERATIONS 0.5MG/SPRAY N021642 001 Jan 31, 2005 May CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

>A> @ AIPING PHARM INC 5MG A072854 002 Feb 03, 2006 Jun CAHN
>A> @ 10MG A072854 001 Nov 19, 1991 Jun CAHN
>D> @ CHARTWELL RX 5MG A072854 002 Feb 03, 2006 Jun CAHN
>D> @ 10MG A072854 001 Nov 19, 1991 Jun CAHNCYCLOPENTOLATE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CYCLOPENTOLATE HYDROCHLORIDE

@ SAPTALIS PHARMS 0.5% A205937 001 Dec 09, 2015 Mar CAHN

CYCLOPHOSPHAMIDEINJECTABLE; INJECTION
CYCLOPHOSPHAMIDEAP HIKMA 500MG/VIAL A216958 001 Dec 18, 2023 Jan CAHN
AP 1GM/VIAL A216958 002 Dec 18, 2023 Jan CAHN
AP 2GM/VIAL A216958 003 Dec 18, 2023 Jan CAHNSOLUTION; INTRAVENOUS
CYCLOPHOSPHAMIDE>A> +! AVYXA HOLDINGS 500MG/ML (500MG/ML) N210852 001 Jun 07, 2023 Jun CAHN
>A> +! 1GM/2ML (500MG/ML) N210852 002 Jun 07, 2023 Jun CAHN
>A> +! 2GM/4ML (500MG/ML) N210852 003 Jun 07, 2023 Jun CAHN
+ @ BAXTER HLTHCARE CORP 500MG/2.5ML (200MG/ML) N217651 001 Jun 28, 2023 Jan CAHN
+ @ 1GM/5ML (200MG/ML) N217651 002 Jun 28, 2023 Jan CAHN
>D> +! DR REDDYS 500MG/ML (500MG/ML) N210852 001 Jun 07, 2023 Jun CAHN
>A> +! 500MG/2.5ML (200MG/ML) N212501 001 Jul 30, 2020 Jun CAHN
>D> +! 1GM/2ML (500MG/ML) N210852 002 Jun 07, 2023 Jun CAHN
>A> +! 1GM/5ML (200MG/ML) N212501 002 Jul 30, 2020 Jun CAHN
>D> +! 2GM/4ML (500MG/ML) N210852 003 Jun 07, 2023 Jun CAHN
>A> +! 2GM/10ML (200MG/ML) N212501 003 Nov 19, 2021 Jun CAHN
>D> +! INGENUS PHARMS LLC 500MG/2.5ML (200MG/ML) N212501 001 Jul 30, 2020 Jun CAHN
>D> +! 1GM/5ML (200MG/ML) N212501 002 Jul 30, 2020 Jun CAHN
>D> +! 2GM/10ML (200MG/ML) N212501 003 Nov 19, 2021 Jun CAHN

CYCLOSPORINEEMULSION;OPHTHALMIC
CYCLOSPORINE

AB	DEVA HOLDING AS	0.05%	A209811	001	May 21, 2024	May	NEWA	
>A>	AB	SAPTALIS PHARMS	0.05%	A211943	001	Jul 05, 2024	Jun	NEWA
>D>	AB	TEVA PHARMS USA INC	0.05%	A203880	001	Dec 14, 2023	Jun	DISC
>A>	@		0.05%	A203880	001	Dec 14, 2023	Jun	DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

@	PATRIN	2MG/5ML	A204823	001	Dec 27, 2016	Apr	DISC
@	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Feb	DISC

CYSTEINE HYDROCHLORIDESOLUTION;INTRAVENOUS
ELCYS

+	@	EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023	Jan	DISC
---	---	--------------	-----------------------	---------	-----	--------------	-----	------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

DABIGATRAN ETEXILATE MESYLATE

>A>	AB	ALEMBIC	EQ 75MG BASE	A215233	001	Jun 14, 2024	Jun	NEWA
>A>	AB		EQ 150MG BASE	A215233	002	Jun 14, 2024	Jun	NEWA
	AB	MSN	EQ 75MG BASE	A213879	001	May 22, 2024	May	NEWA
	AB		EQ 150MG BASE	A213879	002	May 22, 2024	May	NEWA

DACTINOMYCIN

INJECTABLE;INJECTION

COSMEGEN

+	@	RECORDATI RARE	0.5MG/VIAL	N050682	001		Jan	DISC
AP	!	EUGIA PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan	CHRS

DANICOPAN

TABLET;ORAL

VOYDEYA

+		ALEXION PHARMS INC	50MG	N218037	001	Mar 29, 2024	Mar	NEWA
+	!		100MG	N218037	002	Mar 29, 2024	Mar	NEWA

DAPRODUSTAT

TABLET;ORAL

JESDUVROQ

+	@	GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023	May	DISC
+	@		2MG	N216951	002	Feb 01, 2023	May	DISC
+	@		4MG	N216951	003	Feb 01, 2023	May	DISC
+	@		6MG	N216951	004	Feb 01, 2023	May	DISC
+	@		8MG	N216951	005	Feb 01, 2023	May	DISC

DAPSONE

GEL;TOPICAL

DAPSONE

@	PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023	Jan	DISC	
@		7.5%	A212657	001	Nov 01, 2023	Jan	DISC	
>D>	AB	TARO	5%	A209506	001	Oct 16, 2017	Jun	CAHN
>A>	AB		5%	A209506	001	Oct 16, 2017	Jun	CAHN
	AB	ZYDUS	7.5%	A214019	001	May 08, 2024	Apr	NEWA
	AB	ZYDUS LIFESCIENCES	7.5%	A214019	001	May 08, 2024	May	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

@	ENDO OPERATIONS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	May	CAHN
@		EQ 15MG BASE	A091190	002	Mar 13, 2015	May	CAHN

DARUNAVIR

TABLET;ORAL

DARUNAVIR

AB	ZYDUS LIFESCIENCES	600MG	A214085	001	Dec 13, 2023	May	CAHN
AB		800MG	A214085	002	Dec 13, 2023	May	CAHN

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

AP	HETERO LABS LTD VI	50MG/VIAL	A215355	001	May 10, 2024	May	NEWA
----	--------------------	-----------	---------	-----	--------------	-----	------

DEFERASIROXGRANULE; ORAL
DEFERASIROX

AB	MYLAN	90MG	A213146	001	May 03, 2024	Apr	NEWA
AB		180MG	A213146	002	May 03, 2024	Apr	NEWA
AB		360MG	A213146	003	May 03, 2024	Apr	NEWA

TABLET; ORAL
DEFERASIROX

AB	MYLAN	90MG	A211395	001	Mar 22, 2024	Mar	NEWA
AB		180MG	A211395	002	Mar 22, 2024	Mar	NEWA
AB		360MG	A211395	003	Mar 22, 2024	Mar	NEWA

TABLET, FOR SUSPENSION; ORAL
DEFERASIROX

AB	GLENMARK SPECLT	125MG	A209433	001	Jan 06, 2020	May	CAHN
AB		250MG	A209433	002	Jan 06, 2020	May	CAHN
AB		500MG	A209433	003	Jan 06, 2020	May	CAHN

DEFLAZACORTSUSPENSION; ORAL
DEFLAZACORT

AB	TRIS PHARMA INC	22.75MG/ML	A217813	001	Apr 25, 2024	Apr	NFTG
----	-----------------	------------	---------	-----	--------------	-----	------

EMFLAZA

AB	+! PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr	CFTG
----	---------------	------------	---------	-----	--------------	-----	------

TABLET; ORAL
DEFLAZACORT

AB	AUROBINDO PHARMA LTD	6MG	A217123	001	Feb 09, 2024	Feb	NFTG
AB		18MG	A217123	002	Feb 09, 2024	Feb	NFTG
AB		30MG	A217123	003	Feb 09, 2024	Feb	NFTG
AB		36MG	A217123	004	Feb 09, 2024	Feb	NFTG

EMFLAZA

AB	+ PTC THERAP	6MG	N208684	001	Feb 09, 2017	Feb	CFTG
AB	+	18MG	N208684	002	Feb 09, 2017	Feb	CFTG
AB	+	30MG	N208684	003	Feb 09, 2017	Feb	CFTG
AB	+!	36MG	N208684	004	Feb 09, 2017	Feb	CFTG

DEOXYCHOLIC ACIDSOLUTION; SUBCUTANEOUS
KYBELLA

AP	+! ABBVIE	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Jan	CAHN
----	-----------	--------------------	---------	-----	--------------	-----	------

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

AB	CHARTWELL RX	10MG	A072103	002	May 24, 1988	Mar	CAHN
AB		25MG	A072103	003	May 24, 1988	Mar	CAHN
AB		50MG	A072103	004	May 24, 1988	Mar	CAHN
AB		75MG	A072103	005	Jun 20, 1988	Mar	CAHN
AB		100MG	A072103	001	Jun 20, 1988	Mar	CAHN
AB		150MG	A072103	006	Jun 20, 1988	Mar	CAHN

DESLORATADINETABLET; ORAL
DESLORATADINE
@ CHARTWELL RX

5MG

A078364	001	Dec 03, 2010	Jan	CAHN
---------	-----	--------------	-----	------

DESMOPRESSIN ACETATETABLET; ORAL
DESMOPRESSIN ACETATE

	@ ACTAVIS LABS FL INC	0.1MG	A076470	001	Jul 01, 2005	Feb	DISC
	@	0.2MG	A076470	002	Jul 01, 2005	Feb	DISC
AB	AUROBINDO PHARMA	0.1MG	A213095	001	Mar 21, 2024	Mar	NEWA
AB		0.2MG	A213095	002	Mar 21, 2024	Mar	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28		DESOGESTREL AND ETHINYL ESTRADIOL					
AB	NAARI PTE LTD	0.15MG;0.03MG	A207067	001	Sep 13, 2018	Apr	CMFD
	@ XIROMED	0.15MG;0.03MG	A202085	001	May 20, 2015	Apr	CAHN
	EMOQUETTE						
	@ ENDO OPERATIONS	0.15MG;0.03MG	A076675	001	Feb 25, 2011	May	CAHN
	KIMIDESS						
AB	ENDO OPERATIONS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	May	CAHN

DESONIDE

OINTMENT; TOPICAL		DESONIDE					
	@ HIKMA	0.05%	A208836	001	Mar 27, 2017	Mar	DISC

DESOXIMETASONE

CREAM; TOPICAL		DESOXIMETASONE					
	@ COSETTE	0.25%	A209595	001	Mar 04, 2020	Mar	DISC
	@ SAPTALIS PHARMS	0.05%	A203787	001	Jan 06, 2017	Feb	CAHN
	@	0.25%	A203234	001	Jun 12, 2015	Feb	CAHN
OINTMENT; TOPICAL		DESOXIMETASONE					
	@ COSETTE	0.25%	A206740	001	Dec 23, 2016	Apr	DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL		DESVENLAFAXINE SUCCINATE					
>D>	@ MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun	CAHN
>D>	@	EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun	CAHN
>A>	@	EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun	CAHN

DEUTETRABENAZINE

TABLET, EXTENDED RELEASE; ORAL		AUSTEDO XR					
+	TEVA	30MG	N216354	004	May 29, 2024	May	NEWA
+		36MG	N216354	005	May 29, 2024	May	NEWA
+		42MG	N216354	006	May 29, 2024	May	NEWA
		48MG	N216354	007	May 29, 2024	May	NEWA

DEXAMETHASONE

TABLET; ORAL		DEXAMETHASONE					
	@ KEY THERAP	1.5MG	A088237	001	Apr 28, 1983	May	DISC
BP		1.5MG	A088237	001	Apr 28, 1983	Apr	CAHN
	@ PANGEA	0.25MG	A088149	001	Apr 28, 1983	Jan	CAHN
AB	ZYDUS LIFESCIENCES	0.5MG	A216282	001	Feb 07, 2024	Mar	CAHN
AB		0.75MG	A216282	002	Feb 07, 2024	Mar	CAHN
AB		1MG	A216284	001	May 09, 2024	May	CAHN
AB		1.5MG	A216282	003	Feb 07, 2024	Mar	CAHN
AB		2MG	A216283	001	Feb 07, 2024	Mar	CAHN
AB		4MG	A216282	004	Feb 07, 2024	Mar	CAHN
AB		6MG	A216282	005	Feb 07, 2024	Mar	CAHN
AB	ZYDUS PHARMS	0.5MG	A216282	001	Feb 07, 2024	Jan	NEWA
AB		0.75MG	A216282	002	Feb 07, 2024	Jan	NEWA
AB		1MG	A216284	001	May 09, 2024	May	NEWA
AB		1.5MG	A216282	003	Feb 07, 2024	Jan	NEWA
AB		2MG	A216283	001	Feb 07, 2024	Jan	NEWA
AB		4MG	A216282	004	Feb 07, 2024	Jan	NEWA
AB		6MG	A216282	005	Feb 07, 2024	Jan	NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION		DEXAMETHASONE SODIUM PHOSPHATE					
	@ GENEYORK PHARMS	EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Feb	DISC
>A>	AP	HIKMA	A084282	001		Jun	CAHN
>A>	AP	!	A087702	001	Sep 07, 1982	Jun	CAHN
	AP	MICRO LABS	A217797	001	Mar 27, 2024	Mar	NEWA
>D>	AP	WEST-WARD PHARMS INT	A084282	001		Jun	CAHN
>D>	AP	!	A087702	001	Sep 07, 1982	Jun	CAHN

DEXCHLORPHENIRAMINE MALEATE

	SYRUP;ORAL						
	DEXCHLORPHENIRAMINE MALEATE						
	+ @ PAI HOLDINGS PHARM	2MG/5ML	A 088251	001	Mar 23, 1984	Mar	DISC
	POLMON						
	! CAPELLON PHARMS LLC	2MG/5ML	A 202520	001	Jul 16, 2018	Mar	CTEC
AA	!	2MG/5ML	A 202520	001	Jul 16, 2018	Mar	CHRS

DEXLANSOPRAZOLE

	CAPSULE, DELAYED RELEASE;ORAL						
	DEXLANSOPRAZOLE						
AB	MYLAN	30MG	A 205205	001	Jan 19, 2024	Jan	NEWA
AB		60MG	A 205205	002	Jan 19, 2024	Jan	NEWA

DEXTROAMPHETAMINE SULFATE

	CAPSULE, EXTENDED RELEASE;ORAL						
	DEXTROAMPHETAMINE SULFATE						
>D>	@ MYLAN	5MG	A 206735	001	Jan 27, 2016	Jun	CAHN
>D>	@	10MG	A 206735	002	Jan 27, 2016	Jun	CAHN
>D>	@	15MG	A 206735	003	Jan 27, 2016	Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	5MG	A 206735	001	Jan 27, 2016	Jun	CAHN
>A>	@	10MG	A 206735	002	Jan 27, 2016	Jun	CAHN
>A>	@	15MG	A 206735	003	Jan 27, 2016	Jun	CAHN
	TABLET;ORAL						
	DEXTROAMPHETAMINE SULFATE						
AA	AZURITY	2.5MG	A 090533	001	Oct 25, 2011	Mar	CAHN
AA		5MG	A 090533	002	Oct 25, 2011	Mar	CAHN
AA		7.5MG	A 090533	003	Oct 25, 2011	Mar	CAHN
AA		10MG	A 090533	004	Oct 25, 2011	Mar	CAHN
AA		15MG	A 090533	005	Oct 25, 2011	Mar	CAHN
AA		20MG	A 090533	006	Oct 25, 2011	Mar	CAHN
AA		30MG	A 090533	007	Oct 25, 2011	Mar	CAHN
	@ TRIS PHARMA INC	5MG	A 206095	001	Aug 18, 2022	Jan	DISC
	@	10MG	A 206095	002	Aug 18, 2022	Jan	DISC

DEXTROSE

	INJECTABLE; INJECTION						
	DEXTROSE 5%						
AP	AM REGENT	50MG/ML	A 217263	001	Apr 08, 2024	Apr	CTNA
AP		50MG/ML	A 217263	001	Apr 08, 2024	Mar	NEWA

DIAZEPAM

	FILM;BUCCAL						
	LIBERVANT						
	+ AQUESTIVE	5MG	N 218623	001	Apr 26, 2024	Apr	NEWA
	+	7.5MG	N 218623	002	Apr 26, 2024	Apr	NEWA
	+	10MG	N 218623	003	Apr 26, 2024	Apr	NEWA
	+	12.5MG	N 218623	004	Apr 26, 2024	Apr	NEWA
	+!	15MG	N 218623	005	Apr 26, 2024	Apr	NEWA
	INJECTABLE; INJECTION						
	DIAZEPAM						
AP	ALEMBIC	10MG/2ML (5MG/ML)	A 218450	001	Apr 25, 2024	Apr	NEWA
	@ HIKMA	5MG/ML (5MG/ML)	A 070311	002	Dec 16, 1985	Jan	NEWA
	@	10MG/2ML (5MG/ML)	A 070311	003	Dec 16, 1985	Jan	NEWA
AP		50MG/10ML (5MG/ML)	A 070311	001	Dec 16, 1985	Jan	CPOT
	TABLET;ORAL						
	DIAZEPAM						
	@ ENDO OPERATIONS	2MG	A 070228	002	Sep 26, 1985	May	CAHN
	@	5MG	A 070228	003	Sep 26, 1985	May	CAHN
	@	10MG	A 070228	001	Sep 26, 1985	May	CAHN

DICHLORPHENAMIDE

	TABLET;ORAL						
	ORMALVI						
AB	TORRENT	50MG	A 215924	001	Dec 29, 2022	Feb	CTNA

DICLOFENAC POTASSIUMFOR SOLUTION;ORAL
DICLOFENAC POTASSIUM

AB	ENDO OPERATIONS	50MG	A202964	001	May 02, 2016	May	CAHN
>A>	AB	TARO	A218011	001	Jun 14, 2024	Jun	NEWA

DICLOFENAC SODIUMSOLUTION;TOPICAL
DICLOFENAC SODIUM

AB	!	LUPIN PHARMS	2%	A208021	001	Sep 20, 2022	Mar	CHRS
		PENNSAID						
	+	@ HORIZON	2%	N204623	001	Jan 16, 2014	Mar	DISC
		SOLUTION/DROPS;OPHTHALMIC						
		DICLOFENAC SODIUM						
>D>		@ AKORN	0.1%	A077845	001	Apr 17, 2008	Jun	CAHN
>A>		@ SAPTALIS PHARMS	0.1%	A077845	001	Apr 17, 2008	Jun	CAHN

DICYCLOMINE HYDROCHLORIDECAPSULE;ORAL
DICYCLOMINE HYDROCHLORIDE

>A>	AB	ANNORA PHARMA	10MG	A218018	001	Jul 01, 2024	Jun	NEWA
		INJECTABLE;INJECTION						
		BENTYL						
	+	@ ABBVIE	10MG/ML	N008370	001	Oct 15, 1984	Apr	DISC
		DICYCLOMINE HYDROCHLORIDE						
AP	!	FOSUN PHARMA	10MG/ML	A210979	001	Jul 02, 2018	Apr	CHRS
		SYRUP;ORAL						
		DICYCLOMINE HYDROCHLORIDE						
AA	!	ENDO OPERATIONS	10MG/5ML	A040169	001	Mar 24, 2005	Apr	CAHN
		TABLET;ORAL						
		DICYCLOMINE HYDROCHLORIDE						
AB		ANNORA PHARMA	20MG	A217566	001	May 07, 2024	Apr	NEWA

DIFLORASONE DIACETATEOINTMENT;TOPICAL
DIFLORASONE DIACETATE

>D>		@ AKORN	0.05%	A206572	001	Jul 24, 2015	Jun	CAHN
>A>		@ SAPTALIS PHARMS	0.05%	A206572	001	Jul 24, 2015	Jun	CAHN

DIFLUPREDNATEEMULSION;OPHTHALMIC
DIFLUPREDNATE

AB		EPIC PHARMA LLC	0.05%	A207284	001	May 14, 2024	May	NEWA
----	--	-----------------	-------	---------	-----	--------------	-----	------

DIGOXINELIXIR;ORAL
DIGOXIN

AA		VISTAPHARM LLC	0.05MG/ML	A213000	001	Oct 04, 2019	Feb	CAHN
		INJECTABLE;INJECTION						
		DIGOXIN						
>A>	AP	HIKMA	0.25MG/ML	A083391	001		Jun	CAHN
>D>	AP	WEST-WARD PHARMS INT	0.25MG/ML	A083391	001		Jun	CAHN

DIHYDROERGOTAMINE MESYLATESPRAY, METERED;NASAL
DIHYDROERGOTAMINE MESYLATE

		@ AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Mar	DISC
		TRUDHESA						
>A>	+	IMPEL PHARMS	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Jun	CAHN
>D>	+	JN BIDCO	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Jun	CAHN
	+		0.725MG/SPRAY	N213436	001	Sep 02, 2021	Feb	CAHN

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB3		ENDO OPERATIONS	120MG	A074984	001	Dec 20, 1999	Apr	CAHN
AB3			180MG	A074984	002	Dec 20, 1999	Apr	CAHN
AB3			240MG	A074984	003	Dec 20, 1999	Apr	CAHN
AB3			300MG	A074984	004	Dec 20, 1999	Apr	CAHN
		@	360MG	A209766	001	May 30, 2018	May	CAHN

	CAPSULE, EXTENDED RELEASE;ORAL							
	DILTIAZEM HYDROCHLORIDE							
	@ SUN PHARM	360MG		A 090492	005	Oct 28, 2011	Feb	DISC
	INJECTABLE;INJECTION							
	DILTIAZEM HYDROCHLORIDE							
AP	HIKMA	5MG/ML		A 078538	001	Dec 17, 2008	Mar	CAHN
	@ HIKMA FARMACEUTICA	5MG/ML		A 202651	001	Aug 09, 2012	Mar	DISC
	<u>DIMETHYL FUMARATE</u>							
	CAPSULE, DELAYED RELEASE;ORAL							
	DIMETHYL FUMARATE							
>A>	AB	MACLEODS PHARMS LTD	120MG	A 210377	001	Jun 26, 2024	Jun	NEWA
>A>	AB		240MG	A 210377	002	Jun 26, 2024	Jun	NEWA
	<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	DIPHENHYDRAMINE HYDROCHLORIDE							
>D>	@ EUROHLTH INTL SARL	50MG/ML		A 083183	001		Jun	CAHN
AP	GLAND PHARMA LTD	50MG/ML		A 218448	001	Mar 20, 2024	Mar	NEWA
>A>	@ HIKMA	50MG/ML		A 083183	001		Jun	CAHN
AP	! MYLAN INSTITUTIONAL	50MG/ML		A 040498	001	Jul 12, 2005	May	CHRS
	<u>DIPYRIDAMOLE</u>							
	TABLET;ORAL							
	DIPYRIDAMOLE							
	@ GENUS	25MG		A 040898	001	Apr 23, 2008	Jan	CAHN
	@	50MG		A 040898	002	Apr 23, 2008	Jan	CAHN
	@	75MG		A 040898	003	Apr 23, 2008	Jan	CAHN
AB	! IMPAX LABS	75MG		A 040782	003	Jul 18, 2007	May	CHRS
	PERSANTINE							
	+ @ BOEHRINGER INGELHEIM	25MG		N 012836	003	Dec 22, 1986	May	DISC
	+ @	50MG		N 012836	004	Feb 06, 1987	May	DISC
	+ @	75MG		N 012836	005	Feb 06, 1987	May	DISC
	<u>DIVALPROEX SODIUM</u>							
	TABLET, DELAYED RELEASE;ORAL							
	DIVALPROEX SODIUM							
	@ ENDO OPERATIONS	EQ 500MG VALPROIC ACID		A 078411	001	Nov 03, 2008	May	CAHN
>D>	@ MYLAN	EQ 125MG VALPROIC ACID		A 090062	001	Mar 17, 2009	Jun	CAHN
>D>	@	EQ 250MG VALPROIC ACID		A 090062	002	Mar 17, 2009	Jun	CAHN
>D>	@	EQ 500MG VALPROIC ACID		A 090062	003	Mar 17, 2009	Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	EQ 125MG VALPROIC ACID		A 090062	001	Mar 17, 2009	Jun	CAHN
>A>	@	EQ 250MG VALPROIC ACID		A 090062	002	Mar 17, 2009	Jun	CAHN
>A>	@	EQ 500MG VALPROIC ACID		A 090062	003	Mar 17, 2009	Jun	CAHN
	TABLET, EXTENDED RELEASE;ORAL							
	DIVALPROEX SODIUM							
	@ ENDO OPERATIONS	EQ 250MG VALPROIC ACID		A 078445	001	Feb 26, 2009	May	CAHN
	@	EQ 500MG VALPROIC ACID		A 078445	002	Aug 04, 2009	May	CAHN
	<u>DOCETAXEL</u>							
	INJECTABLE;INJECTION							
	DOCETAXEL							
AP	ACIC PHARMS	80MG/4ML (20MG/ML)		A 216677	002	Feb 28, 2024	Feb	NEWA
AP		20MG/ML (20MG/ML)		A 216677	001	Feb 28, 2024	Feb	NEWA
>D>	@ MYLAN LABS LTD	20MG/ML (20MG/ML)		A 203892	001	May 11, 2023	Jun	CAHN
>D>	@	80MG/4ML (20MG/ML)		A 203892	002	May 11, 2023	Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	20MG/ML (20MG/ML)		A 203892	001	May 11, 2023	Jun	CAHN
>A>	@	80MG/4ML (20MG/ML)		A 203892	002	May 11, 2023	Jun	CAHN
	SOLUTION;INTRAVENOUS							
	DOCIVYX							
	+! AVYXA HOLDINGS	20MG/2ML (10MG/ML)		N 215813	001	Nov 22, 2022	Apr	CMFD
	+ @	20MG/2ML (10MG/ML)		N 215813	001	Nov 22, 2022	Apr	CTNA
	+ @	20MG/2ML (10MG/ML)		N 215813	001	Nov 22, 2022	Jan	CAHN
	+!	80MG/8ML (10MG/ML)		N 215813	002	Nov 22, 2022	Apr	CMFD
	+ @	80MG/8ML (10MG/ML)		N 215813	002	Nov 22, 2022	Apr	CTNA
	+ @	80MG/8ML (10MG/ML)		N 215813	002	Nov 22, 2022	Jan	CAHN
	+!	160MG/16ML (10MG/ML)		N 215813	003	Nov 22, 2022	Apr	CMFD
	+ @	160MG/16ML (10MG/ML)		N 215813	003	Nov 22, 2022	Apr	CTNA
	+ @	160MG/16ML (10MG/ML)		N 215813	003	Nov 22, 2022	Jan	CAHN

>D>	<u>DOLASETRON MESYLATE</u>							
>D>	TABLET;ORAL							
>D>	ANZEMET							
>D>	+!	VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997	Jun DISC	
>A>	+	@	50MG	N020623	001	Sep 11, 1997	Jun DISC	
	<u>DOLUTEGRAVIR SODIUM</u>							
	TABLET;ORAL							
	TIVICAY							
	+	@	VIIV HLHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jan DISC
	+	@		EQ 25MG BASE	N204790	003	Jun 09, 2016	Jan DISC
	<u>DONEPEZIL HYDROCHLORIDE</u>							
	SYSTEM;TRANSDERMAL							
	ADLARITY							
>D>	+		CORIUM	5MG/DAY	N212304	001	Mar 11, 2022	Jun CAHN
>A>	+			5MG/DAY	N212304	001	Mar 11, 2022	Jun CAHN
>D>	+!			10MG/DAY	N212304	002	Mar 11, 2022	Jun CAHN
>A>	+!			10MG/DAY	N212304	002	Mar 11, 2022	Jun CAHN
	TABLET;ORAL							
	DONEPEZIL HYDROCHLORIDE							
	@		ENDO OPERATIONS	23MG	A202542	001	Jul 24, 2013	May CAHN
	@		SUN PHARM INDS	5MG	A090493	001	May 31, 2011	May DISC
	@			10MG	A090493	002	May 31, 2011	May DISC
	TABLET, ORALLY DISINTEGRATING;ORAL							
	DONEPEZIL HYDROCHLORIDE							
AB	!		MACLEODS PHARMS LTD	10MG	A201787	002	Dec 14, 2012	Mar CHRS
	@		SANDOZ	5MG	A091198	001	May 10, 2011	Mar DISC
	@			10MG	A091198	002	May 10, 2011	Mar DISC
	<u>DORZOLAMIDE HYDROCHLORIDE</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	DORZOLAMIDE HYDROCHLORIDE							
	@		HIKMA	EQ 2% BASE	A077846	001	Oct 28, 2008	Mar DISC
	<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE							
	@		HIKMA	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	Mar DISC
	<u>DOXAZOSIN MESYLATE</u>							
	TABLET;ORAL							
	DOXAZOSIN MESYLATE							
AB			AUROBINDO PHARMA USA	EQ 1MG BASE	A075509	001	Oct 19, 2000	Mar CMFD
AB				EQ 2MG BASE	A075509	002	Oct 19, 2000	Mar CMFD
AB				EQ 4MG BASE	A075509	003	Oct 19, 2000	Mar CMFD
AB				EQ 8MG BASE	A075509	004	Oct 19, 2000	Mar CMFD
	<u>DOXEPIN HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	DOXEPIN HYDROCHLORIDE							
	@		ENDO OPERATIONS	EQ 10MG BASE	A071422	002	Nov 09, 1987	Apr CAHN
	@			EQ 25MG BASE	A071422	003	Nov 09, 1987	Apr CAHN
	@			EQ 50MG BASE	A071422	004	Nov 09, 1987	Apr CAHN
	@			EQ 75MG BASE	A071422	005	Nov 09, 1987	Apr CAHN
	@			EQ 100MG BASE	A071422	001	Nov 09, 1987	Apr CAHN
AB	!			EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr CAHN
	TABLET;ORAL							
	DOXEPIN HYDROCHLORIDE							
>A>	AB		AJANTA PHARMA LTD	EQ 3MG BASE	A218564	001	Jul 01, 2024	Jun NEWA
>A>	AB			EQ 6MG BASE	A218564	002	Jul 01, 2024	Jun NEWA
>A>		@	ZYDUS LIFESCIENCES	EQ 3MG BASE	A202761	001	Aug 16, 2023	Jun CAHN
>A>		@		EQ 6MG BASE	A202761	002	Aug 16, 2023	Jun CAHN
>D>		@	ZYDUS PHARMS	EQ 3MG BASE	A202761	001	Aug 16, 2023	Jun CAHN
>D>		@		EQ 6MG BASE	A202761	002	Aug 16, 2023	Jun CAHN

DOXERCALCIFEROLINJECTABLE; INJECTION
DOXERCALCIFEROL

	@ AMNEAL	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	Jan	DISC
	@	4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	Jan	DISC
AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jan	CMFD

DOXYCYCLINECAPSULE; ORAL
DOXYCYCLINE

>A>	AB	ALEMBIC	40MG	A217674	001	Jun 27, 2024	Jun	NEWA
		@ COSETTE	EQ 50MG BASE	A204446	001	May 28, 2015	Apr	DISC
		@	EQ 75MG BASE	A204446	002	May 28, 2015	Apr	DISC
		@	EQ 100MG BASE	A204446	003	May 28, 2015	Apr	DISC
	AB	DR REDDYS	40MG	A218034	001	Apr 08, 2024	Mar	NFTG
	AB	LUPIN	40MG	A216631	001	Apr 08, 2024	Mar	NFTG
		ORACEA						
	AB	+! GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Mar	CFTG
		FOR SUSPENSION; ORAL						
		DOXYCYCLINE						
>D>	AB	LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Jun	CHRS
>A>	AB	!	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Jun	CHRS
>D>		VIBRAMYCIN						
>D>	AB	+! PFIZER	EQ 25MG BASE/5ML	N050006	001		Jun	DISC
>A>		+ @	EQ 25MG BASE/5ML	N050006	001		Jun	DISC

DOXYCYCLINE HYCLATECAPSULE; ORAL
ACTICLATE CAP

+ @ CHARTWELL RX

EQ 75MG BASE

N208253 001 Apr 26, 2016 Jan CAHN

INJECTABLE; INJECTION
DOXYCYCLINE HYCLATE

>A>	AP	HAINAN POLY	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Jun	NEWA
>A>	AP		EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Jun	NEWA
	AP	LUPIN LTD	EQ 100MG BASE/VIAL	A217794	001	Mar 14, 2024	Mar	NEWA

TABLET; ORAL
ACTICLATE

	AB	+ CHARTWELL RX	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jan	CAHN
	AB	+!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jan	CAHN
		DOXYCYCLINE HYCLATE						
		@ NOSTRUM LABS INC	EQ 100MG BASE	A209560	001	Apr 15, 2024	May	DISC
	AB		EQ 100MG BASE	A209560	001	Apr 15, 2024	Apr	NEWA
		@ TORRENT	EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr	DISC
	AB		EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr	NEWA
		@	EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr	DISC
	AB		EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr	NEWA
		TABLET, DELAYED RELEASE; ORAL						
		DORYX						
		+ @ MAYNE PHARMA	EQ 75MG BASE	N050795	001	May 06, 2005	Feb	DISC
		+ @	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb	DISC

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

	AB	ENDO OPERATIONS	10MG; 10MG	A208518	001	Dec 06, 2017	Apr	CAHN
--	----	-----------------	------------	---------	-----	--------------	-----	------

DRONABINOLCAPSULE; ORAL
DRONABINOL

		@ HIKMA	2.5MG	A079217	001	Jun 20, 2014	Mar	DISC
		@	5MG	A079217	002	Jun 20, 2014	Mar	DISC
		@	10MG	A079217	003	Jun 20, 2014	Mar	DISC

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

DRONEDARONE HYDROCHLORIDE

	AB	LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Jan	NFTG
		MULTAQ						
	AB	+! SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Jan	CFTG

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

@ UPSHER SMITH LABS	100MG	A213661	001	Feb 18, 2021	Apr	DISC
@	200MG	A213661	002	Feb 18, 2021	Apr	DISC
@	300MG	A213661	003	Feb 18, 2021	Apr	DISC

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

+ SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr	CMFD
+	EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr	CMFD
+	EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr	CMFD
+!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr	CMFD

DULOXETINE HYDROCHLORIDE

@ ANCHEN PHARMS	EQ 20MG BASE	A090780	001	Oct 28, 2015	Feb	DISC
@	EQ 30MG BASE	A090780	002	Oct 28, 2015	Feb	DISC
@	EQ 60MG BASE	A090780	003	Oct 28, 2015	Feb	DISC
@ ENDO OPERATIONS	EQ 20MG BASE	A090780	001	Oct 28, 2015	May	CAHN
@	EQ 30MG BASE	A090780	002	Oct 28, 2015	May	CAHN
@	EQ 60MG BASE	A090780	003	Oct 28, 2015	May	CAHN

DUTASTERIDE

CAPSULE;ORAL

AVODART

AB	+!	WAYLIS THERAP	0.5MG	N021319	001	Nov 20, 2001	Mar	CAHN
		DUTASTERIDE						
AB		CHARTWELL	0.5MG	A200899	001	Nov 20, 2015	Mar	CAHN
>D>		@ MYLAN	0.5MG	A203241	001	Jun 14, 2016	Jun	CAHN
>A>		@ NORVIUM BIOSCIENCE	0.5MG	A203241	001	Jun 14, 2016	Jun	CAHN
		@ VINTAGE	0.5MG	A202421	001	Nov 20, 2015	Feb	DISC

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		ENDO OPERATIONS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Apr	CAHN
		JALYN						
AB	+!	WAYLIS THERAP	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Apr	CAHN

EDARAVONE

SOLUTION;INTRAVENOUS

EDARAVONE

AP		DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	NEWA
AP		GLAND PHARMA LTD	30MG/100ML (0.3MG/ML)	A216199	001	May 06, 2024	Apr	NFTG
AP			60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	NFTG
AP		HIKMA	30MG/100ML (0.3MG/ML)	A215508	001	May 06, 2024	Apr	NFTG
AP		LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr	NEWA
		RADICAVA						
AP	+!	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CFTG
AP	+!		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CFTG

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

AB		MACLEODS PHARMS LTD	600MG	A091579	001	May 10, 2024	May	NEWA
----	--	---------------------	-------	---------	-----	--------------	-----	------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@ STRIDES PHARMA	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Mar	DISC
------------------	-------------------	---------	-----	--------------	-----	------

EFINACONAZOLE

SOLUTION;TOPICAL

EFINACONAZOLE

@ ZYDUS LIFESCIENCES	10%	A212178	001	Jul 15, 2022	May	CAHN
----------------------	-----	---------	-----	--------------	-----	------

>A>	<u>ELAFIBRANOR</u>							
>A>	TABLET;ORAL							
>A>	IQIRVO							
>A>	+!	IPSEN	80MG	N218860	001	Jun 10, 2024	Jun	NEWA
	<u>ELIGLUSTAT TARTRATE</u>							
	CAPSULE;ORAL							
	ELIGLUSTAT TARTRATE							
>A>	AB	APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jun	NEWA
	<u>ELTROMBOPAG OLAMINE</u>							
	FOR SUSPENSION;ORAL							
	ELTROMBOPAG OLAMINE							
AB		ANNORA PHARMA	EQ 12.5MG ACID/PACKET	A216620	001	Apr 18, 2024	Apr	NFTG
AB			EQ 25MG ACID/PACKET	A216620	002	Apr 18, 2024	Apr	NFTG
		PROMACTA KIT						
AB	+	NOVARTIS	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018	Apr	CFTG
AB	+	!	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Apr	CFTG
	<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE</u>							
	TABLET;ORAL							
	DESCOVY							
AB	+	GILEAD SCIENCES INC	120MG;EQ 15MG BASE	N208215	002	Jan 07, 2022	May	CFTG
AB	+	!	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	May	CFTG
		EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE						
AB		APOTEX	120MG;EQ 15MG BASE	A214053	001	May 17, 2024	May	NFTG
AB			200MG;EQ 25MG BASE	A214053	002	May 17, 2024	May	NFTG
	<u>ENALAPRIL MALEATE</u>							
	FOR SOLUTION;ORAL							
	EPANED KIT							
	+	@ AZURITY	1MG/ML	N204308	001	Aug 13, 2013	Mar	CAHN
	SOLUTION;ORAL							
	ENALAPRIL MALEATE							
AB		AMNEAL	1MG/ML	A212894	001	Jun 29, 2022	Mar	CMFD
	<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>							
	TABLET;ORAL							
	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE							
	@	COSETTE	5MG;12.5MG	A075727	001	Sep 18, 2001	Apr	DISC
	@		10MG;25MG	A075727	002	Sep 18, 2001	Apr	DISC
>A>	<u>ENSIFENTRINE</u>							
>A>	SUSPENSION;INHALATION							
>A>	OHTUVAYRE							
>A>	+	VERONA PHARMA	3MG/2.5ML	N217389	001	Jun 26, 2024	Jun	NEWA
	<u>ENTECAVIR</u>							
	TABLET;ORAL							
	ENTECAVIR							
>D>	@	CASI PHARMS INC	0.5MG	A206672	001	May 11, 2017	Jun	CAHN
>D>	@		1MG	A206672	002	May 11, 2017	Jun	CAHN
>A>	@	CHARTWELL RX	0.5MG	A206672	001	May 11, 2017	Jun	CAHN
>A>	@		1MG	A206672	002	May 11, 2017	Jun	CAHN
>D>	AB	VITRUVIAS	0.5MG	A212106	001	Aug 10, 2020	Jun	DISC
>A>	@		0.5MG	A212106	001	Aug 10, 2020	Jun	DISC
>D>	AB		1MG	A212106	002	Aug 10, 2020	Jun	DISC
>A>	@		1MG	A212106	002	Aug 10, 2020	Jun	DISC
>D>	@	YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021	Jun	CMFD
>A>	AB		0.5MG	A208195	001	Nov 10, 2021	Jun	CMFD
>D>	@		1MG	A208195	002	Nov 10, 2021	Jun	CMFD
>A>	AB		1MG	A208195	002	Nov 10, 2021	Jun	CMFD
	<u>EPHEDRINE HYDROCHLORIDE</u>							
	SOLUTION;INTRAVENOUS							
	REZIPRES							
	+	@ DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	May	DISC

EPHEDRINE SULFATESOLUTION; INTRAVENOUS
EPHEDRINE SULFATE

+!	ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Apr	CAHN
+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Apr	CAHN

EPINEPHRINESOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
EPINEPHRINE

+!	BPI LABS	1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	Apr	NEWA
+!		30MG/30ML (1MG/ML)	N205029	004	Feb 14, 2024	Feb	NEWA

SOLUTION; INTRAVENOUS
EPINEPHRINE

>D>	+!	BPI LABS	1MG/ML (1MG/ML)	N205029	003	May 12, 2023	Jun	DISC
>A>	+ @		1MG/ML (1MG/ML)	N205029	003	May 12, 2023	Jun	DISC

EPINEPHRINE; LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
XYLOCAINE W/ EPINEPHRINE

+ @	FRESENIUS KABI USA	0.01MG/ML; 2%	N006488	003		Feb	CRLD
-----	--------------------	---------------	---------	-----	--	-----	------

EPLERENONETABLET; ORAL
EPLERENONE

	@	PRASCO	25MG	A203896	001	Feb 02, 2017	Mar	DISC
	@		50MG	A203896	002	Feb 02, 2017	Mar	DISC
AB		SLATE RUN PHARMA	25MG	A212765	001	Aug 10, 2020	Feb	CAHN
AB			50MG	A212765	002	Aug 10, 2020	Feb	CAHN

EPLONTERSEN SODIUMSOLUTION; SUBCUTANEOUS
WAINUA (AUTOINJECTOR)

+!	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Feb	CTNA
+!		EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Jan	CAHN

EPOPROSTENOL SODIUMINJECTABLE; INJECTION
EPOPROSTENOL SODIUM

AP1		MEITHEAL	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Jan	CAHN
AP1			EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Jan	CAHN
AP2		MYLAN	EQ 0.5MG BASE/VIAL	A213913	001	Jun 12, 2024	May	NEWA
AP2			EQ 1.5MG BASE/VIAL	A213913	002	Jun 12, 2024	May	NEWA

EPTIFIBATIDEINJECTABLE; INJECTION
EPTIFIBATIDE

	@	ACCORD HLTHCARE	2MG/ML	A205557	001	Nov 06, 2017	May	DISC
	@		75MG/100ML	A205557	002	Nov 06, 2017	May	DISC
AP		HONG KONG	2MG/ML	A213599	001	May 09, 2024	May	NEWA
AP			75MG/100ML	A213599	002	May 09, 2024	May	NEWA

ERGOTAMINE TARTRATETABLET; SUBLINGUAL
ERGOMAR

!	PANGEA	2MG	A087693	001	Feb 24, 1983	Feb	CAHN
---	--------	-----	---------	-----	--------------	-----	------

ERIBULIN MESYLATESOLUTION; INTRAVENOUS
ERIBULIN MESYLATE

AP		GLAND PHARMA LTD	1MG/2ML (0.5MG/ML)	A218047	001	Apr 05, 2024	Mar	NFTG
>A>	AP	JIANGXI QINGFENG	1MG/2ML (0.5MG/ML)	A218281	001	Jun 28, 2024	Jun	NEWA
		HALAVEN						
AP	+!	EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010	Mar	CFTG

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

	ERLOTINIB HYDROCHLORIDE						
AB	HETERO LABS LTD V	EQ 25MG BASE	A209267	001	May 24, 2024	May	NEWA
AB		EQ 100MG BASE	A209267	002	May 24, 2024	May	NEWA
AB		EQ 150MG BASE	A209267	003	May 24, 2024	May	NEWA
	@ NATCO PHARMA LTD	EQ 25MG BASE	A208488	001	Nov 05, 2019	Apr	DISC

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

	@ SUN PHARM	EQ 1GM BASE/VIAL	A209145	001	May 02, 2023	Jan	DISC
--	-------------	------------------	---------	-----	--------------	-----	------

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYTHROMYCIN

AB	AZURITY	250MG	A062746	001	Dec 22, 1986	Mar	CAHN
----	---------	-------	---------	-----	--------------	-----	------

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

AT	! BAUSCH AND LOMB	0.5%	A064067	001	Jul 29, 1994	Mar	CHRS
	@ PADAGIS US	0.5%	A062447	001	Sep 26, 1983	Mar	DISC

TABLET;ORAL

ERYTHROMYCIN

AB	AZURITY	250MG	A061621	001		Mar	CAHN
AB		500MG	A061621	002		Mar	CAHN

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

AB	AZURITY	250MG	A062298	001		Mar	CAHN
AB		333MG	A062298	003	Mar 29, 1982	Mar	CAHN
AB	!	500MG	A062298	002		Mar	CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

	@ ENDO OPERATIONS	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	May	CAHN
	@	EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	May	CAHN

TABLET;ORAL

E.E.S. 400

	@ AZURITY	EQ 400MG BASE	A061905	001		Mar	CAHN
BX	!	EQ 400MG BASE	A061905	002	Aug 12, 1982	Mar	CAHN

ERYTHROMYCIN ETHYLSUCCINATE

BX	!	AZURITY	EQ 400MG BASE	A061904	001		Mar	CAHN
----	---	---------	---------------	---------	-----	--	-----	------

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE

	@ AZURITY	EQ 125MG BASE	A060359	002		Mar	CAHN
	!	EQ 250MG BASE	A060359	001		Mar	CAHN
	@	EQ 500MG BASE	A060359	003		Mar	CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

	@ PHARM ASSOC	EQ 5MG BASE	A077512	001	Sep 12, 2012	Mar	DISC
	@	EQ 10MG BASE	A077512	002	Sep 12, 2012	Mar	DISC
	@	EQ 20MG BASE	A077512	003	Sep 12, 2012	Mar	DISC

ESLICARBAZEPINE ACETATE

TABLET;ORAL

ESLICARBAZEPINE ACETATE

	@ APOTEX	200MG	A211236	001	Dec 07, 2023	Apr	DISC
	@	400MG	A211236	002	Dec 07, 2023	Apr	DISC
	@	600MG	A211236	003	Dec 07, 2023	Apr	DISC
	@	800MG	A211236	004	Dec 07, 2023	Apr	DISC
AB	LUPIN LTD	200MG	A211246	001	Mar 27, 2024	Mar	NEWA
AB		400MG	A211246	002	Mar 27, 2024	Mar	NEWA
AB		600MG	A211246	003	Mar 27, 2024	Mar	NEWA
AB		800MG	A211246	004	Mar 27, 2024	Mar	NEWA
	@ TORRENT	200MG	A211227	001	Feb 27, 2024	Mar	DISC
AB		200MG	A211227	001	Feb 27, 2024	Feb	NEWA
	@	400MG	A211227	002	Feb 27, 2024	Mar	DISC

TABLET; ORAL

ESLICARBAZEPINE ACETATE							
AB		400MG	A211227	002	Feb 27, 2024	Feb	NEWA
	@	600MG	A211227	003	Feb 27, 2024	Mar	DISC
AB		600MG	A211227	003	Feb 27, 2024	Feb	NEWA
	@	800MG	A211227	004	Feb 27, 2024	Mar	DISC
AB		800MG	A211227	004	Feb 27, 2024	Feb	NEWA

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM							
	@	ACCORD HLTHCARE	EQ 40MG BASE/VIAL	A205379	001	Sep 25, 2015	May DISC
	!	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	May CHRS
	@	SUN PHARM	EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	May DISC

ESTRADIOL

GEL, METERED; TRANSDERMAL

ESTRADIOL							
AB		SOLARIS PHARMA CORP	0.06% (1.25GM/ACTIVATION)	A216160	001	Apr 22, 2024	Apr NFTG
		ESTROGEL					
AB	+!	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	Apr CFTG

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

LUNELLE							
	+ @	PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000	Feb CRLD

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGEN							
AO	+!	ENDO OPERATIONS	10MG/ML	N009402	002		Apr CAHN
AO	+!		20MG/ML	N009402	004		Apr CAHN
AO	+!		40MG/ML	N009402	003		Apr CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE							
AB		NAARI PTE LTD	1MG; 0.5MG	A210233	001	Feb 28, 2018	Apr CMFD

>D> ESTRAMUSTINE PHOSPHATE SODIUM

>D> CAPSULE; ORAL

>D> EMCYT

>D>	+!	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045	001		Jun DISC
>A>	+ @		EQ 140MG PHOSPHATE	N018045	001		Jun DISC

ESZOPICLONE

TABLET; ORAL

LUNESTA							
AB	+	WAYLIS THERAP	1MG	N021476	001	Dec 15, 2004	Apr CAHN
AB	+		2MG	N021476	002	Dec 15, 2004	Apr CAHN
AB	+!		3MG	N021476	003	Dec 15, 2004	Apr CAHN

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

ETHACRYNATE SODIUM							
AP		ENDO OPERATIONS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Apr CAHN
AP		STERIMAX	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020	Mar CAHN

ETHACRYNIC ACID

TABLET; ORAL

ETHACRYNIC ACID							
	@	ENDO OPERATIONS	25MG	A208501	001	Jul 21, 2017	May CAHN
	@	PAR PHARM INC	25MG	A208501	001	Jul 21, 2017	Apr DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL							
AB		XIROMED	0.03MG; 0.15MG	A200490	001	Apr 21, 2015	Apr CAHN
		MINZOYA					
AB3		LUPIN LTD	0.02MG; 0.1MG	A217087	001	Feb 15, 2024	Feb NEWA

TABLET;ORAL-28							
LEVONORGESTREL AND ETHINYL ESTRADIOL							
	@ XIROMED	0.02MG;0.1MG	A202247	001	Dec 08, 2014	Apr	CAHN
	@	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018	May	CAHN
MYZILRA							
AB	ENDO OPERATIONS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502	001	Nov 23, 2011	May	CAHN
ORSYTHIA							
	@ ENDO OPERATIONS	0.02MG;0.1MG	A077099	001	May 11, 2011	May	CAHN
<u>ETHINYL ESTRADIOL; NORETHINDRONE</u>							
TABLET;ORAL-28							
CYCLAFEM 0.5/35							
	@ ENDO OPERATIONS	0.035MG;0.5MG	A203413	001	Dec 16, 2015	Apr	CAHN
CYCLAFEM 1/35							
	@ ENDO OPERATIONS	0.035MG;1MG	A076337	001	Nov 12, 2010	May	CAHN
CYCLAFEM 7/7/7							
	@ ENDO OPERATIONS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076338	001	Nov 16, 2010	May	CAHN
GILDAGIA							
AB	ENDO OPERATIONS	0.035MG;0.4MG	A078376	001	Nov 06, 2012	May	CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL							
	@ XIROMED	0.035MG;0.4MG	A200897	001	May 11, 2015	Apr	CAHN
	@	0.05MG;1MG	A203006	001	Aug 05, 2013	Apr	CAHN
TABLET, CHEWABLE;ORAL							
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	+! TEVA BRANDED PHARM	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Mar	CAHN
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>							
CAPSULE;ORAL							
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	@ AMNEAL PHARMS	0.02MG;1MG	A214292	001	Jul 20, 2021	Feb	DISC
TABLET;ORAL							
GILDESS 24 FE							
AB	ENDO OPERATIONS	0.02MG;1MG	A090293	001	Dec 01, 2014	May	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
	@ XIROMED	0.0025MG;0.5MG	A207260	001	Feb 02, 2017	Apr	CAHN
	@	0.005MG;1MG	A207259	001	Dec 27, 2016	Apr	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	@ XIROMED	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	@ XIROMED	0.02MG;1MG	A206120	001	Sep 12, 2017	May	CAHN
OSHIH							
	@ AUROBINDO PHARMA	0.02MG;1MG	A216558	001	Dec 06, 2023	May	DISC
TABLET;ORAL-21							
GILDESS 1.5/30							
	@ ENDO OPERATIONS	0.03MG;1.5MG	A077075	002	Jul 24, 2012	May	CAHN
GILDESS 1/20							
	@ ENDO OPERATIONS	0.02MG;1MG	A077077	002	Jul 24, 2012	May	CAHN
TABLET;ORAL-28							
GILDESS FE 1.5/30							
	@ ENDO OPERATIONS	0.03MG;1.5MG	A077075	001	Apr 28, 2005	May	CAHN
GILDESS FE 1/20							
	@ ENDO OPERATIONS	0.02MG;1MG	A077077	001	May 20, 2005	May	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	XIROMED	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Apr	CAHN
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>							
TABLET;ORAL-28							
NORGESTIMATE AND ETHINYL ESTRADIOL							
	@ XIROMED	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A202132	001	Sep 09, 2015	May	CAHN
	@	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A201897	001	Jan 27, 2016	May	CAHN
PREVIFEM							
AB	ENDO OPERATIONS	0.035MG;0.25MG	A076334	001	Jan 09, 2004	May	CAHN
TRI-PREVIFEM							
	@ ENDO OPERATIONS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335	001	Mar 26, 2004	May	CAHN

ETHOSUXIMIDECAPSULE;ORAL
ETHOSUXIMIDE

AB	EPIC PHARMA LLC	250MG	A040686	001	May 28, 2008	Jan	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

ETODOLACTABLET;ORAL
ETODOLAC

AB	IPCA LABS LTD	400MG	A204729	001	May 01, 2024	Apr	NEWA
AB		500MG	A204729	002	May 01, 2024	Apr	NEWA
>A>	PANGEA	400MG	A074903	001	Apr 11, 1997	Jun	CAHN
>A>		500MG	A074903	002	Apr 19, 1999	Jun	CAHN
>D>	SANDOZ	400MG	A074903	001	Apr 11, 1997	Jun	CAHN
>D>		500MG	A074903	002	Apr 19, 1999	Jun	CAHN

ETOMIDATEINJECTABLE;INJECTION
ETOMIDATE

@	ENDO OPERATIONS	2MG/ML	A091297	001	Jun 20, 2012	May	CAHN
---	-----------------	--------	---------	-----	--------------	-----	------

EZETIMIBETABLET;ORAL
EZETIMIBE

AB	MACLEODS PHARMS LTD	10MG	A211159	001	Apr 29, 2024	Apr	NEWA
----	---------------------	------	---------	-----	--------------	-----	------

EZETIMIBE; SIMVASTATINTABLET;ORAL
EZETIMIBE AND SIMVASTATIN

AB	AUROBINDO PHARMA USA	10MG;10MG	A200082	001	Dec 17, 2020	Mar	CMFD
AB		10MG;20MG	A200082	002	Dec 17, 2020	Mar	CMFD
AB		10MG;40MG	A200082	003	Dec 17, 2020	Mar	CMFD
AB		10MG;80MG	A200082	004	Dec 17, 2020	Mar	CMFD

FAMOTIDINEFOR SUSPENSION;ORAL
FAMOTIDINE

AB	CEROVENE INC	40MG/5ML	A217605	001	Jan 16, 2024	Jan	NEWA
----	--------------	----------	---------	-----	--------------	-----	------

FAMOTIDINE; IBUPROFENTABLET;ORAL
FAMOTIDINE AND IBUPROFEN

@	TORRENT	26.6MG;800MG	A215925	001	Mar 18, 2024	Mar	NEWA
AB	!	ALKEM LABS LTD	A211890	001	Aug 03, 2021	Feb	CHRS

FEBUXOSTATTABLET;ORAL
FEBUXOSTAT

@	LUPIN LTD	40MG	A205406	001	Jan 17, 2024	Apr	DISC
AB		40MG	A205406	001	Jan 17, 2024	Jan	NEWA
@		80MG	A205406	002	Jan 17, 2024	Apr	DISC
AB		80MG	A205406	002	Jan 17, 2024	Jan	NEWA
>D>	MSN	40MG	A210461	001	Dec 30, 2019	Jun	CTEC
>A>	BX	40MG	A210461	001	Dec 30, 2019	Jun	CTEC
>D>	AB	80MG	A210461	002	Dec 30, 2019	Jun	CTEC
>A>	BX	80MG	A210461	002	Dec 30, 2019	Jun	CTEC

FEDRATINIB HYDROCHLORIDECAPSULE;ORAL
INREBIC

+	BRISTOL-MYERS	EQ 100MG BASE	N212327	001	Aug 16, 2019	Feb	CAHN
---	---------------	---------------	---------	-----	--------------	-----	------

FELODIPINETABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB	ENDO OPERATIONS	2.5MG	A200815	001	Oct 28, 2011	Apr	CAHN
AB		5MG	A200815	002	Oct 28, 2011	Apr	CAHN
AB		10MG	A200815	003	Oct 28, 2011	Apr	CAHN

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB		CHARTWELL	67MG	A211407	001	Jan 31, 2024	Mar	CAHN
AB			134MG	A211407	002	Jan 31, 2024	Mar	CAHN
AB			200MG	A211407	003	Jan 31, 2024	Mar	CAHN
	@	INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar	DISC
	@		134MG	A207378	002	Mar 28, 2017	Mar	DISC
	@		200MG	A207378	003	Mar 28, 2017	Mar	DISC
AB		YOUNGTECH PHARMS INC	67MG	A211407	001	Jan 31, 2024	Jan	NEWA
AB			134MG	A211407	002	Jan 31, 2024	Jan	NEWA
AB			200MG	A211407	003	Jan 31, 2024	Jan	NEWA

TABLET;ORAL

FENOFIBRATE

AB	!	AUROBINDO PHARMA	145MG	A205118	002	May 05, 2016	Mar	CHRS
>D>	AB	CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Jun	CTEC
>A>	BX		40MG	A217732	001	Sep 07, 2023	Jun	CTEC
>D>	AB		120MG	A217732	002	Sep 07, 2023	Jun	CTEC
>A>	BX		120MG	A217732	002	Sep 07, 2023	Jun	CTEC
AB	!	MYLAN PHARMS INC	120MG	A204475	002	Jun 23, 2016	May	CHRS
AB		YICHANG HUMANWELL	54MG	A218548	001	Apr 24, 2024	Apr	NEWA
AB			160MG	A218548	002	Apr 24, 2024	Apr	NEWA

FENOGLIDE

	+	@	SALIX	40MG	N022118	001	Aug 10, 2007	May	DISC
	+	@		120MG	N022118	002	Aug 10, 2007	May	DISC
			TRICOR						
	+	@	ABBVIE	145MG	N021656	002	Nov 05, 2004	Mar	DISC

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

CORLOPAM

	+	@	HOSPIRA	EQ 10MG BASE/ML	N019922	001	Sep 23, 1997	May	DISC
			FENOLDOPAM MESYLATE						
		@	HIKMA	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	May	DISC
		@	SANDOZ	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	May	DISC

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

			MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023	May	CTEC
AB	!		RISING	EQ 400MG BASE	A214475	001	Jul 18, 2022	May	CHRS
			NALFON						
	+	@	KEY THERAP	EQ 200MG BASE	N017604	003		May	DISC
AB	+			EQ 200MG BASE	N017604	003		Apr	CAHN
	+	@		EQ 400MG BASE	N017604	004	Jul 21, 2009	May	DISC
AB	+	!		EQ 400MG BASE	N017604	004	Jul 21, 2009	Apr	CAHN

TABLET;ORAL

FENOPROFEN CALCIUM

		@	KEY THERAP	EQ 600MG BASE	A072267	001	Aug 17, 1988	May	DISC
	!			EQ 600MG BASE	A072267	001	Aug 17, 1988	Apr	CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

		@	ANI PHARMS	4MG	A204504	001	Jan 04, 2023	Apr	DISC
		@		8MG	A204504	002	Jan 04, 2023	Apr	DISC

FIDAXOMICIN

TABLET;ORAL

DIFICID

AB	+	!	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Jan	CFTG
			FIDAXOMICIN						
AB			ACTAVIS LABS FL	200MG	A208443	001	Jan 16, 2024	Jan	NEWA

FINASTERIDE

TABLET;ORAL

FINASTERIDE

		@	CIPLA	1MG	A077335	001	Nov 20, 2014	Mar	DISC
--	--	---	-------	-----	---------	-----	--------------	-----	------

FINASTERIDE; TADALAFILCAPSULE;ORAL
ENTADFI

AB	+!	BLUE WATER BIOTECH	5MG;5MG	N215423	001	Dec 09, 2021	Mar	CFTG
		FINASTERIDE AND TADALAFIL						
AB		ZYDUS	5MG;5MG	A218232	001	Mar 15, 2024	Mar	NFTG
AB		ZYDUS LIFESCIENCES	5MG;5MG	A218232	001	Mar 15, 2024	May	CAHN

FINGOLIMOD HYDROCHLORIDECAPSULE;ORAL
FINGOLIMOD HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 0.5MG BASE	A207983	001	Feb 28, 2024	Feb	NEWA
AB		BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Feb	CMFD

FLORTAUCIPIR F-18SOLUTION;INTRAVENOUS
TAUVID

>D>	+!	AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020	Jun	DISC
>A>	+ @		30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020	Jun	DISC
>D>	+!		50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020	Jun	DISC
>A>	+ @		50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020	Jun	DISC

FLUDARABINE PHOSPHATEINJECTABLE;INJECTION
FLUDARABINE PHOSPHATE

>A>	@	EXTROVIS	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011	Jun	CAHN
>D>	@	MYLAN LABS LTD	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011	Jun	CAHN
	@	RISING	50MG/VIAL	A200648	001	Oct 16, 2012	Feb	CAHN

FLUDEOXYGLUCOSE F-18INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP	!	CARDINAL HEALTH 414	20-500mCi/ML	A203603	002	Sep 27, 2018	May	CHRS
	@	SOFIE	20-500mCi/ML	A203665	001	Feb 14, 2013	May	DISC

FLUOCINOLONE ACETONIDEOIL;TOPICAL
FLUOCINOLONE ACETONIDE

	@	SAPTALIS PHARMS	0.01%	A091514	001	Jun 25, 2015	Feb	CAHN
AT		TARO	0.01%	A209336	001	May 19, 2016	Jan	CAHN

OIL/DROPS;OTIC
FLUOCINOLONE ACETONIDE

	@	SAPTALIS PHARMS	0.01%	A202705	001	Sep 09, 2016	Feb	CAHN
--	---	-----------------	-------	---------	-----	--------------	-----	------

SHAMPOO;TOPICAL
CAPEX

	+ @	GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990	May	DISC
--	-----	------------------	-------	---------	-----	--------------	-----	------

FLUOCINONIDECREAM;TOPICAL
FLUOCINONIDE

	@	PADAGIS ISRAEL	0.1%	A090256	001	Jan 14, 2014	Jan	DISC
--	---	----------------	------	---------	-----	--------------	-----	------

GEL;TOPICAL
FLUOCINONIDE

	+ @	ALVOGEN	0.05%	N017373	001		May	DISC
	@	COSETTE	0.05%	A072537	001	Feb 07, 1989	Apr	DISC
	@	PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Jan	CAHN

SOLUTION;TOPICAL
FLUOCINONIDE

	@	COSETTE	0.05%	A071535	001	Dec 02, 1988	Apr	DISC
--	---	---------	-------	---------	-----	--------------	-----	------

FLUOROURACILCREAM;TOPICAL
FLUOROURACIL

>A>	@	EXTROVIS	0.5%	A203122	001	Apr 20, 2015	Jun	CAHN
>D>	@	MYLAN	0.5%	A203122	001	Apr 20, 2015	Jun	CAHN

INJECTABLE;INJECTION
FLUOROURACIL

AP		EUGIA PHARMA SPECILTS	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr	CMFD
AP			1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr	CMFD
AP			2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Apr	CMFD

INJECTABLE; INJECTION
FLUOROURACIL

AP		5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Apr	CMFD
----	--	---------------------	---------	-----	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

	@ SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Jan	DISC
--	----------------------	--------------	---------	-----	--------------	-----	------

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

	@ BAJAJ	EQ 20MG BASE/5ML	A075920	001	Jan 29, 2002	Mar	CAHN
--	---------	------------------	---------	-----	--------------	-----	------

	@ SAPTALIS PHARMS	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002	Mar	CAHN
--	-------------------	------------------	---------	-----	--------------	-----	------

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB	ENDO OPERATIONS	EQ 10MG BASE	A203836	001	Aug 19, 2016	Apr	CAHN
----	-----------------	--------------	---------	-----	--------------	-----	------

AB		EQ 20MG BASE	A203836	002	Aug 19, 2016	Apr	CAHN
----	--	--------------	---------	-----	--------------	-----	------

AB		EQ 60MG BASE	A209419	001	Nov 16, 2017	Apr	CAHN
----	--	--------------	---------	-----	--------------	-----	------

AB	STRIDES PHARMA	EQ 10MG BASE	A212684	001	Apr 05, 2024	Mar	NEWA
----	----------------	--------------	---------	-----	--------------	-----	------

AB		EQ 20MG BASE	A212684	002	Apr 05, 2024	Mar	NEWA
----	--	--------------	---------	-----	--------------	-----	------

	@ TEVA	EQ 10MG BASE	A075872	001	Jan 29, 2002	Jan	DISC
--	--------	--------------	---------	-----	--------------	-----	------

	@	EQ 20MG BASE	A075872	002	Jan 04, 2019	Jan	DISC
--	---	--------------	---------	-----	--------------	-----	------

	@ TEVA PHARMS USA	EQ 60MG BASE	A211051	001	Dec 03, 2018	Jan	DISC
--	-------------------	--------------	---------	-----	--------------	-----	------

>D>	AB	UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	Jun	DISC
-----	----	-------------------	--------------	---------	-----	--------------	-----	------

>A>		@	EQ 10MG BASE	A211696	001	Jan 30, 2019	Jun	DISC
-----	--	---	--------------	---------	-----	--------------	-----	------

>D>	AB		EQ 20MG BASE	A211696	002	Jan 30, 2019	Jun	DISC
-----	----	--	--------------	---------	-----	--------------	-----	------

>A>		@	EQ 20MG BASE	A211696	002	Jan 30, 2019	Jun	DISC
-----	--	---	--------------	---------	-----	--------------	-----	------

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB	ENDO OPERATIONS	EQ 25MG BASE;EQ 3MG BASE	A077742	001	Nov 02, 2012	Apr	CAHN
----	-----------------	--------------------------	---------	-----	--------------	-----	------

AB		EQ 25MG BASE;EQ 6MG BASE	A077742	002	Nov 02, 2012	Apr	CAHN
----	--	--------------------------	---------	-----	--------------	-----	------

AB		EQ 25MG BASE;EQ 12MG BASE	A077742	003	Nov 02, 2012	Apr	CAHN
----	--	---------------------------	---------	-----	--------------	-----	------

AB		EQ 50MG BASE;EQ 6MG BASE	A077742	004	Nov 02, 2012	Apr	CAHN
----	--	--------------------------	---------	-----	--------------	-----	------

AB		EQ 50MG BASE;EQ 12MG BASE	A077742	005	Nov 02, 2012	Apr	CAHN
----	--	---------------------------	---------	-----	--------------	-----	------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AO	ENDO OPERATIONS	25MG/ML	A203732	001	Jul 03, 2014	Apr	CAHN
----	-----------------	---------	---------	-----	--------------	-----	------

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	RISING	1MG	A218283	001	Jun 07, 2024	May	NEWA
----	--------	-----	---------	-----	--------------	-----	------

AB		2.5MG	A218283	002	Jun 07, 2024	May	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		5MG	A218283	003	Jun 07, 2024	May	NEWA
----	--	-----	---------	-----	--------------	-----	------

AB		10MG	A218283	004	Jun 07, 2024	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Feb	CAHN
----	---------------	-----	---------	-----	--------------	-----	------

AB		2.5MG	A215141	002	Oct 20, 2021	Feb	CAHN
----	--	-------	---------	-----	--------------	-----	------

AB		5MG	A215141	003	Oct 20, 2021	Feb	CAHN
----	--	-----	---------	-----	--------------	-----	------

AB		10MG	A215141	004	Oct 20, 2021	Feb	CAHN
----	--	------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

POWDER; INHALATION

ARMONAIR DIGIHALER

>D>	+	TEVA PHARM	0.055MG/INH	N208798	004	Feb 20, 2020	Jun	DISC
-----	---	------------	-------------	---------	-----	--------------	-----	------

>A>	+	@	0.055MG/INH	N208798	004	Feb 20, 2020	Jun	DISC
-----	---	---	-------------	---------	-----	--------------	-----	------

>D>	+		0.113MG/INH	N208798	005	Feb 20, 2020	Jun	DISC
-----	---	--	-------------	---------	-----	--------------	-----	------

>A>	+	@	0.113MG/INH	N208798	005	Feb 20, 2020	Jun	DISC
-----	---	---	-------------	---------	-----	--------------	-----	------

>D>	+	!	0.232MG/INH	N208798	006	Feb 20, 2020	Jun	DISC
-----	---	---	-------------	---------	-----	--------------	-----	------

>A>	+	@	0.232MG/INH	N208798	006	Feb 20, 2020	Jun	DISC
-----	---	---	-------------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

	@ HIKMA	0.05MG/SPRAY	A077570	001	Jan 16, 2008	Mar	DISC
--	---------	--------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

AIRDUO DIGIHALER

>D>							
-----	--	--	--	--	--	--	--

>D>	+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019	Jun	DISC
-----	---	------------	---------------------------------	---------	-----	--------------	-----	------

>A>	+	@	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019	Jun	DISC
-----	---	---	---------------------------------	---------	-----	--------------	-----	------

>D>	+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019	Jun	DISC
-----	---	--	---------------------------------	---------	-----	--------------	-----	------

		POWDER; INHALATION							
		AIRDUO DIGIHALER							
>A>	+	@	0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019	Jun	DISC	
>D>	+		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019	Jun	DISC	
>A>	+	@	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019	Jun	DISC	
		<u>FLUVOXAMINE MALEATE</u>							
		CAPSULE, EXTENDED RELEASE; ORAL							
		FLUVOXAMINE MALEATE							
AB		ENDO OPERATIONS	100MG	A091476	001	Mar 13, 2013	Apr	CAHN	
AB			150MG	A091476	002	Mar 13, 2013	Apr	CAHN	
		TABLET; ORAL							
		FLUVOXAMINE MALEATE							
AB		BIONPHARMA	25MG	A217917	001	Jan 22, 2024	Jan	NEWA	
AB			50MG	A217917	002	Jan 22, 2024	Jan	NEWA	
AB			100MG	A217917	003	Jan 22, 2024	Jan	NEWA	
		<u>FOLIC ACID</u>							
		TABLET; ORAL							
		FOLIC ACID							
		@ ENDO OPERATIONS	1MG	A040756	001	Jun 04, 2010	May	CAHN	
		<u>FORMOTEROL FUMARATE</u>							
		SOLUTION; INHALATION							
		FORMOTEROL FUMARATE							
>A>	AN	MICRO LABS	0.02MG/2ML	A218304	001	Jun 26, 2024	Jun	NEWA	
	AN	RITEDOSE CORP	0.02MG/2ML	A216486	001	Nov 25, 2022	May	CAHN	
		<u>FOSAMPRENAVIR CALCIUM</u>							
		TABLET; ORAL							
		FOSAMPRENAVIR CALCIUM							
AB	!	MYLAN	EQ 700MG BASE	A204060	001	Apr 15, 2016	Jan	CHRS	
		LEXIVA							
	+	@ VIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Jan	DISC	
		<u>FOSAPREPITANT DIMEGLUMINE</u>							
		POWDER; INTRAVENOUS							
		FOSAPREPITANT DIMEGLUMINE							
		@ ACCORD HLTHCARE	EQ 150MG BASE/VIAL	A204025	001	Aug 26, 2020	May	DISC	
		<u>FOSCARNET SODIUM</u>							
		INJECTABLE; INJECTION							
		FOSCARNET SODIUM							
AP		AMNEAL	2.4GM/100ML	A216602	001	Mar 01, 2024	Feb	NEWA	
		<u>FOSFOMYCIN TROMETHAMINE</u>							
		FOR SOLUTION; ORAL							
		FOSFOMYCIN TROMETHAMINE							
AA		AMNEAL	EQ 3GM BASE/PACKET	A216600	001	Mar 25, 2024	Mar	NEWA	
		<u>FROVATRIPTAN SUCCINATE</u>							
		TABLET; ORAL							
		FROVA							
AB	+	! ENDO OPERATIONS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Apr	CAHN	
		<u>FULVESTRANT</u>							
		SOLUTION; INTRAMUSCULAR							
		FULVESTRANT							
>D>		TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Jun	DISC	
>A>		@	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Jun	DISC	
		<u>FUROSEMIDE</u>							
		INJECTABLE; INJECTION							
		FUROSEMIDE							
AP		SABA ILAC SANAYIVE	10MG/ML	A215856	001	Apr 02, 2024	Mar	NEWA	

<u>GABAPENTIN</u>							
CAPSULE;ORAL							
GABAPENTIN							
	@	SUN PHARM INDS LTD	100MG	A 077242	001	Aug 24, 2006	May DISC
	@		300MG	A 077242	002	Aug 24, 2006	May DISC
	@		400MG	A 077242	003	Aug 24, 2006	May DISC
SOLUTION;ORAL							
GABAPENTIN							
AA		ANNORA PHARMA	250MG/5ML	A 217682	001	Jan 17, 2024	Jan NEWA
TABLET;ORAL							
GABAPENTIN							
AB1		ACI	600MG	A 203244	002	Jul 12, 2013	Jan CTEC
AB1			800MG	A 203244	001	Jul 12, 2013	Jan CTEC
AB1		ACTAVIS ELIZABETH	600MG	A 075694	001	Oct 21, 2004	Jan CTEC
AB1			800MG	A 075694	002	Oct 21, 2004	Jan CTEC
AB1		ALKEM LABS LTD	600MG	A 206402	001	Dec 23, 2015	Jan CTEC
AB1			800MG	A 206402	002	Dec 23, 2015	Jan CTEC
AB2		ANNORA PHARMA	300MG	A 218075	001	Feb 26, 2024	Feb NEWA
AB2			600MG	A 218075	002	Feb 26, 2024	Feb NEWA
AB1		APOTEX	100MG	A 077894	001	Oct 10, 2006	Jan CTEC
AB1			300MG	A 077894	002	Oct 10, 2006	Jan CTEC
AB1			400MG	A 077894	003	Oct 10, 2006	Jan CTEC
AB1		ASCENT PHARMS INC	600MG	A 214957	001	Oct 01, 2021	Jan CTEC
AB1			800MG	A 214957	002	Oct 01, 2021	Jan CTEC
AB1		AUROBINDO PHARMA LTD	600MG	A 200651	001	Oct 06, 2011	Jan CTEC
AB1			800MG	A 200651	002	Oct 06, 2011	Jan CTEC
AB1		CSPC OUYI	600MG	A 207057	001	Oct 26, 2017	Jan CTEC
AB1			800MG	A 207057	002	Oct 26, 2017	Jan CTEC
AB1		GLENMARK PHARMS LTD	600MG	A 077662	001	Aug 18, 2006	Jan CTEC
AB1			800MG	A 077662	002	Aug 18, 2006	Jan CTEC
AB1		GRANULES	600MG	A 217116	001	Mar 28, 2023	Jan CTEC
AB1			800MG	A 217116	002	Mar 28, 2023	Jan CTEC
AB2		HUMANWELL	300MG	A 216252	001	Feb 26, 2024	Feb NEWA
AB2			600MG	A 216252	002	Feb 26, 2024	Feb NEWA
	@	INVAGEN PHARMS	600MG	A 202764	001	Oct 16, 2012	Mar DISC
AB1			600MG	A 202764	001	Oct 16, 2012	Jan CTEC
	@		800MG	A 202764	002	Oct 16, 2012	Mar DISC
AB1			800MG	A 202764	002	Oct 16, 2012	Jan CTEC
AB1		IPCA LABS LTD	600MG	A 209855	001	May 29, 2024	May NEWA
AB1			800MG	A 209855	002	May 29, 2024	May NEWA
AB1		IVAX SUB TEVA PHARMS	100MG	A 076017	001	Apr 28, 2004	Jan CTEC
AB1			300MG	A 076017	002	Apr 28, 2004	Jan CTEC
AB1			400MG	A 076017	003	Apr 28, 2004	Jan CTEC
AB1		LAURUS	600MG	A 217965	001	Apr 08, 2024	Mar NEWA
AB1			800MG	A 217965	002	Apr 08, 2024	Mar NEWA
AB1		RISING	600MG	A 217995	001	Jul 19, 2023	Jan CTEC
AB1			800MG	A 217995	002	Jul 19, 2023	Jan CTEC
AB1		RUBICON	600MG	A 077661	004	Sep 13, 2006	Jan CTEC
AB1			800MG	A 077661	005	Sep 13, 2006	Jan CTEC
AB1		SCIEGEN PHARMS INC	600MG	A 205101	001	Feb 04, 2016	Jan CTEC
AB1			800MG	A 205101	002	Feb 04, 2016	Jan CTEC
AB1		STRIDES PHARMA	600MG	A 211313	001	Mar 04, 2024	Feb NEWA
AB1			800MG	A 211313	002	Mar 04, 2024	Feb NEWA
AB1		SUN PHARM INDS LTD	600MG	A 077525	001	Aug 24, 2006	Jan CTEC
AB1			800MG	A 077525	002	Aug 24, 2006	Jan CTEC
AB2		ZYDUS PHARMS	300MG	A 203934	001	Jan 24, 2024	Jan NEWA
AB2			600MG	A 203934	002	Jan 24, 2024	Jan NEWA
AB1		ZYDUS PHARMS USA INC	600MG	A 078926	001	Feb 11, 2011	Jan CTEC
AB1			800MG	A 078926	002	Feb 11, 2011	Jan CTEC
GRALISE							
AB2	+	ALMATICA	300MG	N 022544	001	Jan 28, 2011	Jan CTEC
AB2	+		600MG	N 022544	002	Jan 28, 2011	Jan CTEC
BX	+		600MG	N 022544	002	Jan 28, 2011	Jan CHRS
	+		900MG	N 022544	005	Apr 18, 2023	Jan CHRS
NEURONTIN							
AB1	+	VIATRIS	600MG	N 020882	001	Oct 09, 1998	Jan CTEC
AB1	+		800MG	N 020882	002	Oct 09, 1998	Jan CTEC

GADODIAMIDEINJECTABLE; INJECTION
OMNISCAN

+ @	GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007	Mar	CRLD
+ @		28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007	Mar	DISC

GADOTERATE MEGLUMINESOLUTION; INTRAVENOUS
GADOTERATE MEGLUMINE

>A>	AP	HAINAN POLY	1.8845GM/5ML (376.9MG/ML)	A218073	001	Jun 17, 2024	Jun	NEWA
>A>	AP		3.769GM/10ML (376.9MG/ML)	A218073	002	Jun 17, 2024	Jun	NEWA
>A>	AP		5.6535GM/15ML (376.9MG/ML)	A218073	003	Jun 17, 2024	Jun	NEWA
>A>	AP		7.538GM/20ML (376.9MG/ML)	A218073	004	Jun 17, 2024	Jun	NEWA
>A>	AP		37.69GM/100ML (376.9MG/ML)	A218073	005	Jun 17, 2024	Jun	NEWA

GANCICLOVIR SODIUMINJECTABLE; INJECTION
GANCICLOVIR SODIUM

AP	ENDO OPERATIONS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	May	CAHN
----	-----------------	--------------------	---------	-----	--------------	-----	------

GATIFLOXACINSOLUTION/DROPS; OPHTHALMIC
GATIFLOXACIN

@	HIKMA	0.5%	A203189	001	Sep 03, 2014	Mar	DISC
---	-------	------	---------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

@	ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011	Apr	DISC
@		EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011	Apr	DISC
@		EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011	Apr	DISC

GENTAMICIN SULFATEOINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

>D>	@	AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995	Jun	CAHN
>A>	@	SAPTALIS PHARMS	EQ 0.3% BASE	A064093	001	Aug 31, 1995	Jun	CAHN

SOLUTION/DROPS; OPHTHALMIC
GENTAK

@	SAPTALIS PHARMS	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb	CAHN
---	-----------------	--------------	---------	-----	--------------	-----	------

GEPIRONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
EXXUA

>D>	+	FABRE KRAMER	EQ 18.2MG BASE	N021164	001	Sep 22, 2023	Jun	DISC
>A>	+	@	EQ 18.2MG BASE	N021164	001	Sep 22, 2023	Jun	DISC
>D>	+		EQ 36.3MG BASE	N021164	002	Sep 22, 2023	Jun	DISC
>A>	+	@	EQ 36.3MG BASE	N021164	002	Sep 22, 2023	Jun	DISC
>D>	+		EQ 54.5MG BASE	N021164	003	Sep 22, 2023	Jun	DISC
>A>	+	@	EQ 54.5MG BASE	N021164	003	Sep 22, 2023	Jun	DISC
>D>	+	!	EQ 72.6MG BASE	N021164	004	Sep 22, 2023	Jun	DISC
>A>	+	@	EQ 72.6MG BASE	N021164	004	Sep 22, 2023	Jun	DISC

GIVINOSTAT HYDROCHLORIDESUSPENSION; ORAL
DUVYZAT

+	!	ITALFARMACO SPA	EQ 8.86MG BASE/ML	N217865	001	Mar 21, 2024	Mar	NEWA
---	---	-----------------	-------------------	---------	-----	--------------	-----	------

GLIPIZIDETABLET; ORAL
GLIPIZIDE

@	ACCORD HLTHCARE	5MG	A074550	001	Sep 11, 1997	May	DISC	
@		10MG	A074550	002	Sep 11, 1997	May	DISC	
>D>	AB	SANDOZ	5MG	A074305	001	Apr 07, 1995	Jun	DISC
>A>	@		5MG	A074305	001	Apr 07, 1995	Jun	DISC
>D>	AB		10MG	A074305	002	Apr 07, 1995	Jun	DISC
>A>	@		10MG	A074305	002	Apr 07, 1995	Jun	DISC

TABLET, EXTENDED RELEASE; ORAL
GLIPIZIDE

@	ENDO OPERATIONS	5MG	A076159	002	Sep 20, 2013	May	CAHN
@		10MG	A076159	001	Sep 20, 2013	May	CAHN

GLUCAGON HYDROCHLORIDE

POWDER; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
GLUCAGON

+! FRESENIUS KABI USA EQ 1MG BASE/VIAL N201849 002 Sep 19, 2019 Apr CMS1

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB	HERITAGE PHARMS	1.25MG; 250MG	A079009	001	Jun 03, 2009	Feb	CMFD
AB		2.5MG; 500MG	A079009	002	Jun 03, 2009	Feb	CMFD
AB		5MG; 500MG	A079009	003	Jun 03, 2009	Feb	CMFD

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

GLYCEROL PHENYLBUTYRATE

@ ENDO OPERATIONS 1.1GM/ML A205742 001 Dec 02, 2021 May CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP NIVAGEN PHARMS INC 0.2MG/ML A212591 001 Oct 13, 2021 Feb CAHN

TABLET; ORAL

GLYCOPYRROLATE

>A>	AA	QUAGEN	1MG	A212696	001	Jul 10, 2024	Jun	NEWA
>A>	AA		2MG	A212696	002	Jul 10, 2024	Jun	NEWA

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

PREVDUO

+! AZURITY 0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML) N216903 001 Feb 23, 2023 Feb CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

>D>	AT	AMRING PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Jun	CAHN
>A>	AT	NORDIC PHARMA	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Jun	CAHN

GRISEOFULVIN, MICROSIZE

TABLET; ORAL

FULVICIN-U/F

AB	CHARTWELL RX	250MG	A060569	002		Jan	CTEC
		250MG	A060569	002		Jan	CAIN
AB		500MG	A060569	001		Jan	CTEC
		500MG	A060569	001		Jan	CAIN

GRISEOFULVIN

AB SANDOZ 250MG A091592 001 Aug 07, 2013 Jan CTEC

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

FULVICIN P/G

AB	CHARTWELL RX	125MG	A061996	001		Jan	CTEC
		125MG	A061996	001		Jan	CAIN
AB		250MG	A061996	002		Jan	CTEC
		250MG	A061996	002		Jan	CAIN

FULVICIN P/G 165

CHARTWELL RX 165MG A061996 003 Apr 06, 1982 Jan CAIN

FULVICIN P/G 330

CHARTWELL RX 330MG A061996 004 Apr 06, 1982 Jan CAIN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	XIROMED	EQ 1MG BASE	A218326	001	Feb 23, 2024	Feb	NEWA
AB		EQ 2MG BASE	A218326	002	Feb 23, 2024	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	WANBANG BIOPHARMS	EQ 1MG BASE	A217638	001	Jun 12, 2024	May	NEWA
AB		EQ 2MG BASE	A217638	002	Jun 12, 2024	May	NEWA

TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

AB		EQ 3MG BASE		A217638	003	Jun 12, 2024	May	NEWA
AB		EQ 4MG BASE		A217638	004	Jun 12, 2024	May	NEWA

HALCINONIDE

OINTMENT;TOPICAL

HALOG

	+ @ SUN PHARM INDS INC	0.1%		N017824	001		Jan	DISC
--	------------------------	------	--	---------	-----	--	-----	------

SOLUTION;TOPICAL

HALCINONIDE

ENCUBE

		0.1%		A217671	001	May 29, 2024	May	NFTG
--	--	------	--	---------	-----	--------------	-----	------

HALOG

	+ @ SUN PHARM INDS INC	0.1%		N017823	001		Jan	DISC
--	------------------------	------	--	---------	-----	--	-----	------

HALOBETASOL PROPIONATE

LOTION;TOPICAL

ULTRAVATE

	+ @ MICAL PHARMS	0.05%		N208183	001	Nov 06, 2015	May	CAHN
--	------------------	-------	--	---------	-----	--------------	-----	------

	+ @ SUN PHARM INDUSTRIES	0.05%		N208183	001	Nov 06, 2015	May	DISC
--	--------------------------	-------	--	---------	-----	--------------	-----	------

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB	AUROBINDO PHARMA LTD	0.5MG		A218789	001	Apr 19, 2024	Apr	NEWA
----	----------------------	-------	--	---------	-----	--------------	-----	------

AB		1MG		A218789	002	Apr 19, 2024	Apr	NEWA
----	--	-----	--	---------	-----	--------------	-----	------

AB		2MG		A218789	003	Apr 19, 2024	Apr	NEWA
----	--	-----	--	---------	-----	--------------	-----	------

AB		5MG		A218789	004	Apr 19, 2024	Apr	NEWA
----	--	-----	--	---------	-----	--------------	-----	------

AB		10MG		A218789	005	Apr 19, 2024	Apr	NEWA
----	--	------	--	---------	-----	--------------	-----	------

AB		20MG		A218789	006	Apr 19, 2024	Apr	NEWA
----	--	------	--	---------	-----	--------------	-----	------

AB	CHARTWELL RX	0.5MG		A071209	002	Nov 17, 1986	Jan	CAHN
----	--------------	-------	--	---------	-----	--------------	-----	------

AB		1MG		A071209	003	Nov 17, 1986	Jan	CAHN
----	--	-----	--	---------	-----	--------------	-----	------

	@	2MG		A071209	004	Nov 17, 1986	Jan	CAHN
--	---	-----	--	---------	-----	--------------	-----	------

AB		5MG		A071209	001	Nov 17, 1986	Jan	CAHN
----	--	-----	--	---------	-----	--------------	-----	------

AB		10MG		A071210	001	Mar 11, 1988	Jan	CAHN
----	--	------	--	---------	-----	--------------	-----	------

AB		20MG		A071211	001	Mar 11, 1988	Jan	CAHN
----	--	------	--	---------	-----	--------------	-----	------

AB	MANKIND PHARMA	0.5MG		A216918	001	Apr 11, 2024	Apr	NEWA
----	----------------	-------	--	---------	-----	--------------	-----	------

AB		1MG		A216918	002	Apr 11, 2024	Apr	NEWA
----	--	-----	--	---------	-----	--------------	-----	------

AB		2MG		A216918	003	Apr 11, 2024	Apr	NEWA
----	--	-----	--	---------	-----	--------------	-----	------

AB		5MG		A216918	004	Apr 11, 2024	Apr	NEWA
----	--	-----	--	---------	-----	--------------	-----	------

AB		10MG		A216918	005	Apr 11, 2024	Apr	NEWA
----	--	------	--	---------	-----	--------------	-----	------

AB		20MG		A216918	006	Apr 11, 2024	Apr	NEWA
----	--	------	--	---------	-----	--------------	-----	------

AB	SCIEGEN PHARMS INC	5MG		A071130	002	Feb 17, 1987	May	CMS1
----	--------------------	-----	--	---------	-----	--------------	-----	------

AB		10MG		A071130	003	May 12, 1987	May	CMS1
----	--	------	--	---------	-----	--------------	-----	------

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

@ TEVA PHARMS USA

		EQ 50MG BASE/ML		A075393	001	May 11, 1999	Jan	DISC
--	--	-----------------	--	---------	-----	--------------	-----	------

@

		EQ 100MG BASE/ML		A075393	002	May 11, 1999	Jan	DISC
--	--	------------------	--	---------	-----	--------------	-----	------

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALOPERIDOL

AA	RUBICON	EQ 2MG BASE/ML		A218371	001	Jan 31, 2024	Jan	NEWA
----	---------	----------------	--	---------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

>A>	@ ASPEN GLOBAL INC	1,000 UNITS/ML		N000552	008		Jun	CAHN
-----	--------------------	----------------	--	---------	-----	--	-----	------

>A>	@	5,000 UNITS/ML		N000552	009		Jun	CAHN
-----	---	----------------	--	---------	-----	--	-----	------

>A>	@	10,000 UNITS/ML		N000552	010		Jun	CAHN
-----	---	-----------------	--	---------	-----	--	-----	------

>D>	@ ORGANON USA INC	1,000 UNITS/ML		N000552	008		Jun	CAHN
-----	-------------------	----------------	--	---------	-----	--	-----	------

>D>	@	5,000 UNITS/ML		N000552	009		Jun	CAHN
-----	---	----------------	--	---------	-----	--	-----	------

>D>	@	10,000 UNITS/ML		N000552	010		Jun	CAHN
-----	---	-----------------	--	---------	-----	--	-----	------

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%

+!	FRESENIUS KABI USA	40 UNITS/ML		N017029	021	Aug 24, 2017	Mar	NEWA
----	--------------------	-------------	--	---------	-----	--------------	-----	------

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

+!	FRESENIUS KABI USA	50 UNITS/ML		N017029	022	Aug 24, 2017	Mar	NEWA
----	--------------------	-------------	--	---------	-----	--------------	-----	------

+!		100 UNITS/ML		N017029	023	Aug 24, 2017	Mar	NEWA
----	--	--------------	--	---------	-----	--------------	-----	------

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%

+!	FRESENIUS KABI USA	50 UNITS/ML		N017029	024	Aug 24, 2017	Mar	NEWA
----	--------------------	-------------	--	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%

	+!		100 UNITS/ML	N017029	025	Aug 24, 2017	Mar	NEWA
		LIQUAEMIN LOCK FLUSH						
>A>	@	ASPEN GLOBAL INC	100 UNITS/ML	N000552	007		Jun	CAHN
>D>	@	ORGANON USA INC	100 UNITS/ML	N000552	007		Jun	CAHN
		LIQUAEMIN SODIUM						
>A>	@	ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	004		Jun	CAHN
>A>	@		5,000 UNITS/ML	N000552	003		Jun	CAHN
>A>	@		10,000 UNITS/ML	N000552	005		Jun	CAHN
>A>	@		20,000 UNITS/ML	N000552	001		Jun	CAHN
>A>	@		40,000 UNITS/ML	N000552	002		Jun	CAHN
>D>	@	ORGANON USA INC	1,000 UNITS/ML	N000552	004		Jun	CAHN
>D>	@		5,000 UNITS/ML	N000552	003		Jun	CAHN
>D>	@		10,000 UNITS/ML	N000552	005		Jun	CAHN
>D>	@		20,000 UNITS/ML	N000552	001		Jun	CAHN
>D>	@		40,000 UNITS/ML	N000552	002		Jun	CAHN
		LIQUAEMIN SODIUM PRESERVATIVE FREE						
>A>	@	ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986	Jun	CAHN
>A>	@		5,000 UNITS/ML	N000552	012	Apr 11, 1986	Jun	CAHN
>A>	@		10,000 UNITS/ML	N000552	013	Apr 11, 1986	Jun	CAHN
>D>	@	ORGANON USA INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986	Jun	CAHN
>D>	@		5,000 UNITS/ML	N000552	012	Apr 11, 1986	Jun	CAHN
>D>	@		10,000 UNITS/ML	N000552	013	Apr 11, 1986	Jun	CAHN

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

	+!	ENDO OPERATIONS	50MG	N022058	001	May 03, 2007	Apr	CAHN
		VANTAS						
	+	@ ENDO OPERATIONS	50MG	N021732	001	Oct 12, 2004	May	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	!	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Mar	CHRS
	@	GENUS	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Apr	CAHN
	@	PAI HOLDINGS PHARM	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Mar	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
>D>	@	MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	Jun	CAHN
>A>	@	NORVIUM BIOSCIENCE	20MG/ML	A204680	001	Apr 28, 2016	Jun	CAHN

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

	@	INVAGEN PHARMS	10MG	A090255	001	Dec 15, 2008	Mar	DISC
	@		25MG	A090255	002	Dec 15, 2008	Mar	DISC
	@		50MG	A090255	003	Dec 15, 2008	Mar	DISC
	@		100MG	A090255	004	Dec 15, 2008	Mar	DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB		I3 PHARMS	37.5MG; 20MG	A215988	001	Jan 17, 2024	Jan	NEWA
----	--	-----------	--------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

	@	GRANULES	12.5MG; 50MG	A218015	001	Sep 29, 2023	Mar	DISC
	@		12.5MG; 100MG	A218015	002	Sep 29, 2023	Mar	DISC
	@		25MG; 100MG	A218015	003	Sep 29, 2023	Mar	DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

	@	SUN PHARM INDS	25MG; 50MG	A090654	001	Jan 19, 2012	May	DISC
	@		25MG; 100MG	A090654	002	Jan 19, 2012	May	DISC
	@		50MG; 100MG	A090654	003	Jan 19, 2012	May	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

@	TEVA PHARMS USA	12.5MG;40MG	A200532	002	Apr 24, 2017	May	DISC
---	-----------------	-------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A201356	001	Apr 20, 2011	Mar	DISC
---	----------------	---------------------	---------	-----	--------------	-----	------

@		12.5MG;EQ 20MG BASE	A201356	002	Apr 20, 2011	Mar	DISC
---	--	---------------------	---------	-----	--------------	-----	------

@		25MG;EQ 20MG BASE	A201356	003	Apr 20, 2011	Mar	DISC
---	--	-------------------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

AP	+	FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Feb	CFTG
----	---	--------------------	----------	---------	-----	--------------	-----	------

AP	+		0.5MG/0.5ML	N019034	007	Feb 10, 2017	Feb	CFTG
----	---	--	-------------	---------	-----	--------------	-----	------

	+		0.5MG/0.5ML	N019034	007	Feb 10, 2017	Jan	NEWA
--	---	--	-------------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

AP		HIKMA	0.2MG/ML	A216899	001	Feb 09, 2024	Feb	NFTG
----	--	-------	----------	---------	-----	--------------	-----	------

AP			0.5MG/0.5ML	A216899	002	Feb 09, 2024	Feb	NFTG
----	--	--	-------------	---------	-----	--------------	-----	------

AP			1MG/ML	A216899	003	Feb 09, 2024	Feb	NEWA
----	--	--	--------	---------	-----	--------------	-----	------

AP			2MG/ML	A216899	004	Feb 09, 2024	Feb	NEWA
----	--	--	--------	---------	-----	--------------	-----	------

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

@	GENUS	5MG/5ML	A207108	001	Apr 22, 2020	Jan	CAHN
---	-------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@	GENUS	2MG	A077471	002	Dec 09, 2009	Jan	CAHN
---	-------	-----	---------	-----	--------------	-----	------

@		4MG	A077471	003	Dec 09, 2009	Jan	CAHN
---	--	-----	---------	-----	--------------	-----	------

@		8MG	A077471	001	Dec 09, 2009	Jan	CAHN
---	--	-----	---------	-----	--------------	-----	------

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

>A>	AB	ALLIED	200MG	A040150	001	Jan 27, 1996	Jun	CAHN
-----	----	--------	-------	---------	-----	--------------	-----	------

>D>	AB	APPCO	100MG	A210441	002	Sep 19, 2022	Jun	CHRS
-----	----	-------	-------	---------	-----	--------------	-----	------

>A>	AB	!	100MG	A210441	002	Sep 19, 2022	Jun	CHRS
-----	----	---	-------	---------	-----	--------------	-----	------

>D>	AB	CREEKWOOD PHARMS	200MG	A040150	001	Jan 27, 1996	Jun	CAHN
-----	----	------------------	-------	---------	-----	--------------	-----	------

AB			200MG	A040150	001	Jan 27, 1996	Apr	CMFD
----	--	--	-------	---------	-----	--------------	-----	------

@			200MG	A040150	001	Jan 27, 1996	Jan	CAHN
---	--	--	-------	---------	-----	--------------	-----	------

AB		SENORES PHARMS	200MG	A212902	001	May 14, 2020	Feb	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

AB		TEVA PHARMS	200MG	A040081	001	Sep 30, 1994	Feb	CMFD
----	--	-------------	-------	---------	-----	--------------	-----	------

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

AB		QILU	500MG	A218021	001	Mar 06, 2024	Feb	NEWA
----	--	------	-------	---------	-----	--------------	-----	------

SOLUTION; ORAL

XROMI

+	!	NOVA LABS LTD	100MG/ML	N216593	001	Apr 04, 2024	Apr	NEWA
---	---	---------------	----------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

>D>		@	APOZEAL PHARMS	10MG/5ML	A210634	001	Feb 26, 2019	Jun	CMFD
-----	--	---	----------------	----------	---------	-----	--------------	-----	------

>A>	AA			10MG/5ML	A210634	001	Feb 26, 2019	Jun	CMFD
-----	----	--	--	----------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@	INVAGEN PHARMS	10MG	A040812	001	Mar 12, 2008	Mar	DISC
---	----------------	------	---------	-----	--------------	-----	------

@		25MG	A040812	002	Mar 12, 2008	Mar	DISC
---	--	------	---------	-----	--------------	-----	------

@		50MG	A040812	003	Mar 12, 2008	Mar	DISC
---	--	------	---------	-----	--------------	-----	------

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

IBANDRONATE SODIUM

@	SUN PHARM	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	May	DISC
---	-----------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

IBANDRONATE SODIUM

@	WATSON LABS TEVA	EQ 150MG BASE	A079003	001	Mar 20, 2012	May	DISC
---	------------------	---------------	---------	-----	--------------	-----	------

IBRUTINIBTABLET; ORAL
IMBRUVICA

+! PHARMACYCLICS LLC 420MG N210563 003 Feb 16, 2018 Jan CHRS

IBUPROFENTABLET; ORAL
IBUPROFEN

@ ENDO OPERATIONS	300MG	A 071230	001	Oct 22, 1986	May	CAHN
@	400MG	A 071231	001	Oct 22, 1986	May	CAHN
@	400MG	A 071644	001	Feb 01, 1988	May	CAHN
@	600MG	A 071232	001	Oct 22, 1986	May	CAHN
@	800MG	A 072004	001	Nov 18, 1987	May	CAHN

IBUTILIDE FUMARATEINJECTABLE; INJECTION
IBUTILIDE FUMARATE

AP AVET LIFESCIENCES 0.1MG/ML A204146 001 Apr 01, 2024 Mar NEWA

ICATIBANT ACETATEINJECTABLE; SUBCUTANEOUS
ICATIBANT ACETATE

>A> AP ALEMBIC EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A213773 001 Jun 14, 2024 Jun NEWA

ICOSAPENT ETHYLCAPSULE; ORAL
ICOSAPENT ETHYL

AB ASCENT PHARMS INC	1GM	A216811	002	Feb 16, 2024	Feb	NEWA
AB ZYDUS LIFESCIENCES	500MG	A217656	001	Apr 20, 2023	Apr	CAHN
AB	1GM	A217656	002	Apr 20, 2023	Apr	CAHN

IDARUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
IDARUBICIN HYDROCHLORIDE

@ RISING 1MG/ML A200144 001 Oct 11, 2012 Feb CAHN

IFOSFAMIDEINJECTABLE; INJECTION
IFOSFAMIDE

>A> @ EXTROVIS	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012	Jun	CAHN
>A> @	3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012	Jun	CAHN
>D> @ MYLAN LABS LTD	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012	Jun	CAHN
>D> @	3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012	Jun	CAHN

ILOPROSTSOLUTION; INHALATION
VENTAVIS+ @ ACTELION 10MCG/ML (10MCG/ML) N021779 002 Dec 08, 2005 Mar DISC
+ @ 20MCG/ML (20MCG/ML) N021779 003 Aug 07, 2009 Mar DISCSOLUTION; INTRAVENOUS
AURLUMYN

+! EICOS SCI 100MCG/ML (100MCG/ML) N217933 001 Feb 13, 2024 Feb NEWA

>A> IMETELSTAT SODIUM>A> POWDER; INTRAVENOUS
>A> RYTELO>A> +! GERON EQ 47MG BASE/VIAL N217779 001 Jun 06, 2024 Jun NEWA
>A> +! EQ 188MG BASE/VIAL N217779 002 Jun 06, 2024 Jun NEWAIMIPRAMINE HYDROCHLORIDETABLET; ORAL
IMIPRAMINE HYDROCHLORIDE

AB ! LEADING	50MG	A 040903	003	Oct 24, 2012	Apr	CHRS
+ @ SPECGX LLC	10MG	A 087846	002	May 22, 1984	Apr	DISC
+ @	25MG	A 087846	003	May 22, 1984	Apr	DISC
TOFRANIL						
+ @ SPECGX LLC	50MG	A 087846	001	May 22, 1984	Apr	DISC

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

>A>		INDIUM IN-111 PENTETREOTIDE KIT						
>A>	AP	SUN PHARM INDS INC	3mCi/ML	A212785	001	Jul 01, 2024	Jun	NFTG
		OCTREOSCAN						
>D>	+	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jun	CFTG
>A>	AP	+	3mCi/ML	N020314	001	Jun 02, 1994	Jun	CFTG

INDOMETHACIN

SUPPOSITORY; RECTAL

		INDOMETHACIN						
AB		ZYDUS LIFESCIENCES	50MG	A216184	001	Aug 02, 2023	Apr	CAHN
		SUSPENSION; ORAL						
		INDOCIN						
AB	+	ZYLA	25MG/5ML	N018332	001	Oct 10, 1985	Jan	CTEC
		INDOMETHACIN						
AB		NOVITIUM PHARMA	25MG/5ML	A217883	001	Jan 12, 2024	Jan	NEWA

IOBENGUANE I-131

SOLUTION; INTRAVENOUS

		AZEDRA						
		+ @ PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018	Feb	DISC

IOPAMIDOL

INJECTABLE; INJECTION

		IOPAMIDOL						
AP		HAINAN POLY	51%	A217134	002	Apr 09, 2024	Mar	NEWA
AP			61%	A217134	003	Apr 09, 2024	Mar	NEWA
AP			76%	A217134	004	Apr 09, 2024	Mar	NEWA
		ISOVUE-250						
AP	+	BRACCO	51%	N018735	007	Jul 06, 1992	Mar	CTEC
		ISOVUE-300						
AP	+	BRACCO	61%	N018735	002	Dec 31, 1985	Mar	CTEC
		ISOVUE-370						
AP	+	BRACCO	76%	N018735	003	Dec 31, 1985	Mar	CTEC

IRBESARTAN

TABLET; ORAL

		IRBESARTAN						
AB		IPCA LABS LTD	75MG	A211056	001	May 22, 2024	May	NEWA
AB			150MG	A211056	002	May 22, 2024	May	NEWA
AB			300MG	A211056	003	May 22, 2024	May	NEWA

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

		ISOPROTERENOL HYDROCHLORIDE						
		@ CIPLA	0.2MG/ML	A210322	001	Jun 12, 2018	Mar	DISC
>D>	AP	EUGIA PHARMA	0.2MG/ML	A211864	001	Feb 09, 2021	Jun	DISC
>A>		@	0.2MG/ML	A211864	001	Feb 09, 2021	Jun	DISC

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

		DILATRATE-SR						
		+ @ ENDO OPERATIONS	40MG	N019790	001	Sep 02, 1988	May	CAHN
		TABLET; ORAL						
		ISOSORBIDE DINITRATE						
AB		ENDO OPERATIONS	40MG	A211290	001	Nov 23, 2021	Apr	CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL

		MONOKET						
AB	+	OMNIVIUM PHARMS	10MG	N020215	002	Jun 30, 1993	Jan	CAHN
AB	+	!	20MG	N020215	001	Jun 30, 1993	Jan	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
		ISOSORBIDE MONONITRATE						
AB		CHARTWELL MOLECULAR	120MG	A075155	003	Aug 04, 2000	Mar	CHRS
AB	!	RICONPHARMA LLC	120MG	A210918	003	Nov 05, 2018	Mar	CHRS
AB		SHANDONG	30MG	A214115	002	Feb 08, 2024	Feb	NEWA
AB			60MG	A214115	003	Feb 08, 2024	Feb	NEWA
AB			120MG	A214115	001	Apr 29, 2022	Mar	CMFD

TABLET, EXTENDED RELEASE;ORAL						
ISOSORBIDE MONONITRATE						
AB	ZYDUS PHARMS	30MG	A218255	001	Feb 15, 2024	Feb NEWA
AB		60MG	A218255	002	Feb 15, 2024	Feb NEWA
AB		120MG	A218255	003	Feb 15, 2024	Feb NEWA
<u>ISOSULFAN BLUE</u>						
SOLUTION;SUBCUTANEOUS						
ISOSULFAN BLUE						
AP	AM REGENT	1%	A210294	001	May 17, 2023	May CDFR
AP		50MG/5ML (10MG/ML)	A210294	001	May 17, 2023	May CPOT
	@ BELOTECA	1%	A210714	001	Jan 16, 2019	May CDFR
	@	50MG/5ML (10MG/ML)	A210714	001	Jan 16, 2019	May CPOT
	@ EUGIA PHARMA	1%	A206831	001	Feb 02, 2016	May CDFR
	@	50MG/5ML (10MG/ML)	A206831	001	Feb 02, 2016	May CPOT
	@ FRESENIUS KABI USA	1%	A211869	001	Sep 08, 2022	May CDFR
	@	50MG/5ML (10MG/ML)	A211869	001	Sep 08, 2022	May CPOT
AP	MEITHEAL	1%	A213130	001	Nov 03, 2021	May CDFR
AP		50MG/5ML (10MG/ML)	A213130	001	Nov 03, 2021	May CPOT
AP	MSN	1%	A216090	001	Sep 16, 2022	May CDFR
AP		50MG/5ML (10MG/ML)	A216090	001	Sep 16, 2022	May CPOT
AP	! MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	May CDFR
AP	!	50MG/5ML (10MG/ML)	A090874	001	Jul 20, 2010	May CPOT
	@ SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019	May CDFR
	@	50MG/5ML (10MG/ML)	A210558	001	Jul 12, 2019	May CPOT
	LYMPHAZURIN					
	+ @ COVIDIEN	1%	N018310	001		May CDFR
	+ @	50MG/5ML (10MG/ML)	N018310	001		May CPOT
<u>ISOTRETINOIN</u>						
CAPSULE;ORAL						
ISOTRETINOIN						
AB2	AUROBINDO PHARMA	10MG	A218194	001	Jan 29, 2024	Jan NEWA
AB2		20MG	A218194	002	Jan 29, 2024	Jan NEWA
AB2		25MG	A218194	003	Jan 29, 2024	Jan NEWA
AB2		30MG	A218194	004	Jan 29, 2024	Jan NEWA
AB2		35MG	A218194	005	Jan 29, 2024	Jan NEWA
AB2		40MG	A218194	006	Jan 29, 2024	Jan NEWA
<u>ITRACONAZOLE</u>						
CAPSULE;ORAL						
ITRACONAZOLE						
	@ ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May DISC
	@ RISING	100MG	A205724	001	Dec 13, 2016	Apr CAHN
<u>IVABRADINE HYDROCHLORIDE</u>						
TABLET;ORAL						
IVABRADINE HYDROCHLORIDE						
AB	INGENUS PHARMS LLC	EQ 5MG BASE	A214051	001	Dec 30, 2021	May CMFD
AB		EQ 7.5MG BASE	A214051	002	Dec 30, 2021	May CMFD
<u>IVERMECTIN</u>						
CREAM;TOPICAL						
IVERMECTIN						
AB	ZYDUS LIFESCIENCES	1%	A215210	001	Aug 02, 2022	Mar CAHN
<u>KETOCONAZOLE</u>						
AEROSOL, FOAM;TOPICAL						
EXTINA						
	+ @ MYLAN	2%	N021738	001	Jun 12, 2007	Feb DISC
KETOCONAZOLE						
AB	! XIROMED	2%	A213601	001	May 21, 2021	Feb CHRS
TABLET;ORAL						
KETOCONAZOLE						
AB	SENORES PHARMS	200MG	A075912	001	Jan 10, 2002	Feb CAHN
<u>KETOROLAC TROMETHAMINE</u>						
SOLUTION/DROPS;OPHTHALMIC						
KETOROLAC TROMETHAMINE						
AT	CAPLIN	0.5%	A218204	001	Mar 26, 2024	Mar NEWA

L-GLUTAMINEFOR SOLUTION;ORAL
ENDARI

>D>	+	EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017	Jun CFTG
>A>	AA	+	5GM/PACKET	N208587	001	Jul 07, 2017	Jun CFTG
>A>		L-GLUTAMINE					
>A>	AA	NOVITIUM PHARMA	5GM/PACKET	A215647	001	Jul 08, 2024	Jun NFTG

LABETALOL HYDROCHLORIDETABLET;ORAL
LABETALOL HYDROCHLORIDE

AB		ENDO OPERATIONS	100MG	A200908	001	Jul 10, 2012	Apr CAHN
AB	!		200MG	A200908	002	Jul 10, 2012	Apr CAHN
AB			300MG	A200908	003	Jul 10, 2012	Apr CAHN

LACOSAMIDESOLUTION;INTRAVENOUS
LACOSAMIDE

AP		DR REDDYS	200MG/20ML (10MG/ML)	A217718	001	Mar 25, 2024	Mar NEWA
AP		HAINAN POLY	200MG/20ML (10MG/ML)	A217311	001	Feb 13, 2024	Feb NEWA
AP		HIKMA	200MG/20ML (10MG/ML)	A216806	001	Apr 05, 2024	Mar NEWA

SOLUTION;ORAL

LACOSAMIDE

	@	AMNEAL PHARMS	10MG/ML	A204839	001	Mar 27, 2024	Apr DISC
AA			10MG/ML	A204839	001	Mar 27, 2024	Mar NEWA
AA		AUROBINDO PHARMA LTD	10MG/ML	A209224	001	Jan 24, 2024	Jan NEWA
AA		CHARTWELL RX	10MG/ML	A215154	001	May 15, 2024	May NEWA

TABLET;ORAL

LACOSAMIDE

AB		MACLEODS PHARMS LTD	50MG	A208466	001	May 24, 2024	May NEWA
AB			100MG	A208466	002	May 24, 2024	May NEWA
AB			150MG	A208466	003	May 24, 2024	May NEWA
AB			200MG	A208466	004	May 24, 2024	May NEWA
AB		MEDLEY PHARMS	50MG	A218014	001	Apr 02, 2024	Mar NEWA
AB			100MG	A218014	002	Apr 02, 2024	Mar NEWA
AB			150MG	A218014	003	Apr 02, 2024	Mar NEWA
AB			200MG	A218014	004	Apr 02, 2024	Mar NEWA
	@	ZYDUS PHARMS	50MG	A204947	001	Dec 15, 2023	May DISC
	@		100MG	A204947	002	Dec 15, 2023	May DISC
	@		150MG	A204947	003	Dec 15, 2023	May DISC
	@		200MG	A204947	004	Dec 15, 2023	May DISC

LACTULOSESOLUTION;ORAL
LACTULOSE

	@	HIKMA	10GM/15ML	A074076	001	Jul 03, 1995	Mar DISC
AA	!	PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	Mar CHRS

SOLUTION;ORAL, RECTAL

GENERLAC

>A>	AA	CHARTWELL RX	10GM/15ML	A074603	001	Oct 31, 1996	Jun CAHN
>D>	AA	WOCKHARDT BIO AG	10GM/15ML	A074603	001	Oct 31, 1996	Jun CAHN
		LACTULOSE					
	@	PAI HOLDINGS PHARM	10GM/15ML	A074077	001	Jul 03, 1995	Feb DISC

LAMIVUDINE

SOLUTION;ORAL

EPIVIR-HBV

+ @ GLAXOSMITHKLINE 5MG/ML

N021004 001 Dec 08, 1998 Apr DISC

TABLET;ORAL

EPIVIR-HBV

+ @ GLAXOSMITHKLINE 100MG

N021003 001 Dec 08, 1998 Apr DISC

LAMIVUDINE

AB	!	APOTEX	100MG	A202941	001	Jan 02, 2014	Apr CHRS
>D>	@	MYLAN	150MG	A204528	001	Mar 04, 2016	Jun CAHN
>D>	@		300MG	A204528	002	Mar 04, 2016	Jun CAHN
	@	MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Jan DISC
	@		300MG	A078545	002	Mar 05, 2019	Jan DISC
>A>	@	NATCO	150MG	A204528	001	Mar 04, 2016	Jun CAHN
>A>	@		300MG	A204528	002	Mar 04, 2016	Jun CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

	+ @ VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	Jan	DISC
	LAMIVUDINE AND ZIDOVUDINE						
AB	! HETERO LABS LTD III	150MG;300MG	A079124	001	Sep 17, 2015	Jan	CHRS
>D>	@ MYLAN	150MG;300MG	A204005	001	Aug 28, 2014	Jun	CAHN
>A>	@ NATCO	150MG;300MG	A204005	001	Aug 28, 2014	Jun	CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	GLENMARK PHARMS LTD	25MG	A090169	001	May 12, 2012	Mar	CAHN
AB		100MG	A090169	002	May 12, 2012	Mar	CAHN
AB		150MG	A090169	003	May 12, 2012	Mar	CAHN
AB		200MG	A090169	004	May 12, 2012	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

	@ ANCHEN PHARMS	25MG	A201374	001	Dec 26, 2012	Feb	DISC
	@	50MG	A201374	002	Dec 26, 2012	Feb	DISC
	@	100MG	A201374	003	Dec 26, 2012	Feb	DISC
	@	200MG	A201374	004	Dec 26, 2012	Feb	DISC
	@	250MG	A201374	005	Dec 26, 2012	Feb	DISC
	@	300MG	A201374	006	Dec 26, 2012	Feb	DISC
	@ ENDO OPERATIONS	25MG	A201374	001	Dec 26, 2012	May	CAHN
AB		25MG	A201791	001	Jan 18, 2013	Apr	CAHN
	@	50MG	A201374	002	Dec 26, 2012	May	CAHN
AB		50MG	A201791	002	Jan 18, 2013	Apr	CAHN
	@	100MG	A201374	003	Dec 26, 2012	May	CAHN
AB		100MG	A201791	003	Jan 18, 2013	Apr	CAHN
	@	200MG	A201374	004	Dec 26, 2012	May	CAHN
AB		200MG	A201791	004	Jan 18, 2013	Apr	CAHN
	@	250MG	A201374	005	Dec 26, 2012	May	CAHN
AB		250MG	A201791	005	Jan 18, 2013	Apr	CAHN
	@	300MG	A201374	006	Dec 26, 2012	May	CAHN
AB		300MG	A201791	006	Jan 18, 2013	Apr	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

LAMOTRIGINE

AB	ENDO OPERATIONS	25MG	A204158	001	Oct 27, 2015	Apr	CAHN
AB		50MG	A204158	002	Oct 27, 2015	Apr	CAHN
AB		100MG	A204158	003	Oct 27, 2015	Apr	CAHN
AB		200MG	A204158	004	Oct 27, 2015	Apr	CAHN

LANREOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

LANREOTIDE ACETATE

AB	INVAGEN PHARMS	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	A217193	001	May 21, 2024	May	NFTG
AB		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	A217193	002	May 21, 2024	May	NFTG
AB		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	A217193	003	May 21, 2024	May	NFTG
	SOMATULINE DEPOT						
AB	+! IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007	May	CFTG
AB	+!	EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007	May	CFTG
AB	+!	EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007	May	CFTG

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

@ SUN PHARM

@

15MG

30MG

A202637	001	Sep 13, 2013	May	DISC
A091509	001	Sep 13, 2013	May	DISC

LEFAMULIN ACETATE

SOLUTION; INTRAVENOUS

XENLETA

+! NABRIVA

EQ 150MG BASE/15ML (EQ 10MG
BASE/ML)

N211673	001	Aug 19, 2019	Apr	CMFD
---------	-----	--------------	-----	------

LENALIDOMIDECAPSULE; ORAL
LENALIDOMIDE

AB	QILU	2.5MG	A217265	001	Feb 22, 2024	Feb	NEWA
AB		5MG	A217265	002	Feb 22, 2024	Feb	NEWA
AB		10MG	A217265	003	Feb 22, 2024	Feb	NEWA
AB		15MG	A217265	004	Feb 22, 2024	Feb	NEWA
AB		20MG	A217265	005	Feb 22, 2024	Feb	NEWA
AB		25MG	A217265	006	Feb 22, 2024	Feb	NEWA

LEUCOVORIN CALCIUMINJECTABLE; INJECTION
LEUCOVORIN CALCIUM

>D>	AP	KINDOS	EQ 50MG BASE/VIAL	A216590	001	Jul 19, 2023	Jun	CAHN
>D>	AP		EQ 100MG BASE/VIAL	A216590	002	Jul 19, 2023	Jun	CAHN
>D>	AP		EQ 200MG BASE/VIAL	A216590	003	Jul 19, 2023	Jun	CAHN
>D>	AP		EQ 350MG BASE/VIAL	A216590	004	Jul 19, 2023	Jun	CAHN
>D>	AP		EQ 500MG BASE/VIAL	A216590	005	Jul 19, 2023	Jun	CAHN
>A>	AP	MEITHEAL	EQ 50MG BASE/VIAL	A216590	001	Jul 19, 2023	Jun	CAHN
>A>	AP		EQ 100MG BASE/VIAL	A216590	002	Jul 19, 2023	Jun	CAHN
>A>	AP		EQ 200MG BASE/VIAL	A216590	003	Jul 19, 2023	Jun	CAHN
>A>	AP		EQ 350MG BASE/VIAL	A216590	004	Jul 19, 2023	Jun	CAHN
>A>	AP		EQ 500MG BASE/VIAL	A216590	005	Jul 19, 2023	Jun	CAHN

LEVALBUTEROL HYDROCHLORIDESOLUTION; INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN	!	MYLAN SPECIALITY LP	EQ 0.25% BASE	A078309	001	Mar 20, 2009	Apr	CHRS
		@ SUN PHARM	EQ 0.0103% BASE	A207820	001	Nov 05, 2018	May	DISC
		@	EQ 0.021% BASE	A207820	002	Nov 05, 2018	May	DISC
		@	EQ 0.042% BASE	A207820	003	Nov 05, 2018	May	DISC
AN	!	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr	CHRS
AN	!		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr	CHRS
AN	!		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr	CHRS
		XOPENEX						
	+	@ HIKMA	EQ 0.0103% BASE	N020837	003	Jan 30, 2002	Apr	DISC
	+	@	EQ 0.021% BASE	N020837	001	Mar 25, 1999	Apr	DISC
	+	@	EQ 0.042% BASE	N020837	002	Mar 25, 1999	Apr	DISC
	+	@	EQ 0.25% BASE	N020837	004	Jul 18, 2003	Apr	DISC

LEVAMLODIPINE MALEATETABLET; ORAL
CONJUPRI

+		CSPC OUYI	EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Mar	CMFD
+	!		EQ 5MG BASE	N212895	003	Dec 19, 2019	Mar	CMFD

LEVETIRACETAMINJECTABLE; INTRAVENOUS
LEVETIRACETAM

AP		ADRASTEIA PHARMA	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
		@ SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010	May	DISC
		LEVETIRACETAM IN SODIUM CHLORIDE						
AP		B BRAUN MEDICAL INC	500MG/100ML (5MG/ML)	A209705	001	Feb 27, 2024	Feb	NEWA
AP			1GM/100ML (10MG/ML)	A209705	002	Feb 27, 2024	Feb	NEWA
AP			1.5GM/100ML (15MG/ML)	A209705	003	Feb 27, 2024	Feb	NEWA
AP		BAXTER HLTHCARE CORP	500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Feb	CTNA
AP			1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Feb	CTNA
AP			1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Feb	CTNA
		@ FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Mar	DISC
		@	1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Mar	DISC
		@	1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Mar	DISC
AP		HIKMA	500MG/100ML (5MG/ML)	A211356	001	Feb 12, 2024	Feb	NEWA
AP			1GM/100ML (10MG/ML)	A211356	002	Feb 12, 2024	Feb	NEWA
AP			1.5GM/100ML (15MG/ML)	A211356	003	Feb 12, 2024	Feb	NEWA
	+	@ HQ SPCLT PHARMA	250MG/50ML (5MG/ML)	N202543	004	Dec 14, 2020	Feb	DISC
		SOLUTION; ORAL						
		LEVETIRACETAM						
		@ HIKMA	100MG/ML	A090601	001	Feb 28, 2012	Mar	DISC
		@ STRIDES PHARMA	100MG/ML	A214673	001	Nov 20, 2023	May	DISC

TABLET;ORAL

LEVETIRACETAM

@	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	May	DISC
@		500MG	A090843	002	Feb 14, 2011	May	DISC
@		750MG	A090843	003	Feb 14, 2011	May	DISC
@		1GM	A090843	004	Feb 14, 2011	May	DISC
@	GRANULES	250MG	A217878	001	Jun 13, 2023	Mar	DISC
@		500MG	A217878	002	Jun 13, 2023	Mar	DISC
@		750MG	A217878	003	Jun 13, 2023	Mar	DISC
@		1GM	A217878	004	Jun 13, 2023	Mar	DISC
@	INVAGEN PHARMS	250MG	A078234	001	Jan 15, 2009	Mar	DISC
@		500MG	A078234	002	Jan 15, 2009	Mar	DISC
@		750MG	A078234	003	Jan 15, 2009	Mar	DISC

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

@	ANCHEN PHARMS	500MG	A091360	001	Oct 04, 2011	Feb	DISC
@		750MG	A091360	002	Oct 04, 2011	Feb	DISC
@	ENDO OPERATIONS	500MG	A091360	001	Oct 04, 2011	May	CAHN
@		750MG	A091360	002	Oct 04, 2011	May	CAHN

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

>D>	@	PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997	001	Aug 05, 1999	Jun	CRLD
>A>	+	@	EQ 2.5MG BASE/ML	N020997	001	Aug 05, 1999	Jun	CRLD
>D>	@		EQ 5MG BASE/ML	N020997	002	Aug 05, 1999	Jun	CRLD
>A>	+	@	EQ 5MG BASE/ML	N020997	002	Aug 05, 1999	Jun	CRLD
>D>	@		EQ 7.5MG BASE/ML	N020997	003	Aug 05, 1999	Jun	CRLD
>A>	+	@	EQ 7.5MG BASE/ML	N020997	003	Aug 05, 1999	Jun	CRLD

LEVOCARNITINE

SOLUTION;ORAL

LEVOCARNITINE

@	HIKMA	1GM/10ML	A077399	001	Oct 25, 2007	Mar	DISC
---	-------	----------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		IPCA LABS LTD	5MG	A204626	001	May 06, 2024	Apr	NEWA
----	--	---------------	-----	---------	-----	--------------	-----	------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

>D>	@	BAXTER HLTHCARE CORP	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	DISC
>D>	@	MYLAN ASI	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	CAHN
>D>	@		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	CAHN
>A>	@	NORVIUM BIOSCIENCE	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	CAHN
>A>	@		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	CAHN

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		KNACK	EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jan	NEWA
AP			EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jan	NEWA
AP			EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jan	NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

@	SAPTALIS PHARMS	0.5%	A090268	001	Dec 20, 2010	Mar	CAHN
---	-----------------	------	---------	-----	--------------	-----	------

TABLET;ORAL

LEVOFLOXACIN

@	CELLTRION	250MG	A090367	001	Jun 20, 2011	Apr	DISC
@		500MG	A090367	002	Jun 20, 2011	Apr	DISC
@		750MG	A090367	003	Jun 20, 2011	Apr	DISC

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

FUSILEV

+	@	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	May	DISC
+	!		EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar	CTEC

LEVOLEUCOVORIN CALCIUM

@	MEITHEAL	EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Mar	DISC
---	----------	-------------------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

>D>	@	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	Jun	CAHN
-----	---	----------------	----------------------------------------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS
LEVOLEUCOVORIN CALCIUM

>D>	@	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	Jun	CAHN
>A>	@ NORVIUM BIOSCIENCE	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	Jun	CAHN
>A>	@	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	Jun	CAHN

LEVONORGESTREL

>D>	INTRAUTERINE DEVICE; INTRAUTERINE							
>D>	KYLEENA							
>D>	+!	BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016	Jun	CDFR
>D>	LILETTA							
>D>	+!	MEDICINES360	52MG	N206229	001	Feb 26, 2015	Jun	CDFR
>D>	MIRENA							
>D>	+!	BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000	Jun	CDFR
>D>	SKYLA							
>D>	+!	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013	Jun	CDFR
>A>	SYSTEM; INTRAUTERINE							
>A>	KYLEENA							
>A>	+!	BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016	Jun	CDFR
>A>	LILETTA							
>A>	+!	MEDICINES360	52MG	N206229	001	Feb 26, 2015	Jun	CDFR
>A>	MIRENA							
>A>	+!	BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000	Jun	CDFR
>A>	SKYLA							
>A>	+!	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013	Jun	CDFR
>A>	TABLET; ORAL							
>A>	LEVONORGESTREL							
>A>	@ XIROMED	0.75MG	A202740	001	Sep 02, 2016	May	CAHN	

LEVOTHYROXINE SODIUMPOWDER; INTRAVENOUS
LEVOTHYROXINE SODIUM

@ ENDO OPERATIONS	200MCG/VIAL	A205366	001	Dec 07, 2015	May	CAHN
-------------------	-------------	---------	-----	--------------	-----	------

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM							
AB1, AB2, AB3, AB4	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.05MG	A207588	002	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.075MG	A207588	003	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.088MG	A207588	004	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.1MG	A207588	005	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.112MG	A207588	006	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.125MG	A207588	007	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.137MG	A207588	008	May 10, 2022	Feb	CTEC
AB1, AB2, AB3,		0.15MG	A207588	009	May 10, 2022	Feb	CTEC

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB4								
AB1,		0.175MG		A207588	010	May 10, 2022	Feb	CTEC
AB2,								
AB3,								
AB4								
AB1,		0.2MG		A207588	011	May 10, 2022	Feb	CTEC
AB2,								
AB3,								
AB4								
AB1,		0.3MG		A207588	012	May 10, 2022	Feb	CTEC
AB2,								
AB3,								
AB4								

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

>A>	AT	AUROBINDO PHARMA LTD	5%	A217117	001	Jun 18, 2024	Jun	NEWA
		@ COSETTE	5%	A211019	001	Dec 12, 2018	Apr	DISC

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	1%	A088586	002		Apr	CMS1
AP			2%	A088586	003		Apr	CMS1
		LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE					
>A>		@ EXTROVIS	2%	A090665	001	Sep 27, 2010	Jun	CAHN
>A>	AP	HIKMA	1%	A084625	001		Jun	CAHN
>A>	AP		2%	A084625	002		Jun	CAHN
>D>		@ MYLAN LABS LTD	2%	A090665	001	Sep 27, 2010	Jun	CAHN
>D>	AP	WEST-WARD PHARMS INT	1%	A084625	001		Jun	CAHN
>D>	AP		2%	A084625	002		Jun	CAHN

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT		PAI HOLDINGS PHARM	2%	A218138	001	Feb 20, 2024	Feb	NEWA
----	--	--------------------	----	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT		THE J MOLNER	4%	A218411	001	Apr 29, 2024	Apr	NEWA
----	--	--------------	----	---------	-----	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

>D>		@ HIKMA	2.5%;2.5%	A076290	001	Sep 25, 2003	Mar	DISC
>D>		@ PAI HOLDINGS PHARM	2.5%;2.5%	A205887	001	Jun 29, 2018	Jun	CMFD
>A>	AB		2.5%;2.5%	A205887	001	Jun 29, 2018	Jun	CMFD
>D>		@ RHODES PHARMS	2.5%;2.5%	A213253	001	Sep 21, 2020	Jun	CMFD
>A>	AB		2.5%;2.5%	A213253	001	Sep 21, 2020	Jun	CMFD

LIFITEGRAST

SOLUTION/DROPS;OPHTHALMIC

LIFITEGRAST

		@ EUGIA PHARMA	5%	A215063	001	Nov 07, 2023	May	DISC
		@ MICRO LABS	5%	A215081	001	Aug 04, 2023	May	DISC
		XIIDRA						
	+	BAUSCH AND LOMB INC	5%	N208073	001	Jul 11, 2016	May	CTEC
AB	+		5%	N208073	001	Jul 11, 2016	Jan	CAHN

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

AP		GENEYORK PHARMS	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	May	CMFD
----	--	-----------------	------------------	---------	-----	--------------	-----	------

LIOthyRONINE SODIUM

INJECTABLE;INJECTION

TRIOSTAT

	+	@ ENDO OPERATIONS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	May	CAHN
--	---	-------------------	-------------------	---------	-----	--------------	-----	------

TABLET;ORAL

LIOthyRONINE SODIUM

AB		BIOCON PHARMA	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Mar	CAHN
AB			EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Feb	CAHN
AB			EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Mar	CAHN

TABLET;ORAL								
LIOTHYRONINE SODIUM								
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Feb	CAHN	
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Mar	CAHN	
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Feb	CAHN	
AB	CARNEGIE	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Jan	NEWA	
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Jan	NEWA	
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Jan	NEWA	
<u>LIRAGLUTIDE</u>								
SOLUTION;SUBCUTANEOUS								
SAXENDA								
+	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014	Mar	CAIN	
	VICTOZA							
+	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010	Mar	CAIN	
<u>LISDEXAMFETAMINE DIMESYLATE</u>								
CAPSULE;ORAL								
LISDEXAMFETAMINE DIMESYLATE								
	@ ACTAVIS ELIZABETH	10MG	A202802	001	Aug 25, 2023	Feb	DISC	
	@	20MG	A202802	002	Aug 25, 2023	Feb	DISC	
	@	30MG	A202802	003	Aug 25, 2023	Feb	DISC	
	@	40MG	A202802	004	Aug 25, 2023	Feb	DISC	
	@	50MG	A202802	005	Aug 25, 2023	Feb	DISC	
	@	60MG	A202802	006	Aug 25, 2023	Feb	DISC	
	@	70MG	A202802	007	Aug 25, 2023	Feb	DISC	
AB	HIKMA	10MG	A202827	007	Jan 17, 2024	Jan	NEWA	
TABLET, CHEWABLE;ORAL								
LISDEXAMFETAMINE DIMESYLATE								
AB	MSN	10MG	A218306	001	Feb 02, 2024	Jan	NEWA	
AB		20MG	A218306	002	Feb 02, 2024	Jan	NEWA	
AB		30MG	A218306	003	Feb 02, 2024	Jan	NEWA	
AB		40MG	A218306	004	Feb 02, 2024	Jan	NEWA	
AB		50MG	A218306	005	Feb 02, 2024	Jan	NEWA	
AB		60MG	A218306	006	Feb 02, 2024	Jan	NEWA	
	@ TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Feb	DISC	
	@	20MG	A215415	002	Aug 25, 2023	Feb	DISC	
	@	30MG	A215415	003	Aug 25, 2023	Feb	DISC	
	@	40MG	A215415	004	Aug 25, 2023	Feb	DISC	
	@	50MG	A215415	005	Aug 25, 2023	Feb	DISC	
	@	60MG	A215415	006	Aug 25, 2023	Feb	DISC	
<u>LISINOPRIL</u>								
TABLET;ORAL								
LISINOPRIL								
	@ ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	May	DISC	
	@	5MG	A202554	002	Jul 30, 2013	May	DISC	
	@	10MG	A202554	003	Jul 30, 2013	May	DISC	
	@	20MG	A202554	004	Jul 30, 2013	May	DISC	
	@	30MG	A202554	005	Jul 30, 2013	May	DISC	
	@	40MG	A202554	006	Jul 30, 2013	May	DISC	
<u>LITHIUM CITRATE</u>								
SYRUP;ORAL								
LITHIUM CITRATE								
	@ PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Feb	DISC	
AA	!	RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	NEWA
	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	CTEC
AA	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Feb	CHRS
AA		SAPTALIS PHARMS	EQ 300MG CARBONATE/5ML	A217183	001	Mar 18, 2024	Mar	NEWA
AA			EQ 300MG CARBONATE/5ML	A217183	001	Feb 29, 2024	Feb	NEWA
<u>LOMITAPIDE MESYLATE</u>								
CAPSULE;ORAL								
JUXTAPID								
+	CHIESI	EQ 5MG BASE	N203858	001	Dec 21, 2012	Jan	CAHN	
+		EQ 10MG BASE	N203858	002	Dec 21, 2012	Jan	CAHN	
+		EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan	CAHN	
+		EQ 30MG BASE	N203858	004	Apr 23, 2015	Jan	CAHN	
+	@	EQ 40MG BASE	N203858	005	Apr 23, 2015	Jan	CAHN	
+	@	EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan	CAHN	

LOMUSTINECAPSULE;ORAL
GLEOSTINE

+ @	LATINA PHARMA	5MG	N017588	004	Dec 19, 2014	Feb	CAHN
+		10MG	N017588	001		Feb	CAHN
+	!	40MG	N017588	002		May	CHRS
+		40MG	N017588	002		Feb	CAHN
+		100MG	N017588	003		May	CHRS
+	!	100MG	N017588	003		Feb	CAHN

LONAFARNIBCAPSULE;ORAL
ZOKINVY

+	SENTYNL THERAPS INC	50MG	N213969	001	Nov 20, 2020	May	CAHN
+	!	75MG	N213969	002	Nov 20, 2020	May	CAHN

LOPINAVIR; RITONAVIR

TABLET;ORAL

LOPINAVIR AND RITONAVIR

AB	MYLAN LABS LTD	100MG;25MG	A079074	001	Feb 07, 2024	Jan	NEWA
AB		200MG;50MG	A079074	002	Feb 07, 2024	Jan	NEWA

LORAZEPAMCONCENTRATE;ORAL
LORAZEPAM

@ HIKMA 2MG/ML

A200169 001 Jan 30, 2012 Mar DISC

INJECTABLE;INJECTION

LORAZEPAM

@ ENDO OPERATIONS 2MG/ML

A074793 001 Mar 16, 2000 Apr CAHN

@ 4MG/ML

A074793 002 Mar 16, 2000 Apr CAHN

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

@ AIPING PHARM INC 25MG

A090544 001 Oct 06, 2010 Feb CAHN

@ 50MG

A090544 002 Oct 06, 2010 Feb CAHN

@ 100MG

A090544 003 Oct 06, 2010 Feb CAHN

AB APOTEX 25MG

A218551 001 Jun 04, 2024 May NEWA

AB 50MG

A218551 002 Jun 04, 2024 May NEWA

AB 100MG

A218551 003 Jun 04, 2024 May NEWA

AB CHARTWELL RX 25MG

A077424 001 Oct 06, 2010 Jan CAHN

AB 50MG

A077424 002 Oct 06, 2010 Jan CAHN

AB 100MG

A077424 003 Oct 06, 2010 Jan CAHN

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEPREDNOL ETABONATE

AB HIKMA 0.5%

A213956 001 Nov 29, 2023 Apr CAHN

SUSPENSION/DROPS;OPHTHALMIC

LOTEPREDNOL ETABONATE

AB LUPIN LTD 0.5%

A215719 001 Apr 24, 2024 Apr NEWA

>A> AB PADAGIS US 0.2%

A215203 001 Jul 10, 2024 Jun NEWA

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

@ ENDO OPERATIONS 8MCG

A201442 001 Jun 27, 2022 Apr CAHN

@ 24MCG

A201442 002 Jun 27, 2022 Apr CAHN

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB SLATE RUN PHARMA 20MG

A212091 001 Dec 28, 2020 Feb CAHN

AB 40MG

A212091 002 Dec 28, 2020 Feb CAHN

AB 60MG

A212091 003 Dec 28, 2020 Feb CAHN

AB 80MG

A212091 004 Dec 28, 2020 Feb CAHN

AB 120MG

A212091 005 Dec 28, 2020 Feb CAHN

MACITENTANTABLET; ORAL
MACITENTAN

@ APOTEX	10MG	A211195	001	Jan 09, 2024	Apr DISC
@ ZYDUS LIFESCIENCES	10MG	A211224	001	Apr 06, 2021	May CAHN
OPSUMIT					
+! ACTELION	10MG	N204410	001	Oct 18, 2013	Apr CTEC

MACITENTAN; TADALAFILTABLET; ORAL
OPSYNVI

+ ACTELION	10MG; 20MG	N218490	001	Mar 22, 2024	Mar NEWA
+!	10MG; 40MG	N218490	002	Mar 22, 2024	Mar NEWA

MAFENIDE ACETATEFOR SOLUTION; TOPICAL
MAFENIDE ACETATE

@ ENDO OPERATIONS	5%	A201511	001	Feb 12, 2013	May CAHN
-------------------	----	---------	-----	--------------	----------

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

>D> AA	TARO	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	A206431	001	Mar 19, 2024	Jun CMS1
AA		1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	A206431	001	Mar 19, 2024	Mar NEWA
		SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE				
>A> AA	BIONPHARMA	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	A204135	001	Jun 24, 2024	Jun NEWA
>A> AA	TARO	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	A206431	001	Mar 19, 2024	Jun CMS1

MANNITOLPOWDER; INHALATION
ARIDOL KIT

+! PHARMAXIS EUROPE	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	May CAHN
---------------------	----------------------------	---------	-----	--------------	----------

MARAVIROCTABLET; ORAL
SELZENTRY

+ @ VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016	Jan DISC
+ @	75MG	N022128	004	Nov 04, 2016	Jan DISC

MAVORIXAFORCAPSULE; ORAL
XOLREMDI

+! X4 PHARMS	100MG	N218709	001	Apr 26, 2024	Apr NEWA
--------------	-------	---------	-----	--------------	----------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011	Mar CHRS
AA	!	50MG	A201451	003	Feb 23, 2011	Feb CMFD
	@ INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Mar DISC
	@	25MG	A200432	002	Feb 17, 2022	Mar DISC
	@	50MG	A200432	003	Feb 17, 2022	Mar DISC

TABLET, CHEWABLE; ORAL

MECLIZINE HYDROCHLORIDE

@ INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Mar DISC
------------------	------	---------	-----	--------------	----------

MEDROXYPROGESTERONE ACETATEINJECTABLE; INJECTION
MEDROXYPROGESTERONE ACETATE

AB	HONG KONG	150MG/ML	A076553	001	Jul 28, 2004	Jan CAHN
----	-----------	----------	---------	-----	--------------	----------

MEGESTROL ACETATESUSPENSION; ORAL
MEGACE ES

AB	+! ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	May CAHN
	MEGESTROL ACETATE					
	@ CHARTWELL	125MG/ML	A204688	001	Dec 01, 2017	Mar CAHN
	@ HIKMA	40MG/ML	A203960	001	Jun 09, 2017	Mar DISC
AB	NOVITIUM PHARMA	40MG/ML	A077404	001	Feb 16, 2006	May CMFD

MELOXICAM

TABLET; ORAL

MELOXICAM

>A>	AB	AIPING PHARM INC	7.5MG	A 077920	001	Jul 19, 2006	Jun	CAHN
>A>	AB		15MG	A 077920	002	Jul 19, 2006	Jun	CAHN
>D>	AB	SCIEGEN PHARMS INC	7.5MG	A 077920	001	Jul 19, 2006	Jun	CAHN
	AB		7.5MG	A 077920	001	Jul 19, 2006	Apr	CMFD
>D>	AB		15MG	A 077920	002	Jul 19, 2006	Jun	CAHN
	AB		15MG	A 077920	002	Jul 19, 2006	Apr	CMFD
	AB	! ZYDUS PHARMS USA	15MG	A 077921	002	Jul 19, 2006	Jan	CTEC
		MOBIC						
	+	@ BOEHRINGER INGELHEIM	7.5MG	N 020938	001	Apr 13, 2000	Jan	DISC
	+	@	15MG	N 020938	002	Aug 23, 2000	Jan	DISC

MELPHALAN

TABLET; ORAL

MELPHALAN

@ ALVOGEN

2MG

A 207809 001 Mar 22, 2017 May DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

@ ENDO OPERATIONS

EQ 50MG BASE/VIAL

A 204773 001 Aug 22, 2016 May CAHN

AP HETERO LABS

EQ 50MG BASE/VIAL

A 215024 001 May 23, 2024 May NEWA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

@ ENDO OPERATIONS

7MG

A 205784 001 Jun 09, 2017 Apr CAHN

@

14MG

A 205784 002 Jun 09, 2017 Apr CAHN

@

21MG

A 205784 003 Jun 09, 2017 Apr CAHN

@

28MG

A 205784 004 Jun 09, 2017 Apr CAHN

AB XIAMEN LP PHARM CO

21MG

A 213985 004 Feb 06, 2024 Jan NEWA

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

RENATA

5MG

A 209527 001 May 07, 2018 Jan CAHN

AB

10MG

A 209527 002 May 07, 2018 Jan CAHN

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

AA ! EPIC PHARMA LLC

50MG

A 040331 001 May 28, 1999 Feb CTEC

AA !

50MG

A 040331 001 May 28, 1999 Feb CHRS

AA GENUS

50MG

A 040893 001 Jun 24, 2009 Feb CMFD

@

50MG

A 040893 001 Jun 24, 2009 Jan CAHN

@

75MG

A 040893 002 Jun 24, 2009 Jan CAHN

@

100MG

A 040893 003 Jun 24, 2009 Jan CAHN

@

150MG

A 040893 004 Jun 24, 2009 Jan CAHN

MESALAMINE

TABLET, DELAYED RELEASE; ORAL

MESALAMINE

AB ANNORA PHARMA

1.2GM

A 216334 001 Feb 05, 2024 Jan NEWA

MESNA

INJECTABLE; INTRAVENOUS

MESNA

@ RISING

100MG/ML

A 203364 001 Jul 18, 2014 Feb CAHN

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

!

GENUS

10MG/5ML

A 073632 001 Jul 22, 1992 Jan CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

>A> AB1 HARMAN FINOCHEM

500MG

A 218673 001 Jul 05, 2024 Jun NEWA

>A> AB

750MG

A 218673 002 Jul 05, 2024 Jun NEWA

AB3 MACLEODS PHARMS LTD

1GM

A 211163 001 Mar 13, 2024 Mar NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

@	CHARTWELL RX	500MG;EQ 15MG BASE	A 091273	001	Apr 16, 2013	Jan	CAHN
@		850MG;EQ 15MG BASE	A 091273	002	Apr 16, 2013	Jan	CAHN

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

AA	VISTAPHARM LLC	10MG/ML	A 040088	001	Nov 30, 1994	Apr	CAHN
----	----------------	---------	----------	-----	--------------	-----	------

SOLUTION; ORAL

METHADONE HYDROCHLORIDE

>D>	AA	VISTAPHARM LLC	5MG/5ML	A 090707	001	Jun 30, 2010	Jun	DISC
>A>		@	5MG/5ML	A 090707	001	Jun 30, 2010	Jun	DISC
	AA		5MG/5ML	A 090707	001	Jun 30, 2010	Apr	CAHN
>D>	AA		10MG/5ML	A 090707	002	Jun 30, 2010	Jun	DISC
>A>		@	10MG/5ML	A 090707	002	Jun 30, 2010	Jun	DISC
	AA		10MG/5ML	A 090707	002	Jun 30, 2010	Apr	CAHN

TABLET; ORAL

METHADONE HYDROCHLORIDE

>A>		@	ELITE LABS INC	5MG	A 210484	001	Aug 02, 2018	Jun	CAHN
>A>		@		10MG	A 210484	002	Aug 02, 2018	Jun	CAHN
>D>		@	NOSTRUM LABS INC	5MG	A 210484	001	Aug 02, 2018	Jun	CAHN
>D>		@		10MG	A 210484	002	Aug 02, 2018	Jun	CAHN
		@	VISTAPHARM LLC	5MG	A 040241	001	May 29, 1998	Apr	CAHN
	AA			10MG	A 040241	002	May 29, 1998	Apr	CAHN
	AA			10MG	A 204166	001	Mar 16, 2020	Apr	CAHN

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB	JUBILANT CADISTA	1GM	A 217675	001	Dec 01, 2023	Apr	CAHN
----	------------------	-----	----------	-----	--------------	-----	------

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	DBL PHARMS	500MG	A 203550	001	Feb 08, 2017	Feb	CAHN	
AA		750MG	A 203550	002	Feb 08, 2017	Feb	CAHN	
AA	HANGZHOU BINJIANG	500MG	A 200958	001	Oct 21, 2011	Mar	CAHN	
AA		750MG	A 200958	002	Oct 21, 2011	Mar	CAHN	
AB	!	1GM	A 200958	003	Dec 06, 2021	Mar	CAHN	
	ROBAXIN							
+	@	ENDO OPERATIONS	500MG	N 011011	004		May	CAHN
		ROBAXIN-750						
+	@	ENDO OPERATIONS	750MG	N 011011	006		May	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

>A>		@	EXTROVIS	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A 201530	001	Mar 29, 2012	Jun	CAHN
>D>		@	MYLAN	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A 201530	001	Mar 29, 2012	Jun	CAHN

TABLET; ORAL

METHOTREXATE SODIUM

AB	ALEMBIC	EQ 2.5MG BASE	A 217552	001	Jun 03, 2024	May	NEWA	
AB	ELITE LABS INC	EQ 2.5MG BASE	A 216453	001	May 16, 2024	May	NEWA	
	@	LOTUS PHARM CO LTD	EQ 2.5MG BASE	A 209787	001	Apr 23, 2021	Apr	DISC

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA	AACE PHARMS	2.5MG	A 216786	001	Feb 01, 2024	Jan	NEWA
AA		5MG	A 216786	002	Feb 01, 2024	Jan	NEWA
AA	NE RX PHARMA	2.5MG	A 216786	001	Feb 01, 2024	May	CAHN
AA		5MG	A 216786	002	Feb 01, 2024	May	CAHN

METHYLDOPA

TABLET; ORAL

METHYLDOPA

	@	CHARTWELL RX	250MG	N 018934	001	Jun 29, 1984	Feb	DISC
			250MG	N 018934	001	Jun 29, 1984	Jan	CMFD
	@		500MG	N 018934	002	Jun 29, 1984	Feb	DISC

	TABLET;ORAL								
	METHYLDOPA								
	!	500MG		N018934	002	Jun 29, 1984	Jan	CMFD	
	<u>METHYLENE BLUE</u>								
	SOLUTION;INTRAVENOUS								
	METHYLENE BLUE								
AP	ZYDUS LIFESCIENCES	10MG/2ML (5MG/ML)		A215636	001	Dec 05, 2023	Apr	CAHN	
AP		50MG/10ML (5MG/ML)		A215636	002	Dec 05, 2023	Apr	CAHN	
	<u>METHYLPHENIDATE HYDROCHLORIDE</u>								
	SOLUTION;ORAL								
	METHYLPHENIDATE HYDROCHLORIDE								
	@ BRECKENRIDGE	5MG/5ML		A201466	001	Nov 12, 2013	Mar	DISC	
	@	10MG/5ML		A201466	002	Nov 12, 2013	Mar	DISC	
	TABLET;ORAL								
	METHYLPHENIDATE HYDROCHLORIDE								
AB	CEDIPROF INC	5MG		A208737	001	Feb 01, 2019	Mar	CMFD	
AB		10MG		A208737	002	Feb 01, 2019	Mar	CMFD	
AB		20MG		A208737	003	Feb 01, 2019	Mar	CMFD	
	<u>METHYLPREDNISOLONE</u>								
	TABLET;ORAL								
	METHYLPREDNISOLONE								
AB	ENDO OPERATIONS	4MG		A040183	001	Dec 22, 1998	Apr	CAHN	
	@ PRAXGEN	4MG		A212262	001	Jun 27, 2019	Feb	DISC	
	<u>METHYLPREDNISOLONE ACETATE</u>								
	INJECTABLE;INJECTION								
	METHYLPREDNISOLONE ACETATE								
AB	ENDO OPERATIONS	40MG/ML		A214297	001	Jan 21, 2022	Apr	CAHN	
AB		80MG/ML		A214297	002	Jan 21, 2022	Apr	CAHN	
AB	HONG KONG	40MG/ML		A040557	001	Feb 23, 2005	Jan	CAHN	
AB		80MG/ML		A040557	002	Feb 23, 2005	Jan	CAHN	
	@ TEVA PHARMS USA	40MG/ML		A040620	001	Oct 27, 2006	Jan	DISC	
	@	80MG/ML		A040620	002	Oct 27, 2006	Jan	DISC	
	<u>METOCLOPRAMIDE HYDROCHLORIDE</u>								
	SOLUTION;ORAL								
	METOCLOPRAMIDE HYDROCHLORIDE								
AA	! GENUS	EQ 5MG BASE/5ML		A072744	001	May 28, 1991	Apr	CAHN	
	<u>METOLAZONE</u>								
	TABLET;ORAL								
	METOLAZONE								
AB	LEADING	2.5MG		A218606	001	Apr 17, 2024	Apr	NEWA	
AB		5MG		A218606	002	Apr 17, 2024	Apr	NEWA	
AB		10MG		A218606	003	Apr 17, 2024	Apr	NEWA	
	<u>METOPROLOL SUCCINATE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	METOPROLOL SUCCINATE								
	@ GRANULES	EQ 25MG TARTRATE		A216509	001	Aug 07, 2023	Mar	DISC	
	@	EQ 50MG TARTRATE		A216509	002	Aug 07, 2023	Mar	DISC	
	@	EQ 100MG TARTRATE		A216509	003	Aug 07, 2023	Mar	DISC	
	@	EQ 200MG TARTRATE		A216509	004	Aug 07, 2023	Mar	DISC	
AB	SUNSHINE	EQ 25MG TARTRATE		A214004	004	May 23, 2024	May	NEWA	
	<u>METRONIDAZOLE</u>								
	GEL;TOPICAL								
	METROGEL								
	+ @ GALDERMA LABS LP	0.75%		N019737	001	Nov 22, 1988	May	DISC	
	METRONIDAZOLE								
AB	! COSETTE	0.75%		A078178	001	Jan 19, 2011	May	CHRS	
	GEL;VAGINAL								
	METRONIDAZOLE								
AB	ENCUBE	1.3%		A216795	001	Mar 18, 2024	Mar	NFTG	
	NUVESSA								
AB	+! CHEMO RESEARCH SL	1.3%		N205223	001	Mar 24, 2014	Mar	CFTG	

TABLET; ORAL

METRONIDAZOLE

@	FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	Mar	DISC
@		500MG	A207309	002	May 16, 2016	Mar	DISC

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB	ZENARA	150MG	A215315	001	Aug 26, 2022	Apr	CAHN
AB		200MG	A215315	002	Aug 26, 2022	Apr	CAHN
AB		250MG	A215315	003	Aug 26, 2022	Apr	CAHN

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

AP	BIOCON PHARMA	EQ 50MG BASE/VIAL	A216438	001	May 29, 2024	May	NEWA
AP		EQ 100MG BASE/VIAL	A216438	002	May 29, 2024	May	NEWA

MIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

+ @	EXELA PHARMA	50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022	May	DISC
-----	--------------	--------------------	---------	-----	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Jan	DISC
---	--------------------	----------------	---------	-----	--------------	-----	------

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB	ENDO OPERATIONS	2.5MG	A207169	001	Oct 29, 2018	Apr	CAHN
AB		5MG	A207169	002	Oct 29, 2018	Apr	CAHN
AB		10MG	A207169	003	Oct 29, 2018	Apr	CAHN

MIDOSTAURIN

CAPSULE; ORAL

MIDOSTAURIN

>A>	AB	DR REDDYS	25MG	A215921	001	Jun 28, 2024	Jun	NEWA
	AB	LUPIN	25MG	A216015	001	May 10, 2024	May	NEWA
	AB	TEVA PHARMS	25MG	A216076	001	Apr 29, 2024	Apr	NFTG
		RYDAPT						
	AB	+! NOVARTIS	25MG	N207997	001	Apr 28, 2017	Apr	CFTG

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5%

>D>	AP	WOODWARD	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Jun	DISC
>A>		@	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Jun	DISC

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

	@	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Jan	DISC
	@		EQ 65MG BASE	A091118	003	Dec 03, 2019	Jan	DISC
	@		EQ 80MG BASE	A091118	004	Sep 25, 2014	Jan	DISC
	@		EQ 90MG BASE	A091118	005	Sep 25, 2014	Jan	DISC
	@		EQ 105MG BASE	A091118	006	Sep 25, 2014	Jan	DISC
	@		EQ 115MG BASE	A091118	007	Dec 03, 2019	Jan	DISC
	@		EQ 135MG BASE	A091118	008	Sep 25, 2014	Jan	DISC
	@	ZYDUS PHARMS	EQ 45MG BASE	A203553	001	Nov 16, 2017	Jan	DISC
	@		EQ 55MG BASE	A203553	002	Jun 16, 2023	Jan	DISC
	@		EQ 65MG BASE	A203553	003	Jun 16, 2023	Jan	DISC
	@		EQ 80MG BASE	A203553	004	Nov 16, 2017	Jan	DISC
	@		EQ 90MG BASE	A203553	005	Nov 16, 2017	Jan	DISC
	@		EQ 105MG BASE	A203553	006	Nov 16, 2017	Jan	DISC
	@		EQ 115MG BASE	A203553	007	Jun 16, 2023	Jan	DISC
	@		EQ 135MG BASE	A203553	008	Nov 16, 2017	Jan	DISC
>D>		SOLODYN						
>D>	AB	+ BAUSCH	EQ 55MG BASE	N050808	008	Aug 27, 2010	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL
SOLODYN

>A>	+	@	EQ 55MG BASE	N050808	008	Aug 27, 2010	Jun DISC
>D>	AB	+	EQ 65MG BASE	N050808	004	Jul 23, 2009	Jun DISC
>A>	+	@	EQ 65MG BASE	N050808	004	Jul 23, 2009	Jun DISC
>D>	AB	+	EQ 80MG BASE	N050808	007	Aug 27, 2010	Jun DISC
>A>	+	@	EQ 80MG BASE	N050808	007	Aug 27, 2010	Jun DISC
>D>	AB	+	EQ 105MG BASE	N050808	006	Aug 27, 2010	Jun DISC
>A>	+	@	EQ 105MG BASE	N050808	006	Aug 27, 2010	Jun DISC
>D>	AB	+	EQ 115MG BASE	N050808	005	Jul 23, 2009	Jun DISC
>A>	+	@	EQ 115MG BASE	N050808	005	Jul 23, 2009	Jun DISC

MINOXIDIL

TABLET;ORAL
MINOXIDIL

AB	ENDO OPERATIONS	2.5MG	A071826	001	Nov 14, 1988	Apr CAHN
AB		10MG	A071839	001	Nov 14, 1988	Apr CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL
MIRABEGRON

AB	ALKEM LABS LTD	25MG	A215948	001	Feb 12, 2024	Feb NEWA
AB		50MG	A215948	002	Feb 12, 2024	Feb NEWA
AB	ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Mar CMFD
AB		50MG	A209488	002	Sep 29, 2022	Mar CMFD

MIRTAZAPINE

TABLET;ORAL
MIRTAZAPINE

>D>	AB	AIPING PHARM INC	15MG	A076219	001	Jun 19, 2003	Jun CAHN
	AB		15MG	A076219	001	Jun 19, 2003	Feb CAHN
>D>	AB		30MG	A076219	002	Jun 19, 2003	Jun CAHN
	AB		30MG	A076219	002	Jun 19, 2003	Feb CAHN
>D>	AB		45MG	A076219	003	Jun 19, 2003	Jun CAHN
	AB		45MG	A076219	003	Jun 19, 2003	Feb CAHN
>A>	AB	CHARTWELL RX	15MG	A076219	001	Jun 19, 2003	Jun CAHN
>A>	AB		30MG	A076219	002	Jun 19, 2003	Jun CAHN
>A>	AB		45MG	A076219	003	Jun 19, 2003	Jun CAHN

MITOMYCIN

INJECTABLE;INJECTION
MITOMYCIN

AP	FRESENIUS KABI USA	5MG/VIAL	A211269	001	Apr 05, 2024	Mar NEWA
AP		20MG/VIAL	A211269	002	Apr 05, 2024	Mar NEWA
AP		40MG/VIAL	A211269	003	Apr 05, 2024	Mar NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION
MITOXANTRONE HYDROCHLORIDE

@	RISING	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar CAHN
---	--------	------------------------------------	---------	-----	--------------	----------

MOBOCERTINIB SUCCINATE

CAPSULE;ORAL
EXKIVITY

+	@	TAKEDA PHARMS USA	EQ 40MG BASE	N215310	001	Sep 15, 2021	Apr DISC
---	---	-------------------	--------------	---------	-----	--------------	----------

MOMETASONE FUROATE

LOTION;TOPICAL
MOMETASONE FUROATE

@	COSETTE	0.1%	A077678	001	Nov 21, 2007	Apr DISC
---	---------	------	---------	-----	--------------	----------

SPRAY, METERED;NASAL
MOMETASONE FUROATE

AB	AUROBINDO PHARMA	0.05MG/SPRAY	A215878	001	Mar 18, 2024	Mar NEWA
----	------------------	--------------	---------	-----	--------------	----------

MONTELUKAST SODIUM

GRANULE;ORAL
MONTELUKAST SODIUM

@	TEVA PHARMS	EQ 4MG BASE/PACKET	A090955	001	Aug 03, 2012	Jan DISC
---	-------------	--------------------	---------	-----	--------------	----------

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

	@ HIKMA	100MG/5ML	A208809	001	Jul 06, 2017	Mar	DISC
AA	WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Jan	CMFD
AA		20MG/5ML	A211454	002	Feb 12, 2021	Jan	CMFD
AA		100MG/5ML	A211454	003	Feb 12, 2021	Jan	CMFD

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VIGAMOX

AT1	+! HARROW EYE	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Jan	CAHN
-----	---------------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

>D>	@ MYLAN	EQ 400MG BASE	A204635	001	Aug 31, 2015	Jun	CAHN
>A>	@ NATCO	EQ 400MG BASE	A204635	001	Aug 31, 2015	Jun	CAHN

MYCOPHENOLATE MOFETIL

SUSPENSION;ORAL

MYHIBBIN

	+! AZURITY	200MG/ML	N216482	001	May 01, 2024	May	NEWA
--	------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

MYCOPHENOLATE MOFETIL

	@ AMNEAL	500MG	A090606	001	Jul 16, 2010	Feb	DISC
AB	AUROBINDO PHARMA	500MG	A217937	001	Feb 20, 2024	Feb	NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP	ENDO OPERATIONS	500MG/VIAL	A203575	001	Oct 28, 2016	Apr	CAHN
----	-----------------	------------	---------	-----	--------------	-----	------

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC SODIUM

AB	AUROBINDO PHARMA LTD	EQ 180MG BASE	A218603	001	Feb 27, 2024	Feb	NEWA
AB		EQ 360MG BASE	A218603	002	Feb 27, 2024	Feb	NEWA
>A>	AB	BIOCON PHARMA	A217031	001	Nov 29, 2023	Jun	CAHN
>A>	AB		A217031	002	Nov 29, 2023	Jun	CAHN
>D>	AB	NOVUGEN	A216637	001	May 29, 2024	Jun	CAHN
	AB		A216637	001	May 29, 2024	May	NEWA
>D>	AB		A216637	002	May 29, 2024	Jun	CAHN
	AB		A216637	002	May 29, 2024	May	NEWA
>D>	AB	SKG PHARMA	A217031	001	Nov 29, 2023	Jun	CAHN
	AB		A217031	001	Nov 29, 2023	Apr	CAHN
>D>	AB		A217031	002	Nov 29, 2023	Jun	CAHN
	AB		A217031	002	Nov 29, 2023	Apr	CAHN
>A>	AB	WANBANG BIOPHARMS	A216637	001	May 29, 2024	Jun	CAHN
>A>	AB		A216637	002	May 29, 2024	Jun	CAHN

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NUBAIN

	+ @ ENDO OPERATIONS	10MG/ML	N018024	001		May	CAHN
	+ @	20MG/ML	N018024	002	May 27, 1982	May	CAHN

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALMEFENE HYDROCHLORIDE

>D>	@ CHENGDU SHUODE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	Jun	CMFD
>A>	!	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	Jun	CMFD
	@	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	May	DISC
>D>	@	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	Jun	CMFD
>A>	AP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	Jun	CMFD
	@	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	May	DISC
>D>	!	PURDUE PHARMA LP	A212955	001	Feb 08, 2022	Jun	CTEC
>A>	AP	!	A212955	001	Feb 08, 2022	Jun	CTEC
	!	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May	CTEC

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

>D>	AP	EUGIA PHARMA	0.4MG/ML	A212455	001	Oct 15, 2019	Jun	DISC
>A>	@		0.4MG/ML	A212455	001	Oct 15, 2019	Jun	DISC
	AP	FRESENIUS KABI USA	0.4MG/ML	A213573	001	Apr 02, 2024	Mar	NEWA
	AP		1MG/ML	A213573	002	Apr 02, 2024	Mar	NEWA
	AP	HIKMA	0.4MG/ML	A212300	002	Mar 07, 2024	Mar	NEWA
	AP	MANKIND PHARMA	0.4MG/ML	A218404	001	Feb 29, 2024	Feb	NEWA

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS
ZIMHI

+!	ZMI PHARMA	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021	May	CAHN
----	------------	-----------------------	---------	-----	--------------	-----	------

SPRAY; NASAL

REZENOPY

+!	SUMMIT BIOSCI	10MG/SPRAY	N215487	001	Apr 19, 2024	Apr	NEWA
----	---------------	------------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

NALOXONE HYDROCHLORIDE

>D>		TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	Jun	CMKT
-----	--	-----------------	-----------	---------	-----	--------------	-----	------

REXTOVY

+!	AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023	Apr	CMFD
----	----------------------	-----------	---------	-----	--------------	-----	------

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

NALTREXONE

@	TEVA PHARMS USA INC	380MG/VIAL	A213195	001	Jul 06, 2023	Jan	DISC
---	---------------------	------------	---------	-----	--------------	-----	------

VIVITROL

+!	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006	Jan	CTEC
----	----------	------------	---------	-----	--------------	-----	------

NAPROXEN

TABLET; ORAL

NAPROXEN

@	INVAGEN PHARMS	250MG	A091305	001	Aug 24, 2011	Mar	DISC
---	----------------	-------	---------	-----	--------------	-----	------

@		375MG	A091305	002	Aug 24, 2011	Mar	DISC
---	--	-------	---------	-----	--------------	-----	------

@		500MG	A091305	003	Aug 24, 2011	Mar	DISC
---	--	-------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

AB	NOVITIUM PHARMA	375MG	A218497	001	Jun 12, 2024	May	NEWA
----	-----------------	-------	---------	-----	--------------	-----	------

AB		500MG	A218497	002	Jun 12, 2024	May	NEWA
----	--	-------	---------	-----	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

@	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	May	DISC
---	--------------------	---------------	---------	-----	--------------	-----	------

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

@	APOTEX	EQ 10MG BASE	A209741	001	Feb 27, 2024	May	DISC
---	--------	--------------	---------	-----	--------------	-----	------

AB		EQ 10MG BASE	A209741	001	Feb 27, 2024	Feb	NEWA
----	--	--------------	---------	-----	--------------	-----	------

@		EQ 20MG BASE	A209741	002	Feb 27, 2024	May	DISC
---	--	--------------	---------	-----	--------------	-----	------

AB		EQ 20MG BASE	A209741	002	Feb 27, 2024	Feb	NEWA
----	--	--------------	---------	-----	--------------	-----	------

>D>	@	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	Jun	CMFD
-----	---	---------------------	---------------	---------	-----	--------------	-----	------

>A>	AB		EQ 2.5MG BASE	A203821	001	May 25, 2017	Jun	CMFD
-----	----	--	---------------	---------	-----	--------------	-----	------

>D>	@		EQ 5MG BASE	A203821	002	May 25, 2017	Jun	CMFD
-----	---	--	-------------	---------	-----	--------------	-----	------

>A>	AB		EQ 5MG BASE	A203821	002	May 25, 2017	Jun	CMFD
-----	----	--	-------------	---------	-----	--------------	-----	------

>D>	@		EQ 10MG BASE	A203821	003	May 25, 2017	Jun	CMFD
-----	---	--	--------------	---------	-----	--------------	-----	------

>A>	AB		EQ 10MG BASE	A203821	003	May 25, 2017	Jun	CMFD
-----	----	--	--------------	---------	-----	--------------	-----	------

>D>	@		EQ 20MG BASE	A203821	004	May 25, 2017	Jun	CMFD
-----	---	--	--------------	---------	-----	--------------	-----	------

>A>	AB		EQ 20MG BASE	A203821	004	May 25, 2017	Jun	CMFD
-----	----	--	--------------	---------	-----	--------------	-----	------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

>A>	@	CHARTWELL RX	50MG	A076302	001	Sep 16, 2003	Jun	CAHN
-----	---	--------------	------	---------	-----	--------------	-----	------

>A>	@		100MG	A076302	002	Sep 16, 2003	Jun	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

>A>	@		150MG	A076302	003	Sep 16, 2003	Jun	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

>A>	@		200MG	A076302	004	Sep 16, 2003	Jun	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

>A>	@		250MG	A076302	005	Sep 16, 2003	Jun	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

>D>	@	FOSUN PHARMA	50MG	A076302	001	Sep 16, 2003	Jun	CAHN
-----	---	--------------	------	---------	-----	--------------	-----	------

>D>	@		100MG	A076302	002	Sep 16, 2003	Jun	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

>D>	@		150MG	A076302	003	Sep 16, 2003	Jun	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

>D>	@	200MG	A076302	004	Sep 16, 2003	Jun	CAHN
>D>	@	250MG	A076302	005	Sep 16, 2003	Jun	CAHN

NELARABINE

INJECTABLE;INTRAVENOUS

NELARABINE

>D>	AP	KINDOS	250MG/50ML (5MG/ML)	A216038	001	Jan 10, 2023	Jun	CAHN
>A>	AP	MEITHEAL	250MG/50ML (5MG/ML)	A216038	001	Jan 10, 2023	Jun	CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

	+ @	EXELA PHARMA	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	May	DISC
--	-----	--------------	------------------	---------	-----	--------------	-----	------

NEOSTIGMINE METHYLSULFATE

AP		ENDO OPERATIONS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr	CAHN
AP			10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr	CAHN
	@	EUGIA PHARMA	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023	May	DISC
	@		10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023	May	DISC
AP		NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Jan	CAHN
AP			10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Jan	CAHN

NESIRITIDE

FOR SOLUTION;INTRAVENOUS

NATRECOR

	+ @	SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001	Mar	CAIN
--	-----	-----------	------------	---------	-----	--------------	-----	------

NEVIRAPINE

SUSPENSION;ORAL

NEVIRAPINE

>D>	AA	AUROBINDO	50MG/5ML	A077702	001	May 22, 2012	Jun	CHRS	
>A>	AA	!	50MG/5ML	A077702	001	May 22, 2012	Jun	CHRS	
>D>		VIRAMUNE							
>D>	AA	+!	BOEHRINGER INGELHEIM	50MG/5ML	N020933	001	Sep 11, 1998	Jun	DISC
>A>		+ @		50MG/5ML	N020933	001	Sep 11, 1998	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

>D>	AB	MACLEODS PHARMS LTD	400MG	A206879	001	Oct 06, 2017	Jun	CHRS
>A>	AB	!	400MG	A206879	001	Oct 06, 2017	Jun	CHRS
>D>		VIRAMUNE XR						
>D>		+ BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012	Jun	DISC
>A>		+ @	100MG	N201152	002	Nov 08, 2012	Jun	DISC
>D>	AB	+!	400MG	N201152	001	Mar 25, 2011	Jun	DISC
>A>		+ @	400MG	N201152	001	Mar 25, 2011	Jun	DISC

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB		SKG PHARMA	20MG	A218202	001	Apr 10, 2024	Mar	NEWA
AB			30MG	A218202	002	Apr 10, 2024	Mar	NEWA

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP		RK PHARMA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Feb	CMFD
AP	+!	CHIESI	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr	CFTG
AP	+!	CHIESI	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr	CFTG
AP		INFORLIFE	40MG/200ML (0.2MG/ML)	A203978	002	Apr 17, 2024	Apr	NFTG
AP		INFORLIFE	20MG/200ML (0.1MG/ML)	A203978	001	Apr 17, 2024	Apr	NFTG

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

	@	ENDO OPERATIONS	30MG	A077899	001	Dec 13, 2006	May	CAHN
	@		60MG	A077899	002	Dec 13, 2006	May	CAHN
	@		90MG	A077899	003	May 25, 2012	May	CAHN

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

@	APOTEX	EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr	DISC
@		EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr	DISC
@		EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr	DISC
TASIGNA							
+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr	CTEC
+		EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr	CTEC
+	!	EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr	CTEC

NIMODIPINE

SOLUTION;ORAL

>A>	NIMODIPINE						
>A>	ANNORA PHARMA	3MG/ML	A216937	001	Jul 09, 2024	Jun	NFTG

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

+	@	GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Feb	DISC
---	---	-----------------	---------------	---------	-----	--------------	-----	------

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL

OGSIVEO

+	SPRINGWORKS	EQ 50MG BASE	N217677	001	Nov 27, 2023	Apr	CHRS
+		EQ 100MG BASE	N217677	002	Apr 04, 2024	Apr	NEWA
+	!	EQ 150MG BASE	N217677	003	Apr 04, 2024	Apr	NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

>D>	@	AMTA	8.5MG	A216606	001	Apr 10, 2023	Jun	CMFD
>A>	AB		8.5MG	A216606	001	Apr 10, 2023	Jun	CMFD

NITRIC OXIDE

GAS; INHALATION

INOMAX

+	!	MALLINCKRODT HOSP	4880PPM	N020845	004	Jan 17, 2023	May	NEWA
!		NOXIVENT						
!		LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	May	CHRS

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

@	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Feb	DISC
@		50MG	A091095	002	Jun 18, 2015	Feb	DISC
@		100MG	A091095	003	Jun 18, 2015	Feb	DISC

NITROGLYCERIN

OINTMENT; INTRA-ANAL

NITROGLYCERIN

AB	COSETTE	0.4%	A216103	001	Feb 16, 2024	Feb	NFTG		
AB	RECTIV								
AB	+	!	ABBVIE	0.4%	N021359	001	Jun 21, 2011	Feb	CFTG

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP	DDREG PHARMA	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	NEWA
AP	RISING	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	CAHN

SOLUTION; INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+	!	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Jan	CMFD
+	!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Jan	CMFD
+	!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Jan	CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

@	RISING	EQ 10MG BASE	A074234	001	Jul 26, 1993	Feb	CAHN
@		EQ 25MG BASE	A074234	002	Jul 26, 1993	Feb	CAHN
@		EQ 50MG BASE	A074234	003	Jul 26, 1993	Feb	CAHN
@		EQ 75MG BASE	A074234	004	Jul 26, 1993	Feb	CAHN

NYSTATIN

POWDER;TOPICAL

NYSTATIN

AT	ADRASTEA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Mar	CAHN
----	-----------------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

@	COSETTE	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Apr	DISC
---	---------	-----------------------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

MYKACET

@	COSETTE	100,000 UNITS/GM;0.1%	A062733	001	Mar 06, 1987	Apr	DISC
---	---------	-----------------------	---------	-----	--------------	-----	------

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP	SHUANGCHENG	EQ 0.1MG BASE/ML	A217860	001	May 02, 2024	Apr	NEWA
AB	TEVA PHARMS USA INC	EQ 10MG BASE/VIAL	A210317	001	Dec 05, 2023	Jan	CTEC
AB		EQ 20MG BASE/VIAL	A210317	002	Dec 05, 2023	Jan	CTEC
AB		EQ 30MG BASE/VIAL	A210317	003	Dec 05, 2023	Jan	CTEC
	SANDOSTATIN LAR						
AB	+ NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998	Jan	CTEC
AB	+	EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998	Jan	CTEC
AB	+	EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998	Jan	CTEC

ODEVIXIBAT

CAPSULE;ORAL

BYLVAY

+	IPSEN	0.4MG	N215498	002	Jul 20, 2021	Jan	CAHN
+	!	1.2MG	N215498	004	Jul 20, 2021	Jan	CAHN

CAPSULE, PELLETS;ORAL

BYLVAY

+	IPSEN	0.2MG	N215498	001	Jul 20, 2021	Jan	CAHN
+	!	0.6MG	N215498	003	Jul 20, 2021	Jan	CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT	AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb	NEWA
AT	CAPLIN	0.3%	A217904	001	Apr 12, 2024	Apr	NEWA

SOLUTION/DROPS;OTIC

OFLOXACIN

@	HIKMA	0.3%	A076616	001	Mar 17, 2008	Mar	DISC
---	-------	------	---------	-----	--------------	-----	------

OLANZAPINE

TABLET;ORAL

OLANZAPINE

@	INDOCO	2.5MG	A206155	001	Jul 31, 2020	Mar	DISC
@		5MG	A206155	002	Jul 31, 2020	Mar	DISC
@		7.5MG	A206155	003	Jul 31, 2020	Mar	DISC
@		10MG	A206155	004	Jul 31, 2020	Mar	DISC
@		15MG	A206155	005	Jul 31, 2020	Mar	DISC
@		20MG	A206155	006	Jul 31, 2020	Mar	DISC
@	SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012	May	DISC
@		5MG	A091038	002	Apr 23, 2012	May	DISC
@		7.5MG	A091038	003	Apr 23, 2012	May	DISC
@		10MG	A091038	004	Apr 23, 2012	May	DISC
@		15MG	A091038	005	Apr 23, 2012	May	DISC
@		20MG	A091038	006	Apr 23, 2012	May	DISC

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

@	SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012	May	DISC
@		10MG	A090881	002	Feb 28, 2012	May	DISC

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

@	15MG	A090881	003	Feb 28, 2012	May	DISC
@	20MG	A090881	004	Feb 28, 2012	May	DISC

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	BRECKENRIDGE	5MG	A206227	001	Jan 25, 2024	Jan	NEWA
AB		20MG	A206227	002	Jan 25, 2024	Jan	NEWA
AB		40MG	A206227	003	Jan 25, 2024	Jan	NEWA
AB	CHARTWELL RX	5MG	A206227	001	Jan 25, 2024	Mar	CAHN
AB		20MG	A206227	002	Jan 25, 2024	Mar	CAHN
AB		40MG	A206227	003	Jan 25, 2024	Mar	CAHN
AB	INVENTIA	5MG	A208659	001	May 18, 2020	May	CMFD
AB		20MG	A208659	002	May 18, 2020	May	CMFD
AB		40MG	A208659	003	May 18, 2020	May	CMFD

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

@	HIKMA	0.665MG/SPRAY	A213757	001	Aug 19, 2020	Mar	DISC
---	-------	---------------	---------	-----	--------------	-----	------

>D> OMACETAXINE MEPESUCCINATE

>D> POWDER;SUBCUTANEOUS

>D> SYNRIPO

>D>	+	!	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Jun	DISC
>A>	+	@		3.5MG/VIAL	N203585	001	Oct 26, 2012	Jun	DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	CHARTWELL	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Mar	CAHN
----	-----------	------------------------------------------------------------------------	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	!	AJANTA PHARMA LTD	40MG;1.1GM	A204228	002	Jul 15, 2016	Mar	CHRS	
		ZEGERID							
	+	@	SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Mar	DISC
	+	@		40MG;1.1GM	N021849	002	Feb 27, 2006	Mar	DISC

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	!	AJANTA PHARMA LTD	40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Mar	CHRS	
		ZEGERID							
	+	@	SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Mar	DISC
	+	@		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Mar	DISC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

>D>	AB	MYLAN	4MG	A078139	001	Jun 25, 2007	Jun	DISC	
>A>		@	4MG	A078139	001	Jun 25, 2007	Jun	DISC	
>D>	AB		8MG	A078139	002	Jun 25, 2007	Jun	DISC	
>A>		@	8MG	A078139	002	Jun 25, 2007	Jun	DISC	
		@	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Jan	DISC
		@		8MG	A078602	002	Feb 24, 2011	Jan	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

@	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	May	DISC
---	-----------------	----------------	---------	-----	--------------	-----	------

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

@	PHARM ASSOC	EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007	Feb	DISC
---	-------------	-----------------	---------	-----	--------------	-----	------

@	TARO	EQ 4MG BASE/5ML	A077009	001	Nov 30, 2007	May	DISC
---	------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

>D>		@	CASI PHARMS INC	EQ 4MG BASE	A077517	001	Jun 25, 2007	Jun	CAHN
>D>		@		EQ 8MG BASE	A077517	002	Jun 25, 2007	Jun	CAHN

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

>D>	@	EQ 24MG BASE	A077517	003	Jun 25, 2007	Jun CAHN
>A>	@ CHARTWELL RX	EQ 4MG BASE	A077517	001	Jun 25, 2007	Jun CAHN
>A>	@	EQ 8MG BASE	A077517	002	Jun 25, 2007	Jun CAHN
>A>	@	EQ 24MG BASE	A077517	003	Jun 25, 2007	Jun CAHN

OPICAPONE

CAPSULE;ORAL

ONGENTYS

+	AMNEAL	25MG	N212489	001	Apr 24, 2020	Apr CAHN
+	!	50MG	N212489	002	Apr 24, 2020	Apr CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

>D>	@ IMPAX PHARMS	100MG	A040368	001	Jun 23, 2000	Jun CAHN
>A>	@ STEVENS J	100MG	A040368	001	Jun 23, 2000	Jun CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	LAURUS	EQ 30MG BASE	A218565	001	May 01, 2024	Apr NEWA
AB		EQ 45MG BASE	A218565	002	May 01, 2024	Apr NEWA
AB		EQ 75MG BASE	A218565	003	May 01, 2024	Apr NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	AUROBINDO PHARMA LTD	EQ 6MG BASE/ML	A218131	001	May 10, 2024	May NEWA
>A> AB	ORYZA	EQ 6MG BASE/ML	A217303	001	Jul 02, 2024	Jun NEWA

OSPEMIFENE

TABLET;ORAL

OSPEMIFENE

AB	HETERO LABS LTD V	60MG	A215574	001	Feb 13, 2024	Feb NFTG
AB	+! DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Feb CFTG

OXALIPLATIN

INJECTABLE;INTRAVENOUS

ELOXATIN

>D> AP	+! SANOFI AVENTIS US	50MG/10ML (5MG/ML)	N021759	001	Jan 31, 2005	Jun DISC
>A>	+ @	50MG/10ML (5MG/ML)	N021759	001	Jan 31, 2005	Jun DISC
>D> AP	+! @	100MG/20ML (5MG/ML)	N021759	002	Jan 31, 2005	Jun DISC
>A>	+ @	100MG/20ML (5MG/ML)	N021759	002	Jan 31, 2005	Jun DISC

OXALIPLATIN

>D> AP	GLAND	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jun CHRS
>A> AP	!	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jun CHRS
>D> AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jun CHRS
>A> AP	!	100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jun CHRS
>D> AP	KINDOS	50MG/10ML (5MG/ML)	A217348	001	Jan 11, 2024	Jun CAHN
AP		50MG/10ML (5MG/ML)	A217348	001	Jan 11, 2024	Jan NEWA
>D> AP		100MG/20ML (5MG/ML)	A217348	002	Jan 11, 2024	Jun CAHN
AP		100MG/20ML (5MG/ML)	A217348	002	Jan 11, 2024	Jan NEWA
>A> AP	MEITHEAL	50MG/10ML (5MG/ML)	A217348	001	Jan 11, 2024	Jun CAHN
>A> AP		100MG/20ML (5MG/ML)	A217348	002	Jan 11, 2024	Jun CAHN

OXAPROZIN

TABLET;ORAL

OXAPROZIN

>A> AB	PANGEA	600MG	A075845	001	Jan 31, 2001	Jun CAHN
>D> AB	SANDOZ	600MG	A075845	001	Jan 31, 2001	Jun CAHN
	@ TEVA	600MG	A075849	001	Jul 03, 2002	Jan DISC

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB	ALKEM LABS LTD	300MG/5ML	A213183	001	Mar 18, 2023	Mar NEWA
AB	BIOCON PHARMA	300MG/5ML	A218278	001	Mar 01, 2024	Apr CAHN
AB	CARNEGIE	300MG/5ML	A218278	001	Mar 01, 2024	Feb NEWA
AB	MEDLEY PHARMS	300MG/5ML	A217782	001	Feb 14, 2024	Feb NEWA
AB	RISING	300MG/5ML	A218278	001	Mar 01, 2024	Mar CAHN

TABLET;ORAL

OXCARBAZEPINE							
AB	RUBICON	150MG	A207717	001	Mar 05, 2024	Feb	NEWA
AB		300MG	A207717	002	Mar 05, 2024	Feb	NEWA
AB		600MG	A207717	003	Mar 05, 2024	Feb	NEWA
	@ ZYDUS	150MG	A211747	001	Jul 03, 2023	Jan	DISC
	@	300MG	A211747	002	Jul 03, 2023	Jan	DISC
	@	600MG	A211747	003	Jul 03, 2023	Jan	DISC

TABLET, EXTENDED RELEASE;ORAL

OXCARBAZEPINE							
AB	AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Feb	NEWA
AB		300MG	A217659	002	Feb 22, 2024	Feb	NEWA
AB		600MG	A217659	003	Feb 22, 2024	Feb	NEWA
OXTELLAR XR							
AB	+ SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012	Feb	CTEC
AB	+	300MG	N202810	002	Oct 19, 2012	Feb	CTEC
AB	+!	600MG	N202810	003	Oct 19, 2012	Feb	CTEC

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

OXYBUTYNIN CHLORIDE							
	@ PHARM ASSOC	5MG/5ML	A075137	001	Dec 18, 1998	Feb	DISC

TABLET;ORAL

OXYBUTYNIN CHLORIDE							
	@ EYWA	5MG	A211062	001	Feb 06, 2019	Mar	DISC

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE							
	@ HIKMA	5MG/5ML	A208817	001	Aug 10, 2017	Mar	DISC
	@	100MG/5ML	A208795	001	Aug 07, 2017	Mar	DISC
+	@ VISTAPHARM LLC	5MG/5ML	N201194	001	Jan 12, 2012	Apr	CAHN
	@ XTTRIUM LABS INC	5MG/5ML	A206456	001	Jun 16, 2015	Mar	CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE							
>D>	AB SUN PHARM INDS INC	5MG	A090659	001	Apr 10, 2009	Jun	DISC
>A>	@	5MG	A090659	001	Apr 10, 2009	Jun	DISC
>D>	AB	10MG	A090659	005	Nov 06, 2012	Jun	DISC
>A>	@	10MG	A090659	005	Nov 06, 2012	Jun	DISC
>D>	AB	15MG	A090659	002	Apr 10, 2009	Jun	DISC
>A>	@	15MG	A090659	002	Apr 10, 2009	Jun	DISC
>D>	AB	20MG	A090659	004	Nov 06, 2012	Jun	DISC
>A>	@	20MG	A090659	004	Nov 06, 2012	Jun	DISC
>D>	AB	30MG	A090659	003	Apr 10, 2009	Jun	DISC
>A>	@	30MG	A090659	003	Apr 10, 2009	Jun	DISC

OXYMETHOLONE

TABLET;ORAL

ANADROL-50							
>D>	+ @ MYLAN SPECIALITY LP	50MG	N016848	001		Jun	CAHN
>A>	+ @ NORVIUM BIOSCIENCE	50MG	N016848	001		Jun	CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OPANA ER							
+	@ ENDO OPERATIONS	5MG	N021610	001	Jun 22, 2006	May	CAHN
+	@	7.5MG	N021610	005	Feb 29, 2008	May	CAHN
+	@	10MG	N021610	002	Jun 22, 2006	May	CAHN
+	@	15MG	N021610	006	Feb 29, 2008	May	CAHN
+	@	20MG	N021610	003	Jun 22, 2006	May	CAHN
+	@	30MG	N021610	007	Feb 29, 2008	May	CAHN
+	@	40MG	N021610	004	Jun 22, 2006	May	CAHN

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA							
+	BRISTOL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	Jan	CAHN
+		EQ 0.46MG BASE	N209899	002	Mar 25, 2020	Jan	CAHN
+	!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	Jan	CAHN

PACLITAXELPOWDER; INTRAVENOUS
ABRAXANE

AB	+	BRISTOL-MYERS	100MG/VIAL	N021660	001	Jan 07, 2005	Jan CTEC
		PACLITAXEL					
AB	+	AM REGENT	100MG/VIAL	N211875	001	Jul 27, 2022	Apr CTEC
AB	+	TEVA PHARMS INC	100MG/VIAL	N216338	001	May 11, 2023	Jan CMFD

PALBOCICLIBTABLET; ORAL
IBRANCE

AB	+	PFIZER	75MG	N212436	001	Nov 01, 2019	May CFTG
	+		75MG	N212436	001	Nov 01, 2019	Jan CTEC
AB	+		100MG	N212436	002	Nov 01, 2019	May CFTG
	+		100MG	N212436	002	Nov 01, 2019	Jan CTEC
AB	+		125MG	N212436	003	Nov 01, 2019	May CFTG
	+		125MG	N212436	003	Nov 01, 2019	Jan CTEC
		PALBOCICLIB					
AB		SYNTHON PHARMS INC	75MG	A215570	001	Jun 05, 2024	May NFTG
AB			100MG	A215570	002	Jun 05, 2024	May NFTG
AB			125MG	A215570	003	Jun 05, 2024	May NFTG

PALIPERIDONETABLET, EXTENDED RELEASE; ORAL
PALIPERIDONE

>A>	AB	AJANTA PHARMA LTD	1.5MG	A218514	001	Jun 26, 2024	Jun NEWA
>A>	AB		3MG	A218514	002	Jun 26, 2024	Jun NEWA
>A>	AB		6MG	A218514	003	Jun 26, 2024	Jun NEWA
>A>	AB		9MG	A218514	004	Jun 26, 2024	Jun NEWA
>D>	AB	LUPIN LTD	1.5MG	A208643	001	Jun 29, 2022	Jun CTEC
>A>	BX		1.5MG	A208643	001	Jun 29, 2022	Jun CTEC
>D>	AB		3MG	A208643	002	Jun 29, 2022	Jun CTEC
>A>	BX		3MG	A208643	002	Jun 29, 2022	Jun CTEC
>D>	AB		6MG	A208643	003	Jun 29, 2022	Jun CTEC
>A>	BX		6MG	A208643	003	Jun 29, 2022	Jun CTEC
>D>	AB		9MG	A208643	004	Jun 29, 2022	Jun CTEC
>A>	BX		9MG	A208643	004	Jun 29, 2022	Jun CTEC

PALIPERIDONE PALMITATESUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
INVEGA SUSTENNA

AB	+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	May CTEC
AB	+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	May CTEC
AB	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	May CTEC
AB	+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	May CTEC
AB	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	May CTEC
		PALIPERIDONE PALMITATE					
AB		TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	May CMFD
AB			78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	May CMFD
AB			117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	May CMFD
AB			156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	May CMFD
AB			234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	May CMFD

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

>A>	AP	MEITHEAL	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A215861	001	Aug 14, 2023	Jun CAHN
>D>	AP	NANJING KING-FRIEND	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A215861	001	Aug 14, 2023	Jun CAHN

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@ AVYXA HOLDINGS

EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

N203050 001 Mar 01, 2016 Apr CAHN

@

EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

N203050 002 Mar 01, 2016 Apr CAHN

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE

! DR REDDYS 1MG/ML A072759 001 Jul 31, 1990 May CTEC
@ HOSPIRA 1MG/ML A072320 001 Jan 19, 1989 May DISC

PANTOPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS
PANTOPRAZOLE SODIUM

AP HANGZHOU ZHONGMEI EQ 40MG BASE/VIAL A209524 001 Aug 30, 2021 Mar CAHN
@ SUN PHARM EQ 40MG BASE/VIAL A077674 001 Aug 19, 2019 Feb DISC

SOLUTION; INTRAVENOUS

PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE CORP EQ 40MG BASE/100ML (EQ 0.4MG
BASE/ML) N217512 001 Feb 14, 2024 Feb NEWA

+! EQ 40MG BASE/50ML (EQ 0.8MG
BASE/ML) N217512 002 Feb 14, 2024 Feb NEWA

+! EQ 80MG BASE/100ML (EQ 0.8MG
BASE/ML) N217512 003 Feb 14, 2024 Feb NEWA

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB MANKIND PHARMA EQ 20MG BASE A215880 002 Apr 25, 2024 Apr NEWA

PARICALCITOL

SOLUTION; INTRAVENOUS

PARICALCITOL

@ HOSPIRA 0.002MG/ML (0.002MG/ML) N201657 001 Oct 21, 2014 May DISC

@ 0.005MG/ML (0.005MG/ML) N201657 002 Oct 21, 2014 May DISC

@ 0.01MG/2ML (0.005MG/ML) N201657 003 Oct 21, 2014 May DISC

PATIROMER SORBITEX CALCIUM

POWDER; ORAL

VELTASSA

+ @ VIFOR PHARMA EQ 1GM BASE/PACKET N205739 004 Oct 02, 2023 Feb DISC

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

PAZOPANIB HYDROCHLORIDE

AB NOVUGEN EQ 200MG BASE A218231 001 Apr 23, 2024 Apr NEWA

PEGULICIANINE ACETATE

POWDER; INTRAVENOUS

LUMISIGHT

+! LUMICELL EQ 40MG BASE/VIAL N214511 001 Apr 17, 2024 Apr NEWA

>A> PEMETREXED DIPOTASSIUM

>A> POWDER; INTRAVENOUS

>A> PEMETREXED

>A> +! AVYXA HOLDINGS EQ 100MG BASE/VIAL N210661 001 Jun 28, 2024 Jun NEWA

>A> +! EQ 500MG BASE/VIAL N210661 002 Jun 28, 2024 Jun NEWA

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

PEMETREXED DISODIUM

>A> AP HETERO LABS LTD VI EQ 100MG BASE/VIAL A215460 001 Jun 14, 2024 Jun NEWA

>A> AP EQ 500MG BASE/VIAL A215460 002 Jun 14, 2024 Jun NEWA

>A> AP RELIANCE LIFE EQ 100MG BASE/VIAL A211899 001 May 25, 2022 Jun CAHN

>A> AP EQ 500MG BASE/VIAL A211899 002 May 25, 2022 Jun CAHN

>D> AP WAVERLEY PHARMA INC EQ 100MG BASE/VIAL A211899 001 May 25, 2022 Jun CAHN

>D> AP EQ 500MG BASE/VIAL A211899 002 May 25, 2022 Jun CAHN

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

+ @ ENDO OPERATIONS 10MG N018976 001 Dec 30, 1987 May CAHN

+ @ 20MG N018976 004 Jan 05, 1989 May CAHN

PENICILLAMINE

CAPSULE;ORAL		PENICILLAMINE					
AB	ENDO OPERATIONS	250MG	A211231	001	Dec 23, 2019	Apr	CAHN
TABLET;ORAL		PENICILLAMINE					
AB	ENDO OPERATIONS	250MG	A211196	001	Dec 23, 2019	Apr	CAHN

PENICILLIN V POTASSIUM

TABLET;ORAL		PENICILLIN V POTASSIUM					
AB	! AUROBINDO PHARMA	EQ 500MG BASE	A065435	002	Apr 29, 2008	Jan	CHRS
	@ SANDOZ	EQ 250MG BASE	A064071	001	Nov 30, 1995	Jan	DISC
	@	EQ 500MG BASE	A064071	002	Nov 30, 1995	Jan	DISC

PENTOBARBITAL

ELIXIR;ORAL		NEMBUTAL					
	@ SAPTALIS PHARMS	18.2MG/5ML	A083244	001		Apr	CAHN

PENTOBARBITAL SODIUM

SUPPOSITORY;RECTAL		NEMBUTAL					
	@ SAPTALIS PHARMS	30MG	A083247	001	Jan 25, 1982	Mar	CAHN
	@	60MG	A083247	002	Jan 25, 1982	Mar	CAHN
	@	120MG	A083247	003	Jan 25, 1982	Mar	CAHN
	@	200MG	A083247	004	Jan 25, 1982	Mar	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL		PENTOXIFYLLINE					
AB	ANI PHARMS	400MG	A074878	001	Jul 09, 1997	Jan	CMFD
>D>	@ RISING	400MG	A074425	001	Jul 08, 1997	Jun	CMFD
>A>	AB	400MG	A074425	001	Jul 08, 1997	Jun	CMFD

PERMETHRIN

CREAM;TOPICAL		PERMETHRIN					
	@ DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jan	DISC

PERPHENAZINE

TABLET;ORAL		PERPHENAZINE					
AB	ENDO OPERATIONS	2MG	A040226	001	Dec 31, 1998	Apr	CAHN
AB		4MG	A040226	002	Dec 31, 1998	Apr	CAHN
AB		8MG	A040226	003	Dec 31, 1998	Apr	CAHN
AB		16MG	A040226	004	Dec 31, 1998	Apr	CAHN
AB	MACLEODS PHARMS LTD	2MG	A212545	001	May 06, 2024	Apr	NEWA
AB		4MG	A212545	002	May 06, 2024	Apr	NEWA
AB		8MG	A212545	003	May 06, 2024	Apr	NEWA
AB		16MG	A212545	004	May 06, 2024	Apr	NEWA

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL		PHENOXYBENZAMINE HYDROCHLORIDE					
AB	! ENDO OPERATIONS	10MG	A204522	001	Jan 24, 2017	May	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL		ADIPEX-P					
+	@ TEVA	37.5MG	A088023	001	Aug 02, 1983	Feb	DISC
		PHENTERMINE HYDROCHLORIDE					
	@ INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Mar	DISC
	@	30MG	A202858	002	Feb 14, 2014	Mar	DISC
	@	30MG	A204414	001	May 05, 2014	Mar	DISC
	@	37.5MG	A202846	001	Feb 05, 2014	Mar	DISC
AA	! NUVO PHARM	37.5MG	A205017	001	Sep 25, 2014	Feb	CHRS
TABLET;ORAL		PHENTERMINE HYDROCHLORIDE					
	@ INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Mar	DISC

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

>A>		PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE					
>A>	AB	ACTAVIS LABS FL INC	EQ 3.75MG BASE;23MG	A204982	001	Jun 25, 2024	Jun NFTG
>A>	AB		EQ 7.5MG BASE;46MG	A204982	002	Jun 25, 2024	Jun NFTG
>A>	AB		EQ 11.25MG BASE;69MG	A204982	003	Jun 25, 2024	Jun NFTG
>A>	AB		EQ 15MG BASE;92MG	A204982	004	Jun 25, 2024	Jun NFTG
		QSYMIA					
>D>	+	VIVUS LLC	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	Jun CFTG
>A>	AB	+	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	Jun CFTG
		+	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	May CAHN
>D>	+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	Jun CFTG
>A>	AB	+	EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	Jun CFTG
		+	EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	May CAHN
>D>	+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	Jun CFTG
>A>	AB	+	EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	Jun CFTG
		+	EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	May CAHN
>D>	+	!	EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	Jun CFTG
>A>	AB	+	EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	Jun CFTG
		+	EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	May CAHN

PHENTOLAMINE MESYLATESOLUTION;OPHTHALMIC
RYZUMVI

+	!	FAMYGEN LIFE SCI	EQ 0.75% BASE	N217064	001	Sep 25, 2023	Jan CAHN
---	---	------------------	---------------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDESOLUTION;INTRAVENOUS
PHENYLEPHRINE HYDROCHLORIDE

		@ ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	May DISC
		@	50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	May DISC
		@	100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	May DISC
AP1		ASPIRO	10MG/ML (10MG/ML)	A218110	001	May 10, 2024	May NEWA
AP1			50MG/5ML (10MG/ML)	A218110	002	May 10, 2024	May NEWA
AP1			100MG/10ML (10MG/ML)	A218110	003	May 10, 2024	May NEWA
		@ ENDO OPERATIONS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Apr CAHN
AP1			50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Apr CAHN
AP1			100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Apr CAHN
AP1		HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Mar NEWA
AP1			50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Mar NEWA
AP1			100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Mar NEWA

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT		CAPLIN	2.5%	A215183	001	May 23, 2024	May NEWA
AT			10%	A215183	002	May 23, 2024	May NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	!	GENUS	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Apr CAHN
		@ HIKMA	5MG/5ML;6.25MG/5ML	A040675	001	Dec 23, 2014	Mar DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

		@ PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002	Feb DISC
		@ VISTAPHARM	125MG/5ML	A040342	001	Jan 31, 2001	Apr DISC
		@	125MG/5ML	A040342	002	Aug 18, 2005	Apr DISC

TABLET, CHEWABLE;ORAL

PHENYTOIN

AB		TARO	50MG	A200565	001	Apr 17, 2014	Apr CAHN
----	--	------	------	---------	-----	--------------	----------

PHENYTOIN SODIUM

INJECTABLE;INJECTION

PHENYTOIN SODIUM

>A>	AP	+	!	HIKMA	50MG/ML	A084307	001	Jun CAHN
>D>	AP	+	!	WEST-WARD PHARMS INT	50MG/ML	A084307	001	Jun CAHN

PIMAVANSERIN TARTRATE

		CAPSULE;ORAL							
		NUPLAZID							
AB	+!	ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018	Jan	CFTG	
		PIMAVANSERIN							
		@ MSN	EQ 34MG BASE	A214925	001	Jan 16, 2024	Feb	DISC	
AB			EQ 34MG BASE	A214925	001	Jan 16, 2024	Jan	NEWA	
AB		ZYDUS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan	CAHN	
AB		ZYDUS PHARMS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan	NEWA	
		TABLET;ORAL							
		NUPLAZID							
AB	+!	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018	Jan	CFTG	
		PIMAVANSERIN							
AB		ZYDUS	EQ 10MG BASE	A214502	001	Jan 16, 2024	Jan	CAHN	
AB		ZYDUS PHARMS	EQ 10MG BASE	A214502	001	Jan 16, 2024	Jan	NEWA	

PIMOZIDE

		TABLET;ORAL							
		PIMOZIDE							
		ENDO OPERATIONS	1MG	A204521	001	Sep 28, 2015	Apr	CAHN	
	!		2MG	A204521	002	Sep 28, 2015	Apr	CAHN	

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

		INJECTABLE;INJECTION							
		PIPERACILLIN AND TAZOBACTAM							
		@ EUGIA PHARMA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A217409	002	Oct 12, 2023	Apr	DISC	
		@	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A217409	001	Oct 12, 2023	Apr	DISC	
		@ FRESENIUS KABI USA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A206204	001	May 11, 2018	Feb	DISC	

PIROXICAM

		CAPSULE;ORAL							
		PIROXICAM							
		@ FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016	Mar	DISC	
		@	20MG	A207938	002	Sep 09, 2016	Mar	DISC	

PITAVASTATIN CALCIUM

		TABLET;ORAL							
		PITAVASTATIN CALCIUM							
AB		HETERO LABS LTD V	EQ 1MG BASE	A205977	001	Apr 30, 2024	Apr	NEWA	
AB			EQ 2MG BASE	A205977	002	Apr 30, 2024	Apr	NEWA	
AB			EQ 4MG BASE	A205977	003	Apr 30, 2024	Apr	NEWA	

PIVMECILLINAM HYDROCHLORIDE

		TABLET;ORAL							
		PIVYA							
	+!	UTILITY THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Apr	NEWA	

PLERIXAFOR

		SOLUTION;SUBCUTANEOUS							
		PLERIXAFOR							
AP		GLAND PHARMA LTD	24MG/1.2ML (20MG/ML)	A206644	001	May 03, 2024	Apr	NEWA	
>D>	AP	KINDOS	24MG/1.2ML (20MG/ML)	A215698	001	Jul 24, 2023	Jun	CAHN	
>A>	AP	MEITHEAL	24MG/1.2ML (20MG/ML)	A215698	001	Jul 24, 2023	Jun	CAHN	
		@ ZYDUS PHARMS	24MG/1.2ML (20MG/ML)	A208980	001	Jul 26, 2023	May	DISC	

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

		FOR SOLUTION;ORAL							
		PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE							
>A>		@ EXTROVIS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090409	001	Apr 02, 2010	Jun	CAHN	
>D>		@ MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090409	001	Apr 02, 2010	Jun	CAHN	
>D>		@ NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090019	001	May 27, 2009	Jun	CMFD	
>A>	AA		420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090019	001	May 27, 2009	Jun	CMFD	

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE WITH FLAVOR PACKS

	@ MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	DISC
--	-----------------------	--------------------------------------------------------	---------	-----	--------------	-----	------

PEG 3350 AND ELECTROLYTES

>A>	@ EXTROVIS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Jun	CAHN
>D>	@ MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Jun	CAHN
	NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr	CTEC

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP	ADRASTEIA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb	CAHN
----	------------------	----------------------------	---------	-----	--------------	-----	------

POMALIDOMIDE

CAPSULE;ORAL

POMALIDOMIDE

AB	APOTEX	1MG	A210164	001	Jun 11, 2024	May	NEWA
AB		2MG	A210164	002	Jun 11, 2024	May	NEWA
AB		3MG	A210164	003	Jun 11, 2024	May	NEWA
AB		4MG	A210164	004	Jun 11, 2024	May	NEWA
	POMALYST						
AB	+ BRISTOL	1MG	N204026	001	Feb 08, 2013	May	CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	May	CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	May	CTEC
AB	+!	4MG	N204026	004	Feb 08, 2013	May	CTEC

PONESIMOD

TABLET;ORAL

PONVORY

+!	VANDA PHARMS INC	2MG	N213498	001	Mar 18, 2021	May	CAHN
+		3MG	N213498	002	Mar 18, 2021	May	CAHN
+		4MG	N213498	003	Mar 18, 2021	May	CAHN
+		5MG	N213498	004	Mar 18, 2021	May	CAHN
+		6MG	N213498	005	Mar 18, 2021	May	CAHN
+		7MG	N213498	006	Mar 18, 2021	May	CAHN
+		8MG	N213498	007	Mar 18, 2021	May	CAHN
+		9MG	N213498	008	Mar 18, 2021	May	CAHN
+		10MG	N213498	009	Mar 18, 2021	May	CAHN
+		20MG	N213498	010	Mar 18, 2021	May	CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

	@ ANCHEN PHARMS	8MEQ	A202886	001	Dec 26, 2013	Feb	DISC
	@	10MEQ	A202886	002	Dec 26, 2013	Feb	DISC
	@ ENDO OPERATIONS	8MEQ	A202886	001	Dec 26, 2013	May	CAHN
	@	10MEQ	A202886	002	Dec 26, 2013	May	CAHN

FOR SOLUTION;ORAL

POKONZA

>A>	+ GENUS	10MEQ	N208019	002	Aug 25, 2023	Jun	CAHN
>D>	+ PHARMA RES SOFTWARE	10MEQ	N208019	002	Aug 25, 2023	Jun	CAHN
	POTASSIUM CHLORIDE						
>A>	AA + GENUS	20MEQ	N208019	001	Aug 19, 2015	Jun	CAHN
>A>	+!	40MEQ	N208019	003	Aug 25, 2023	Jun	CAHN
>D>	AA + PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Jun	CAHN
>D>	+!	40MEQ	N208019	003	Aug 25, 2023	Jun	CAHN

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA	STRIDES PHARMA	20MEQ/15ML	A211665	002	Jan 16, 2024	Jan	NEWA
----	----------------	------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

	@ CHARTWELL RX	10MEQ	A206630	001	Mar 29, 2019	May	CAHN
	@	15MEQ	A206630	002	Mar 29, 2019	May	CAHN
	@	20MEQ	A206630	003	Mar 29, 2019	May	CAHN
AB1	MACLEODS PHARMS LTD	10MEQ	A216269	001	May 09, 2024	May	NEWA
AB1		15MEQ	A216269	002	May 09, 2024	May	NEWA

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB1 20MEQ A216269 003 May 09, 2024 May NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CITRATE

@ TORRENT 5MEQ A213986 001 Feb 06, 2024 Feb DISC
AB 5MEQ A213986 001 Feb 06, 2024 Jan NEWA
@ 10MEQ A213986 002 Feb 06, 2024 Feb DISC
AB 10MEQ A213986 002 Feb 06, 2024 Jan NEWA
@ 15MEQ A213986 003 Feb 06, 2024 Feb DISC
AB 15MEQ A213986 003 Feb 06, 2024 Jan NEWA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS
POTASSIUM PHOSPHATES

>A> AP SOMERSET THERAPS LLC 1.18GM/5ML (236MG/ML);1.12GM/5ML A217726 001 Jul 11, 2024 Jun NEWA
(224MG/ML)
>A> AP 3.54GM/15ML (236MG/ML);3.36GM/15ML A217726 002 Jul 11, 2024 Jun NEWA
(224MG/ML)

PRALSETINIB

CAPSULE;ORAL
GAVRETO

>D> +! BLUEPRINT MEDICINES 100MG N213721 001 Sep 04, 2020 Jun CAHN
+! 100MG N213721 001 Sep 04, 2020 Feb CAHN
>A> +! RIGEL PHARMS 100MG N213721 001 Sep 04, 2020 Jun CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB GLENMARK PHARMS LTD 0.125MG A090781 001 Oct 08, 2010 Mar CAHN
AB ! 0.25MG A090781 002 Oct 08, 2010 Mar CAHN
AB 0.5MG A090781 003 Oct 08, 2010 Mar CAHN
AB 0.75MG A090781 006 Sep 11, 2015 Mar CAHN
AB 1MG A090781 004 Oct 08, 2010 Mar CAHN
AB 1.5MG A090781 005 Oct 08, 2010 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

@ ENDO OPERATIONS 0.375MG A202206 001 Feb 06, 2014 May CAHN
@ 0.75MG A202206 002 Feb 06, 2014 May CAHN
@ 1.5MG A202206 003 Feb 06, 2014 May CAHN
@ 2.25MG A202206 004 Feb 06, 2014 May CAHN
@ 3MG A202206 005 Feb 06, 2014 May CAHN
@ 3.75MG A202206 006 Feb 06, 2014 May CAHN
@ 4.5MG A202206 007 Feb 06, 2014 May CAHN

PRAZIQUANTEL

TABLET;ORAL

BILTRICIDE

>D> AB +! BAYER HLTHCARE 600MG N018714 001 Dec 29, 1982 Jun CHRS
>A> AB + 600MG N018714 001 Dec 29, 1982 Jun CHRS
PRAZIQUANTEL
>D> AB ENDO OPERATIONS 600MG A208820 001 Nov 27, 2017 Jun CHRS
>A> AB ! 600MG A208820 001 Nov 27, 2017 Jun CHRS
AB 600MG A208820 001 Nov 27, 2017 Apr CAHN

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

@ HIKMA 15MG/5ML A040401 001 Feb 27, 2003 Mar DISC
@ PHARM ASSOC 15MG/5ML A040399 001 Mar 05, 2003 Feb DISC

TABLET;ORAL

PREDNISOLONE

AB ZHEJIANG XIANJU 5MG A218083 001 May 02, 2024 Apr NEWA

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

@ ENDO OPERATIONS	EQ 15MG BASE/5ML	A 079010	001	May 26, 2009	May	CAHN
@ HIKMA	EQ 5MG BASE/5ML	A 075183	001	Mar 26, 2003	Mar	DISC
@ PHARM ASSOC	EQ 30MG BASE/5ML	A 204962	001	Mar 11, 2020	Mar	DISC

PREDNISON

SOLUTION;ORAL

PREDNISON INTENSOL

+! HIKMA	5MG/ML	A 088810	001	Feb 20, 1985	Jan	CRLD
----------	--------	----------	-----	--------------	-----	------

TABLET;ORAL

PREDNISON

AB	ENDO OPERATIONS	1MG	A 040584	001	Dec 21, 2004	Apr	CAHN	
AB		2.5MG	A 040581	001	Dec 21, 2004	Apr	CAHN	
AB		5MG	A 040256	001	Jul 12, 2002	Apr	CAHN	
AB		10MG	A 040256	002	Jul 12, 2002	Apr	CAHN	
AB		20MG	A 040392	001	Feb 12, 2003	Apr	CAHN	
	@ GENEYORK PHARMS	1MG	A 211496	001	Dec 28, 2018	Feb	DISC	
	@	2.5MG	A 210525	004	Dec 07, 2018	Feb	DISC	
	@	5MG	A 210525	005	Dec 07, 2018	Feb	DISC	
	@	10MG	A 210525	001	Dec 04, 2018	Feb	DISC	
	@	20MG	A 210525	002	Dec 04, 2018	Feb	DISC	
	@	50MG	A 210525	003	Dec 04, 2018	Feb	DISC	
>A>	AB	STRIDES PHARMA	2.5MG	A 208412	004	Nov 20, 2020	Jun	CMS1
>A>	AB		5MG	A 208412	005	Nov 20, 2020	Jun	CMS1

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB	ACI	25MG	A 215755	001	Apr 26, 2023	Feb	CMFD
AB		50MG	A 215755	002	Apr 26, 2023	Feb	CMFD
AB		75MG	A 215755	003	Apr 26, 2023	Feb	CMFD
AB		100MG	A 215755	004	Apr 26, 2023	Feb	CMFD
AB		150MG	A 215755	005	Apr 26, 2023	Feb	CMFD
AB		200MG	A 215755	006	Apr 26, 2023	Feb	CMFD
AB		225MG	A 215755	007	Apr 26, 2023	Feb	CMFD
AB		300MG	A 215755	008	Apr 26, 2023	Feb	CMFD
	@ CADILA PHARMS LTD	25MG	A 206452	001	Jul 12, 2023	Jan	DISC
	@	50MG	A 206452	002	Jul 12, 2023	Jan	DISC
	@	75MG	A 206452	003	Jul 12, 2023	Jan	DISC
	@	100MG	A 206452	004	Jul 12, 2023	Jan	DISC
	@	150MG	A 206452	005	Jul 12, 2023	Jan	DISC
	@	200MG	A 206452	006	Jul 12, 2023	Jan	DISC
	@	225MG	A 206452	007	Jul 12, 2023	Jan	DISC
	@	300MG	A 206452	008	Jul 12, 2023	Jan	DISC
	@ CIPLA	25MG	A 212280	001	Jan 10, 2020	May	DISC
	@	50MG	A 212280	002	Jan 10, 2020	May	DISC
	@	75MG	A 212280	003	Jan 10, 2020	May	DISC
	@	100MG	A 212280	004	Jan 10, 2020	May	DISC
	@	150MG	A 212280	005	Jan 10, 2020	May	DISC
	@	200MG	A 212280	006	Jan 10, 2020	May	DISC
	@	225MG	A 212280	007	Jan 10, 2020	May	DISC
	@	300MG	A 212280	008	Jan 10, 2020	May	DISC
AB	INDOCO	25MG	A 208113	001	May 17, 2024	May	NEWA
AB		50MG	A 208113	002	May 17, 2024	May	NEWA
AB		75MG	A 208113	004	May 17, 2024	May	NEWA
AB		100MG	A 208113	005	May 17, 2024	May	NEWA
AB		150MG	A 208113	003	May 17, 2024	May	NEWA
AB		200MG	A 208113	006	May 17, 2024	May	NEWA
AB		225MG	A 208113	007	May 17, 2024	May	NEWA
AB		300MG	A 208113	008	May 17, 2024	May	NEWA
AB	STRIDES PHARMA	25MG	A 209883	001	Jan 24, 2024	Jan	NEWA
AB		50MG	A 209883	002	Jan 24, 2024	Jan	NEWA
AB		75MG	A 209883	003	Jan 24, 2024	Jan	NEWA
AB		100MG	A 209883	004	Jan 24, 2024	Jan	NEWA
AB		150MG	A 209883	005	Jan 24, 2024	Jan	NEWA
AB		200MG	A 209883	006	Jan 24, 2024	Jan	NEWA
AB		225MG	A 209883	007	Jan 24, 2024	Jan	NEWA
AB		300MG	A 209883	008	Jan 24, 2024	Jan	NEWA
	@ SUN PHARM	25MG	A 091157	001	Nov 29, 2019	Jan	DISC
	@	50MG	A 091157	002	Nov 29, 2019	Jan	DISC

	CAPSULE;ORAL							
	PREGABALIN							
	@	75MG	A091157	003	Nov 29, 2019	Jan	DISC	
	@	100MG	A091157	004	Nov 29, 2019	Jan	DISC	
	@	150MG	A091157	005	Nov 29, 2019	Jan	DISC	
	@	200MG	A091157	006	Nov 29, 2019	Jan	DISC	
	@	225MG	A091157	007	Nov 29, 2019	Jan	DISC	
	@	300MG	A091157	008	Nov 29, 2019	Jan	DISC	
	TABLET, EXTENDED RELEASE;ORAL							
	PREGABALIN							
>D>	@ MYLAN	330MG	A211431	001	Jul 02, 2021	Jun	CAHN	
>A>	@ NORVIUM BIOSCIENCE	330MG	A211431	001	Jul 02, 2021	Jun	CAHN	
	<u>PRIMIDONE</u>							
	SUSPENSION;ORAL							
	MYSOLINE							
	+ @ FHTA	250MG/5ML	N010401	001		Jan	CAHN	
	TABLET;ORAL							
	PRIMIDONE							
AB	CARNEGIE	50MG	A218366	001	Jan 23, 2024	Jan	NEWA	
AB		250MG	A218366	002	Jan 23, 2024	Jan	NEWA	
	<u>PROCAINAMIDE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	PROCAINAMIDE HYDROCHLORIDE							
>A>	@ HIKMA	100MG/ML	A089029	001	Apr 17, 1986	Jun	CAHN	
>D>	@ WEST-WARD PHARMS INT	100MG/ML	A089029	001	Apr 17, 1986	Jun	CAHN	
	<u>PROCHLORPERAZINE MALEATE</u>							
	TABLET;ORAL							
	PROCHLORPERAZINE MALEATE							
AB	AJANTA PHARMA LTD	EQ 5MG BASE	A218515	001	May 09, 2024	Apr	NEWA	
AB		EQ 10MG BASE	A218515	002	May 09, 2024	Apr	NEWA	
	<u>PROMETHAZINE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	PROMETHAZINE HYDROCHLORIDE							
>A>	AP	+! HIKMA	A083312	001		Jun	CAHN	
>A>	AP	+!	A083312	002		Jun	CAHN	
>D>	AP	+! WEST-WARD PHARMS INT	A083312	001		Jun	CAHN	
>D>	AP	+!	A083312	002		Jun	CAHN	
	<u>PROPAPENONE HYDROCHLORIDE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL							
	PROPAPENONE HYDROCHLORIDE							
AB	SINOTHERAPEUTICS INC	225MG	A210339	001	Jan 04, 2019	May	CTEC	
AB		325MG	A210339	002	Jan 04, 2019	May	CTEC	
AB		425MG	A210339	003	Jan 04, 2019	May	CTEC	
AB	TWI PHARMS	225MG	A212928	001	Jun 18, 2020	Mar	CAHN	
AB		325MG	A212928	002	Jun 18, 2020	Mar	CAHN	
AB		425MG	A212928	003	Jun 18, 2020	Mar	CAHN	
	<u>PROPOFOL</u>							
	INJECTABLE;INJECTION							
	PROPOFOL							
>A>	AB	ASPIRO	A217013	001	Jun 20, 2024	Jun	NEWA	
	<u>PROPRANOLOL HYDROCHLORIDE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL							
	PROPRANOLOL HYDROCHLORIDE							
	@ LUPIN LTD	60MG	A204349	001	Jan 12, 2024	Apr	DISC	
AB		60MG	A204349	001	Jan 12, 2024	Jan	NEWA	
	@	80MG	A204349	002	Jan 12, 2024	Apr	DISC	
AB		80MG	A204349	002	Jan 12, 2024	Jan	NEWA	
	@	120MG	A204349	003	Jan 12, 2024	Apr	DISC	
AB		120MG	A204349	003	Jan 12, 2024	Jan	NEWA	
	@	160MG	A204349	004	Jan 12, 2024	Apr	DISC	
AB		160MG	A204349	004	Jan 12, 2024	Jan	NEWA	
	SOLUTION;ORAL							
	HEMANGEOL							
	+! PIERRE FABRE	4.28MG/ML	N205410	001	Mar 14, 2014	May	CAHN	

<u>TABLET;ORAL</u>							
PROPRANOLOL HYDROCHLORIDE							
AB	ENDO OPERATIONS	10MG	A070221	002	Aug 01, 1986	Apr	CAHN
AB		20MG	A070221	003	Aug 01, 1986	Apr	CAHN
AB		40MG	A070221	004	Aug 01, 1986	Apr	CAHN
AB		60MG	A070221	005	Sep 24, 1986	Apr	CAHN
AB		80MG	A070221	001	Apr 14, 1986	Apr	CAHN
<u>PROPYLTHIOURACIL</u>							
TABLET;ORAL							
PROPYLTHIOURACIL							
AB	+!	ENDO OPERATIONS	50MG	N006188	001		Apr CAHN
<u>PYRIDOSTIGMINE BROMIDE</u>							
TABLET;ORAL							
PYRIDOSTIGMINE BROMIDE							
AB	ANI PHARMS	60MG	A040512	001	Oct 08, 2003	Jan	CMFD
AB	MLV	30MG	A211181	002	May 14, 2019	Mar	CAHN
AB		60MG	A211181	001	Jul 20, 2018	Mar	CAHN
<u>QUETIAPINE FUMARATE</u>							
TABLET;ORAL							
QUETIAPINE FUMARATE							
AB	IPCA LABS LTD	EQ 25MG BASE	A205983	001	May 20, 2024	May	NEWA
AB		EQ 50MG BASE	A205983	002	May 20, 2024	May	NEWA
AB		EQ 100MG BASE	A205983	003	May 20, 2024	May	NEWA
AB		EQ 200MG BASE	A205983	004	May 20, 2024	May	NEWA
AB		EQ 300MG BASE	A205983	005	May 20, 2024	May	NEWA
AB		EQ 400MG BASE	A205983	006	May 20, 2024	May	NEWA
TABLET, EXTENDED RELEASE;ORAL							
QUETIAPINE FUMARATE							
	@	ENDO OPERATIONS	EQ 50MG BASE	A090482	001	May 09, 2017	May CAHN
	@		EQ 150MG BASE	A090482	002	May 09, 2017	May CAHN
	@		EQ 150MG BASE	A090757	001	Dec 01, 2017	May CAHN
	@		EQ 200MG BASE	A090482	003	May 09, 2017	May CAHN
	@		EQ 200MG BASE	A090757	002	Dec 01, 2017	May CAHN
	@		EQ 300MG BASE	A090482	004	May 09, 2017	May CAHN
	@		EQ 300MG BASE	A090757	003	Dec 01, 2017	May CAHN
	@		EQ 400MG BASE	A090482	005	May 09, 2017	May CAHN
	@		EQ 400MG BASE	A090757	004	Dec 01, 2017	May CAHN
	@	PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Feb DISC
	@		EQ 150MG BASE	A090482	002	May 09, 2017	Feb DISC
	@		EQ 200MG BASE	A090482	003	May 09, 2017	Feb DISC
	@		EQ 300MG BASE	A090482	004	May 09, 2017	Feb DISC
	@		EQ 400MG BASE	A090482	005	May 09, 2017	Feb DISC
AB		PRINSTON INC	EQ 400MG BASE	A208781	005	Mar 11, 2024	Mar NEWA
<u>QUINAPRIL HYDROCHLORIDE</u>							
TABLET;ORAL							
QUINAPRIL HYDROCHLORIDE							
	@	INVAGEN PHARMS	EQ 5MG BASE	A078457	001	Aug 24, 2007	Mar DISC
	@		EQ 10MG BASE	A078457	002	Aug 24, 2007	Mar DISC
	@		EQ 20MG BASE	A078457	003	Aug 24, 2007	Mar DISC
	@		EQ 40MG BASE	A078457	004	Aug 24, 2007	Mar DISC
<u>RABEPRAZOLE SODIUM</u>							
TABLET, DELAYED RELEASE;ORAL							
ACIPHEX							
	+ @	WAYLIS THERAP	10MG	N020973	001	May 29, 2002	Apr CAHN
AB	+!		20MG	N020973	002	Aug 19, 1999	Apr CAHN
<u>RAMIPRIL</u>							
CAPSULE;ORAL							
RAMIPRIL							
	@	ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	May DISC
	@		2.5MG	A202392	002	Apr 15, 2014	May DISC
	@		5MG	A202392	003	Apr 15, 2014	May DISC
	@		10MG	A202392	004	Apr 15, 2014	May DISC

RANITIDINE HYDROCHLORIDE

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

@ LANNETT CO INC	EQ 15MG BASE/ML	A091288	001	Dec 09, 2010	Mar	DISC
@ PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	Mar	DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ ENDO OPERATIONS	EQ 150MG BASE	A075180	001	Jan 28, 1999	May	CAHN
@	EQ 300MG BASE	A075180	002	Jan 28, 1999	May	CAHN
@ PAR PHARM	EQ 150MG BASE	A075180	001	Jan 28, 1999	Feb	DISC
@	EQ 300MG BASE	A075180	002	Jan 28, 1999	Feb	DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

@ PIRAMAL HLTHCARE UK	500MG	A213085	001	Jul 25, 2023	Jan	DISC
@	1GM	A213085	002	Jul 25, 2023	Jan	DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

>A> AB	MACLEODS PHARMS LTD	EQ 0.5MG BASE	A208866	001	Jun 28, 2024	Jun	NEWA
>A> AB		EQ 1MG BASE	A208866	002	Jun 28, 2024	Jun	NEWA
AB	SKG PHARMA	EQ 0.5MG BASE	A218163	001	Apr 09, 2024	Mar	NEWA
AB		EQ 1MG BASE	A218163	002	Apr 09, 2024	Mar	NEWA

REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

REMIFENTANIL HYDROCHLORIDE

>A> AP	NIVAGEN PHARMS INC	EQ 1MG BASE/VIAL	A215635	001	Jun 28, 2024	Jun	NEWA
>A> AP		EQ 2MG BASE/VIAL	A215635	002	Jun 28, 2024	Jun	NEWA
>A> AP		EQ 5MG BASE/VIAL	A215635	003	Jun 28, 2024	Jun	NEWA

RESMETIROM

TABLET;ORAL

REZDIFFRA

+	MADRIGAL	60MG	N217785	001	Mar 14, 2024	Mar	NEWA
+		80MG	N217785	002	Mar 14, 2024	Mar	NEWA
+	!	100MG	N217785	003	Mar 14, 2024	Mar	NEWA

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

+	@ ALMIRALL	1%	N022055	001	Apr 12, 2007	May	DISC
---	------------	----	---------	-----	--------------	-----	------

REZAFUNGIN ACETATE

POWDER;INTRAVENOUS

REZZAYO

>D>	+	CIDARA THERAPS	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Jun	CAHN
>A>	+	MUNDIPHARMA	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Jun	CAHN

RIFAMPIN

CAPSULE;ORAL

RIFAMPIN

@	HIKMA	150MG	A065028	001	Mar 14, 2001	Mar	DISC
@		300MG	A065028	002	Mar 14, 2001	Mar	DISC

RILPIVIRINE HYDROCHLORIDE

TABLET, FOR SUSPENSION;ORAL

EDURANT PED

+	!	JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Mar	NEWA
---	---	---------------	---------------	---------	-----	--------------	-----	------

RILUZOLE

TABLET;ORAL

RILUTEK

+	@	COVIS	50MG	N020599	001	Dec 12, 1995	May	DISC
---	---	-------	------	---------	-----	--------------	-----	------

RILUZOLE

AB	!	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	May	CHRS
----	---	----------------	------	---------	-----	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

RISEDRONATE SODIUM

>D>	AB	AUROBINDO PHARMA	150MG	A206768	001	Oct 21, 2016	Jun	CTEC
>A>	BX		150MG	A206768	001	Oct 21, 2016	Jun	CTEC

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

RISVAN

+		LABS FARMS ROVI SA	75MG	N214835	001	Mar 29, 2024	Mar	NEWA
+	!		100MG	N214835	002	Mar 29, 2024	Mar	NEWA

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

AB	+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan	CMS1
AB	+	!	25MG/VIAL	N021346	001	Oct 29, 2003	Jan	CMS1
AB	+		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan	CMS1
AB	+		50MG/VIAL	N021346	003	Oct 29, 2003	Jan	CMS1

RISPERIDONE

AB		TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan	CMS1
AB			25MG/VIAL	A214068	002	Dec 05, 2023	Jan	CMS1
AB			37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan	CMS1
AB			50MG/VIAL	A214068	004	Dec 05, 2023	Jan	CMS1

SOLUTION; ORAL

RISPERIDONE

@		HIKMA	1MG/ML	A076904	001	Jul 29, 2009	Mar	DISC
@		PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Feb	DISC

TABLET; ORAL

RISPERIDONE

>A>	AB	IPCA LABS LTD	0.25MG	A205104	001	Jun 26, 2024	Jun	NEWA
>A>	AB		0.5MG	A205104	002	Jun 26, 2024	Jun	NEWA
>A>	AB		1MG	A205104	003	Jun 26, 2024	Jun	NEWA
>A>	AB		2MG	A205104	004	Jun 26, 2024	Jun	NEWA
>A>	AB		3MG	A205104	005	Jun 26, 2024	Jun	NEWA
>A>	AB		4MG	A205104	006	Jun 26, 2024	Jun	NEWA
	AB	RENATA	0.25MG	A078707	001	Dec 29, 2008	Feb	CAHN
	AB		0.5MG	A078707	002	Dec 29, 2008	Feb	CAHN
	AB		1MG	A078707	003	Dec 29, 2008	Feb	CAHN
	AB		2MG	A078707	004	Dec 29, 2008	Feb	CAHN
	AB		3MG	A078707	005	Dec 29, 2008	Feb	CAHN
	AB		4MG	A078707	006	Dec 29, 2008	Feb	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

	AB	ENDO OPERATIONS	0.25MG	A077494	001	Apr 30, 2009	Apr	CAHN
	AB		0.5MG	A077494	002	Apr 30, 2009	Apr	CAHN
	AB		1MG	A077494	003	Oct 26, 2009	Apr	CAHN
	AB		2MG	A077494	004	Apr 30, 2009	Apr	CAHN
	AB		3MG	A077494	005	Apr 30, 2009	Apr	CAHN
	AB		4MG	A077494	006	Apr 30, 2009	Apr	CAHN

RITONAVIR

CAPSULE; ORAL

RITONAVIR

		MYLAN	100MG	A205024	001	Feb 16, 2024	Feb	NEWA
--	--	-------	-------	---------	-----	--------------	-----	------

RIVASTIGMINE TARTRATE

SOLUTION; ORAL

EXELON

+	@	NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Apr	CRLD
---	---	----------	----------------	---------	-----	--------------	-----	------

RIZATRIPTAN BENZOATE

FILM; ORAL

RIZAFILM

>D>								
>D>								
>D>		GENSCO	EQ 10MG BASE	N205394	001	Apr 14, 2023	Jun	DISC
>A>		@	EQ 10MG BASE	N205394	001	Apr 14, 2023	Jun	DISC

TABLET; ORAL

RIZATRIPTAN BENZOATE

@		INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Apr	DISC
@			EQ 10MG BASE	A204339	002	Jul 01, 2013	Apr	DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	CAPLIN	200MG/100ML (2MG/ML)	A212808	005	May 23, 2024	May	NEWA
AP		400MG/200ML (2MG/ML)	A212808	006	May 23, 2024	May	NEWA
	@ HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	May	DISC
	@	40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	May	DISC
	@	100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	May	DISC
	@	150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	May	DISC
	@	150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	May	DISC
	@	200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	May	DISC

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

	@ SANDOZ	EQ 5MG BASE	A079171	001	Jul 19, 2016	Jan	DISC
	@	EQ 10MG BASE	A079171	002	Jul 19, 2016	Jan	DISC
	@	EQ 20MG BASE	A079171	003	Jul 19, 2016	Jan	DISC
	@	EQ 40MG BASE	A079171	004	Jul 19, 2016	Jan	DISC

SACUBITRIL; VALSARTAN

CAPSULE, PELLETS; ORAL

ENTRESTO SPRINKLE

	+ NOVARTIS	6MG; 6MG	N218591	001	Apr 12, 2024	Apr	NEWA
	+!	15MG; 16MG	N218591	002	Apr 12, 2024	Apr	NEWA

TABLET; ORAL

ENTRESTO

AB	+ NOVARTIS PHARMS CORP	24MG; 26MG	N207620	001	Jul 07, 2015	May	CFTG
AB	+	49MG; 51MG	N207620	002	Jul 07, 2015	May	CFTG
AB	+!	97MG; 103MG	N207620	003	Jul 07, 2015	May	CFTG

SACUBITRIL AND VALSARTAN

AB	ALEMBIC	24MG; 26MG	A213682	001	May 28, 2024	May	NFTG
AB		49MG; 51MG	A213682	002	May 28, 2024	May	NFTG
AB		97MG; 103MG	A213682	003	May 28, 2024	May	NFTG
AB	CRYSTAL	24MG; 26MG	A213605	001	May 28, 2024	May	NFTG
AB		49MG; 51MG	A213605	002	May 28, 2024	May	NFTG
AB		97MG; 103MG	A213605	003	May 28, 2024	May	NFTG
AB	LAURUS	24MG; 26MG	A213676	001	May 28, 2024	May	NFTG
AB		49MG; 51MG	A213676	002	May 28, 2024	May	NFTG
AB		97MG; 103MG	A213676	003	May 28, 2024	May	NFTG
>A>	AB ZYDUS PHARMS	24MG; 26MG	A213719	001	Jul 09, 2024	Jun	NEWA
>A>	AB	49MG; 51MG	A213719	002	Jul 09, 2024	Jun	NEWA
>A>	AB	97MG; 103MG	A213719	003	Jul 09, 2024	Jun	NEWA

SAFINAMIDE MESYLATE

TABLET; ORAL

SAFINAMIDE MESYLATE

AB	PRINSTON INC	EQ 50MG BASE	A215739	001	Apr 25, 2024	Apr	NEWA
AB		EQ 100MG BASE	A215739	002	Apr 25, 2024	Apr	NEWA
	XADAGO						
AB	+ MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Apr	CTEC
AB	+!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Apr	CTEC

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

SAXAGLIPTIN

	@ AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Feb	DISC
	@	EQ 5MG BASE	A205941	002	Jul 31, 2023	Feb	DISC

SCOPOLAMINE

SYSTEM; TRANSDERMAL

SCOPOLAMINE

AB	RHODES PHARMS	1MG/72HR	A215329	001	May 06, 2024	Apr	NEWA
----	---------------	----------	---------	-----	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

	@ KENTON	5MG	A074912	001	Apr 30, 1998	May	CAHN
--	----------	-----	---------	-----	--------------	-----	------

SELEXIPAG

TABLET;ORAL

SELEXIPAG

@	ZYDUS LIFESCIENCES	0.2MG	A214302	001	Dec 21, 2022	May	CAHN
@		0.4MG	A214302	002	Dec 21, 2022	May	CAHN
@		0.6MG	A214302	003	Dec 21, 2022	May	CAHN
@		0.8MG	A214302	004	Dec 21, 2022	May	CAHN
@		1MG	A214302	005	Dec 21, 2022	May	CAHN
@		1.2MG	A214302	006	Dec 21, 2022	May	CAHN
@		1.4MG	A214302	007	Dec 21, 2022	May	CAHN
@		1.6MG	A214302	008	Dec 21, 2022	May	CAHN

SELPERCATINIB

TABLET;ORAL

RETEVMO

+	LOXO ONCOL ELI LILLY	40MG	N218160	001	Apr 10, 2024	Apr	NEWA
+		80MG	N218160	002	Apr 10, 2024	Apr	NEWA
+		120MG	N218160	003	Apr 10, 2024	Apr	NEWA
+	!	160MG	N218160	004	Apr 10, 2024	Apr	NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	APPCO	EQ 25MG BASE	A077713	001	Feb 06, 2007	May	CAHN
@		EQ 50MG BASE	A077713	002	Feb 06, 2007	May	CAHN
@		EQ 100MG BASE	A077713	003	Feb 06, 2007	May	CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

AB	MACLEODS PHARMS LTD	800MG/PACKET	A207291	001	Apr 25, 2024	Apr	NEWA
AB		2.4GM/PACKET	A207291	002	Apr 25, 2024	Apr	NEWA

TABLET;ORAL

SEVELAMER CARBONATE

@	ANXIN	800MG	A212970	001	Apr 09, 2020	Apr	DISC
AB	STRIDES PHARMA	800MG	A211915	001	May 09, 2024	May	NEWA

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

@	MYLAN PHARMS INC	EQ 20MG BASE	A201150	001	Nov 09, 2012	Apr	DISC	
>D>	AB	UMEDICA	EQ 25MG BASE	A209302	003	Jun 15, 2021	Jun	CTEC
>A>	BX		EQ 25MG BASE	A209302	003	Jun 15, 2021	Jun	CTEC
>D>	AB		EQ 50MG BASE	A209302	001	Aug 25, 2020	Jun	CTEC
>A>	BX		EQ 50MG BASE	A209302	001	Aug 25, 2020	Jun	CTEC
>D>	AB		EQ 100MG BASE	A209302	002	Aug 25, 2020	Jun	CTEC
>A>	BX		EQ 100MG BASE	A209302	002	Aug 25, 2020	Jun	CTEC

SILODOSIN

CAPSULE;ORAL

SILODOSIN

AB	CHARTWELL RX	4MG	A204726	001	Mar 31, 2017	Mar	CAHN
AB		8MG	A204726	002	Mar 31, 2017	Mar	CAHN

SILVER SULFADIAZINE

CREAM;TOPICAL

SSD

AB	+	DR REDDYS LA	1%	N018578	001	Feb 25, 1982	Jan	CRLD
AB	!		1%	N018578	001	Feb 25, 1982	Jan	CHRS

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

+	SALERNO PHARMS	20MG/5ML	N206679	001	Apr 21, 2016	Apr	CAHN
+	!	40MG/5ML	N206679	002	Apr 21, 2016	Apr	CAHN

SINCALIDE

		INJECTABLE; INJECTION						
		KINEVAC						
AP	+	BRACCO	0.005MG/VIAL		N017697	001		May CTEC
		POWDER; INTRAVENOUS						
		KINEVAC						
AP	+	BRACCO	0.005MG/VIAL		N017697	001		May CDFR
		SINCALIDE						
AP	+	MAIA PHARMS INC	0.005MG/VIAL		N210850	001	Nov 22, 2022	May CTEC

SODIUM ACETATE

		INJECTABLE; INJECTION						
		SODIUM ACETATE						
AP		FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)		A206687	001	Oct 30, 2017	Apr CPOT
AP		MILLA PHARMS	400MEQ/100ML (4MEQ/ML)		A214805	002	Aug 25, 2023	Apr CPOT
		SOLUTION; INTRAVENOUS						
		SODIUM ACETATE						
AP	!	FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)		A206687	001	Oct 30, 2017	Apr CDFR
AP		HIKMA	40MEQ/20ML (2MEQ/ML)		A216920	001	Mar 15, 2024	Mar NEWA
AP			100MEQ/50ML (2MEQ/ML)		A216920	002	Mar 15, 2024	Mar NEWA
AP			200MEQ/100ML (2MEQ/ML)		A216920	003	Mar 15, 2024	Mar NEWA
AP	+	HOSPIRA	2MEQ/ML		N018893	001	May 04, 1983	Mar CDFR
AP	+		40MEQ/20ML (2MEQ/ML)		N018893	001	May 04, 1983	Mar CPOT
AP	+		100MEQ/50ML (2MEQ/ML)		N018893	002	Sep 02, 2014	Mar CMS1
AP	+		200MEQ/100ML (2MEQ/ML)		N018893	003	Sep 02, 2014	Mar CMS1
AP		MILLA PHARMS	2MEQ/ML		A214805	001	May 04, 2021	Mar CDFR
AP			40MEQ/20ML (2MEQ/ML)		A214805	004	Jan 22, 2024	Mar CMS1
AP			100MEQ/50ML (2MEQ/ML)		A214805	001	May 04, 2021	Mar CPOT
AP			200MEQ/100ML (2MEQ/ML)		A214805	003	May 04, 2021	Mar CMS1
AP			400MEQ/100ML (4MEQ/ML)		A214805	002	Aug 25, 2023	Apr CDFR

SODIUM BICARBONATE

		INJECTABLE; INJECTION						
		SODIUM BICARBONATE						
>A>	AP	LONG GROVE PHARMS	1MEQ/ML		A216042	001	Feb 27, 2024	Jun CAHN
>D>	AP	NIVAGEN PHARMS INC	1MEQ/ML		A216042	001	Feb 27, 2024	Jun CAHN
	AP		1MEQ/ML		A216042	001	Feb 27, 2024	Feb NEWA
	AP	STERISCIENCE	1MEQ/ML		A217594	001	Jun 28, 2023	Apr CMFD
		@	1MEQ/ML		A217594	001	Jun 28, 2023	Jan DISC

SODIUM CHLORIDE

		SOLUTION; INJECTION						
		SODIUM CHLORIDE 0.9%						
		@ HIKMA	90MG/10ML (9MG/ML)		A201850	001	Jan 20, 2012	Mar DISC
		SOLUTION; IRRIGATION						
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>A>	AT	FRESENIUS KABI USA	900MG/100ML		A213688	001	Jun 24, 2024	Jun NEWA

SODIUM FLUORIDE F-18

		INJECTABLE; INTRAVENOUS						
		SODIUM FLUORIDE F-18						
AP	!	PETNET	10-200mCi/ML		A203890	001	Sep 28, 2015	Jan CHRS

SODIUM PHENYL BUTYRATE

		POWDER; ORAL						
		SODIUM PHENYL BUTYRATE						
AB		ENDO OPERATIONS	3GM/TEASPOONFUL		A203918	001	Jun 15, 2016	Apr CAHN
		TABLET; ORAL						
		SODIUM PHENYL BUTYRATE						
AB		ENDO OPERATIONS	500MG		A204395	001	Apr 15, 2016	Apr CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

		INJECTABLE; INJECTION						
		SODIUM PHOSPHATES						
>A>	AP	AM REGENT	142MG/ML; 276MG/ML		A218314	001	Jun 21, 2024	Jun NEWA

>A>	<u>SOFPIRONIUM BROMIDE</u>				
>A>	GEL, METERED;TOPICAL				
>A>	SOFDRA				
>A>	+!	BOTANIX SB	EQ 12.45% BASE (EQ 72MG BASE/ACTUATION)	N217347 001	Jun 18, 2024 Jun NEWA
	<u>SOLIFENACIN SUCCINATE</u>				
	TABLET;ORAL				
	SOLIFENACIN SUCCINATE				
AB		MACLEODS PHARMS LTD	5MG	A204374 001	Feb 20, 2024 Feb NEWA
AB			10MG	A204374 002	Feb 20, 2024 Feb NEWA
	<u>SOTALOL HYDROCHLORIDE</u>				
	TABLET;ORAL				
	SOTALOL HYDROCHLORIDE				
	@	RISING	80MG	A075725 001	Dec 19, 2000 Feb CAHN
	@		120MG	A075725 002	Dec 19, 2000 Feb CAHN
	@		160MG	A075725 003	Dec 19, 2000 Feb CAHN
	@		240MG	A075725 004	Dec 19, 2000 Feb CAHN
	<u>STERILE WATER FOR INJECTION</u>				
	LIQUID;N/A				
	STERILE WATER FOR INJECTION				
AP		AM REGENT	100% (5ML)	A217341 003	Feb 09, 2024 Feb NEWA
	<u>SUCCINYLCHOLINE CHLORIDE</u>				
	INJECTABLE;INJECTION				
	SUCCINYLCHOLINE CHLORIDE				
	@	ACCORD HLTHCARE	20MG/ML	A213705 001	May 20, 2020 May DISC
	@	EUGIA PHARMA	20MG/ML	A217808 001	Oct 16, 2023 Apr DISC
AP		NIVAGEN PHARMS INC	20MG/ML	A211625 001	May 19, 2020 Jan CAHN
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS				
	SUCCINYLCHOLINE CHLORIDE				
AP		DR REDDYS	100MG/5ML (20MG/ML)	A218467 001	Jan 17, 2024 Jan NEWA
AP	+!	HIKMA	100MG/5ML (20MG/ML)	N215143 001	Aug 20, 2021 Jan CFTG
>A>	AP	STERISCIENCE	100MG/5ML (20MG/ML)	A217873 001	Jul 09, 2024 Jun NEWA
	<u>SUCRALFATE</u>				
	SUSPENSION;ORAL				
	SUCRALFATE				
AB		ABON PHARMS LLC	1GM/10ML	A216726 001	Mar 21, 2024 Mar NEWA
AB		PD PARTNERS	1GM/10ML	A213549 001	Jan 17, 2024 Jan NEWA
AB		STRIDES PHARMA	1GM/10ML	A216474 001	May 21, 2024 May NEWA
AB		VISTAPHARM LLC	1GM/10ML	A211884 001	Mar 15, 2022 Apr CAHN
	<u>SUGAMMADEX SODIUM</u>				
	SOLUTION;INTRAVENOUS				
	SUGAMMADEX SODIUM				
	@	ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290 001	Oct 04, 2023 Mar DISC
	@		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290 002	Oct 04, 2023 Mar DISC
	<u>SULFAMETHOXAZOLE; TRIMETHOPRIM</u>				
	SUSPENSION;ORAL				
	SULFAMETHOXAZOLE AND TRIMETHOPRIM				
AB	!	AUROBINDO PHARMA	200MG/5ML;40MG/5ML	A091348 001	Jun 08, 2010 Mar CHRS
	@	HIKMA	200MG/5ML;40MG/5ML	A074650 001	Dec 29, 1997 Mar DISC
	<u>SULFANILAMIDE</u>				
	CREAM;VAGINAL				
	AVC				
>D>	+ @	MYLAN SPECIALITY LP	15%	N006530 003	Jan 27, 1987 Jun CAHN
>A>	+ @	NORVIUM BIOSCIENCE	15%	N006530 003	Jan 27, 1987 Jun CAHN
	SUPPOSITORY;VAGINAL				
	AVC				
>D>	@	MYLAN SPECIALITY LP	1.05GM	N006530 004	Jan 27, 1987 Jun CAHN
>A>	@	NORVIUM BIOSCIENCE	1.05GM	N006530 004	Jan 27, 1987 Jun CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

IMITREX

	+ @	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	001	Dec 28, 1992	Jan	DISC
--	-----	-----------------	-------------------------------------	---------	-----	--------------	-----	------

SUMATRIPTAN SUCCINATE

>A>	AP	CAPLIN	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A213998	001	Jul 13, 2021	Jun	CAHN
	@	ENDO OPERATIONS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	May	CAHN
	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	May	CAHN
	AP	! EUGIA PHARMA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013	Jan	CHRS
	@	PAR PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	Feb	DISC
>D>	AP	SOMERSET	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A213998	001	Jul 13, 2021	Jun	CAHN

SUMAVEL DOSEPRO

	+ @	ENDO OPERATIONS	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	May	CAHN
	+ @		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	May	CAHN

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB		EUGIA PHARMA	EQ 12.5MG BASE	A218615	001	Mar 14, 2024	Mar	NEWA
AB			EQ 25MG BASE	A218615	002	Mar 14, 2024	Mar	NEWA
AB			EQ 37.5MG BASE	A218615	003	Mar 14, 2024	Mar	NEWA
AB			EQ 50MG BASE	A218615	004	Mar 14, 2024	Mar	NEWA
AB		NOVUGEN	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	May	CMFD
	@		EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Feb	DISC
AB			EQ 25MG BASE	A218012	002	Aug 21, 2023	May	CMFD
	@		EQ 25MG BASE	A218012	002	Aug 21, 2023	Feb	DISC
AB			EQ 37.5MG BASE	A218012	003	Aug 21, 2023	May	CMFD
	@		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Feb	DISC
AB			EQ 50MG BASE	A218012	004	Aug 21, 2023	May	CMFD
	@		EQ 50MG BASE	A218012	004	Aug 21, 2023	Feb	DISC

TACROLIMUS

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

AB	+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jan	CFTG
AB	+		EQ 1MG BASE	N204096	002	Jul 19, 2013	Jan	CFTG
AB	+	!	EQ 5MG BASE	N204096	003	Jul 19, 2013	Jan	CFTG

TACROLIMUS

AB		CHENGDU	EQ 0.5MG BASE	A215012	001	Jan 25, 2024	Jan	NFTG
AB			EQ 1MG BASE	A215012	002	Jan 25, 2024	Jan	NFTG
AB			EQ 5MG BASE	A215012	003	Jan 25, 2024	Jan	NFTG

TADALAFIL

TABLET;ORAL

TADALAFIL

AB1		HANGZHOU BINJIANG	2.5MG	A208824	001	Oct 27, 2020	Mar	CAHN
AB1			5MG	A208824	002	Oct 27, 2020	Mar	CAHN
AB1			10MG	A208824	003	Oct 27, 2020	Mar	CAHN
AB1			20MG	A208824	004	Oct 27, 2020	Mar	CAHN
AB1		SHANDONG	20MG	A216279	001	Mar 04, 2024	Feb	NEWA
>D>	AB1	UMEDICA	2.5MG	A211298	001	Oct 23, 2020	Jun	CTEC
>A>	BX		2.5MG	A211298	001	Oct 23, 2020	Jun	CTEC
>D>	AB1		5MG	A211298	002	Oct 23, 2020	Jun	CTEC
>A>	BX		5MG	A211298	002	Oct 23, 2020	Jun	CTEC
>D>	AB1		10MG	A211298	003	Oct 23, 2020	Jun	CTEC
>A>	BX		10MG	A211298	003	Oct 23, 2020	Jun	CTEC
>D>	AB1		20MG	A211298	004	Oct 23, 2020	Jun	CTEC
>A>	BX		20MG	A211298	004	Oct 23, 2020	Jun	CTEC
>A>		TABLET, CHEWABLE;ORAL						
>A>		CHEWTADZY						
>A>	+	B BETTER	5MG	N218527	001	Jun 28, 2024	Jun	NEWA
>A>	+		10MG	N218527	002	Jun 28, 2024	Jun	NEWA
>A>	+	!	20MG	N218527	003	Jun 28, 2024	Jun	NEWA

T AFLUPROST

SOLUTION/DROPS;OPHTHALMIC

T AFLUPROST

	@ INGENUS PHARMS LLC	0.0015%	A218002	001	Apr 05, 2024	May	DISC
AT		0.0015%	A218002	001	Apr 05, 2024	Mar	NEWA

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA

+	PFIZER	EQ 0.1MG BASE	N217439	001	Mar 07, 2024	Mar	NEWA
+		EQ 0.25MG BASE	N217439	002	Mar 07, 2024	Mar	NEWA
+		EQ 0.35MG BASE	N217439	003	Mar 07, 2024	Mar	NEWA
+		EQ 0.5MG BASE	N217439	004	Mar 07, 2024	Mar	NEWA
+		EQ 0.75MG BASE	N217439	005	Mar 07, 2024	Mar	NEWA
+	!	EQ 1MG BASE	N217439	006	Mar 07, 2024	Mar	NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

	@ ENDO OPERATIONS	0.4MG	A202010	001	Jan 04, 2013	May	CAHN
--	-------------------	-------	---------	-----	--------------	-----	------

TAVABOROLE

SOLUTION;TOPICAL

KERYDIN

+	@ ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	Mar	DISC
---	---------------------	----	---------	-----	--------------	-----	------

TAVABOROLE

AB	!	ENCUBE	5%	A211297	001	Oct 13, 2020	Mar	CHRS
----	---	--------	----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE;INJECTION

MYOVIEW

>D>	+	GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996	Jun	CAHN
>A>	+	MEDI-PHYSICS	N/A	N020372	001	Feb 09, 1996	Jun	CAHN

MYOVIEW 30ML

>D>	+	GE HEALTHCARE	N/A	N020372	002	Jul 07, 2005	Jun	CAHN
>A>	+	MEDI-PHYSICS	N/A	N020372	002	Jul 07, 2005	Jun	CAHN

TEDUGLUTIDE

POWDER;SUBCUTANEOUS

GATTEX KIT

+	!	TAKEDA PHARMS USA	5MG/VIAL	N203441	001	Dec 21, 2012	Mar	CAIN
---	---	-------------------	----------	---------	-----	--------------	-----	------

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB		CHARTWELL RX	15MG	A071427	001	Jan 12, 1988	Jan	CAHN
AB			30MG	A071428	001	Jan 12, 1988	Jan	CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

>A>	@	EXTROVIS	5MG	A205227	001	Jun 29, 2016	Jun	CAHN
>A>	@		20MG	A205227	002	Jun 29, 2016	Jun	CAHN
>A>	@		100MG	A205227	003	Jun 29, 2016	Jun	CAHN
>A>	@		140MG	A205227	004	Jun 29, 2016	Jun	CAHN
>A>	@		180MG	A205227	005	Jun 29, 2016	Jun	CAHN
>A>	@		250MG	A205227	006	Jun 29, 2016	Jun	CAHN
>D>	@	MYLAN	5MG	A205227	001	Jun 29, 2016	Jun	CAHN
>D>	@		20MG	A205227	002	Jun 29, 2016	Jun	CAHN
>D>	@		100MG	A205227	003	Jun 29, 2016	Jun	CAHN
>D>	@		140MG	A205227	004	Jun 29, 2016	Jun	CAHN
>D>	@		180MG	A205227	005	Jun 29, 2016	Jun	CAHN
>D>	@		250MG	A205227	006	Jun 29, 2016	Jun	CAHN

TENAPANOR HYDROCHLORIDE

TABLET;ORAL

XPHOZAH

+	@	ARDELYX INC	EQ 10MG BASE	N213931	001	Oct 17, 2023	Apr	DISC
---	---	-------------	--------------	---------	-----	--------------	-----	------

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

	TENOFOVIR ALAFENAMIDE FUMARATE						
	@ APOTEX	EQ 25MG BASE	A213867	001	Mar 21, 2024	May	DISC
AB		EQ 25MG BASE	A213867	001	Mar 21, 2024	Mar	NEWA

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

	TENOFOVIR DISOPROXIL FUMARATE						
>D>	@ CASI PHARMS INC	300MG	A209550	001	Feb 26, 2018	Jun	CAHN
>A>	@ CHARTWELL RX	300MG	A209550	001	Feb 26, 2018	Jun	CAHN
AB	MYLAN LABS LTD	300MG	A079071	001	Feb 29, 2024	Feb	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	TERAZOSIN HYDROCHLORIDE						
AB	BIONPHARMA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Jan	CMFD
AB		EQ 2MG BASE	A075667	002	Jul 28, 2000	Jan	CMFD
AB		EQ 5MG BASE	A075667	003	Jul 28, 2000	Jan	CMFD
AB		EQ 10MG BASE	A075667	004	Jul 28, 2000	Jan	CMFD

TERBINAFFINE

GEL; TOPICAL

LAMISIL

	@ KARO HLTHCARE	1%	N020846	001	Apr 29, 1998	Feb	CAHN
--	-----------------	----	---------	-----	--------------	-----	------

TERBINAFFINE HYDROCHLORIDE

SOLUTION; TOPICAL

LAMISIL

	@ KARO HLTHCARE	1%	N020749	001	Oct 17, 1997	Feb	CAHN
--	-----------------	----	---------	-----	--------------	-----	------

TABLET; ORAL

TERBINAFFINE HYDROCHLORIDE

	@ CIPLA	EQ 250MG BASE	A077137	001	Jul 02, 2007	Mar	DISC
--	---------	---------------	---------	-----	--------------	-----	------

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

AP	AREVA PHARMS	1MG/ML	A200122	001	Nov 08, 2013	Apr	CAHN
----	--------------	--------	---------	-----	--------------	-----	------

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

	@ AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	May	DISC
	@	14MG	A209613	002	Sep 28, 2018	May	DISC
	@ MYLAN	7MG	A209702	001	Feb 28, 2020	Apr	DISC
	@	14MG	A209702	002	Feb 28, 2020	Apr	DISC
AB	TORRENT	7MG	A209697	001	Apr 04, 2024	Mar	NEWA
AB		14MG	A209697	002	Apr 04, 2024	Mar	NEWA

TERIPARATIDE

SOLUTION; SUBCUTANEOUS

TERIPARATIDE

>A>	+! ALMAJECT	0.6MG/2.4ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Jun	NEWA
-----	-------------	-------------------------	---------	-----	--------------	-----	------

TESTOSTERONE

GEL; TRANSDERMAL

TESTIM

AB2	+! ENDO OPERATIONS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Apr	CAHN
-----	--------------------	-----------------	---------	-----	--------------	-----	------

GEL, METERED; TRANSDERMAL

FORTESTA

	+ @ ENDO OPERATIONS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Apr	CAHN
	+ @ ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jan	DISC

TESTOSTERONE

	! ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan	CTEC
AB	!	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan	CHRS
AB1	!	12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Apr	CTEC
AB1	ENCUBE	12.5MG/1.25GM ACTUATION	A212984	002	Feb 09, 2024	Apr	NEWA

PELLET; IMPLANTATION

TESTOPEL

	! ENDO OPERATIONS	75MG	A080911	001		Apr	CAHN
--	-------------------	------	---------	-----	--	-----	------

SOLUTION, METERED;TRANSDERMAL
TESTOSTERONE

AT	ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Apr	CAHN
AT	FEMPHARM	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Mar	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

AO	EUGIA PHARMA	200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA
AO		200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA

TESTOSTERONE UNDECANOATE

CAPSULE; ORAL
TLANDO

+	!	VERITY	112.5MG	N208088	001	Mar 28, 2022	Jan	CAHN
---	---	--------	---------	---------	-----	--------------	-----	------

INJECTABLE; INTRAMUSCULAR
AVEED

+	!	ENDO OPERATIONS	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014	Apr	CAHN
---	---	-----------------	----------------------	---------	-----	--------------	-----	------

TETRABENAZINE

TABLET; ORAL
TETRABENAZINE

AB	SLATE RUN PHARMA	12.5MG	A213316	001	Jan 22, 2020	Feb	CAHN
AB		25MG	A213316	002	Jan 22, 2020	Feb	CAHN

TETRACYCLINE HYDROCHLORIDE

SUSPENSION; ORAL
SUMYCIN

@	ENDO OPERATIONS	125MG/5ML	A060400	001		May	CAHN
---	-----------------	-----------	---------	-----	--	-----	------

TABLET; ORAL
SUMYCIN

	!	STRIDES PHARMA	250MG	A061147	001		Jan	CMFD
	!		500MG	A061147	004		Jan	CMFD

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEO-24

		ENDO OPERATIONS	100MG	A087943	002	Aug 22, 1983	Apr	CAHN
+			200MG	A087943	001	Aug 22, 1983	Apr	CAHN
			300MG	A087943	003	Aug 22, 1983	Apr	CAHN
	!		400MG	A087943	004	Feb 28, 1992	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL
THEOPHYLLINE

AB	ZYDUS LIFESCIENCES	300MG	A218063	001	May 21, 2024	May	CAHN
AB		450MG	A218063	002	May 21, 2024	May	CAHN
AB	ZYDUS PHARMS	300MG	A218063	001	May 21, 2024	May	NEWA
AB		450MG	A218063	002	May 21, 2024	May	NEWA

THIOTEPA

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL
THIOTEPA

>D>	AP	KINDOS	15MG/VIAL	A216037	001	Dec 26, 2023	Jun	CAHN	
>D>	AP		100MG/VIAL	A216037	002	Dec 26, 2023	Jun	CAHN	
>A>	AP	MEITHEAL	15MG/VIAL	A216037	001	Dec 26, 2023	Jun	CAHN	
>A>	AP		100MG/VIAL	A216037	002	Dec 26, 2023	Jun	CAHN	
>A>		SOLUTION; INTRAVENOUS							
>A>		TEPYLUTE							
>A>	+	!	SHORLA	15MG/1.5ML (10MG/ML)	N216984	001	Jun 25, 2024	Jun	NEWA

TIGECYCLINE

POWDER; INTRAVENOUS
TIGECYCLINE

@	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	May	DISC
---	---------------------	-----------	---------	-----	--------------	-----	------

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOLOL MALEATE

>D>	AB	AMNEAL	EQ 0.25% BASE	A216343	001	May 23, 2024	Jun	DISC
>A>		@	EQ 0.25% BASE	A216343	001	May 23, 2024	Jun	DISC
	AB		EQ 0.25% BASE	A216343	001	May 23, 2024	May	NEWA
>D>	AB		EQ 0.5% BASE	A216343	002	May 23, 2024	Jun	DISC

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC
TIMOLOL MALEATE

>A>	@	EQ 0.5% BASE	A216343	002	May 23, 2024	Jun	DISC
AB		EQ 0.5% BASE	A216343	002	May 23, 2024	May	NEWA
SOLUTION/DROPS;OPHTHALMIC							
TIMOLOL MALEATE							
	@	SAPTALIS PHARMS	EQ 0.5% BASE	A074466	001	Mar 25, 1997	May CAHN
>A>	AT1	SOMERSET	EQ 0.25% BASE	A217764	002	Jul 03, 2024	Jun NEWA
>A>	AT1		EQ 0.5% BASE	A217764	001	Jul 03, 2024	Jun NEWA
>A>	AT2	SOMERSET THERAPS LLC	EQ 0.5% BASE	A216653	001	Jul 03, 2024	Jun NEWA

TIOPRONINTABLET, DELAYED RELEASE;ORAL
THIOLA EC

AB	+	MISSION PHARMACAL	100MG	N211843	001	Jun 28, 2019	Jan CFTG
TIOPRONIN							
>D>	@	ENDO OPERATIONS	100MG	A217219	001	Feb 24, 2023	Jun CMFD
>A>	AB		100MG	A217219	001	Feb 24, 2023	Jun CMFD
>D>	@		300MG	A217219	002	Feb 24, 2023	Jun CMFD
>A>	AB		300MG	A217219	002	Feb 24, 2023	Jun CMFD
AB		TORRENT	100MG	A216990	001	Jan 30, 2024	Jan NFTG
AB			300MG	A216990	002	Jan 30, 2024	Jan NEWA

TIRZEPATIDESOLUTION;SUBCUTANEOUS
MOUNJARO

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	007	Jul 28, 2023	Jan NEWA
+	!		5MG/0.5ML (5MG/0.5ML)	N215866	008	Jul 28, 2023	Jan NEWA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	009	Jul 28, 2023	Jan NEWA
+	!		10MG/0.5ML (10MG/0.5ML)	N215866	010	Jul 28, 2023	Jan NEWA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	011	Jul 28, 2023	Jan NEWA
+	!		15MG/0.5ML (15MG/0.5ML)	N215866	012	Jul 28, 2023	Jan NEWA
MOUNJARO (AUTOINJECTOR)							
+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022	Jan CTNA
+	!		5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022	Jan CTNA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022	Jan CTNA
+	!		10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022	Jan CTNA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022	Jan CTNA
+	!		15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022	Jan CTNA
ZEPBOUND							
+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	007	Mar 28, 2024	Mar NEWA
+	!		5MG/0.5ML (5MG/0.5ML)	N217806	008	Mar 28, 2024	Mar NEWA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	009	Mar 28, 2024	Mar NEWA
+	!		10MG/0.5ML (10MG/0.5ML)	N217806	010	Mar 28, 2024	Mar NEWA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	011	Mar 28, 2024	Mar NEWA
+	!		15MG/0.5ML (15MG/0.5ML)	N217806	012	Mar 28, 2024	Mar NEWA
ZEPBOUND (AUTOINJECTOR)							
+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	001	Nov 08, 2023	Mar CTNA
+	!		5MG/0.5ML (5MG/0.5ML)	N217806	002	Nov 08, 2023	Mar CTNA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	003	Nov 08, 2023	Mar CTNA
+	!		10MG/0.5ML (10MG/0.5ML)	N217806	004	Nov 08, 2023	Mar CTNA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	005	Nov 08, 2023	Mar CTNA
+	!		15MG/0.5ML (15MG/0.5ML)	N217806	006	Nov 08, 2023	Mar CTNA

TIZANIDINE HYDROCHLORIDECAPSULE;ORAL
TIZANIDINE HYDROCHLORIDE

AB		APPCO	EQ 4MG BASE	A213365	001	May 13, 2024	May NEWA
AB			EQ 6MG BASE	A213365	002	May 13, 2024	May NEWA
	@	ENDO OPERATIONS	EQ 2MG BASE	A207199	001	Mar 14, 2017	May CAHN
	@		EQ 4MG BASE	A207199	002	Mar 14, 2017	May CAHN
	@		EQ 6MG BASE	A207199	003	Mar 14, 2017	May CAHN
TABLET;ORAL							
TIZANIDINE HYDROCHLORIDE							
>D>	@	CASI PHARMS INC	EQ 2MG BASE	A076280	001	Nov 26, 2002	Jun CAHN
	@		EQ 2MG BASE	A076280	001	Nov 26, 2002	Apr DISC
>D>	@		EQ 4MG BASE	A076280	002	Jun 27, 2002	Jun CAHN
	@		EQ 4MG BASE	A076280	002	Jun 27, 2002	Apr DISC
>A>	@	CHARTWELL RX	EQ 2MG BASE	A076280	001	Nov 26, 2002	Jun CAHN
>A>	@		EQ 4MG BASE	A076280	002	Jun 27, 2002	Jun CAHN
	@	ENDO OPERATIONS	EQ 2MG BASE	A207170	001	Jan 26, 2017	May CAHN
	@		EQ 4MG BASE	A207170	002	Jan 26, 2017	May CAHN

TOBRAMYCINSOLUTION/DROPS;OPHTHALMIC
TOBRAMYCIN

AT	!	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Apr	CHRS
		TOBREX						
	+	@ NOVARTIS	0.3%	N050541	001		Apr	DISC

TOFACITINIB CITRATESOLUTION;ORAL
TOFACITINIB CITRATE

AA		HIKMA	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	Apr	CAHN
		TABLET, EXTENDED RELEASE;ORAL						
>D>		TOFACITINIB						
>D>	AB	AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024	Jun	DISC
>A>		@	EQ 11MG BASE	A218462	001	Jun 03, 2024	Jun	DISC
	AB		EQ 11MG BASE	A218462	001	Jun 03, 2024	May	NEWA
		XELJANZ XR						
>D>	AB	+ PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Jun	CTEC
>A>		+	EQ 11MG BASE	N208246	001	Feb 23, 2016	Jun	CTEC
	AB	+	EQ 11MG BASE	N208246	001	Feb 23, 2016	May	CTEC

TOLCAPONETABLET;ORAL
TOLCAPONE

	@	ENDO OPERATIONS	100MG	A204584	001	Mar 26, 2015	May	CAHN
	@	PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	DISC

TOPIRAMATECAPSULE;ORAL
TOPIRAMATE

>A>	AB	ALKEM LABS LTD	15MG	A218482	001	Jun 13, 2024	Jun	NEWA
>A>	AB		25MG	A218482	002	Jun 13, 2024	Jun	NEWA
	AB	STRIDES PHARMA	15MG	A078418	001	Oct 14, 2009	Apr	CMFD
	AB		25MG	A078418	002	Oct 14, 2009	Apr	CMFD
		CAPSULE, EXTENDED RELEASE;ORAL						
		TOPIRAMATE						
	@	AJANTA PHARMA LTD	25MG	A215663	001	Aug 15, 2023	Feb	DISC
	@		50MG	A215663	002	Aug 15, 2023	Feb	DISC
	@		100MG	A215663	003	Aug 15, 2023	Feb	DISC
	@		200MG	A215663	004	Aug 15, 2023	Feb	DISC
		TABLET;ORAL						
		TOPIRAMATE						
	@	AIPING PHARM INC	25MG	A078499	001	Jan 07, 2010	Feb	CAHN
	@		50MG	A078499	002	Jan 07, 2010	Feb	CAHN
	@		100MG	A078499	003	Jan 07, 2010	Feb	CAHN
	@		200MG	A078499	004	Jan 07, 2010	Feb	CAHN
	@	SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Jan	DISC
	@		100MG	A076327	002	Mar 27, 2009	Jan	DISC
	@		200MG	A076327	003	Mar 27, 2009	Jan	DISC

TOPOTECAN HYDROCHLORIDEINJECTABLE;INJECTION
TOPOTECAN HYDROCHLORIDE

	@	RISING	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012	Mar	CAHN
--	---	--------	------------------	---------	-----	--------------	-----	------

TORSEMIDESOLUTION;INTRAVENOUS
DEMADEX

	+	@ ROCHE	50MG/5ML (10MG/ML)	N020137	002	Aug 23, 1993	Mar	CDFR
	+	@	20MG/2ML (10MG/ML)	N020137	001	Aug 23, 1993	Mar	CDFR
		TORSEMIDE						
	@	AM REGENT	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Mar	CDFR
	@		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Mar	CDFR
	@	WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Mar	CDFR
	@		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Mar	CDFR

TOVORAFENIB

FOR SUSPENSION;ORAL

OJEMDA

+! DAY ONE BIOPHARMS 25MG/ML N218033 001 Apr 23, 2024 Apr NEWA

TABLET;ORAL

OJEMDA

+! DAY ONE BIOPHARMS 100MG N217700 001 Apr 23, 2024 Apr NEWA

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

RUBICON

75MG

A208708 004 Apr 04, 2024 Mar NFTG

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

@ ENDO OPERATIONS

100MG

A200491 001 Jun 27, 2012 Apr CAHN

@

200MG

A200491 002 Jun 27, 2012 Apr CAHN

@

300MG

A200491 003 Jun 27, 2012 Apr CAHN

@ SUN PHARM

100MG

A091607 001 Dec 30, 2011 May DISC

@

300MG

A091607 003 Dec 30, 2011 May DISC

TRANEXAMIC ACID

SOLUTION;INTRAVENOUS

TRANEXAMIC ACID

AP GLAND PHARMA LTD 1GM/100ML (10MG/ML) A218599 001 Apr 16, 2024 Apr NEWA

AP NEXUS 1GM/100ML (10MG/ML) A216877 001 Apr 16, 2024 Apr NEWA

TABLET;ORAL

TRANEXAMIC ACID

AB RUBICON 650MG A218320 001 Jun 11, 2024 May NEWA

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVOPROST

AT LUPIN LTD 0.004% A207040 001 May 03, 2024 Apr NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB CROSSMEDIKA SA 50MG A211116 001 May 20, 2024 May NEWA

AB 100MG A211116 002 May 20, 2024 May NEWA

AB 150MG A211116 003 May 20, 2024 May NEWA

AB 300MG A211116 004 May 20, 2024 May NEWA

TRETINOIN

CAPSULE;ORAL

TRETINOIN

AB ENDO OPERATIONS 10MG A201687 001 Oct 24, 2012 Apr CAHN

CREAM;TOPICAL

TRETINOIN

AB ALEMBIC 0.1% A217804 001 Apr 29, 2024 Apr NEWA

AB ZYDUS LIFESCIENCES 0.1% A218561 001 Apr 25, 2024 Apr NEWA

TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

@ AUROBINDO PHARMA LTD 0.1%

A211315 001 Mar 18, 2020 Jan CAHN

@ 0.5%

A211315 002 Mar 18, 2020 Jan CAHN

@ COSETTE 0.5%

A208925 001 Oct 06, 2017 Apr DISC

>A> + @ EXTROVIS 0.025% N011600 003 Jun CAHN

>A> + @ 0.1% N011600 001 Jun CAHN

>D> + @ MYLAN 0.025% N011600 003 Jun CAHN

>D> + @ 0.1% N011600 001 Jun CAHN

PASTE;DENTAL

TRIAMCINOLONE ACETONIDE

>D> AT AKORN 0.1% A206312 001 Aug 11, 2016 Jun CAHN

>A> AT SAPTALIS PHARMS 0.1% A206312 001 Aug 11, 2016 Jun CAHN

SPRAY;TOPICAL

TRIAMCINOLONE ACETONIDE

AT SAPTALIS PHARMS 0.147MG/GM A207094 001 Dec 07, 2016 Feb CAHN

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

@ HIKMA 0.125MG

A 074224 001 Jun 01, 1994 Feb DISC

@ 0.25MG

A 074224 002 Jun 01, 1994 Feb DISC

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

TRIENTINE HYDROCHLORIDE

AB ENDO OPERATIONS 250MG

A 210096 001 Sep 25, 2019 Apr CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TIGAN

+! ENDO OPERATIONS 100MG/ML

N 017530 001

Apr CAHN

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB BRECKENRIDGE EQ 25MG BASE

A 208127 001 Apr 15, 2016 Mar CAHN

AB ! EQ 50MG BASE

A 208127 002 Apr 15, 2016 Mar CAHN

AB EQ 100MG BASE

A 208127 003 Apr 15, 2016 Mar CAHN

TROSPIUM CHLORIDE

TABLET; ORAL

TROSPIUM CHLORIDE

>A> AB MACLEODS PHARMS LTD 20MG

A 206472 001 Jun 18, 2024 Jun NEWA

AB ZAMEER PHARMS 20MG

A 215781 001 Feb 16, 2022 Feb CAHN

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+! GLAXO GRP ENGLAND EQ 0.0625MG BASE/INH

N 205382 001 Apr 30, 2014 Jan CPOT

UPADACITINIB

SOLUTION; ORAL

RINVOQ LQ

+! ABBVIE 1MG/ML

N 218347 001 Apr 26, 2024 Apr NEWA

URSODIOL

TABLET; ORAL

URSODIOL

AB ENDO OPERATIONS 250MG

A 202540 001 Feb 14, 2013 Apr CAHN

AB 500MG

A 202540 002 Feb 14, 2013 Apr CAHN

VADADUSTAT

TABLET; ORAL

VAFSEO

+ AKEBIA 150MG

N 215192 001 Mar 27, 2024 Mar NEWA

+ 300MG

N 215192 002 Mar 27, 2024 Mar NEWA

+! 450MG

N 215192 003 Mar 27, 2024 Mar NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

>D> AB ADAPTIS EQ 500MG BASE

A 079012 001 May 24, 2010 Jun CAHN

>D> AB EQ 1GM BASE

A 079012 002 May 24, 2010 Jun CAHN

@ CIPLA EQ 500MG BASE

A 077135 001 May 24, 2010 Apr DISC

@ EQ 1GM BASE

A 077135 002 May 24, 2010 Apr DISC

>A> AB GRAVITI PHARMS EQ 500MG BASE

A 079012 001 May 24, 2010 Jun CAHN

>A> AB EQ 1GM BASE

A 079012 002 May 24, 2010 Jun CAHN

VALBENAZINE TOSYLATE

CAPSULE; ORAL

INGREZZA

AB + NEUROCRINE EQ 40MG BASE

N 209241 001 Apr 11, 2017 Mar CFTG

AB +! EQ 80MG BASE

N 209241 002 Oct 04, 2017 Mar CFTG

INGREZZA SPRINKLE

+ NEUROCRINE EQ 40MG BASE

N 218390 001 Apr 30, 2024 Apr NEWA

+ EQ 60MG BASE

N 218390 002 Apr 30, 2024 Apr NEWA

+! EQ 80MG BASE

N 218390 003 Apr 30, 2024 Apr NEWA

	CAPSULE;ORAL							
	VALBENAZINE TOSYLATE							
AB	LUPIN LTD	EQ 40MG BASE	A216064	001	Apr 05, 2024	Mar	NFTG	
AB		EQ 80MG BASE	A216064	002	Apr 05, 2024	Mar	NFTG	
	<u>VALGANCICLOVIR HYDROCHLORIDE</u>							
	TABLET;ORAL							
	VALGANCICLOVIR HYDROCHLORIDE							
AB	GPP	EQ 450MG BASE	A212876	001	Jun 11, 2024	May	NEWA	
	<u>VALPROIC ACID</u>							
	CAPSULE;ORAL							
	VALPROIC ACID							
	@ EYWA	250MG	A207611	001	Aug 05, 2019	Mar	DISC	
	@ SUN PHARM INDS LTD	250MG	A091037	001	Feb 22, 2013	May	DISC	
	SYRUP;ORAL							
	VALPROIC ACID							
	@ HIKMA	250MG/5ML	A074060	001	Jan 13, 1995	Mar	DISC	
AA	QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Jan	CAHN	
	<u>VALRUBICIN</u>							
	SOLUTION;INTRAVESICAL							
	VALSTAR PRESERVATIVE FREE							
AO	+! ENDO OPERATIONS	40MG/ML	N020892	001	Sep 25, 1998	Apr	CAHN	
	<u>VANCOMYCIN HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	VANCOMYCIN HYDROCHLORIDE							
	@ PAI HOLDINGS PHARM	EQ 125MG BASE	A065478	001	Apr 09, 2012	Feb	DISC	
	@	EQ 250MG BASE	A065478	002	Apr 09, 2012	Feb	DISC	
	INJECTABLE;INJECTION							
	VANCOMYCIN HYDROCHLORIDE							
	@ PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	DISC	
	@	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	DISC	
	@ SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Apr	DISC	
	@	EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Apr	DISC	
	VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER							
+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CTNA	
+!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CTNA	
+!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CTNA	
	SOLUTION;INTRAVENOUS							
	VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER							
+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N050671	001	Apr 29, 1993	Feb	CPOT	
+!		EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CDFR	
+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N050671	002	Dec 20, 2010	Feb	CPOT	
+!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CDFR	
+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N050671	003	Mar 01, 1999	Feb	CPOT	
+!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CDFR	
+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N050671	004	Jan 25, 2024	Feb	NEWA	
+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N050671	005	Jan 25, 2024	Feb	NEWA	
	<u>VARENICLINE TARTRATE</u>							
	TABLET;ORAL							
	VARENICLINE TARTRATE							
AB	AJANTA PHARMA LTD	EQ 0.5MG BASE	A213019	001	Mar 19, 2024	Mar	NEWA	
AB		EQ 1MG BASE	A213019	002	Mar 19, 2024	Mar	NEWA	
AB	AVALANCHE PHARM	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Feb	NEWA	
AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Feb	NEWA	
AB	MYLAN	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Feb	NEWA	
AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Feb	NEWA	
	<u>VASOPRESSIN</u>							
	SOLUTION;INTRAVENOUS							
	VASOPRESSIN							
AP	DR REDDYS	20UNITS/ML (20UNITS/ML)	A213988	001	May 08, 2024	Apr	NEWA	
AP	GLAND PHARMA LTD	20UNITS/ML (20UNITS/ML)	A216963	001	Feb 09, 2024	Feb	NEWA	

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB	ALEMBIC	EQ 37.5MG BASE	A217767	001	Jun 06, 2024	May	NEWA
AB		EQ 75MG BASE	A217767	002	Jun 06, 2024	May	NEWA
AB		EQ 150MG BASE	A217767	003	Jun 06, 2024	May	NEWA
	@ ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	May	CAHN
	@	EQ 75MG BASE	A078087	002	Mar 16, 2012	May	CAHN
	@	EQ 150MG BASE	A078087	003	Mar 16, 2012	May	CAHN
	@ NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	May	DISC
	@	EQ 75MG BASE	A200430	002	Apr 04, 2023	May	DISC
	@	EQ 150MG BASE	A200430	003	Apr 04, 2023	May	DISC

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

>D>	AB	AMNEAL PHARMS	EQ 25MG BASE	A079098	001	May 11, 2010	Jun	DISC
>A>		@	EQ 25MG BASE	A079098	001	May 11, 2010	Jun	DISC
>D>	AB		EQ 37.5MG BASE	A079098	002	May 11, 2010	Jun	DISC
>A>		@	EQ 37.5MG BASE	A079098	002	May 11, 2010	Jun	DISC
>D>	AB		EQ 50MG BASE	A079098	003	May 11, 2010	Jun	DISC
>A>		@	EQ 50MG BASE	A079098	003	May 11, 2010	Jun	DISC
>D>	AB		EQ 75MG BASE	A079098	004	May 11, 2010	Jun	DISC
>A>		@	EQ 75MG BASE	A079098	004	May 11, 2010	Jun	DISC
>D>	AB		EQ 100MG BASE	A079098	005	May 11, 2010	Jun	DISC
>A>		@	EQ 100MG BASE	A079098	005	May 11, 2010	Jun	DISC

VERAPAMIL HYDROCHLORIDEINJECTABLE;INJECTION
VERAPAMIL HYDROCHLORIDE

	@ FRESENIUS KABI USA	2.5MG/ML	A216471	001	Apr 23, 2024	May	DISC
AP		2.5MG/ML	A216471	001	Apr 23, 2024	Apr	NEWA

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP	NEPHRON	5MG/2ML (2.5MG/ML)	A213352	002	Sep 16, 2020	Apr	CAHN
AP		10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Apr	CAHN

VIGABATRIN

>A>	SOLUTION;ORAL						
>A>	VIGAFYDE						
>A>	+! PYROS PHARMS	100MG/ML	N217684	001	Jun 17, 2024	Jun	NEWA

VINORELBINE TARTRATEINJECTABLE;INJECTION
VINORELBINE TARTRATE

	@ RISING	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Mar	CAHN
--	----------	-----------------	---------	-----	--------------	-----	------

VORAPAXAR SULFATE

TABLET;ORAL

ZONTIVITY

	+ @ KEY THERAP	EQ 2.08MG BASE	N204886	001	May 08, 2014	May	DISC
	+!	EQ 2.08MG BASE	N204886	001	May 08, 2014	Apr	CAHN

VORICONAZOLEINJECTABLE;INTRAVENOUS
VORICONAZOLE

AP	ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Mar	NEWA
----	--------	------------	---------	-----	--------------	-----	------

WARFARIN SODIUM

TABLET;ORAL

WARFARIN SODIUM

>D>	AB	BARR	1MG	A040145	001	Mar 26, 1997	Jun	DISC
>A>		@	1MG	A040145	001	Mar 26, 1997	Jun	DISC
>D>	AB		2MG	A040145	002	Mar 26, 1997	Jun	DISC
>A>		@	2MG	A040145	002	Mar 26, 1997	Jun	DISC
>D>	AB		2.5MG	A040145	003	Mar 26, 1997	Jun	DISC
>A>		@	2.5MG	A040145	003	Mar 26, 1997	Jun	DISC
>D>	AB		3MG	A040145	008	Nov 05, 1998	Jun	DISC
>A>		@	3MG	A040145	008	Nov 05, 1998	Jun	DISC
>D>	AB		4MG	A040145	004	Mar 26, 1997	Jun	DISC
>A>		@	4MG	A040145	004	Mar 26, 1997	Jun	DISC
>D>	AB		5MG	A040145	005	Mar 26, 1997	Jun	DISC
>A>		@	5MG	A040145	005	Mar 26, 1997	Jun	DISC

TABLET;ORAL

WARFARIN SODIUM

>D>	AB		6MG	A 040145	009	Nov 05, 1998	Jun	DISC
>A>		@	6MG	A 040145	009	Nov 05, 1998	Jun	DISC
>D>	AB		7.5MG	A 040145	006	Mar 26, 1997	Jun	DISC
>A>		@	7.5MG	A 040145	006	Mar 26, 1997	Jun	DISC
>D>	AB		10MG	A 040145	007	Mar 26, 1997	Jun	DISC
>A>		@	10MG	A 040145	007	Mar 26, 1997	Jun	DISC

ZIDOVUDINE

TABLET;ORAL

ZIDOVUDINE

		@ MYLAN PHARMS INC	300MG	A 078922	001	Feb 14, 2008	Apr	DISC
--	--	--------------------	-------	----------	-----	--------------	-----	------

ZINC SULFATE

SOLUTION;INTRAVENOUS

ZINC SULFATE

AP		APOTEX	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A 218059	001	Jun 10, 2024	May	NEWA
>A>	AP	NIVAGEN PHARMS INC	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A 214597	001	Jul 05, 2024	Jun	NEWA
>A>	AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A 214597	002	Jul 05, 2024	Jun	NEWA
>A>	AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A 214597	003	Jul 05, 2024	Jun	NEWA

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

ZOLEDRONIC ACID

		@ HOSPIRA	EQ 4MG BASE/5ML	A 090621	001	Mar 19, 2015	May	DISC
--	--	-----------	-----------------	----------	-----	--------------	-----	------

ZOLMITRIPTAN

SPRAY;NASAL

ZOLMITRIPTAN

AB	!	PADAGIS ISRAEL	5MG/SPRAY	A 212469	002	Sep 30, 2021	Feb	CHRS
----	---	----------------	-----------	----------	-----	--------------	-----	------

TABLET;ORAL

ZOLMITRIPTAN

		@ INVAGEN PHARMS	2.5MG	A 204284	001	Apr 09, 2014	Mar	DISC
--	--	------------------	-------	----------	-----	--------------	-----	------

		@	5MG	A 204284	002	Apr 09, 2014	Mar	DISC
--	--	---	-----	----------	-----	--------------	-----	------

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

		@ INVAGEN PHARMS	5MG	A 078184	001	Sep 07, 2007	Mar	DISC
--	--	------------------	-----	----------	-----	--------------	-----	------

		@	10MG	A 078184	002	Sep 07, 2007	Mar	DISC
--	--	---	------	----------	-----	--------------	-----	------

TABLET;SUBLINGUAL

ZOLPIDEM TARTRATE

AB		ENDO OPERATIONS	1.75MG	A 204229	001	Sep 11, 2017	Apr	CAHN
----	--	-----------------	--------	----------	-----	--------------	-----	------

AB			3.5MG	A 204229	002	Sep 11, 2017	Apr	CAHN
----	--	--	-------	----------	-----	--------------	-----	------

AB			5MG	A 201509	001	Aug 01, 2016	May	CAHN
----	--	--	-----	----------	-----	--------------	-----	------

AB			10MG	A 201509	002	Aug 01, 2016	May	CAHN
----	--	--	------	----------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

		@ ENDO OPERATIONS	6.25MG	A 078148	002	Apr 14, 2011	May	CAHN
--	--	-------------------	--------	----------	-----	--------------	-----	------

		@	12.5MG	A 078148	001	Dec 03, 2010	May	CAHN
--	--	---	--------	----------	-----	--------------	-----	------

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ COSETTE	120MG	N018060	001		Mar	DISC
@	325MG	A072344	001	Mar 27, 1992	Mar	DISC
@	650MG	A072237	001	Mar 27, 1992	Mar	DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024	Apr	CTNA
	250MG;125MG	A218359	001	Mar 26, 2024	Mar	NEWA
GLENMARK PHARMS LTD	250MG;125MG	A218311	001	Apr 26, 2024	Apr	NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

GLAND PHARMA LTD	0.25%	A209706	001	Mar 01, 2024	Feb	NEWA
------------------	-------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	May	NEWA
@ PADAGIS ISRAEL	0.2055MG/SPRAY	A216801	001	May 08, 2024	May	DISC
	0.2055MG/SPRAY	A216801	001	May 08, 2024	Apr	NEWA
AZELASTINE HYDROCHLORIDE ALLERGY						
APOTEX	0.2055MG/SPRAY	A216421	001	May 29, 2024	May	NEWA
AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY						
APOTEX	0.2055MG/SPRAY	A216421	002	May 29, 2024	May	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024	Feb	NFTG
LUMIFY PRESERVATIVE FREE						
+! BAUSCH AND LOMB INC	0.025%	N218424	001	Apr 19, 2024	Apr	NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009	Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Feb	CDFR
BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Feb	CDFR
CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011	Feb	CDFR
@ CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Feb	CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Feb	CDFR
HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	CDFR
PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Feb	CDFR
	5MG/5ML	A090254	002	Apr 09, 2008	Feb	CDFR
@ PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008	Feb	CDFR
QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Feb	CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Feb	CDFR
TARO	5MG/5ML	A090182	002	Apr 22, 2008	Feb	CDFR
	5MG/5ML	A201546	001	May 20, 2011	Feb	CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Feb	CDFR

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009	Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Feb	CDFR
BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Feb	CDFR
CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011	Feb	CDFR
@ CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Feb	CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Feb	CDFR
PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	Feb	CDFR
@ PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008	Feb	CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Feb	CDFR
TARO	5MG/5ML	A090182	001	Apr 22, 2008	Feb	CDFR
	5MG/5ML	A201546	002	May 20, 2011	Feb	CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012	Feb	CDFR

SOLUTION;ORAL							
CHILDREN'S ZYRTEC ALLERGY							
+!	J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007	Feb	CDFR
CHILDREN'S ZYRTEC HIVES RELIEF							
+!	J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Feb	CDFR
TABLET, CHEWABLE;ORAL							
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY							
@	SUN PHARM	5MG	A090142	001	Aug 30, 2011	Mar	DISC
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF							
@	SUN PHARM	5MG	A090142	003	Aug 30, 2011	Mar	DISC
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
>D>	PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018	Jun	CAHN
>A>	PPI-DAC	5MG;120MG	A210719	001	Nov 16, 2018	Jun	CAHN
<u>CLOTTRIMAZOLE</u>							
CREAM;VAGINAL							
TRIVAGIZOLE 3							
	TARO	2%	N021143	001	Apr 12, 2000	Mar	CAHN
<u>DICLOFENAC SODIUM</u>							
GEL;TOPICAL							
DICLOFENAC SODIUM							
@	HIKMA	1%	A209484	001	Nov 21, 2018	Mar	DISC
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN</u>							
TABLET;ORAL							
IBUPROFEN AND DIPHENHYDRAMINE CITRATE							
	PLD ACQUISITIONS LLC	38MG;200MG	A211404	001	Apr 11, 2024	Apr	NEWA
<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>							
SYRUP;ORAL							
DIPHENHYDRAMINE HYDROCHLORIDE							
>D>	@ AKORN	12.5MG/5ML	A072416	001	Sep 28, 1990	Jun	CAHN
>A>	@ SAPTALIS PHARMS	12.5MG/5ML	A072416	001	Sep 28, 1990	Jun	CAHN
<u>DOCOSANOL</u>							
CREAM;TOPICAL							
DOCOSANOL							
	AUROBINDO PHARMA LTD	10%	A217090	001	Mar 01, 2024	Feb	NEWA
	P AND L DEVELOPMENT	10%	A212385	001	Oct 07, 2022	Mar	CAHN
<u>ESOMEPRAZOLE MAGNESIUM</u>							
CAPSULE, DELAYED RELEASE;ORAL							
ESOMEPRAZOLE MAGNESIUM							
	DR REDDYS	EQ 20MG BASE	A207198	001	Apr 30, 2024	Apr	NEWA
	GLENMARK SPECLT	EQ 20MG BASE	A218092	001	Jun 11, 2024	May	NEWA
	GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	Feb	CAHN
TABLET, DELAYED RELEASE;ORAL							
ESOMEPRAZOLE MAGNESIUM							
	AUROBINDO PHARMA LTD	EQ 20MG BASE	A214473	001	Jul 12, 2023	Apr	CMFD
@		EQ 20MG BASE	A214473	001	Jul 12, 2023	Jan	DISC
<u>FAMOTIDINE</u>							
TABLET;ORAL							
FAMOTIDINE							
	CONTRACT PHARMACAL	10MG	A218003	001	May 28, 2024	May	NEWA
		20MG	A218003	002	May 28, 2024	May	NEWA
	GRAVITI PHARMS	10MG	A218461	001	Mar 14, 2024	Mar	NEWA
		20MG	A218461	002	Mar 14, 2024	Mar	NEWA
@	SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr	DISC
@		20MG	A090283	002	Nov 17, 2009	Apr	DISC
<u>FLUTICASONE PROPIONATE</u>							
SPRAY, METERED;NASAL							
FLUTICASONE PROPIONATE							
	AUROBINDO PHARMA LTD	0.05MG/SPRAY	A217088	001	May 10, 2024	May	NEWA
@	HIKMA	0.05MG/SPRAY	A208024	001	Apr 17, 2019	Mar	DISC

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

@ AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A215777	001	Sep 14, 2023	Mar	DISC
PATHEON SOFTGELS	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Mar	CAHN
	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Feb	NEWA

SUSPENSION/DROPS;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD	40MG/ML	A213506	001	Apr 08, 2024	Mar	NEWA
----------------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

IBUPROFEN

ENDO OPERATIONS	200MG	A071229	001	Apr 01, 1987	May	CAHN
@	200MG	A071639	001	Feb 02, 1988	May	CAHN
@	200MG	A072249	001	Jan 10, 1989	May	CAHN

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

NAARI PTE LTD	1.5MG	A207660	001	May 02, 2019	Apr	CMFD
@ XIROMED	0.75MG	A202740	001	Sep 02, 2016	May	CAHN
	1.5MG	A202739	001	Oct 31, 2014	May	CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

@ SAPTALIS PHARMS	1MG/5ML	A074352	001	Nov 17, 1995	Jan	CAHN
-------------------	---------	---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

@ SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006	May	DISC
----------------------	-----------	---------	-----	--------------	-----	------

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

BIONPHARMA	10MG;240MG	A218017	001	May 14, 2024	May	NEWA
------------	------------	---------	-----	--------------	-----	------

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

@ COSETTE	2%	A074366	001	Feb 22, 1996	Apr	DISC
-----------	----	---------	-----	--------------	-----	------

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

>A>	COSETTE	2%,200MG	A074926	001	Apr 16, 1999	Jun	CAHN
>D>	P AND L	2%,200MG	A074926	001	Apr 16, 1999	Jun	CAHN

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

>A>	COSETTE	100MG	A073507	001	Nov 19, 1993	Jun	CAHN
	@	100MG	A074414	001	Apr 30, 1997	Apr	DISC
>D>	P AND L	100MG	A073507	001	Nov 19, 1993	Jun	CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

AUROBINDO PHARMA	5%	A218616	001	Apr 22, 2024	Apr	NEWA
------------------	----	---------	-----	--------------	-----	------

MINOXIDIL (FOR WOMEN)

AUROBINDO PHARMA	5%	A218616	002	Apr 22, 2024	Apr	NEWA
------------------	----	---------	-----	--------------	-----	------

MOMETASONE FUROATE

SPRAY, METERED;NASAL

MOMETASONE FUROATE

APOTEX	0.05MG/SPRAY	A217438	001	Apr 23, 2024	Apr	NEWA
--------	--------------	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL
 NALOXONE HYDROCHLORIDE
 AMNEAL 4MG/SPRAY A217992 001 Apr 23, 2024 Apr NEWA
 >A> TEVA PHARMS USA 4MG/SPRAY A209522 001 Apr 19, 2019 Jun CMKT

NAPROXEN SODIUM

TABLET;ORAL
 NAPROXEN SODIUM
 @ SUN PHARM INDS LTD 220MG A091183 001 May 20, 2011 Jan DISC

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL
 NICORETTE
 + HALEON US HOLDINGS EQ 2MG BASE N022360 001 May 18, 2009 Jan CAHN
 +! EQ 4MG BASE N022360 002 May 18, 2009 Jan CAHN
 NICOTINE POLACRILEX
 >D> PERRIGO R AND D EQ 2MG BASE A090711 001 Jul 10, 2009 Jun CAHN
 >D> EQ 2MG BASE A203690 001 Oct 09, 2012 Jun CAHN
 >D> EQ 4MG BASE A090711 002 Jul 10, 2009 Jun CAHN
 >D> EQ 4MG BASE A203690 002 Oct 09, 2012 Jun CAHN
 >A> PPI-DAC EQ 2MG BASE A090711 001 Jul 10, 2009 Jun CAHN
 >A> EQ 2MG BASE A203690 001 Oct 09, 2012 Jun CAHN
 >A> EQ 4MG BASE A090711 002 Jul 10, 2009 Jun CAHN
 >A> EQ 4MG BASE A203690 002 Oct 09, 2012 Jun CAHN

NORGESTREL

TABLET;ORAL
 OPILL
 +! LABORATOIRE HRA 0.075MG N017031 001 Feb CMFD

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
 OLOPATADINE HYDROCHLORIDE
 @ SAPTALIS PHARMS EQ 0.2% BASE A204723 001 Dec 05, 2017 Jan CAHN
 SOMERSET THERAPS LLC EQ 0.1% BASE A206306 001 Dec 07, 2015 Apr CMKT

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL
 OMEPRAZOLE AND SODIUM BICARBONATE
 DR REDDYS 20MG/PACKET;1.68GM/PACKET A217784 001 May 09, 2024 May NFTG

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
 POLYETHYLENE GLYCOL 3350
 >D> PERRIGO R AND D 17GM/PACKET A090685 001 Oct 06, 2009 Jun CAHN
 >D> 17GM/SCOOPFUL A090685 002 Oct 06, 2009 Jun CAHN
 >A> PPI-DAC 17GM/PACKET A090685 001 Oct 06, 2009 Jun CAHN
 >A> 17GM/SCOOPFUL A090685 002 Oct 06, 2009 Jun CAHN

POVIDONE-IODINE

SPONGE;TOPICAL
 E-Z SCRUB 201
 + @ BECTON DICKINSON 20% N019240 001 Nov 29, 1985 Feb DISC
 E-Z SCRUB 241
 + @ BECTON DICKINSON 10% N019476 001 Jan 07, 1987 Feb DISC

TERBINAFINE

GEL;TOPICAL
 LAMISIL AT
 +! KARO HLTHCARE 1% N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL
 LAMISIL
 +! KARO HLTHCARE 1% N020980 001 Mar 09, 1999 Feb CAHN
 SOLUTION;TOPICAL
 LAMISIL AT
 +! KARO HLTHCARE 1% N021124 001 Mar 17, 2000 Feb CAHN

SPRAY; TOPICAL
LAMISIL AT

+! KARO HLTHCARE 1%

N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE 2024

NO JUNE 2024 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2024 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11977067	Apr 30, 2038	DP			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	>A> 11986468	Jul 28, 2037	U-2830			
	>A> 11986469	Jul 28, 2037	U-2830			
	>A> 11992486	Jul 28, 2037	U-2830			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	>A> 11986468	Jul 28, 2037	U-2830			
	>A> 11986469	Jul 28, 2037	U-2830			
	>A> 11992486	Jul 28, 2037	U-2830			
<u>ACETAMINOPHEN; IBUPROFEN - ACETAMINOPHEN AND IBUPROFEN</u>						
A 218311 001					PC	Nov 03, 2024
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001	11918693	Jul 09, 2041	DP			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	11896567	Oct 26, 2031	U-3744			
	11896567	Oct 26, 2031	U-3745			
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 001					NP	Feb 13, 2027
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 002					NP	Feb 13, 2027
<u>ACYCLOVIR - ACYCLOVIR</u>						
A 212361 001					CGT	Jun 12, 2024
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	>A> 10689377	May 17, 2037	DS DP U-3490			
	>A> 10689377	May 17, 2037	DS DP U-3953			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					I-947 ODE-477	Apr 18, 2027 Apr 18, 2031
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - VIJOICE</u>						
N 218466 001	8227462 8476268	Apr 29, 2033 Sep 10, 2029	DS DP DS DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11903908	Jun 17, 2034	U-3822			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	11890261	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	11890261	Feb 15, 2038	U-2497			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11918685	Oct 06, 2037	U-3447			
	11918685	Oct 06, 2037	U-3448			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	>A> 12005141	Feb 24, 2041	DP U-3309			
	>A> 12005141	Feb 24, 2041	DP U-3310			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	11878011	May 27, 2042	U-3816			
	11931463	Feb 12, 2034	DP U-3866			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	11896562	Mar 10, 2037	U-3299			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	11963952	Jan 30, 2040	U-3901			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	11963952	Jan 30, 2040	U-3901			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 001	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREPITANT - APONVIE</u>						
N 216457 001	11878074	Sep 18, 2035	U-3787			
<u>APROCITENTAN - TRYVIO</u>						
N 217686 001	10919881	Feb 26, 2038	DS DP		NCE	Mar 22, 2029
	11174247	Nov 06, 2037	U-3879			
	11680058	Jul 26, 2038	U-3878			
	11787782	Mar 02, 2038	U-3877			
	8324232	Sep 21, 2029	DS DP U-3878			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	11407735	May 14, 2040	DS		NCE	Oct 29, 2026
	8829195	May 13, 2033	DS U-1374		ODE*	Oct 29, 2028
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11925704	Jun 07, 2037	DP U-3853			
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 217791 001					CGT	Dec 04, 2024
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11951214	Nov 27, 2039	DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	11964980	Apr 10, 2040	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040			U-3168	
	11999744	Apr 10, 2040			U-3506	
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040			U-3168	
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	Jul 28, 2027	DS DP			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		NPP	Jan 26, 2027
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
	7112592	Jan 07, 2026	DS DP U-3818			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11925648	Apr 21, 2041	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	8158616	May 31, 2032	DS DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	RE49948	Sep 05, 2034	DS DP U-3201		I-931	Dec 14, 2026
	RE49948	Sep 05, 2034	DS DP U-3780			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11744816	Mar 14, 2036			I-943	Mar 22, 2027
	11926584	Jun 19, 2040			I-944	Mar 22, 2027
	7335799	Dec 03, 2030	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10912751	Mar 14, 2036	U-3224		I-943	Mar 22, 2027
	10912751	Mar 14, 2036	U-3884		I-945	Mar 22, 2027
	11744816	Mar 14, 2036	U-3692			
	11744816	Mar 14, 2036	U-3883			
	11926584	Jun 19, 2040	U-3873			
	7335799	Dec 03, 2030	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11872214	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11872214	Jan 28, 2031	DP			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040	U-3357			
	11877997	Feb 19, 2040	U-3356			
	>A> 11986456	Feb 19, 2040	U-3947			
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10258564	Nov 22, 2034	U-3797		NCE	Jan 05, 2029
	10258564	Nov 22, 2034	U-3798			
	10258564	Nov 22, 2034	U-3799			
	10265334	Jul 03, 2032	DP			
	10322081	Jul 10, 2035	U-3793			
	10322081	Jul 10, 2035	U-3794			
	10322081	Jul 10, 2035	U-3795			
	10322081	Jul 10, 2035	U-3796			
	10376538	Aug 20, 2030	DP			
	10736839	Jul 10, 2035	U-3790			
	10736839	Jul 10, 2035	U-3791			
	10736839	Jul 10, 2035	U-3792			
	11040006	Jul 10, 2035	DP U-3789			
	11285098	Feb 28, 2034	DP			
	11723858	Jul 10, 2035	DP U-3788			
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	9289442	Jul 03, 2032	DP U-3803			
	9526738	Sep 03, 2031	DP			
	9737561	Aug 20, 2030	U-3802			
	9855211	Feb 27, 2034	DP U-3800			
	9855211	Feb 27, 2034	DP U-3801			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					I-942	Feb 23, 2027
					M-305	Apr 24, 2027
					ODE-468	Feb 23, 2031
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Apr 17, 2025	DS DP		I-942	Feb 23, 2027
	7390791*PED	Oct 17, 2025			ODE-468	Feb 23, 2031
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2025	DS DP			
<u>BIRCH TRITERPENES - FILSUVEZ</u>						
N 215064 001	11083733	Jan 04, 2039	DP		NCE	Dec 18, 2028
	11266660	Jan 04, 2039	U-3811		ODE-460	Dec 18, 2030
	8828444	Jun 21, 2025	DP			
	9352041	Nov 24, 2030	U-3811			
	9827214	Nov 24, 2030	U-3811			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215 001	11903993	May 20, 2039	U-3817			
	11918622	May 20, 2039	U-3817			
	11992514	May 20, 2039	DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 001 >A>	12005069	Sep 23, 2042	DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 002 >A>	12005069	Sep 23, 2042	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS	Y	I-913	May 10, 2026
	7888362*PED	Oct 12, 2026			M-14	May 08, 2027
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 10, 2026
	8349840*PED	Oct 12, 2026			PED	Nov 08, 2027
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE</u>						
N 218424 001	11596600	Jul 27, 2029	U-2222			
	8293742	Jul 14, 2030	U-2222			
	9259425	Jul 14, 2030	U-2222			
<u>BROMFENAC SODIUM - BROMFENAC SODIUM</u>						
A 206027 001					PC	Jul 06, 2024
<u>BUDESONIDE - EOHILIA</u>						
N 213976 001	10293052	Nov 22, 2028	DP		NP	Feb 09, 2027
	11197822	Nov 09, 2026	DP		ODE-466	Feb 09, 2031
	11260064	Jan 10, 2039	DP			
	11357859	Nov 12, 2028	U-3820			
	11413296	Nov 09, 2026	DP			
	11564934	Jan 10, 2039	U-3820			
	8324192	Aug 03, 2029	U-3820			
	8497258	Nov 09, 2026	U-3820			
	8679545	Nov 09, 2026	DP			
	8975243	Nov 09, 2026	U-3820			
	9050368	Aug 01, 2029	DP			
	9119863	Nov 09, 2026	U-3820			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	11896719	Jan 23, 2043	U-3810		ODE-464	Dec 20, 2030
	8491932	May 07, 2029	DP U-3269			
	8491932	May 07, 2029	DP U-3781			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004					I-933	Jan 23, 2027
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11883373	Jan 23, 2043	U-3419			
	11896563	Dec 01, 2041	U-3419			
	11925636	Jan 20, 2043	U-3419			
	11969421	Nov 05, 2034	U-3419			
	11986444	Feb 15, 2043	U-3419			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001 >A>	11998542	Jul 02, 2034	U-1583			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11154509	Apr 25, 2028	U-3815			
	9498486	Apr 25, 2028	U-3814			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001 >A>	11986446	Mar 15, 2033	U-3017			
	>A> 11986446	Mar 15, 2033	U-3324			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11865102	Apr 26, 2039	DS DP U-2781			
	11865102	Apr 26, 2039	DS DP U-3236			
	11865102	Apr 26, 2039	DS DP U-3277			
	11963937	Jun 17, 2035	U-2780			
	11963937	Jun 17, 2035	U-2781			
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001					NCE	Jul 21, 2028
<u>CEDAZURIDINE; DECITABINE - INOOVI</u>						
N 212576 001	11963971	Feb 24, 2041	DP			
<u>CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM - EXBLIFEP</u>						
N 216165 001	11124526	Nov 07, 2034	U-3852		NCE	Feb 22, 2029
	7687488	Dec 03, 2027	DS DP U-3851		GAIN	Feb 22, 2034

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTOBIPROLE MEDOCARIL SODIUM - ZEVTERA</u>						
N 218275 001					NCE GAIN	Apr 03, 2029 Apr 03, 2034
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Mar 21, 2033	DS DP U-2586			
	8487093	Mar 21, 2033	DS DP U-2587			
	8487093	Mar 21, 2033	DS DP U-2840			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	>A> 11992472	Mar 15, 2033	U-1			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11938141	Jul 24, 2028	DP			
	8865690	Jul 24, 2025	U-2942			
	9211295	May 31, 2025	DP			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
N 218158 001	10588913	May 09, 2036	DP		NP	Mar 04, 2027
	11376262	May 09, 2036	DP U-19			
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645 001	11918689	Jul 28, 2041	DP U-3944			
	8062667	Mar 29, 2029	DP			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	10130585	May 09, 2034	U-3642			
	10206891	Nov 01, 2033	U-3641			
	10265281	Nov 01, 2033	U-3639			
	10842762	Nov 01, 2033	U-3640			
	11026899	Nov 01, 2033	U-3639			
	11026900	Nov 01, 2033	U-3639			
	11026901	Nov 01, 2033	U-3638			
	11944594	Nov 01, 2033	U-3864			
	11944595	Nov 01, 2033	U-3867			
	11944595	Nov 01, 2033	U-3868			
	9744144	Nov 01, 2033	U-3643			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	11975047	Oct 27, 2043	U-3904			
	11975047	Oct 27, 2043	U-3905			
	11975047	Oct 27, 2043	U-3906			
	11975047	Oct 27, 2043	U-3907			
	11975047	Oct 27, 2043	U-3908			
	11975047	Oct 27, 2043	U-3909			
	11975047	Oct 27, 2043	U-3910			
	11975047	Oct 27, 2043	U-3911			
	11975047	Oct 27, 2043	U-3912			
	11975047	Oct 27, 2043	U-3913			
	11975047	Oct 27, 2043	U-3914			
	11975047	Oct 27, 2043	U-3915			
	11975047	Oct 27, 2043	U-3916			
	11975047	Oct 27, 2043	U-3917			
	11975047	Oct 27, 2043	U-3918			
	11975047	Oct 27, 2043	U-3919			
	11975047	Oct 27, 2043	U-3920			
	11975047	Oct 27, 2043	U-3921			
	11975047	Oct 27, 2043	U-3922			
	11975047	Oct 27, 2043	U-3923			
	11975047	Oct 27, 2043	U-3924			
	11975047	Oct 27, 2043	U-3925			
	11975047	Oct 27, 2043	U-3926			
<u>CUPRIC CHLORIDE - CUPRIC CHLORIDE</u>						
A 216113 001					>A> CGT	Dec 21, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS</u>						
N 209376 003	11975022	Jul 01, 2041	U-3900			
	11998565	Jul 01, 2041	DP			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP	Y		
	8633162	Aug 27, 2024	U-1479	Y		
	8642556	Aug 27, 2024	DP	Y		
	8648048	Aug 27, 2024	U-1483	Y		
	8685930	Aug 27, 2024	DP	Y		
	9248191	Aug 27, 2024	U-1479	Y		
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	11951153	Feb 28, 2037	U-1483			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11969439	Jan 15, 2039	U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
	11826383	Jan 15, 2039	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	11504333*PED	Dec 29, 2038			ODE-428	Mar 16, 2030
	7994185	Jan 20, 2030	DS DP		PED	Sep 16, 2026
	7994185*PED	Jul 20, 2030			PED	Sep 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP	U-3565		
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025		U-3565		
	8835443*PED	Dec 10, 2025				
<u>DANICOPAN - VOYDEYA</u>						
N 218037 001	9796741	Feb 25, 2035	DS	U-3933	NCE	Mar 29, 2029
					ODE-476	Mar 29, 2031
<u>DANICOPAN - VOYDEYA</u>						
N 218037 002	9796741	Feb 25, 2035	DS	U-3933	NCE	Mar 29, 2029
					ODE-476	Mar 29, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6515117	Oct 04, 2025	DS DP U-2139		M-298	May 08, 2026
	6515117	Oct 04, 2025	DS DP U-493		>A> NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Nov 08, 2026
	7456254	Jun 30, 2025	U-2139		>A> PED	Dec 12, 2027
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040	U-3127		M-298	May 08, 2026
	10973836*PED	Sep 09, 2040			>A> NPP	Jun 12, 2027
	11826376	Jul 18, 2039	U-3766		PED	Nov 08, 2026
	11826376*PED	Jan 18, 2040			>A> PED	Dec 12, 2027
	11903955	Mar 09, 2040	U-3825			
	11903955*PED	Sep 09, 2040				
	6515117	Oct 04, 2025	DS DP U-2139			
	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7456254	Jun 30, 2025	U-2139			
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493		>A> NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			>A> PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6515117	Oct 04, 2025	DS DP U-493		>A> NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			>A> PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6515117	Oct 04, 2025	DS DP U-493		>A> NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			>A> PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6515117	Oct 04, 2025	DS DP U-493		>A> NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			>A> PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493		>A> NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			>A> PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493		>A> NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			>A> PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	11963995	May 21, 2029	U-2327			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	11963995	May 21, 2029	U-2327			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11890272	Jul 17, 2040	U-3756			
	>A> 11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11890272	Jul 17, 2040	U-3756			
	>A> 11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 001	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 002	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 003	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 004	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 005	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001					NPP	Apr 05, 2027
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	>A> 12011506	Sep 05, 2038	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8329752	Nov 22, 2025	DP	Y		
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641	Y		
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP	Y		
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8168209	Nov 22, 2025	DP	Y		
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641	Y		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641	Y		
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP	Y		
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641	Y		
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP	Y		
	8598233*PED	May 22, 2026				
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	11951213	Jun 28, 2031	U-2553			
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001	11951213	Jun 28, 2031	U-2553			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	11957694	Jun 17, 2036	DP			
	11964055	Jun 17, 2036	DP			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	11957660	Nov 01, 2039	DP		ODE-144	May 12, 2029
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-14	Oct 18, 2026
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11872218	Jan 03, 2028	U-1969			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001					NP ODE-462	Dec 13, 2026 Dec 13, 2030
<u>ELAFIBRANOR - IQIRVO</u>						
N 218860 001	>A> 11185519	Mar 30, 2037	U-3955		>A> NCE	Jun 10, 2029
	>A> 11331292	Mar 30, 2037	U-1854			
	>A> 11850223	Mar 30, 2037	U-1854			
	>A> 11857523	Mar 30, 2037	U-3955			
	>A> 7632870	Sep 09, 2024	DP			
	>A> 7943661	Sep 09, 2024	DS DP			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	7419983	Jul 06, 2029	DS DP U-2360			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	7419983	Jul 06, 2029	DS DP			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 001	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 002	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 003	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 004	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002					ODE-457	Jan 07, 2029
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	10683499	Aug 25, 2034	DS DP U-2378		NCE	Dec 21, 2028
	8101743	Apr 01, 2025	DS DP		ODE-461	Dec 21, 2030
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
<u>ESTRADIOL - ESTRADIOL</u>						
A 216160 001					CGT	Oct 23, 2024
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11957684	Sep 29, 2037	U-3129			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11865179	Nov 21, 2032	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11865179	Nov 21, 2032	DS DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	11959486	Jun 27, 2034	DP U-2014			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	11850251	Jun 21, 2039	U-3785			
<u>ETRASIMOD ARGININE - VELSIPITY</u>						
N 216956 001	11884626	Jun 21, 2036	U-3731			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2025	DS DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	8586551*PED	Jan 15, 2024				
<u>FINERENONE - KERENDIA</u>						
N 215341 001	RE49826	Jul 29, 2035	DS			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	RE49826	Jul 29, 2035	DS			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	11980674	Apr 23, 2042	U-2450			
<u>FLUOROMETHOLONE - FLUOROMETHOLONE</u>						
A 216348 001					CGT	Jul 07, 2024
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11969544	Aug 20, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001					I-940	Mar 15, 2027
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	11969544	Aug 20, 2039	DP			
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	8168615	Jul 13, 2029	DP			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001					NCE	Nov 30, 2028
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002					NCE	Nov 30, 2028
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	11938130	Jul 01, 2036	DP			
	11938131	Jul 01, 2036	DP			
	11938132	Jul 01, 2036	DP			
	11938133	Jul 01, 2036	DP			
	11944620	Jul 01, 2036	DP			
	8969336	Nov 28, 2032	DS DP			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	10688047	Oct 28, 2036	DP U-3885		NCE	Mar 21, 2029
	7329689	Jan 15, 2025	DS DP		ODE-473	Mar 21, 2031
	9421184	Feb 03, 2032		U-3885		
	9867799	Feb 03, 2032		U-3885		
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	11891372	Apr 13, 2036				
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	11891372	Apr 13, 2036				
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	8404215	Mar 09, 2032	U-1383	Y		
	9254278	Sep 22, 2030	U-1816			
	9326966	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	11938217	Oct 25, 2038	DP			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	RE47691	Jun 28, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
A 215266	001				PC	Jun 24, 2024
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355	001	11957753	Nov 02, 2031	DP		
		11986527	Nov 02, 2031		U-2625	
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354	001	11957753	Nov 02, 2031	DP		
	>A>	11986527	Nov 02, 2031		U-2625	
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520	001				NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520	002				NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899	002				PC	Nov 11, 2024
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899	003				PC	Dec 02, 2024
<u>HYDROXYUREA - XROMI</u>						
N 216593	001				ODE-470	Apr 04, 2031
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001	8754090	Jun 03, 2031	U-1456	Y >A> M-14	Aug 04, 2025
		8754090*PED	Dec 03, 2031			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	002	8754090	Jun 03, 2031	U-1456	Y >A> M-14	Aug 04, 2025
		8754090*PED	Dec 03, 2031			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	001	8754090	Jun 03, 2031	U-1456	Y >A> M-14	Aug 04, 2025
		8754090*PED	Dec 03, 2031			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	002	8754090	Jun 03, 2031	U-1456	Y >A> M-14	Aug 04, 2025
		8754090*PED	Dec 03, 2031			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	003	8754090	Jun 03, 2031	U-1456	Y >A> M-14	Aug 04, 2025
		8754090*PED	Dec 03, 2031			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	004				>A> M-14	Aug 04, 2025
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003	001	10004746	Jun 03, 2031	U-3846		
		10004746	Jun 03, 2031	U-3847		
		10004746	Jun 03, 2031	U-3848		
		10004746	Jun 03, 2031	U-3849		
		10016435	Jun 03, 2031	U-3845		
		10463668	Oct 24, 2034	U-2970		
		10478439	Jun 03, 2031	U-2666		
		10478439	Jun 03, 2031	U-2970		
		10478439	Jun 03, 2031	U-3422		
		10478439	Jun 03, 2031	U-3842		
		10478439	Jun 03, 2031	U-3843		
		10478439	Jun 03, 2031	U-3844		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10478439	Jun 03, 2031	U-3845			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2970			
	10751342	Jun 03, 2031	U-2666			
	10751342	Jun 03, 2031	U-3842			
	10751342	Jun 03, 2031	U-3843			
	10751342	Jun 03, 2031	U-3844			
	11672803	Jun 03, 2031	U-2666			
	11672803	Jun 03, 2031	U-3842			
	11672803	Jun 03, 2031	U-3843			
	11672803	Jun 03, 2031	U-3844			
	8476284	Dec 28, 2026	U-3843			
	8476284	Dec 28, 2026	U-3844			
	8476284	Dec 28, 2026	U-3845			
	8497277	Dec 28, 2026	U-2666			
	8497277	Dec 28, 2026	U-2970			
	8497277	Dec 28, 2026	U-3422			
	8497277	Dec 28, 2026	U-3842			
	8497277	Dec 28, 2026	U-3843			
	8497277	Dec 28, 2026	U-3844			
	8497277	Dec 28, 2026	U-3845			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-2666			
	8563563	Apr 26, 2027	U-3842			
	8563563	Apr 26, 2027	U-3843			
	8563563	Apr 26, 2027	U-3844			
	8563563	Apr 26, 2027	U-3845			
	8703780	Dec 28, 2026	U-2666			
	8703780	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-2666			
	8952015	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-3843			
	8952015	Dec 28, 2026	U-3844			
	8952015	Dec 28, 2026	U-3845			
	8999999	Jun 03, 2031	U-2666			
	8999999	Jun 03, 2031	U-3842			
	8999999	Jun 03, 2031	U-3843			
	8999999	Jun 03, 2031	U-3844			
	9125889	Jun 03, 2031	U-3845			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-3846			
	9801881	Jun 03, 2031	U-3847			
	9801883	Jun 03, 2031	U-2666			
	9801883	Jun 03, 2031	U-3842			
	9801883	Jun 03, 2031	U-3843			
	9801883	Jun 03, 2031	U-3844			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003					NPP	May 11, 2026
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					I-939	Apr 02, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192	003				I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192	004				I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192	005				I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192	006				I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192	007				I-939	Apr 02, 2027
<u>ILOPROST - AURLUMYN</u>						
N 217933	001				NP ODE-465	Feb 13, 2027 Feb 13, 2031
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779	001	>A> 7494982	Dec 27, 2025	DS DP	>A> ODE-482	Jun 06, 2031
		>A> 9375485	Mar 15, 2033	U-3956		
		>A> 9388415	Sep 09, 2024	U-3956		
		>A> 9388416	Sep 09, 2024	U-3956		
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779	002	>A> 7494982	Dec 27, 2025	DS DP	>A> ODE-482	Jun 06, 2031
		>A> 9375485	Mar 15, 2033	U-3956		
		>A> 9388415	Sep 09, 2024	U-3956		
		>A> 9388416	Sep 09, 2024	U-3956		
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	001	11850245	Apr 30, 2030	U-1455		
		11850245	Apr 30, 2030	U-172		
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 217883	001				CGT	Jul 10, 2024
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276	001	11951101	Jul 15, 2041	U-3895	NCE ODE-456	Dec 05, 2028 Dec 05, 2030
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793	001	11344552	Aug 19, 2036	U-3824	I-932 ODE-463	Feb 13, 2027 Feb 13, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500	001				NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500	002				NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501	001				NPP	Dec 08, 2026
					ODE-453	Dec 08, 2030
					ODE-459	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491	001	11951212	Apr 14, 2035	DP U-3894		
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185	001	>A> 11337943	Jun 05, 2040	DP U-3660		
		>A> 11337943	Jun 05, 2040	DP U-3954		
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185	002	>A> 11337943	Jun 05, 2040	DP U-3660		
		>A> 11337943	Jun 05, 2040	DP U-3954		
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185	003	>A> 11337943	Jun 05, 2040	DP U-3660		
		>A> 11337943	Jun 05, 2040	DP U-3954		
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025	001	11986554	Apr 21, 2036	DP		
<u>LATANOPROST - IYUZEH</u>						
N 216472	001	8637054	Jul 08, 2031	DP U-446		
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795	001	8058467	Feb 21, 2029	DS U-2144		
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028	001	10702529	Oct 21, 2035	DP		
		11026944	Oct 21, 2035	DP		
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028	002	10702529	Oct 21, 2035	DP		
		11026944	Oct 21, 2035	DP		
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973	001	11944611	Jun 04, 2041	U-3507		
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974	001	11944611	Jun 04, 2041	DS DP U-3507		
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947	001	10259791	Aug 26, 2035	DS	I-868	Aug 10, 2024
		10259791*PED	Feb 26, 2036		>A> M-14	Apr 03, 2027
		10407393	Aug 26, 2035	DS	M-269	Jul 21, 2024
		10407393*PED	Feb 26, 2036		M-272	Dec 19, 2024
		11090386	Feb 23, 2036	U-3519	ODE-196	Aug 15, 2025
		11090386*PED	Aug 23, 2036		PED	Feb 15, 2026
		11186547	Aug 26, 2035	DS	>A> PED	Oct 03, 2027
		11186547*PED	Feb 26, 2036			
		7253286	Oct 24, 2025	DS DP		
		7253286*PED	Apr 24, 2026			
		7612208	Sep 19, 2026	DS DP		
		7612208*PED	Mar 19, 2027			
		9006256	Jul 27, 2027	U-1695		
		9006256*PED	Jan 27, 2028			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			>A> M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036		U-3519	ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		>A> PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027		U-1695		
	9006256*PED	Jan 27, 2028				
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	RE46791	Jan 18, 2029	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	11931559	Dec 22, 2041	DS			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	11903940	Mar 02, 2040		U-3821		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004					M-304	Mar 24, 2026
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	11850182	Sep 14, 2029	DP	U-3819		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001 >A>	12004992	Oct 06, 2033	DS			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11850182	Sep 14, 2029	DP U-3819			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	11911388	Apr 10, 2030	U-3854			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11872318	May 03, 2033	DP			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11872318	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11980617	Oct 27, 2039	U-3940			
	8598119	Dec 28, 2029	U-543	Y		
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11980617	Oct 27, 2039	U-3940			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11980617	Oct 27, 2039	U-3940			
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP		>A> NPP	Apr 23, 2027
	10596276*PED	Jan 25, 2039			ODE-166	Jan 26, 2025
	10596278	Jul 25, 2038	DP		ODE-479	Apr 23, 2031
	10596278*PED	Jan 25, 2039			PED	Jul 26, 2025
	11904027	Jul 25, 2038	DP		>A> PED	Oct 23, 2027
	11904027*PED	Jan 25, 2039			PED	Oct 23, 2031
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN - PLUVICTO</u>						
N 215833 001	11951190	Nov 12, 2035	U-3345			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	10512657	Oct 26, 2032	U-3850		I-938	Mar 13, 2027
	11229661	Oct 26, 2032	U-3850		ODE-471	Mar 13, 2031
	11918578	Feb 12, 2040	U-3290			
<u>MAVORIXAFOR - XOLREMDI</u>						
N 218709 001	10548889	Dec 11, 2038	DP		NCE	Apr 26, 2029
	10610527	Dec 22, 2036	U-3932		ODE-480	Apr 26, 2031
	10953003	Dec 14, 2036	DP			
	11045461	Dec 11, 2038	DP			
	11219621	Dec 22, 2036	U-3932			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	11918559	Jul 29, 2039	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	11969503	Jan 02, 2033	DP			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					M-303	Jan 08, 2027
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					M-303	Jan 08, 2027
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11911518	Mar 23, 2032	U-2357			
<u>MIFEPRISTONE - MIFEPRISTONE</u>						
A 211436 001					PC	Jul 17, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	11969435	Jun 19, 2037	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11903938	Aug 17, 2038	DS U-2371			
	RE48608	Oct 20, 2031	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	11944634	Oct 16, 2032	DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	11878049	Jul 31, 2041	U-3782			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	11878049	Jul 31, 2041	U-3782			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	11963962	Dec 02, 2040	U-3928			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11903918	Feb 27, 2035	U-1384			
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	11931455	Aug 16, 2039	DP U-1752			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001					NP	Apr 29, 2024
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001					NP	Apr 19, 2027
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11806428	May 11, 2032	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11872211	May 19, 2043	U-3754		NCE	Nov 27, 2028
	11884634	Aug 09, 2039	DP		ODE-452	Nov 27, 2030
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	>A> 12011434	May 19, 2043	U-3754			
	>A> 12011435	May 19, 2043	U-3754			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS U-3754		ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS U-3754			
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP U-3754			
	11807611	Sep 08, 2042	DP U-3754			
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP U-3754			
	11845732	Aug 09, 2039	DS U-3754			
	11872211	May 19, 2043	U-3754			
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	>A> 12011434	May 19, 2043	U-3754			
	>A> 12011435	May 19, 2043	U-3754			
	7342118	Aug 18, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEQ</u>						
N 217677 002	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEQ</u>						
N 217677 003	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS	U-3754	ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP	U-3754		
	11807611	Sep 08, 2042	DP	U-3754		
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP	U-3754		
	11845732	Aug 09, 2039	DS	U-3754		
	11872211	May 19, 2043		U-3754		
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043		U-3754		
	11925620	May 19, 2043		U-3754		
	11938116	May 19, 2043		U-3754		
	11951096	May 19, 2043		U-3754		
	11957662	May 19, 2043		U-3754		
	>A> 12011434	May 19, 2043		U-3754		
	>A> 12011435	May 19, 2043		U-3754		
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	11931377	Jun 03, 2029	DS DP	U-3903		
	11931377*PED	Dec 03, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 004	11931377	Jun 03, 2029	DS DP	U-3903		
<u>NITROGLYCERIN - NITROGLYCERIN</u>						
A 216103 001					CGT	Aug 21, 2024
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	>A> 12013403	Mar 04, 2036		U-1941		
	>A> 12013403	Mar 04, 2036		U-1942		
	>A> 12013403	Mar 04, 2036		U-1943		
	>A> 12013403	Mar 04, 2036		U-1944		
	>A> 12013403	Mar 04, 2036		U-2093		
	>A> 12013403	Mar 04, 2036		U-2094		
	8361977	Dec 23, 2030	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11857595	Feb 03, 2036		U-3784	ODE-474	Jun 26, 2027
	11890316	Dec 28, 2040		U-3232		
	11969471	Sep 17, 2029	DP			
	>A> 11986529	Sep 17, 2029		U-2857		
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11951111	Nov 12, 2041		U-3886		
	11951111	Nov 12, 2041		U-3887		
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11951111	Nov 12, 2041		U-3886		
	11951111	Nov 12, 2041		U-3887		
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11951111	Nov 12, 2041		U-3886		
	11951111	Nov 12, 2041		U-3887		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11931350	Mar 23, 2032	DS	U-2986		
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11931350	Mar 23, 2032	DS	U-2986		
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11931350	Mar 23, 2032	DS	U-2986		
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001					>A> NPP	Apr 24, 2027
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2025	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2025	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11919838	Apr 20, 2029	U-3862			
	11919838	Apr 20, 2029	U-3863			
<u>OMEFRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	11911473	Jul 16, 2039	U-623			
	11911473	Jul 16, 2039	U-624			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP	U-3869		
	8524746	Jul 14, 2029		U-3869		
	9550759	Jul 26, 2026		U-3870		
	9550759	Jul 26, 2026		U-3871		
	9550759	Jul 26, 2026		U-3872		
	9630955	Dec 12, 2032	DS DP	U-3869		
	9745290	Oct 10, 2027	DP	U-3869		
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP	U-3869		
	8524746	Jul 14, 2029		U-3869		
	9550759	Jul 26, 2026		U-3870		
	9550759	Jul 26, 2026		U-3871		
	9550759	Jul 26, 2026		U-3872		
	9630955	Dec 12, 2032	DS DP	U-3869		
	9745290	Oct 10, 2027	DP	U-3869		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289			
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289			
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	11896599	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200534 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 001					M-14	Jul 21, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535	002				M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 201194	001				M-14	Jul 21, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899	001	10239846	Nov 15, 2030	U-3740		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899	002	10239846	Nov 15, 2030	U-3740		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899	003	10239846	Nov 15, 2030	U-3740		
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014	001	11844841	Dec 09, 2038	DP U-3172		
		11844841	Dec 09, 2038	DP U-3173		
		11844841	Dec 09, 2038	DP U-3174		
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171	001	11903994	Feb 22, 2037	U-3826		
		11903994	Feb 22, 2037	U-3827		
		11903994	Feb 22, 2037	U-3828		
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511	001	10285759	Dec 08, 2031	U-3890	NCE	Apr 17, 2029
		9032965	Dec 08, 2031	U-3890		
		9155471	Oct 12, 2031	U-3890		
		9532835	Dec 08, 2031	U-3890		
		9763577	Sep 14, 2034	DS DP U-3890		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	001	6949571	May 23, 2025	DS DP U-106		
		6949571	May 23, 2025	DS DP U-2088		
		6949571	May 23, 2025	DS DP U-2089		
		6949571	May 23, 2025	DS DP U-2428		
		6949571	May 23, 2025	DS DP U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	002	6949571	May 23, 2025	DS DP U-106		
		6949571	May 23, 2025	DS DP U-2088		
		6949571	May 23, 2025	DS DP U-2089		
		6949571	May 23, 2025	DS DP U-2428		
		6949571	May 23, 2025	DS DP U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	003	6949571	May 23, 2025	DS DP U-106		
		6949571	May 23, 2025	DS DP U-2088		
		6949571	May 23, 2025	DS DP U-2089		
		6949571	May 23, 2025	DS DP U-2428		
		6949571	May 23, 2025	DS DP U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	004	6949571	May 23, 2025	DS DP U-106		
		6949571	May 23, 2025	DS DP U-2088		
		6949571	May 23, 2025	DS DP U-2089		
		6949571	May 23, 2025	DS DP U-2428		
		6949571	May 23, 2025	DS DP U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	005	6949571	May 23, 2025	DS DP U-106		
		6949571	May 23, 2025	DS DP U-2088		
		6949571	May 23, 2025	DS DP U-2089		
		6949571	May 23, 2025	DS DP U-2428		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11857646	Mar 16, 2037		U-665		
	11925695	Mar 16, 2037		U-665		
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11857646	Mar 16, 2037		U-665		
	11925695	Mar 16, 2037		U-665		
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	10278918	Jan 31, 2034	DP			
	10772829	Jan 31, 2034	DP			
	11090261	Jan 31, 2034	DP			
	11400077	Oct 25, 2039		U-3804		
	11844858	Jan 31, 2034	DP			
	9795560	Jan 31, 2034	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	11839487	Jul 15, 2031		U-3685		
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	11851407	Jun 09, 2037	DS DP U-3130			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001					ODE-451	Dec 01, 2030
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002					ODE-451	Dec 01, 2030
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 001	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	11951097	Oct 10, 2042	U-3891			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11872192	Apr 03, 2039	U-2952			
	11963958	Apr 03, 2039	U-2828			
<u>REMEDESIVIR - VEKLURY</u>						
N 214787 001	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10675296*PED	Jan 10, 2039			NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3831		PED	Jul 21, 2025
	10695361	Sep 16, 2036	U-3832		PED	Oct 25, 2025
	10695361*PED	Mar 16, 2037			PED	Apr 22, 2026
	11007208	Sep 16, 2036	U-3831		PED	Jan 13, 2027
	11007208	Sep 16, 2036	U-3832			
	11007208*PED	Mar 16, 2037				
	11266681	Jul 10, 2038	U-3831			
	11266681	Jul 10, 2038	U-3832			
	11266681*PED	Jan 10, 2039				
	11382926	Sep 16, 2036	U-3831			
	11382926	Sep 16, 2036	U-3832			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3835			
	11491169	May 28, 2041	U-3836			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3835			
	11903953	May 28, 2041	U-3836			
	11903953*PED	Nov 28, 2041				
>A>	11975012	May 28, 2041	U-3835			
>A>	11975012	May 28, 2041	U-3836			
>A>	11975012*PED	Nov 28, 2041				
>A>	11975017	Jul 10, 2038	DP			
>A>	11975017*PED	Jan 10, 2039				
	8008264	Sep 06, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10695361	Sep 16, 2036	U-3829		NCE	Oct 22, 2025
	10695361	Sep 16, 2036	U-3830		NPP	Apr 25, 2025
	10695361*PED	Mar 16, 2037			PED	Jul 21, 2025
	11007208	Sep 16, 2036	U-3829		PED	Oct 25, 2025
	11007208	Sep 16, 2036	U-3830		PED	Apr 22, 2026
	11007208*PED	Mar 16, 2037			PED	Jan 13, 2027
	11382926	Sep 16, 2036	U-3829			
	11382926	Sep 16, 2036	U-3830			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3833			
	11491169	May 28, 2041	U-3834			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	>A> 11903953	May 28, 2041	U-3833			
	>A> 11903953	May 28, 2041	U-3834			
	>A> 11903953*PED	Nov 28, 2041				
	>A> 11975012	May 28, 2041	U-3833			
	>A> 11975012	May 28, 2041	U-3834			
	>A> 11975012*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001	9827251	Jan 13, 2034	U-2968			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	>A> 11452725	Jul 24, 2036	U-3755		NCE	Nov 15, 2028
	>A> 11452725	Jul 24, 2036	U-3961		ODE-455	Nov 15, 2030
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	>A> 10294242	Jul 05, 2036	DS			
	>A> 11452725	Jul 24, 2036	U-3755			
	>A> 11452725	Jul 24, 2036	U-3961			
	>A> 9714258	Jan 23, 2035	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
	7125879	Apr 21, 2025	DS DP U-3874			
	7125879*PED	Oct 21, 2025				
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT PED</u>						
N 219016 001	11065198	Oct 23, 2037	DP			
	7125879	Apr 21, 2025	DS DP U-3874			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11896585	Dec 30, 2040	DP			
	11903933	Dec 30, 2040	DP			
	11911370	Dec 30, 2040	DP			
	11918564	Dec 30, 2040	DP			
	11969414	Feb 08, 2041	U-3897			
	11969415	Dec 30, 2040	U-3219			
	>A> 12023325	Aug 12, 2040	U-3960			
	>A> 12023326	Aug 12, 2040	U-3959			
	>A> 12023327	Aug 12, 2040	U-3958			
	>A> 12023328	Dec 30, 2040	U-3957			
<u>RISDIPLAM - EVRYSIDI</u>						
N 213535 001	11938136	Nov 08, 2036	DP			
<u>RISPERIDONE - RISVAN</u>						
N 214835 001	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
	>A> 11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
>A>	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP			
	7157456*PED	Feb 28, 2025				
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	>A> 11992480	Jun 07, 2037	U-3748			
	>A> 12005051	Jun 07, 2037	U-3748			
	>A> 12005052	Jun 07, 2037	DP			
	>A> 12011437	Jun 07, 2037	DP			
	>A> 12016848	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	>A> 11992480	Jun 07, 2037	U-3773		NP	Dec 15, 2026
	>A> 12005051	Jun 07, 2037	U-3773			
	>A> 12005052	Jun 07, 2037	DP			
	>A> 12011437	Jun 07, 2037	DP			
	>A> 12016848	Jun 07, 2037	DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 001	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 002	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 001	11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002	11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 003	11998565	Jul 01, 2041	DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	>A> 10137124	Oct 10, 2037	U-2826		>A> NPP	May 29, 2027
	>A> 10137124	Oct 10, 2037	U-2827		>A> ODE-484	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-2828		>A> ODE-485	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3451			
	>A> 10137124	Oct 10, 2037	U-3452			
	>A> 10137124	Oct 10, 2037	U-3453			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-2826			
	>A> 10172851	Oct 10, 2037	U-2827			
	>A> 10172851	Oct 10, 2037	U-2828			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3451			
	>A> 10172851	Oct 10, 2037	U-3452			
	>A> 10172851	Oct 10, 2037	U-3453			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 213246 001	>A> 10172851	Oct 10, 2037	U-3951			
	>A> 10584124	Oct 10, 2038	DS U-2826			
	>A> 10584124	Oct 10, 2038	DS U-2827			
	>A> 10584124	Oct 10, 2038	DS U-2828			
	>A> 10584124	Oct 10, 2038	DS U-3450			
	>A> 10584124	Oct 10, 2038	DS U-3451			
	>A> 10584124	Oct 10, 2038	DS U-3452			
	>A> 10584124	Oct 10, 2038	DS U-3453			
	>A> 10584124	Oct 10, 2038	DS U-3949			
	>A> 10584124	Oct 10, 2038	DS U-3950			
	>A> 10584124	Oct 10, 2038	DS U-3951			
	>A> 10786489	Oct 10, 2038	DP U-2971			
	>A> 10786489	Oct 10, 2038	DP U-2972			
	>A> 10786489	Oct 10, 2038	DP U-2973			
	>A> 10786489	Oct 10, 2038	DP U-2974			
	>A> 10786489	Oct 10, 2038	DP U-2975			
	>A> 10786489	Oct 10, 2038	DP U-2976			
	>A> 10786489	Oct 10, 2038	DP U-2977			
	>A> 10786489	Oct 10, 2038	DP U-3450			
	>A> 10786489	Oct 10, 2038	DP U-3451			
	>A> 10786489	Oct 10, 2038	DP U-3452			
	>A> 10786489	Oct 10, 2038	DP U-3453			
	>A> 10786489	Oct 10, 2038	DP U-3949			
	>A> 10786489	Oct 10, 2038	DP U-3950			
	>A> 10786489	Oct 10, 2038	DP U-3951			
<u>SELPERCATINIB - RETEVMQ</u>						
N 213246 002	>A> 10137124	Oct 10, 2037	U-2826		>A> NFP	May 29, 2027
	>A> 10137124	Oct 10, 2037	U-2827		>A> ODE-484	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-2828		>A> ODE-485	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3451			
	>A> 10137124	Oct 10, 2037	U-3452			
	>A> 10137124	Oct 10, 2037	U-3453			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-2826			
	>A> 10172851	Oct 10, 2037	U-2827			
	>A> 10172851	Oct 10, 2037	U-2828			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
	>A> 10584124	Oct 10, 2038	DS U-2826			
	>A> 10584124	Oct 10, 2038	DS U-2827			
	>A> 10584124	Oct 10, 2038	DS U-2828			
	>A> 10584124	Oct 10, 2038	DS U-3450			
	>A> 10584124	Oct 10, 2038	DS U-3451			
	>A> 10584124	Oct 10, 2038	DS U-3452			
	>A> 10584124	Oct 10, 2038	DS U-3453			
	>A> 10584124	Oct 10, 2038	DS U-3949			
	>A> 10584124	Oct 10, 2038	DS U-3950			
	>A> 10584124	Oct 10, 2038	DS U-3951			
	>A> 10786489	Oct 10, 2038	DP U-2971			
	>A> 10786489	Oct 10, 2038	DP U-2972			
	>A> 10786489	Oct 10, 2038	DP U-2973			
	>A> 10786489	Oct 10, 2038	DP U-2974			
	>A> 10786489	Oct 10, 2038	DP U-2975			
	>A> 10786489	Oct 10, 2038	DP U-2976			
	>A> 10786489	Oct 10, 2038	DP U-2977			
	>A> 10786489	Oct 10, 2038	DP U-3450			
	>A> 10786489	Oct 10, 2038	DP U-3451			
	>A> 10786489	Oct 10, 2038	DP U-3452			
	>A> 10786489	Oct 10, 2038	DP U-3453			
	>A> 10786489	Oct 10, 2038	DP U-3949			
	>A> 10786489	Oct 10, 2038	DP U-3950			
	>A> 10786489	Oct 10, 2038	DP U-3951			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 213246 002	>A> 10137124	Oct 10, 2037	U-2826		>A> NPP	May 29, 2027
	>A> 10137124	Oct 10, 2037	U-2827		>A> ODE-484	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-2828		>A> ODE-485	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3451			
	>A> 10137124	Oct 10, 2037	U-3452			
	>A> 10137124	Oct 10, 2037	U-3453			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-2826			
	>A> 10172851	Oct 10, 2037	U-2827			
	>A> 10172851	Oct 10, 2037	U-2828			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
	>A> 10584124	Oct 10, 2038	DS U-2826			
	>A> 10584124	Oct 10, 2038	DS U-2827			
	>A> 10584124	Oct 10, 2038	DS U-2828			
	>A> 10584124	Oct 10, 2038	DS U-3450			
	>A> 10584124	Oct 10, 2038	DS U-3451			
	>A> 10584124	Oct 10, 2038	DS U-3452			
	>A> 10584124	Oct 10, 2038	DS U-3453			
	>A> 10584124	Oct 10, 2038	DS U-3949			
	>A> 10584124	Oct 10, 2038	DS U-3950			
	>A> 10584124	Oct 10, 2038	DS U-3951			
	>A> 10786489	Oct 10, 2038	DP U-2971			
	>A> 10786489	Oct 10, 2038	DP U-2972			
	>A> 10786489	Oct 10, 2038	DP U-2973			
	>A> 10786489	Oct 10, 2038	DP U-2974			
	>A> 10786489	Oct 10, 2038	DP U-2975			
	>A> 10786489	Oct 10, 2038	DP U-2976			
	>A> 10786489	Oct 10, 2038	DP U-2977			
	>A> 10786489	Oct 10, 2038	DP U-3450			
	>A> 10786489	Oct 10, 2038	DP U-3451			
	>A> 10786489	Oct 10, 2038	DP U-3452			
	>A> 10786489	Oct 10, 2038	DP U-3453			
	>A> 10786489	Oct 10, 2038	DP U-3949			
	>A> 10786489	Oct 10, 2038	DP U-3950			
	>A> 10786489	Oct 10, 2038	DP U-3951			
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3451			
	>A> 10137124	Oct 10, 2037	U-3452			
	>A> 10137124	Oct 10, 2037	U-3453			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3451			
	>A> 10172851	Oct 10, 2037	U-3452			
	>A> 10172851	Oct 10, 2037	U-3453			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
	>A> 10584124	Oct 10, 2038	DS U-3450	Y		
	>A> 10584124	Oct 10, 2038	DS U-3451	Y		
	>A> 10584124	Oct 10, 2038	DS U-3452	Y		
	>A> 10584124	Oct 10, 2038	DS U-3453	Y		
	>A> 10786489	Oct 10, 2038	DP U-3450	Y		
	>A> 10786489	Oct 10, 2038	DP U-3451	Y		
	>A> 10786489	Oct 10, 2038	DP U-3452	Y		
	>A> 10786489	Oct 10, 2038	DP U-3453	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3451			
	>A> 10137124	Oct 10, 2037	U-3452			
	>A> 10137124	Oct 10, 2037	U-3453			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3451			
	>A> 10172851	Oct 10, 2037	U-3452			
	>A> 10172851	Oct 10, 2037	U-3453			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
	>A> 10584124	Oct 10, 2038	DS U-3450	Y		
	>A> 10584124	Oct 10, 2038	DS U-3451	Y		
	>A> 10584124	Oct 10, 2038	DS U-3452	Y		
	>A> 10584124	Oct 10, 2038	DS U-3453	Y		
	>A> 10786489	Oct 10, 2038	DP U-3450	Y		
	>A> 10786489	Oct 10, 2038	DP U-3451	Y		
	>A> 10786489	Oct 10, 2038	DP U-3452	Y		
	>A> 10786489	Oct 10, 2038	DP U-3453	Y		
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 003	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3451			
	>A> 10137124	Oct 10, 2037	U-3452			
	>A> 10137124	Oct 10, 2037	U-3453			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3451			
	>A> 10172851	Oct 10, 2037	U-3452			
	>A> 10172851	Oct 10, 2037	U-3453			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
	>A> 10584124	Oct 10, 2038	DS U-3450	Y		
	>A> 10584124	Oct 10, 2038	DS U-3451	Y		
	>A> 10584124	Oct 10, 2038	DS U-3452	Y		
	>A> 10584124	Oct 10, 2038	DS U-3453	Y		
	>A> 10786489	Oct 10, 2038	DP U-3450	Y		
	>A> 10786489	Oct 10, 2038	DP U-3451	Y		
	>A> 10786489	Oct 10, 2038	DP U-3452	Y		
	>A> 10786489	Oct 10, 2038	DP U-3453	Y		
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 004	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3451			
	>A> 10137124	Oct 10, 2037	U-3452			
	>A> 10137124	Oct 10, 2037	U-3453			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3451			
	>A> 10172851	Oct 10, 2037	U-3452			
	>A> 10172851	Oct 10, 2037	U-3453			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
	>A> 10584124	Oct 10, 2038	DS U-3450	Y		
	>A> 10584124	Oct 10, 2038	DS U-3451	Y		
	>A> 10584124	Oct 10, 2038	DS U-3452	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 004	>A> 10584124	Oct 10, 2038	DS U-3453	Y		
	>A> 10786489	Oct 10, 2038	DP U-3450	Y		
	>A> 10786489	Oct 10, 2038	DP U-3451	Y		
	>A> 10786489	Oct 10, 2038	DP U-3452	Y		
	>A> 10786489	Oct 10, 2038	DP U-3453	Y		
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	>A> 12029779	Oct 10, 2038	U-3162		I-935	Mar 08, 2027
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					ODE-469	Jan 31, 2030
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	>A> 12005062	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Jul 24, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Jul 24, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Jul 24, 2036	U-3889			
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 216920 001					CGT	Nov 16, 2024
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	>A> 11986446	Mar 15, 2033	U-3324			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	11964018	Jul 01, 2039	U-3898			
	>A> 11992530	Jul 01, 2039	U-3948			
	>A> 11998604	Jul 01, 2039	U-3952			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	>A> 12005036	Dec 30, 2042	U-3693			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	>A> 12005036	Dec 30, 2042	U-3693			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003				>A> NCE		May 28, 2026
				>A> ODE*		May 28, 2028
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	11980623	May 29, 2033	DP			
<u>TADALAFIL - TADLIO</u>						
N 214522 001	11975006	Dec 24, 2038	DP U-3397			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 001	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 002	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 004	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 005	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11826339	Jan 25, 2033		U-3342		
	11826339	Jan 25, 2033		U-3343		
	>A> 11918556	Apr 07, 2033		U-3342		
	>A> 11918556	Apr 07, 2033		U-3343		
	>A> 11918557	Jan 25, 2033		U-3003		
	>A> 11918557	Jan 25, 2033		U-3865		
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11826339	Jan 25, 2033		U-3342		
	>A> 11918556	Apr 07, 2033		U-3342		
	>A> 11918557	Jan 25, 2033		U-3003		
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Sep 12, 2031		U-2736		
	10420775	Sep 12, 2031		U-2736		
	10420775	Sep 12, 2031		U-2852		
	10420775	Sep 12, 2031		U-2853		
	11052093	Apr 13, 2032	DS DP	U-2736		
	11052093	Apr 13, 2032	DS DP	U-2852		
	11052093	Apr 13, 2032	DS DP	U-2853		
	11491163	Apr 11, 2033		U-2736		
	11491163	Apr 11, 2033		U-2852		
	11491163	Apr 11, 2033		U-2853		
	8765732	Sep 12, 2031		U-2852		
	8765732	Sep 12, 2031		U-2853		
	9090562	Sep 12, 2031	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	9549931	Sep 12, 2031	U-2736			
	9549931	Sep 12, 2031	U-2852			
	9549931	Sep 12, 2031	U-2853			
	9855275	Sep 12, 2031	U-2736			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	11890270	Aug 08, 2032	U-2346			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	8754065	Aug 15, 2032	DS DP U-1275			
	8754065	Aug 15, 2032	DS DP U-3880			
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-3880			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11844804	Jun 04, 2033	U-2418			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	11918623	Jun 14, 2039	U-3855			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11911362	Aug 21, 2040	DP U-3413			
	11911362	Aug 21, 2040	DP U-3414			
	11911362	Aug 21, 2040	DP U-3415			
<u>TOVORAFENIB - OJEMDA</u>						
N 217700 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TOVORAFENIB - OJEMDA</u>						
N 218033 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001					NP	Dec 13, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	11826327	Feb 03, 2042	U-3749			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11857542	Dec 22, 2041	U-3786			
	11925709	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	11925709	Jan 30, 2035	DP			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	>A> 11365198	Oct 17, 2036	U-3275		I-946	Apr 26, 2027
	>A> 11365198	Oct 17, 2036	U-3946		NPP	Apr 24, 2027
	>A> 11512092	Oct 17, 2036	U-3275		ODE-481	Apr 26, 2031
	>A> 11512092	Oct 17, 2036	U-3371			
	>A> 11512092	Oct 17, 2036	U-3487			
	>A> 11512092	Oct 17, 2036	U-3946			
	>A> 11773106	Oct 17, 2036	U-3275			
	>A> 11773106	Oct 17, 2036	U-3371			
	>A> 11773106	Oct 17, 2036	U-3487			
	>A> 11773106	Oct 17, 2036	U-3946			
	>A> 11976077	Oct 17, 2036	U-3298			
	>A> 11993605	Oct 17, 2036	U-3275			
	>A> 11993605	Oct 17, 2036	U-3946			
	>A> 11993606	Oct 17, 2036	U-3487			
	>A> 8962629	Jan 15, 2031	DS U-3255			
	>A> 8962629	Jan 15, 2031	DS U-3275			
	>A> 8962629	Jan 15, 2031	DS U-3341			
	>A> 8962629	Jan 15, 2031	DS U-3371			
	>A> 8962629	Jan 15, 2031	DS U-3624			
	>A> 8962629	Jan 15, 2031	DS U-3945			
	>A> 8962629	Jan 15, 2031	DS U-3946			
	RE47221	Aug 16, 2033	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	RE47221	Aug 16, 2033	DS		I-946	Apr 26, 2027
					NPP	Apr 24, 2027
					ODE-481	Apr 26, 2031
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	RE47221	Aug 16, 2033	DS		I-946	Apr 26, 2027
					NPP	Apr 24, 2027
					ODE-481	Apr 26, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO LQ</u>						
N 218347 001	>A> 10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	>A> 11186584	Oct 17, 2036	DS		NP	Apr 26, 2027
	>A> 11661425	Oct 17, 2036	DS		ODE-481	Apr 26, 2031
	>A> 11680069	Oct 17, 2036	DS			
	>A> 11718627	Oct 17, 2036	DS			
	>A> 11773105	Oct 17, 2036	DS			
	>A> 8962629	Jan 15, 2031	DS	U-3945		
	>A> 8962629	Jan 15, 2031	DS	U-3946		
	>A> 9951080	Oct 17, 2036	DS			
	RE47221	Aug 16, 2033	DS			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	10065952	Oct 28, 2036	DS DP	U-1995	I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP	U-3055		
	10844058	Oct 28, 2036	DS DP	U-1995		
	10844058	Oct 28, 2036	DS DP	U-3055		
	10851103	Oct 28, 2036	DS DP	U-1995		
	10851103	Oct 28, 2036	DS DP	U-3055		
	10851104	Oct 28, 2036	DS	U-1995		
	10851104	Oct 28, 2036	DS	U-3055		
	10857137	Oct 10, 2037		U-1995		
	10857148	Oct 10, 2037		U-1995		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 002	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	11690853	Mar 07, 2033	U-3747			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11903941	Oct 19, 2035	U-1900			
	11903942	Oct 19, 2035	DP			
	11903943	Oct 19, 2035	U-1900			
	11911380	Oct 19, 2035	U-1900			
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001 >A>	12016857	Aug 16, 2039	DP			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	11944612	Dec 02, 2036	U-3893			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	11944612	Dec 02, 2036	U-3893			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2145		ODE-467	Mar 07, 2031
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	10570139	Apr 22, 2034	U-3860			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 001	11965040	Jun 12, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 002	11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 003	11965040	Jun 12, 2035	DP			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Dec 24, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 44TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm